nevirapine profile

Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that is used to treat HIV infection. It was first synthesized in the 1980s and was approved by the FDA in 1996. Nevirapine works by blocking the activity of reverse transcriptase, an enzyme that HIV uses to copy its genetic material. This prevents the virus from replicating and spreading. Nevirapine is typically given in combination with other antiretroviral drugs. It is effective in reducing viral load and improving CD4+ cell count. Nevirapine is also used to prevent mother-to-child transmission of HIV. Nevirapine is studied because it is a valuable tool in the fight against HIV infection. It is effective in reducing viral load and improving CD4+ cell count. Nevirapine is also relatively inexpensive and is available in generic formulations. This makes it an important treatment option in resource-limited settings. Nevirapine is also being studied for its potential use in other diseases, such as cancer and autoimmune disorders.'

Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	4463
CHEMBL ID	57
CHEBI ID	63613
SCHEMBL ID	3318
MeSH ID	M0029429

Synonym
BIDD:GT0326
AC-643
11-cyclopropyl-5,11-dihydro-4-methyl-6h-dipyrido[3,2-b:2 ,3 -e][1,4]diazepin-6-one
bdbm1434
2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-10-one
chembl57 ,
HMS3393J09
AB00393001-15
birg-0587
viramune xr
viramune ir
hsdb 7164
nsc 641530
6h-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-
nsc-641530
viramune
smr000048458
MLS000084585 ,
nevirapine & pro 140
11-cyclopropyl-4-methyl-5,11-dihydro-6h-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & pro 140 (anti-ccr5 monoclonal antibody)
bi-rg-587 & cd4-igg
nevirapine & cd4-igg
n11-cyclopropyl-4-methyl-5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & cd4-immunoadhesin
bi-rg-587
nvp ,
birg 0587
birg 587
nsc641530
viramune(tm)
11-cyclopropyl-4-methyl-5,11-dihydro-6h-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one
birg-587
11-cyclopropyl-4-methyl-5h-dipyrido[[?],[?]][1,4]diazepin-6-one
11-cyclopropyl-5,11-dihydro-4-methyl-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
NCGC00065890-02
MLS001055309
nevirapine
C07263
129618-40-2
nev ,
non-nucleoside rt inhibitor nevirapine
MLS000759409
11-cyclopropyl-5,11-dihydro-4-methyl-6h-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
DB00238
nevirapine, anhydrous
1VRT
2HNY
nevirapine anhydrous
D00435
nevirapine (jan/usp/inn)
viramune (tn)
11-cyclopropyl-4-methyl-5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
MLS001201730
birg587
HMS2051J09
chebi:63613 ,
nevirapine teva
nevirapinum anhydrous
NCGC00065890-03
NCGC00065890-04
HMS3264D21
nevirapine [usan:usp:inn:ban]
unii-99dk7fvk1h
99dk7fvk1h ,
NCGC00258324-01
tox21_200770
STK580320
BBL010768
nsc759902
pharmakon1600-01503842
nsc-759902
MLS001424058
dtxsid7031797 ,
dtxcid9010787
tox21_110982
cas-129618-40-2
bi-rg 587
N0922
HMS2231O23
CCG-100939
AKOS005504351
FT-0607215
NCGC00065890-07
AB07544
nevirapine [vandf]
nevirapinum anhydrous [who-ip latin]
nevirapine [usp impurity]
nevirapine [mi]
nevirapine [ema epar]
nevirapine [orange book]
nevirapine [ep monograph]
nevirapine [hsdb]
nevirapine [usan]
nevirapine [mart.]
nevirapine [who-dd]
nevirapine [jan]
nevirapine [inn]
nevirapine anhydrous [who-ip]
nevirapine [usp monograph]
nevirapine anhydrous [usp-rs]
11-cyclopropyl-5,11-dihydro-4-methyl-6h-dipyrido[3,2-b:2', 3'-e][1,4]diazepin-6-one
HMS3371E03
AB00393001-13
HY-10570
MLS006011423
NC00189
SCHEMBL3318
NCGC00065890-05
tox21_110982_1
KS-5019
11-cyclopropyl-5,11-dihydro-4-methyl-6h-dipyrido-[3,2-b:2',3'-e][1,4]diazepin-6-one
11-cyclopropyl-5,11-dihydro-4-methyl-6h-dipyrido[3,2-b :2',3'-e][1,4 ]diazepin-6-one
F2173-0607
tox21 110982
11-cyclopropyl-4-methyl-5h-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6(11h)-one
AB00393001_16
OPERA_ID_934
AB00393001_17
mfcd00866928
2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-10-one
2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one
nevirapine anhydrous, united states pharmacopeia (usp) reference standard
HMS3655I08
nevirapine for peak identification, european pharmacopoeia (ep) reference standard
nevirapine (anhydrous), european pharmacopoeia (ep) reference standard
nevirapine, pharmaceutical secondary standard; certified reference material
HMS3715B10
11-cyclopropyl-4-methyl-5,11-dihydro-6h-dipyrido[3,2-b:2 inverted exclamation mark ,3 inverted exclamation mark -e][1,4]diazepin-6-one
SY009679
SW197569-2
bi-rg 587;nsc 641530;nvp
BCP05587
bi-rg-587; birg 0587; birg587; hsdb 7164; nsc 641530; nvp
Z1521553473
gtpl12676
nevirapine (viramune)
S1742
FT-0672686
nevirapine,(s)
Q263713
AC1280
EN300-119500
2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0,3,8]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one
NCGC00065890-14
nevirapine 100 microg/ml in acetonitrile
nevirapine for peak identification
nevirapine (anhydrous)
nevirapine)
6h-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-

Excerpt	Reference	Relevance
"Nevirapine (NVP) is an effective drug for the treatment of HIV infections, but its use is limited by a high incidence of severe skin rash and liver injury. "	( Sulfation of 12-hydroxy-nevirapine by human SULTs and the effects of genetic polymorphisms of SULT1A1 and SULT2A1. Cao, Y; Kurogi, K; Liu, MC; Sakakibara, Y; Segawa, K; Suiko, M; Uetrecht, J, 2022)	2.47
"Nevirapine (NVP) is a key component of antiretroviral prophylaxis and treatment for neonates. "	( Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates. Aarons, L; Borkird, T; Capparelli, EV; Cressey, TR; Jittayanun, K; Jourdain, G; Lallemant, M; Le Coeur, S; Luvira, A; Phanomcheong, S; Puangsombat, A; Punyawudho, B; Saenjum, C; Sukrakanchana, PO; Urien, S, 2017)	2.26
"Nevirapine (NVP), is an HIV-1 antiretroviral with treatment-limiting hypersensitivity reactions (HSRs) associated with multiple class I and II HLA alleles."	( Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles. Bracey, A; Buus, S; Carrington, M; Chopra, A; Gaudieri, S; Haas, DW; Hunt, DF; Jing, Y; Kaever, T; Koelle, D; Malaker, SA; Mallal, S; McKinnon, EJ; Myers, P; Ostrov, DA; Pavlos, R; Peters, B; Phillips, EJ; Redwood, A; Restrepo, S; Rive, C; Schutte, R; Shabanowitz, J; Speers, E, 2017)	1.4
"Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor frequently used in combination with other antiretroviral agents for highly active antiretroviral therapy (HAART) of patients infected with the human immunodeficiency virus type 1 (HIV-1). "	( Nevirapine induced mitochondrial dysfunction in HepG2 cells. Kittisenachai, S; Paemanee, A; Roytrakul, S; Sirinonthanawech, N; Smith, DR; Sornjai, W; Wongtrakul, J, 2017)	3.34
"Nevirapine is a known inhibitor of cytochrome P450 3A4, which metabolizes artemether and lumefantrine."	( Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children. Aweeka, FT; Barlow-Mosha, L; Carey, V; Gingrich, D; Graham, B; Huang, L; Kamthunzi, P; Lindsey, JC; Marzan, F; Nachman, S; Parikh, S; Ssemambo, PK, 2017)	1.56
"Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) widely used in the treatment of human immunodeficiency virus type 1 (HIV-1) and is the first-choice NNRTI during pregnancy. "	( Sex-dependent metabolism of nevirapine in rats: impact on plasma levels, pharmacokinetics and interaction with nortriptyline. Compañ, P; Peris, JE; Usach, I, 2018)	2.22
"Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) widely used as a component of High Active Antiretroviral Therapy (HAART) since it is inexpensive, readily absorbed after oral administration and non-teratogenic. "	( In vitro assessment of competitive and time-dependent inhibition of the nevirapine metabolism by nortriptyline in rats. Ferrer, JM; Peris, JE; Usach, I, 2018)	2.16
"Nevirapine is a BCS class II drug which shows dissolution rate limited absorption."	( Improving the solubility of nevirapine using A hydrotropy and mixed hydrotropy based solid dispersion approach. Awasthi, R; Dua, K; Kamate, VJ; Madan, JR, )	1.15
"Nevirapine (NVP) is a first-generation non-nucleoside reverse transcriptase inhibitor widely used for the treatment and prophylaxis of human immunodeficiency virus infection. "	( Singularities of nevirapine metabolism: from sex-dependent differences to idiosyncratic toxicity. Antunes, AMM; Caixas, U; Charneira, C; Gonçalves-Dias, C; Marinho, AT; Marques, MM; Miranda, JP; Monteiro, EC; Pereira, SA, 2019)	2.3
"Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used against HIV-1. "	( 2'-Deoxythymidine adducts from the anti-HIV drug nevirapine. Antunes, AM; Beland, FA; Marques, MM; Oliveira, MC; Wolf, B, 2013)	2.09
"Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used in the treatment of HIV infections and has been reported to be toxic to the male reproductive system. "	( Nevirapine induces testicular toxicity in Wistar rats: reversal effect of kolaviron (biflavonoid from Garcinia kola seeds). Adaramoye, OA; Akanni, OO; Farombi, EO, 2013)	3.28
"Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor, widely prescribed for type 1 human immunodeficiency virus infection. "	( Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study. Borgiani, P; Ciccacci, C; Di Fusco, D; Erba, F; Liotta, G; Marazzi, MC; Novelli, G; Palombi, L; Zimba, I, 2013)	2.09
"Nevirapine is an important component of highly active antiretroviral therapy used in the treatment of HIV infection. "	( Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes? Bangsberg, DR; Chinn, LW; Kroetz, DL; Martin, JN; Micheli, JE; Patel, A; Shugarts, SB, 2013)	2.1
"Nevirapine is a non-nucleoside reverse transcriptase (RT) inhibitor used for the treatment of AIDS and the prevention of mother-to-child transmission of HIV-1. "	( Differential responses of human hepatocytes to the non-nucleoside HIV-1 reverse transcriptase inhibitor nevirapine. Beland, FA; Fang, JL, 2013)	2.05
"Nevirapine is a much cheaper drug than its alternative efavirenz, and might be beneficial in resource constrained settings."	( Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study. Ahmad, H; Chandrashekhar, R; Dhooria, S; Ekka, M; Khan, NH; Kumar, S; Pandey, RM; Raghunandan, P; Ranjan, S; Rewari, BB; Samantaray, JC; Sharma, SK; Sinha, S; Velpandian, T; Venkatesh, S, 2013)	2.55
"Nevirapine (NVP) is an anti-retroviral drug used for the treatment of HIV infection, that may cause several severe adverse events, including Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). "	( HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis susceptibility in a population from Mozambique. Borgiani, P; Ciccacci, C; Di Fusco, D; Erba, F; Mancinelli, S; Marazzi, MC; Novelli, G; Palombi, L, 2014)	2.1
"Nevirapine is an inducer of hepatic metabolism. "	( Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects. Allavena, C; André-Garnier, E; Billaud, E; Bonnet, B; Bouchez, S; Bouquié, R; Boutoille, D; Dailly, E; Pineau, S; Raffi, F; Raveleau, A; Reliquet, V, 2014)	2.11
"Nevirapine (NVP) is a frequently used anti-HIV drug. "	( Human sulfotransferase 1A1-dependent mutagenicity of 12-hydroxy-nevirapine: the missing link? Alves, M; Antunes, P; Kranendonk, M; Rueff, J, 2014)	2.08
"Nevirapine is a hydrophobic non-nucleoside reverse transcriptase inhibitor, used in first line regimens of highly active antiretroviral therapy (HAART). "	( Compatibility studies of nevirapine in physical mixtures with excipients for oral HAART. de Oliveira, GG; Ferraz, HG; Severino, P; Souto, EB, 2013)	2.14
"Nevirapine (NVP) is an effective nonnucleoside reverse transcriptase inhibitor (NNRTI) of particular interest as it is often used in resource limited countries. "	( Proteomic analysis of serum and urine of HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term treatment with nevirapine. Janphen, K; Kumrapich, B; Praparattanapan, J; Roytrakul, S; Smith, DR; Supparatpinyo, K; Thongtan, T; Wongtrakul, J, 2014)	2.05
"Nevirapine (NVP) is an orally taken anti-HIV drug associated with severe idiosyncratic reactions elicited by toxic metabolites, with women at increased risk."	( Sex differences in hepatic and intestinal contributions to nevirapine biotransformation in rats. Antunes, AM; Marinho, AT; Marques, MM; Miranda, JP; Pereira, SA; Pinheiro, PF, 2015)	1.38
"Nevirapine is a very potent antiretroviral drug frequently used in the management of Human Immunodeficiency Virus (HIV). "	( Evaluation of anti-ulcerogenic and ulcer-healing activities of nevirapine in rats. Adeyemi, JA; Faborode, SO; Latinwo, GG; Mishra, V; Onasanwo, SA, 2015)	2.1
"Nevirapine (NVP) is a non-nucleoside reverse transcriptase-inhibitor, which is associated with severe idiosyncratic skin rash and hepatotoxicity. "	( Different Reactive Metabolites of Nevirapine Require Distinct Glutathione S-Transferase Isoforms for Bioinactivation. Commandeur, JN; Dekker, SJ; Vermeulen, NP; Vos, JC; Zhang, Y, 2016)	2.16
"Nevirapine is a reverse-transcriptase inhibitor widely used in combination therapy to treat HIV infection. "	( Exploring CYP2B6 activity by measuring the presence ofnevirapine hydroxy metabolites in plasma. Ab Rahman, AK; Hassan, NB; Low, LL; Mustafa, S; Tan, SC; Wan Yusuf, WN, 2016)	2.13
"Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used against the human immunodeficiency virus type 1 (HIV-1), mostly to prevent mother-to-child HIV transmission in developing countries. "	( Synthesis and characterization of DNA adducts from the HIV reverse transcriptase inhibitor nevirapine. Antunes, AM; Beland, FA; Duarte, MP; Gamboa da Costa, G; Heinze, TM; Marques, MM; Santos, PP, 2008)	2.01
"Nevirapine (NVP) is a nonnucleoside reverse transcriptase inhibitor used in HIV patients and recently evaluated as a differentiating and antiproliferative agent in human malignancies. "	( Nevirapine toxicity in non-HIV cancer patients. Barone, C; Cignarelli, M; De Vis, K; Fabiano, A; Fersini, A; Landriscina, M; Lombardi, V; Piscazzi, A; Santodirocco, M, 2008)	3.23
"Nevirapine is a nonnucleoside reverse transcriptase inhibitor used as part of combination therapy for human immunodeficiency virus (HIV) infection. "	( Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis. Cammett, AM; Felizarta, F; MacGregor, TR; Mallolas, J; Miailhes, P; Piliero, PJ; Wruck, JM, 2009)	2.08
"Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used against the human immunodeficiency virus type-1 (HIV-1), mostly to prevent mother-to-child transmission of the virus in developing countries. "	( Amino acid adduct formation by the nevirapine metabolite, 12-hydroxynevirapine--a possible factor in nevirapine toxicity. Antunes, AM; Beland, FA; Godinho, AL; Justino, GC; Marques, MM; Martins, IL, 2010)	2.08
"Nevirapine is a first generation of non-nucleoside reverse transcriptase inhibitors (NNRTIs), which is usually used for the therapy of AIDS."	( Study on the interaction between HIV reverse transcriptase and its non-nucleoside inhibitor nevirapine by capillary electrophoresis. Chen, W; Li, W; Ling, X; Liu, J; Wang, X, 2010)	1.3
"Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used against human immunodeficiency virus type-1 (HIV-1), mostly to prevent mother-to-child HIV-1 transmission in developing countries. "	( Protein adducts as prospective biomarkers of nevirapine toxicity. Antunes, AM; Beland, FA; Coelho, AV; Godinho, AL; Gomes, RA; Marques, MM; Martins, IL; Oliveira, MC, 2010)	2.06
"Nevirapine-based ART is an option for HIV-infected patients who receive rifampin in resource-limited countries or those who cannot tolerate efavirenz."	( Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study. Chimsuntorn, S; Eampokarap, B; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Tantanathip, P; Thongyen, S, 2010)	2.03
"Nevirapine is a poorly water-soluble antiretroviral drug. "	( In vitro protein adsorption studies on nevirapine nanosuspensions for HIV/AIDS chemotherapy. Jansch, M; Müller, RH; Shegokar, R; Singh, KK, 2011)	2.08
"Nevirapine is an important component of paediatric combination HIV therapy. "	( Factors influencing plasma nevirapine levels: a study in HIV-infected children on generic antiretroviral treatment in India. Agibothu Kupparam, HK; Karunaianandham, R; Mahalingam, V; Navaneethapandian, PG; Perumal Kannabiran, B; Ramachandran, G; Shah, I; Sikhamani, R; Soundararajan, L; Swaminathan, S, 2011)	2.11
"Nevirapine is a non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus type-1. "	( Bioavailability of nevirapine in rats after oral and subcutaneous administration, in vivo absorption from gastrointestinal segments and effect of bile on its absorption from duodenum. Peris, JE; Usach, I, 2011)	2.14
"Nevirapine (NVP) is a widely used non-nucleoside reverse transcriptase inhibitor. "	( Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study. Arasteh, K; Battegay, M; Berger, F; Bogner, JR; Livrozet, JM; Macha, S; Mossdorf, E; Plettenberg, A; Quinson, AM; Robinson, P; Stern, J; Witt, MD; Yong, CL; Zhang, W, 2011)	2.09
"Nevirapine is a substrate for ABCC10 and genetic variants influence its plasma concentrations. "	( Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Back, DJ; Brockmeyer, NH; Fätkenheuer, G; Hoffmann, C; Hopper-Borge, E; Khoo, SH; Knechten, H; Liptrott, NJ; Mauss, S; Owen, A; Pirmohamed, M; Pushpakom, S; Siccardi, M; Wyen, C, 2012)	2.09
"Nevirapine (NVP) is an anti-HIV drug associated with severe hepatotoxicity and skin rashes, which raises concerns about its chronic administration. "	( Oxidation of 2-hydroxynevirapine, a phenolic metabolite of the anti-HIV drug nevirapine: evidence for an unusual pyridine ring contraction. Antunes, AM; Beland, FA; Ferreira da Silva, JL; Harjivan, SG; Marques, MM; Novais, DA; Santos, PP; Sidarus, M, 2012)	2.14
"Nevirapine (NVP) is a nonnucleoside reverse transcriptase inhibitor (NNRTI) used worldwide as part of combination antiretroviral therapy in infants and children to treat HIV infection. "	( Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Acosta, EP; Aweeka, FT; Burger, D; Capparelli, EV; Cressey, TR; Kabamba, D; Nikanjam, M; Spector, SA, 2012)	3.26
"Nevirapine (NVP) is an antiretroviral medication that prevents human immunodeficiency virus (HIV) cells from multiplying in the blood. "	( Chronic administration of the antiretroviral nevirapine increases body weight, food, and water intake in albino Wistar rats. Obembe, AO; Osim, EE; Umoren, EB, 2012)	2.08
"Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used for chronic human immunodeficiency virus infections in adults and children. "	( Evaluation of nevirapine dosing recommendations in HIV-infected children. Benaboud, S; Blanche, S; Bouazza, N; Dollfus, C; Faye, A; Foissac, F; Frange, P; Hirt, D; Lachassinne, E; Treluyer, JM; Urien, S, 2013)	2.19
"Nevirapine (NVP) is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase. "	( Nevirapine resistance after single dose prophylaxis. Eshleman, SH; Jackson, JB, )	3.02
"Nevirapine is a non-nucleoside RT inhibitor with a well-characterized inhibitory activity on RT enzymes of retroviral origin."	( Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitor, reduces cell growth and promotes differentiation. Barone, C; Careddu, A; Landriscina, M; Lavia, P; Lorenzini, R; Mangiacasale, R; Mattei, E; Nervi, C; Pittoggi, C; Sciamanna, I; Spadafora, C; Travaglini, L, 2003)	1.3
"Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was first reported in the scientific literature in 1990. "	( Efficacy and durability of nevirapine in antiretroviral drug näive patients. Lange, JM, 2003)	2.06
"Nevirapine is a nonnucleoside reverse transcriptase antiretroviral agent. "	( Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. Belknap, SM; Bennett, C; Chan, J; Johnson, S; Patel, SM; Sha, BE, 2004)	2
"Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis. "	( Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine. Krivoy, N; Pollack, S; Shahar, E; Weltfriend, S, 2004)	1.99
"Nevirapine is an antiretroviral drug that is used for treatment as well as for the prevention of mother-to-child transmission of the human immunodeficiency virus (HIV). "	( RAT CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity. Abraham, AM; Barr, S; Walubo, A, 2006)	2.03
"Nevirapine is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase and is indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. "	( Influence of piperine on the pharmacokinetics of nevirapine under fasting conditions: a randomised, crossover, placebo-controlled study. Kasibhatta, R; Naidu, MU, 2007)	2.04
"Nevirapine is a non-nucleoside reverse transcriptase inhibitor commonly used in human immunodeficiency virus-1 multidrug regimens and associated with life-threatening cutaneous reactions. "	( Nevirapine-induced Stevens-Johnson syndrome in a pediatric patient. Cortes, GY; Mason, AR; Pollack, RB, )	3.02
"Nevirapine (BI-RG-587) is a potent inhibitor of the polymerase activity of reverse transcriptase of human immunodeficiency virus type-1. "	( High-performance liquid chromatography and photoaffinity crosslinking to explore the binding environment of nevirapine to reverse transcriptase of human immunodeficiency virus. Cohen, KA; Grob, PM; Hopkins, JL; Ingraham, RH; Kapadia, SR; Palladino, DE; Stevenson, JM; Van Moffaert, GJ; Warren, TC, 1994)	1.94
"Nevirapine is a highly potent and specific inhibitor of human immunodeficiency virus type 1 (HIV-1) polymerase, but is inactive against HIV-2 and other polymerase. "	( Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2. Effect on kinetic constants and inhibition by non-nucleoside analogs. Bacolla, A; Cousins, RC; Greenwood, DJ; Grygon, CA; Ingraham, RH; Piras, G; Richman, D; Rose, JM; Shih, CK; Warren, TC, 1993)	1.73
"Nevirapine is a nonnucleoside inhibitor of reverse transcriptase (RT) which decreases the level of HIV-1 viral particles in the blood plasma of infected individuals."	( Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo. Dornadula, G; Havlir, D; Pomerantz, RJ; Richman, DD; Wu, Y; Zhang, H, 1996)	1.02
"Nevirapine is a non-nucleoside reverse transcriptase inhibitor of HIV-1 which exhibits synergy in vitro with zidovudine (ZDV) and also is active against ZDV-resistant HIV. "	( A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group. Boucher, CA; Carr, A; Cooper, DA; de Jong, MD; Imrie, A; Sorice, F; Vella, S, 1996)	2.05
"Nevirapine is a potent antiretroviral agent whose use, especially as monotherapy, may be limited by rapid onset of resistance as well as by hypersensitivity reactions. "	( Current clinical experience with nevirapine for HIV infection. Carr, A; Cooper, DA, 1996)	2.02
"Nevirapine is a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1-infected patients. "	( Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection. Beijnen, JH; Hoetelmans, RM; Meenhorst, PL; Mulder, JW; van Heeswijk, RP, 1998)	2.05
"Nevirapine (NVP) is a nonnucleoside reverse transcriptase inhibitor widely used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus disease. "	( Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Dransfield, K; Pollard, RB; Robinson, P, )	1.91
"Nevirapine (NVP) is a potent noncompetitive inhibitor of the reverse transcriptase enzyme, which is necessary for HIV replication. "	( [Antiretroviral agent nevirapine: its pharmacological action and potential for clinical use]. Osugi, T; Takeuchi, S, 1999)	2.06
"Nevirapine (VIRAMUNE) is a non-nucleoside reverse transcriptase inhibitor with activity against human immunodeficiency virus type 1 (HIV-1), currently marketed for the treatment of HIV-1 infected adults. "	( HPLC-UV method for the quantitation of nevirapine in biological matrices following solid phase extraction. Korpalski, DJ; Pav, JW; Rowland, LS, 1999)	2.02
"Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy for the treatment of HIV infection."	( Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy. Clarke, S; Condon, C; Harrington, P; Kelleher, D; Mulcahy, F; Smith, OP, 2000)	1.25
"(4) Nevirapine is a liver enzyme inducer, hence the possibility of drug interactions, especially with protease inhibitors of HIV; the clinical consequences are poorly known."	( Nevirapine: new preparation. In second-line triple-drug anti-HIV regimens. , 1998)	2.22
"Nevirapine is a highly specific inhibitor of HIV-1 reverse transcriptase (RT), an important therapeutic target for the treatment of HIV infection. "	( Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection. Bardsley-Elliot, A; Perry, CM, )	3.02
"Nevirapine is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase. "	( Nevirapine: pharmacokinetic considerations in children and pregnant women. Clarke, DF; Dorenbaum, A; Mirochnick, M, 2000)	3.19
"Nevirapine is a nonnucleoside reverse transcriptase inhibitor (NNRTI) that has the most common treatment limiting side effect of rash. "	( Sex differences in nevirapine rash. Aberg, JA; Bersoff-Matcha, SJ; Hamrick, HJ; Miller, WC; Mundy, LM; Powderly, WG; van Der Horst, C, 2001)	2.08
"Nevirapine is a non-nucleoside reverse transcriptase inhibitor widely used in combination with other antiretroviral agents for the treatment of HIV infection. "	( Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine. Farmer, KL; Hebert, AA; Lahart, CJ; Metry, DW, 2001)	2
"Nevirapine is an antiretroviral agent belonging to the class of non-nucleoside reverse transcriptase inhibitors. "	( Simple and rapid determination of nevirapine in human serum by reversed-phase high-performance liquid chromatography. Gomez, MR; Lopez, RM; Monterde, J; Pou, L; Ruiz, I, 2001)	2.03
"Nevirapine is a non-nucleoside HIV reverse transcriptase inhibitor."	( Nevirapine: ethical dilemmas and care for HIV-infected mothers. Benson, M; Shannon, M, 1995)	2.46
"Nevirapine is a nonnucleoside reverse transcription inhibitor that is used as part of highly active antiretroviral therapeutic combinations. "	( Jaundice and hepatocellular damage associated with nevirapine therapy. Bonacini, M; Poreddy, V; Prakash, M; Tiyyagura, L, 2001)	2.01
"Nevirapine (BI-RG-587) is a potent and specific non-nucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase. "	( Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase. Adams, J; Cohen, KA; Hopkins, J; Ingraham, RH; Kinkade, P; Palladino, DE; Pargellis, C; Rogers, S; Warren, TC; Wu, JC, 1991)	1.99

Excerpt	Reference	Relevance
"Nevirapine has an exceptional record for long-term tolerability with few side effects in human immunodeficiency virus (HIV) combined antiretroviral therapy (cART). "	( Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management? Bregenzer, A; Kahlert, CR; Notter, J; Vernazza, P, 2019)	3.4
"Nevirapine has a short and limited inductive effect on rilpivirine metabolism, which is not clinically significant. "	( Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects. Allavena, C; André-Garnier, E; Billaud, E; Bonnet, B; Bouchez, S; Bouquié, R; Boutoille, D; Dailly, E; Pineau, S; Raffi, F; Raveleau, A; Reliquet, V, 2014)	2.11
"Nevirapine has a half life for enantiomerisation at room temperature of the order of seconds, is not atropisomeric, and cannot exist as separable enantiomers."	( Is nevirapine atropisomeric? Experimental and computational evidence for rapid conformational inversion. Burke, EW; Clayden, J; Hillier, IH; Morris, GA; Vincent, MA, 2012)	1.72
"Nevirapine has a beneficial effect on the lipid profile in both treatment-naive and -experienced patients."	( Nevirapine in the treatment of HIV. Martínez, E; Milinkovic, A, 2004)	2.49
"Nevirapine has a long half-life and achieves high steady-state plasma concentrations relative to the concentration required to inhibit 50% viral replication in vitro (IC(50)) in patients."	( Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. Cooper, CL; van Heeswijk, RP, 2007)	1.45
"Nevirapine has been proved to suppress tumor growth and induce differentiation in several tumor cells, but has not previously been evaluated in metastasis of thyroid cancer."	( Nevirapine inhibits migration and invasion in dedifferentiated thyroid cancer cells. Dong, J; Liao, L; Shang, H; Wang, H; Wang, S; Yao, J; Zhao, J, 2019)	2.68
"Nevirapine has been used as antiretroviral agent since early '90. "	( Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. Cattaneo, D; Cheli, S; Clementi, E; Di Cristo, V; Falvella, FS; Galli, M; Giacomelli, A; Lupo, A; Oreni, ML; Renisi, G; Ridolfo, AL; Riva, A; Rusconi, S, 2018)	2.12
"Nevirapine has an exceptional record for long-term tolerability with few side effects in human immunodeficiency virus (HIV) combined antiretroviral therapy (cART). "	( Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management? Bregenzer, A; Kahlert, CR; Notter, J; Vernazza, P, 2019)	3.4
"Nevirapine has a short and limited inductive effect on rilpivirine metabolism, which is not clinically significant. "	( Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects. Allavena, C; André-Garnier, E; Billaud, E; Bonnet, B; Bouchez, S; Bouquié, R; Boutoille, D; Dailly, E; Pineau, S; Raffi, F; Raveleau, A; Reliquet, V, 2014)	2.11
"Nevirapine has low solubility, an acid medium being the most appropriate medium for assessing the release of the drug from dosage forms."	( Compatibility studies of nevirapine in physical mixtures with excipients for oral HAART. de Oliveira, GG; Ferraz, HG; Severino, P; Souto, EB, 2013)	1.41
"Nevirapine has a half life for enantiomerisation at room temperature of the order of seconds, is not atropisomeric, and cannot exist as separable enantiomers."	( Is nevirapine atropisomeric? Experimental and computational evidence for rapid conformational inversion. Burke, EW; Clayden, J; Hillier, IH; Morris, GA; Vincent, MA, 2012)	1.72
"Nevirapine has a beneficial effect on the lipid profile in both treatment-naive and -experienced patients."	( Nevirapine in the treatment of HIV. Martínez, E; Milinkovic, A, 2004)	2.49
"Nevirapine has a long half-life and achieves high steady-state plasma concentrations relative to the concentration required to inhibit 50% viral replication in vitro (IC(50)) in patients."	( Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. Cooper, CL; van Heeswijk, RP, 2007)	1.45
"Nevirapine has been widely used in pregnancy for its efficacy, low pill burden, bioavailability and rapid transplacental transfer. "	( Safety of nevirapine in pregnancy. Anderson, J; de Ruiter, A; Edwards, SG; Hay, P; McDonald, C; Natarajan, U; Pym, A; Taylor, GP; Velisetty, P; Welch, J, 2007)	2.18
"Nevirapine resistance has been detected in a considerable proportion of women after single-dose nevirapine (SD-NVP) for the prevention of mother-to-child human immunodeficiency virus-1 transmission. "	( Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter? Eshleman, SH; Kourtis, AP; McConnell, MS; Stringer, JS; Weidle, PJ, 2007)	2.11
"Nevirapine has shown antiretroviral efficacy as part of combination therapy with zidovudine and either didanosine or lamivudine in small numbers of paediatric patients in phase I/II trials."	( Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection. Bardsley-Elliot, A; Perry, CM, )	2.3
"Nevirapine has been associated with a skin rash in 32 to 48% of patients."	( Jaundice and hepatocellular damage associated with nevirapine therapy. Bonacini, M; Poreddy, V; Prakash, M; Tiyyagura, L, 2001)	1.28

Excerpt	Reference	Relevance
"Nevirapine (NVP) can cause serious skin rashes and hepatotoxicity. "	( Identification of danger signals in nevirapine-induced skin rash. Sharma, AM; Uetrecht, J; Zhang, X, 2013)	2.11
"Nevirapine treatment can cause a skin rash. "	( A study of the specificity of lymphocytes in nevirapine-induced skin rash. Chen, X; Gou, H; Mannargudi, B; Tharmanathan, T; Uetrecht, JP, 2009)	2.06
"Nevirapine did not inhibit hydroxylation of tolbutamide (CYP2C9) or S-mephenytoin (CYP2C19), but these CYP isoforms were importantly inhibited by delavirdine and efavirenz."	( Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. Daily, JP; Duan, SX; Giancarlo, GM; Granda, BW; Greenblatt, DJ; Harmatz, JS; Shader, RI; von Moltke, LL, 2001)	1.03

Excerpt	Reference	Relevance
"Nevirapine (NVP) treatment is associated with a significant incidence of skin rash in humans, and it also causes a similar immune-mediated skin rash in Brown Norway (BN) rats. "	( 12-OH-nevirapine sulfate, formed in the skin, is responsible for nevirapine-induced skin rash. Novalen, M; Sharma, AM; Tanino, T; Uetrecht, JP, 2013)	2.31
"Nevirapine (0-250 µM) treatment caused a slight increase in the amount of lactate dehydrogenase released into the medium."	( Differential responses of human hepatocytes to the non-nucleoside HIV-1 reverse transcriptase inhibitor nevirapine. Beland, FA; Fang, JL, 2013)	1.33
"Nevirapine treated cells strongly accumulated SA-b-Gal activity and also expressed increased levels of p53 and p21 when analyzed via RT-PCR."	( Nevirapine induces growth arrest and premature senescence in human cervical carcinoma cells. Anastasiadou, V; Antsaklis, A; Kiapekou, E; Loutradis, D; Nikas, V; Patris, G; Rodolakis, A; Stefanidis, K; Vassiliou, LV; Vlachos, G, 2008)	2.51
"Nevirapine treatment can cause a skin rash. "	( A study of the specificity of lymphocytes in nevirapine-induced skin rash. Chen, X; Gou, H; Mannargudi, B; Tharmanathan, T; Uetrecht, JP, 2009)	2.06
"Nevirapine treatment was stopped and was substituted with efavirenz: the patient continued on therapy with tenofovir and lamivudine."	( Hyperhidrosis related to nevirapine therapy. Belda, A; Borrás-Blasco, J; Casterá, E; Jiménez, I; López-Montes, L; Rosique-Robles, D, 2012)	1.4
"Nevirapine (NVP) treatment is associated with a significant incidence of liver injury. "	( Bioactivation of nevirapine to a reactive quinone methide: implications for liver injury. Hayes, MA; Li, Y; Novalen, M; Sharma, AM; Uetrecht, J, 2012)	2.16
"Nevirapine (NVP) treatment is associated with serious skin rashes that appear to be immune-mediated. "	( Nevirapine bioactivation and covalent binding in the skin. Klarskov, K; Sharma, AM; Uetrecht, J, 2013)	3.28
"Nevirapine, used for the treatment of HIV infection, is associated with development of skin rash and liver toxicity. "	( Study of the sequence of events involved in nevirapine-induced skin rash in Brown Norway rats. Caswell, JL; Mannargudi, B; Popovic, M; Shenton, JM; Uetrecht, JP, 2006)	2.04
"Nevirapine-treated babies were tested after 15 months of age, and two of 13 HIV-exposed infants had a positive rapid HIV antibody test (15.3% transmission rate with treatment)."	( Birth attendants trained in "Prevention of Mother-To-Child HIV Transmission" provide care in rural Cameroon, Africa. Diom, E; Meyer, DJ; Mitchell, P; Tih, PM; Wanyu, B, )	0.85
"Mass treatment of nevirapine would increase access to antiretroviral drugs among pregnant women because they can access nevirapine without volunteer counseling and testing, which 31% of pregnant women in developing countries refused to accept due to the fear of stigmatization."	( Mass treatment with nevirapine to prevent mother-to-child transmission of HIV/AIDS in sub-Saharan African countries. Hashimoto, H; Kapiga, SH; Murata, Y, 2002)	0.96
"When treated with nevirapine, Brown Norway rats developed red ears on about day 7 and skin rash on about day 21."	( Study of the sequence of events involved in nevirapine-induced skin rash in Brown Norway rats. Caswell, JL; Mannargudi, B; Popovic, M; Shenton, JM; Uetrecht, JP, 2006)	0.92

Excerpt	Reference	Relevance
" Drug-related adverse events were similar in adults and children, with rash and nausea most frequently reported in adults and rash and granulocytopenia most frequently reported in children."	( Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Dransfield, K; Pollard, RB; Robinson, P, )	0.47
"The number and type of adverse events; nevirapine concentrations in the plasma and breast milk; maternal plasma HIV-1 RNA copy number before and up to 6 weeks after delivery; and HIV-1 infection status of the infants were monitored."	( A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). Allen, M; Bagenda, D; Dransfield, K; Elliott, T; Fleming, T; Fowler, MG; Guay, LA; Hom, D; Horton, S; Jackson, JB; Mirochnick, M; Mmiro, F; Mofenson, L; Murarka, A; Musoke, P; Nakabiito, C; Pav, JW, 1999)	0.82
"Nevirapine was well tolerated by women and infants; no serious adverse events that were related to nevirapine were observed."	( A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). Allen, M; Bagenda, D; Dransfield, K; Elliott, T; Fleming, T; Fowler, MG; Guay, LA; Hom, D; Horton, S; Jackson, JB; Mirochnick, M; Mmiro, F; Mofenson, L; Murarka, A; Musoke, P; Nakabiito, C; Pav, JW, 1999)	1.99
"Eight patients who were infected with human immunodeficiency virus, and who had each sustained an adverse drug reaction while following a regimen including nevirapine, were switched to a regimen including efavirenz."	( The tolerability of efavirenz after nevirapine-related adverse events. Barry, M; Clarke, S; Harrington, P; Mulcahy, F, 2000)	0.78
"(1) Introduce nevirapine at half the target dose, and monitor the skin, mucous membranes and liver to avoid fatal adverse effects."	( Severe hepatic and cutaneous adverse effects with nevirapine. , 2000)	0.92
" To characterize NVP-associated PEP toxicity, CDC and the Food and Drug Administration (FDA) reviewed MedWatch reports of serious adverse events in persons taking NVP for PEP received by FDA (Figure 1)."	( Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000. , 2001)	0.58
"Cutaneous and hepatic adverse reactions and clinical hepatitis were assessed."	( Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. Arnaiz, JA; Blanco, JL; Carné, X; Cruceta, A; García-Viejo, MA; Gatell, JM; Mallolas, J; Marcos, MA; Martínez, E; Milinkovic, A; Mocroft, A; Pérez-Cuevas, JB; Phillips, A, 2001)	0.56
" Three patients discontinued therapy for drug-related adverse events."	( Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. Benson, CA; Brun, SC; Deeks, SG; Eron, JJ; Feinberg, J; Gulick, RM; Hicks, C; Hsu, A; Japour, AJ; Kempf, D; Kessler, HA; King, M; Murphy, RL; Real, K; Riddler, S; Sax, PE; Stryker, R; Sun, E; Thompson, M; Wheeler, D, 2002)	0.55
" All other patients have been taking nevirapine for more than 3 months without any adverse reaction."	( Long-term safety and efficacy of nevirapine tolerance induction. Bousquet, J; Demoly, P; Fabre, J; Messaad, D; Reynes, J, 2002)	0.87
" No significant differences were detected between the treatment groups in virological or immunological response or cessation of study drugs due to adverse events, although it is possible that the study was underpowered to detect differences."	( Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study. Amin, J; Carr, A; Cooper, D; Drummond, F; Emery, S; French, M; Law, M; Roth, N, )	0.33
"Simplification is safe and effective, but it should be offered to patients with shorter treatment duration, and in good clinical and immunovirological conditions."	( Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. Adorni, F; Bini, T; Bongiovanni, M; Capetti, A; Castelnuovo, B; Chiesa, E; Cicconi, P; d'Arminio Monforte, A; Faggion, I; Melzi, S; Mussini, C; Rizzardini, G; Rusconi, S; Sollima, S; Tordato, F, 2003)	0.55
"Antiretroviral therapy is associated with serious adverse events."	( Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. Boswell, H; Fan-Havard, P; Knudtson, E; Para, M, 2003)	0.54
"The A/S/D regimen had a low efficacy and a high frequency of adverse events and cannot be recommended."	( Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. Gerstoft, J; Katzenstein, TL; Kirk, O; Lundgren, JD; Mathiesen, L; Nielsen, H; Obel, N; Pedersen, C, 2003)	0.32
" Using the recommended lead-in dosing schedule in conjunction with good health care management, this adverse event can be controlled in the vast majority of patients."	( Defining the toxicity profile of nevirapine and other antiretroviral drugs. Murphy, RL, 2003)	0.6
" Our data indicate that NVP prophylaxis for 6 months was safe and well tolerated in infants."	( Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. Abdool Karim, SS; Bassett, MT; Coovadia, HM; Emel, L; Eshleman, SH; Fleming, T; George, K; Jones, SA; Katzenstein, DA; Maldonado, Y; Maponga, CC; Mirochnick, MM; Mofenson, LM; Mwatha, A; Shetty, AK; Wells, J, 2003)	0.59
" Assessment consisted of CD4+ cell count, plasma HIV-1 RNA load, and adverse effects of study medications."	( Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection. Carroll, H; Conlon, V; Green, A; Green, DC; Green, R; Jefferson, R; Jordan, WC; Tolbert, L; Yemofio, F, 2003)	1.76
"In HIV-infected women receiving prenatal care and ART, adverse events were uncommon."	( Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. Balasubramanian, R; Culnane, M; Cunningham, CK; Delfraissy, JF; Delke, I; Dorenbaum, A; Fiore, S; Gelber, RD; Maupin, RT; Mofenson, LM; Newell, ML; Watts, DH, 2004)	0.32
" The one adverse event associated with nelfinavir occurred in a subject with a CD4 cell count less than 250 cells/microL."	( Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. Baker, D; Foca, M; Frenkel, LM; Gandia, J; Gonzalez-Garcia, A; Hitti, J; Huang, S; McNamara, J; Nachman, SA; Paul, ME; Provisor, A; Stek, AM; Stevens, LM; Thorpe, EM; Watts, DH; Wei, LJ, 2004)	0.6
"5), severe adverse effects 17."	( Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Andrieux-Meyer, I; Bourgeois, A; Calmy, A; Delaporte, E; Kazatchkine, M; Kouanfack, C; Koulla-Shiro, S; Lactuock, B; Laurent, C; Liégeois, F; Mougnutou, R; Mpoudi-Ngolé, E; Nerrienet, E; Nkoué, N; Nzeusseu, V; Peeters, M; Peytavin, G; Tardy, M; Zekeng, L, )	0.37
" Twelve subjects in the QD Group (14%) discontinued treatment due to adverse events, mainly nevirapine-related hepatitis (6%)."	( Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. Burger, D; Clotet, B; Galindos, MJ; Gel, S; Miralles, C; Moltó, J; Muñoz-Moreno, JA; Negredo, E; Pedrol, E; Puig, J; Ribera, E; Rodriguez Fumaz, C; Rodríguez, E; Ruiz, L; Viciana, P; Videla, S, 2004)	0.79
"The switching of a PI to nevirapine is a safe and well-tolerated option for maintaining long-term virological suppression and immunological control."	( Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load. Arranz, A; de Górgolas, M; Estrada, V; Fernández-Guerrero, M; García, R; Gil, P; Granizo, JJ; Rivas, P; Yera, C, 2004)	0.86
" However, its use has recently been limited because of adverse cutaneous and hepatic effects."	( Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine. Krivoy, N; Pollack, S; Shahar, E; Weltfriend, S, 2004)	0.55
" The incidence of rash in the NVP group was significantly higher in female patients with higher CD4 cell counts, while adverse events in the EFV group were not associated with CD4 cell count."	( The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. Andrews, S; Grinsztejn, B; Lange, JM; Lazanas, MK; Montaner, J; van Leth, F; Wilkins, E, 2005)	0.55
" These data have now provided a clear and clinically relevant understanding of the individual profiles of drugs within the nucleoside analogue reverse transcriptase inhibitor , HIV protease inhibitor and non-nucleoside analogue reverse transcriptase inhibitor drug classes, and have provided a rational basis for assessing and monitoring these adverse effects in clinical practice."	( Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Mallal, S; Nolan, D; Reiss, P, 2005)	0.33
" Based on current knowledge, the immense benefits of antiretroviral prophylaxis in reducing the risk of MTCT, far outweigh the potential for adverse effects."	( The safety of antiretroviral drugs in pregnancy. Newell, ML; Thorne, C, 2005)	0.33
"In 15 centres specializing in HIV in The Netherlands, data on patient characteristics, HAART, adverse events, viral load response, mode of delivery and HIV status of the neonate were obtained from medical records of HIV-infected pregnant women who received HAART during pregnancy between January 1997 and June 2003."	( Nelfinavir and nevirapine side effects during pregnancy. Boer, K; de Wolf, F; Dieleman, J; Godfried, MH; Nellen, J; Schneider, ME; Sprenger, H; Tempelman, C; Timmermans, S; van der Ende, ME, 2005)	0.68
" No major adverse events occurred."	( Nelfinavir and nevirapine side effects during pregnancy. Boer, K; de Wolf, F; Dieleman, J; Godfried, MH; Nellen, J; Schneider, ME; Sprenger, H; Tempelman, C; Timmermans, S; van der Ende, ME, 2005)	0.68
"The relationships between adverse events (AEs) and plasma concentrations of nevirapine (NVP) and efavirenz (EFV) were investigated as part of the large, international, randomized 2NN study."	( Are adverse events of nevirapine and efavirenz related to plasma concentrations? Baraldi, E; Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Montella, F; Robinson, PA; Russell, DB; Thompson, MA; Uip, DE; van Leth, F, 2005)	0.87
"To compare the adverse events after initiation of NVP-based ART among HIV-infected patients who did not receive fluconazole (group A), received fluconazole 400 mg/week (group B), and received fluconazole 200 mg/day (group C)."	( Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study. Chaovavanich, A; Chumpathat, N; Manosuthi, W; Sungkanuparph, S, 2005)	0.63
"Initiation of NVP-based ART among Thais with advance HIV disease receiving fluconazole is safe and well-tolerated."	( Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study. Chaovavanich, A; Chumpathat, N; Manosuthi, W; Sungkanuparph, S, 2005)	0.63
" Therapy was discontinued in 18 patients due to virological failure in 11, adverse events in seven, loss to follow-up or withdrawal of consent in four and death in one."	( Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients. Blanco, JL; Crespo, M; Deig, E; Falcó, V; González, A; Miró, JM; Ocaña, I; Pahissa, A; Pedrol, E; Ribera, E; Rodríguez-Pardo, D; Rubio, M; Soler, A, 2005)	0.55
"A once-daily combination of ddI, 3TC and NVP seems to be an effective, safe and easy-to-take regimen in antiretroviral-naive patients, at least in those who do not have severe immunodepression at baseline."	( Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients. Blanco, JL; Crespo, M; Deig, E; Falcó, V; González, A; Miró, JM; Ocaña, I; Pahissa, A; Pedrol, E; Ribera, E; Rodríguez-Pardo, D; Rubio, M; Soler, A, 2005)	0.55
" Clinical assessment included plasma HIV-1 RNA, blood chemistry, haematology, lymphocyte counts and adverse events reports."	( A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load. Arranz Caso, JA; Castilla, V; Estrada, V; Fernández Guerrero, M; Górgolas, M; López, JC; Molina, JP; Santos, I; Sanz, J, 2005)	0.54
"Nevirapine-based therapy is associated with increased frequency of adverse events among women with CD4+ cell count of 250 cells/microL or greater."	( Third-trimester maternal toxicity with nevirapine use in pregnancy. Brady, MT; Fan-Havard, P; Hughes, L; Joy, S; Koletar, SL; Para, MF; Poi, M, 2005)	2.04
" The incidence of adverse events was determined and analyzed by CD4+ cell count of either less than or greater than or equal to 250 cells/microL, and gestational age when nevirapine was initiated."	( Third-trimester maternal toxicity with nevirapine use in pregnancy. Brady, MT; Fan-Havard, P; Hughes, L; Joy, S; Koletar, SL; Para, MF; Poi, M, 2005)	0.79
" All 3 cases of adverse events occurred in this group within 6 weeks of initiating therapy and with CD4+ cell count greater than 250 cells/microL."	( Third-trimester maternal toxicity with nevirapine use in pregnancy. Brady, MT; Fan-Havard, P; Hughes, L; Joy, S; Koletar, SL; Para, MF; Poi, M, 2005)	0.6
"The incidence of adverse events with nevirapine may be lower than previously reported (13% versus 29%) and may be primarily noted with initiating the drug late in pregnancy."	( Third-trimester maternal toxicity with nevirapine use in pregnancy. Brady, MT; Fan-Havard, P; Hughes, L; Joy, S; Koletar, SL; Para, MF; Poi, M, 2005)	0.87
" Several observational studies have described a higher frequency of antiretroviral-related adverse effects among women compared with men."	( Sex differences in antiretroviral therapy-associated intolerance and adverse events. Clark, R, 2005)	0.33
" Multivariate logistic regression was used to test independent association of CD4 and hepatitis C virus (HCV) infection related to the outcome of toxic effects of NVP."	( Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. Calvet, GA; Cruz, ML; D'Ippolito, MM; João, EC; Matos, HJ; Menezes, JA; Salgado, LA, 2006)	1.78
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
"7% of all adverse events reported during the investigation were attributable to NVP."	( Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. Bonjoch, A; Cervantes, M; Cinquegrana, D; Clotet, B; Cucurull, J; Dalmau, D; Domingo, P; Force, L; Llibre, JM; Masabeu, A; Mascaró, J; Paredes, R; Pedrol, E; Pérez-Alvarez, N; Puig, J; Ribera, E; Vilaró, J, 2006)	0.62
" This is a retrospective analysis of virologic efficacy and changes in adverse neuropsychiatric effects and serum lipid levels after this switch."	( Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. Curtin, JM; Ward, DJ, 2006)	0.64
"To assess the incidence and consequences of adverse reactions among African HIV-positive pregnant women treated with fixed-dose combinations of a nevirapine-containing antiretroviral (ARV) triple therapy."	( Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. da Cruz Gomes, A; Germano, P; Guidotti, G; Liotta, G; Loureiro, S; Mancinelli, S; Marazzi, MC; Narciso, P; Palombi, L; Perno, CF; Valls Blazquez, MC, 2006)	0.94
" Multivariate analysis to assess the impact of several factors on the adverse reaction rate was performed."	( Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. da Cruz Gomes, A; Germano, P; Guidotti, G; Liotta, G; Loureiro, S; Mancinelli, S; Marazzi, MC; Narciso, P; Palombi, L; Perno, CF; Valls Blazquez, MC, 2006)	0.74
"Nevirapine-containing regimens in pregnant woman, at all CD4 cell count levels, appear to be safe in African settings."	( Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. da Cruz Gomes, A; Germano, P; Guidotti, G; Liotta, G; Loureiro, S; Mancinelli, S; Marazzi, MC; Narciso, P; Palombi, L; Perno, CF; Valls Blazquez, MC, 2006)	2.18
" Unfortunately, its adverse effects, mainly hypersensitivity skin reactions and hepatotoxicity, have hampered the use of nevirapine."	( RAT CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity. Abraham, AM; Barr, S; Walubo, A, 2006)	0.8
"Liver toxicity is one of the most relevant adverse effects of antiretroviral therapy."	( Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. Mira, JA; Pineda, JA; Rivero, A, 2007)	0.34
" The objectives were to compare NVP levels, adverse events, and 36-week efficacy of NVP-based ART between patients who did not receive FLU (group A) and those who received FLU 200 mg/day or 400 mg/day (group B)."	( Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. Athichathanabadi, C; Manosuthi, W; Phoorisri, T; Sungkanuparph, S; Uttayamakul, S, 2007)	0.79
" Neutropenia (usually transient) was the most common severe adverse event."	( Safety of HIV-1 Perinatal Transmission Prophylaxis With Zidovudine and Nevirapine in Rural South India. Bethel, J; Dharmarajan, S; Jacob, SM; Junankar, V; Parameshwari, S; Read, JS; Samuel, NM; Stoszek, SK; Van Hook, HM; Xu, J, 2007)	0.57
" All papers, abstracts, or presentations, regardless of study design, that made reference to the response of patients who were switched from one NNRTI to another as a result of an adverse drug reaction were included."	( Is it safe to switch between efavirenz and nevirapine in the event of toxicity? Maartens, G; Mehta, U, 2007)	0.6
" Therefore, it is important to monitor adverse events from NVP, including liver function tests among HIV/AIDS patients with history of drug allergy, especially against sulfamethoxazole, and those concurrently treated with antituberculosis drugs."	( Predisposing factors for nevirapine toxicity among AIDS patients with low baseline CD4 count. Aung, SE; Kaewkungwal, J; Maek-a-nantawat, W; Phonrat, B; Pitisuttithum, P; Tansuphaswadikul, S, )	0.43
"The aim of this article is to present the clinical characteristics and management of an oral adverse effect stemming from the use of the antiretroviral medication Nevirapine (NVP)."	( Oral adverse effects due to the use of Nevirapine. Fonseca, LM; Madureira, DF; Mesquita, RA; Moura, MD; Senna, MI, 2008)	0.81
" From 1996 to 2002 several medications were changed due to their adverse effects: indinavir (renal colic and fever), nelfinavir (cutaneous rash), and efavirenz (nausea and temporary memory loss)."	( Oral adverse effects due to the use of Nevirapine. Fonseca, LM; Madureira, DF; Mesquita, RA; Moura, MD; Senna, MI, 2008)	0.62
"Unfortunately, the clinical features of the oral adverse effect from NVP are not well known."	( Oral adverse effects due to the use of Nevirapine. Fonseca, LM; Madureira, DF; Mesquita, RA; Moura, MD; Senna, MI, 2008)	0.62
"Transmission prophylaxis in offspring of HIV-positive mothers may give rise to adverse effects."	( [Side effects of antiretroviral treatment for transmission prophylaxis in preterm and near-term infants]. Bauer, K; Dunsch, D; Haberl, A; Linde, R; Reitter, A; Schlösser, R, 2007)	0.34
"HIV-infected women on selected ARV regimens or no ARV were administered DMPA 150 mg intramuscularly and evaluated for 12 weeks for adverse events, changes in CD4+ count and HIV RNA levels, and ovulation."	( Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Clax, PA; Cohn, SE; Hitti, J; Lertora, JJ; Muderspach, L; Park, JG; Stek, A; Watts, DH; Yu, S, 2008)	0.35
" Nine Grade 3 or 4 adverse events occurred in seven subjects; none were judged related to DMPA."	( Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Clax, PA; Cohn, SE; Hitti, J; Lertora, JJ; Muderspach, L; Park, JG; Stek, A; Watts, DH; Yu, S, 2008)	0.35
" The primary endpoint was any serious adverse event (SAE) definitely/probably or uncertain whether related to blinded nevirapine/abacavir."	( Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). , 2008)	0.82
"There was a trend towards a lower rate of serious adverse reactions in Ugandan adults with low CD4 starting ARV regimens with abacavir than with nevirapine."	( Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). , 2008)	0.81
"Nevirapine-based therapy is associated with increased frequency of adverse events among HIV-infected pregnant women."	( Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital. Carraro, EA; Cornelsen, TC; Dias, JM; Kondo, W; Macedo, RL; Perini, J; Prandel, E; Sasaki, Md; Sbalquiero, R, 2007)	3.23
" Symptoms disappeared after discontinuation of antiretroviral therapy and we suggest that syncope may be a side effect to one of the three antiretroviral drugs that has not been described previously."	( Syncope as a probable side effect to combination antiretroviral therapy initiated during primary HIV-1 infection. Larsen, CS; Lybaek, D, 2008)	0.35
"To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 HIV-infected individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India."	( Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. Balakrishnan, P; Cecelia, AJ; Devaleenal, B; Flanigan, TP; Kumarasamy, N; Lai, AR; Mayer, KH; Poongulali, S; Saghayam, S; Solomon, S; Venkatesh, KK; Yepthomi, T, 2008)	0.35
"The aim of this study was to measure the cumulative incidence of adverse events (AEs) related to nevirapine in patients switched from efavirenz to immediate full-dose nevirapine (FDN)."	( Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia. Chhneang, V; Fernandez, M; Laureillard, D; Moeung, S; Ngeth, C; Piketty, C; Prak, N; Quillet, C; Riel, V; Song, S, 2008)	0.82
" However, while NVP is a safe treatment in immunocompromised patients, NVP-containing regimens have been associated with severe immune-mediated toxicities in non-HIV individuals."	( Nevirapine toxicity in non-HIV cancer patients. Barone, C; Cignarelli, M; De Vis, K; Fabiano, A; Fersini, A; Landriscina, M; Lombardi, V; Piscazzi, A; Santodirocco, M, 2008)	1.79
" The incidence of adverse hepatic and/or cutaneous effects was determined and correlated to the CD4 cells count."	( [Evaluation of the adverse effects of nevirapine in HIV-infected pregnant women in a South Brazilian University Hospital]. Astori, Ade A; Fernandes, Rde B; Gomes, Sel-K; Kondo, W; Sasaki, Md; Sbalqueiro, RL, 2008)	0.62
" Baseline CD4 counts, viral loads and transaminases were similar in pregnant women with nevirapine adverse effects and those without reaction."	( [Evaluation of the adverse effects of nevirapine in HIV-infected pregnant women in a South Brazilian University Hospital]. Astori, Ade A; Fernandes, Rde B; Gomes, Sel-K; Kondo, W; Sasaki, Md; Sbalqueiro, RL, 2008)	0.84
"The incidence of adverse events with nevirapine in our study was high, but most of them were cutaneous."	( [Evaluation of the adverse effects of nevirapine in HIV-infected pregnant women in a South Brazilian University Hospital]. Astori, Ade A; Fernandes, Rde B; Gomes, Sel-K; Kondo, W; Sasaki, Md; Sbalqueiro, RL, 2008)	0.89
" Sources included adverse event reports from pharmaceutical manufacturers and the US FDA, reports from peer-reviewed journals/scientific meetings and the Research on Adverse Drug events And Reports (RADAR) project."	( Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. Bennett, CL; Chandler, KL; Differding, V; Johnson, S; McKoy, JM; Obadina, E; Palella, F; Parada, JP; Raisch, DW; Scarsi, KK; Scheetz, MH; Sutton, S; Yarnold, PR, 2009)	0.58
" Grade 3-4 adverse events occurred in 3 cases (2 peripheral neuropathy, and 1 suspected lactic acidosis)."	( [Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients]. Chen, Z; Gong, G; He, Y; Liu, C; Liu, M; Yin, W; Zheng, Y; Zhou, H, 2009)	0.35
"Antiretroviral therapy with NVP-based regimens is safe and effective by suppressing HIV viremia and producing continued CD4 cell increases in subjects with HIV or AIDS for 6 years."	( [Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients]. Chen, Z; Gong, G; He, Y; Liu, C; Liu, M; Yin, W; Zheng, Y; Zhou, H, 2009)	0.35
" Hepatitis C virus (HCV) coinfection, adverse events, and reasons for using nevirapine were also recorded."	( Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirapine. Aguirrebengoa, K; Clotet, B; García, MA; Goikoetxea, J; Iribarren, JA; Martínez, E; Muñoz, J; Negredo, E; Perez-Alvarez, N; Portu, J; Rodríguez-Arrondo, F, 2009)	0.8
"Nevirapine is widely used to treat HIV-1 infection to prevent mother-to-child transmission; unfortunately adverse drug reactions have been reported."	( Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Altan, AM; Borgiani, P; Bramanti, P; Ceffa, S; Ciccacci, C; Marazzi, MC; Novelli, G; Palombi, L; Paturzo, G; Sirianni, E, 2010)	3.25
"Patients from Mozambique, 78 with nevirapine-induced hepatotoxicity and 78 without adverse events, were genotyped for ABCB1, CYP2B6, CYP3A4 and CYP3A5 gene variants."	( Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Altan, AM; Borgiani, P; Bramanti, P; Ceffa, S; Ciccacci, C; Marazzi, MC; Novelli, G; Palombi, L; Paturzo, G; Sirianni, E, 2010)	2.08
"In AIDS Clinical Trials Group A5095, 9% of participants who experienced an adverse event related to efavirenz substituted nevirapine."	( Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Gulick, RM; Kmack, A; Krambrink, A; Kuritzkes, DR; Ribaudo, HJ; Schouten, JT; Shikuma, C; Webb, N, 2010)	0.91
"To investigate uptake and provision of antenatal care (ANC) services in the Uzazi Bora project: a demonstration-intervention project for Safe Motherhood and prevention of mother-to-child transmission of HIV in Kenya."	( A Safe Motherhood project in Kenya: assessment of antenatal attendance, service provision and implications for PMTCT. Chersich, MF; Delva, W; Luchters, S; Muigai, E; Oyier, V; Temmerman, M; Yard, E, 2010)	0.36
" However, reports of severe NVP-induced hepatotoxicity and serious adverse cutaneous effects have raised concerns about its use."	( Amino acid adduct formation by the nevirapine metabolite, 12-hydroxynevirapine--a possible factor in nevirapine toxicity. Antunes, AM; Beland, FA; Godinho, AL; Justino, GC; Marques, MM; Martins, IL, 2010)	0.64
"The chewable FDC was safe and provided therapeutically adequate plasma drug exposures in human immunodeficiency virus-infected children."	( A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand. Capparelli, E; Chokephaibulkit, K; Chotpitayasunondh, T; Cressey, TR; Eksaengsri, A; Hongsiriwan, S; McIntosh, K; Muresan, P; Plipat, N; Prasitsuebsai, W; Sirisanthana, V; Smith, ME; Toye, M; Vanprapar, N; Yogev, R, 2010)	0.59
"In resource-limited settings where nevirapine-containing regimen is the preferred regimen in women, data on severe adverse events (SAEs) according to CD4 cell count are limited."	( Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire. Abrams, EJ; Amani-Bosse, C; Bédikou, G; Coffie, PA; Dabis, F; Ekouevi, DK; Tanon, AK; Tonwe-Gold, B, 2010)	0.88
" Despite its clinical efficacy, NVP administration is associated with a variety of toxic responses that include hepatotoxicity and skin rash."	( Protein adducts as prospective biomarkers of nevirapine toxicity. Antunes, AM; Beland, FA; Coelho, AV; Godinho, AL; Gomes, RA; Marques, MM; Martins, IL; Oliveira, MC, 2010)	0.62
"Predictors of adverse events (AE) associated with nevirapine use are needed to better understand reports of severe rash or liver enzyme elevation (LEE) in HIV+ women."	( Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication. Aaron, E; Bachmann, LH; Criniti, S; Gracely, E; Kempf, MC; Kumar, R; Tedaldi, E; Warriner, A, 2010)	0.84
" We analyzed patients' age, gender, HIV transmission route, HIV disease stage, pregnancy, alcohol intake, adverse events, coinfection with hepatitis B or C virus, time until toxicity, and withdrawal rates."	( Nevirapine-associated toxicity in clinical practice in Buenos Aires, Argentina. Antonelli, L; Bottaro, EG; Cassetti, LI; Errea, S; Huberman, MJ; Iannella, Mdel C; Scapellato, PG; Vesperoni, FA, )	1.57
" Rash was the most frequently observed adverse event; it was more frequent in women."	( Nevirapine-associated toxicity in clinical practice in Buenos Aires, Argentina. Antonelli, L; Bottaro, EG; Cassetti, LI; Errea, S; Huberman, MJ; Iannella, Mdel C; Scapellato, PG; Vesperoni, FA, )	1.57
" Multivariate analyses were performed to compare, between the ddI and ZDV groups, the proportion of patients with a viral load <500 copies/ml during follow-up; the increase in the CD4 cell count; survival; treatment changes and severe adverse events."	( Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal. Delaporte, E; Diouf, A; Etard, JF; Girard, PM; Landman, R; Laurent, C; Molinari, N; Ndoye, I; Ngom Guèye, NF; Sow, PS; Tchatchueng Mbougua, JB, 2011)	0.59
"There are few studies from India documenting the adverse effects of generic HAART (Highly Active Anti-retroviral Therapy)."	( Adverse effects after HAART Initiation in resource-limited settings: a prospective study from Mysore, India. Dasegowda, V; Sreenivasan, S, 2010)	0.36
"A prospective study was conducted at Mysore, India, to study the adverse effects after HAART initiation in a cohort of 100 antiretroviral therapy (ART)-naive patients, who were evaluated prospectively every three months by clinical and laboratory monitoring for adverse effects after HAART initiation for one year."	( Adverse effects after HAART Initiation in resource-limited settings: a prospective study from Mysore, India. Dasegowda, V; Sreenivasan, S, 2010)	0.36
" The most common reasons for modifying therapy were development of an adverse effect (eight cases; 57."	( Adverse effects after HAART Initiation in resource-limited settings: a prospective study from Mysore, India. Dasegowda, V; Sreenivasan, S, 2010)	0.36
"A significant proportion of patients had adverse effects of a lower grade severity after HAART."	( Adverse effects after HAART Initiation in resource-limited settings: a prospective study from Mysore, India. Dasegowda, V; Sreenivasan, S, 2010)	0.36
" We characterized relationships between nevirapine-associated cutaneous and hepatic adverse events and genetic variants among HIV-infected adults."	( Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. Cammett, AM; Distel, M; Guo, S; Haas, DW; Hall, D; Huang, Z; Jayadev, S; Mootsikapun, P; Podzamczer, D; Ruxrungtham, K; Storfer, S; Yuan, J, 2011)	0.97
" Cases experienced symptomatic nevirapine-associated severe (grade III/IV) cutaneous and/or hepatic adverse events within 8 weeks of initiating nevirapine."	( Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. Cammett, AM; Distel, M; Guo, S; Haas, DW; Hall, D; Huang, Z; Jayadev, S; Mootsikapun, P; Podzamczer, D; Ruxrungtham, K; Storfer, S; Yuan, J, 2011)	0.99
"We studied 276 evaluable cases (175 cutaneous adverse events, 101 hepatic adverse events) and 587 controls."	( Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. Cammett, AM; Distel, M; Guo, S; Haas, DW; Hall, D; Huang, Z; Jayadev, S; Mootsikapun, P; Podzamczer, D; Ruxrungtham, K; Storfer, S; Yuan, J, 2011)	0.7
"Among patients with at least 150 CD4 T cells/μl, polymorphisms in drug metabolism and immune response pathways were associated with greater likelihood of risk for nevirapine-related adverse events."	( Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. Cammett, AM; Distel, M; Guo, S; Haas, DW; Hall, D; Huang, Z; Jayadev, S; Mootsikapun, P; Podzamczer, D; Ruxrungtham, K; Storfer, S; Yuan, J, 2011)	0.9
" Ten percent (13/123) of the subjects discontinued the treatment due to adverse events."	( Evaluation of the safety and effectiveness of nevirapine plus coformulated tenofovir/emtricitabine as first-line therapy in routine clinical practice. Blanch, J; Cervantes, M; Domingo, P; Ferrer, E; Knobel, H; Llibre, JM; Mallolas, J; Pedrol, E; Vallecillo, G, 2012)	0.64
" The safety profile of NVP XR was similar to NVP IR, but showed numerically fewer treatment-related adverse events."	( Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients. Andrade-Villanueva, J; Bogner, J; Cahn, P; Drulak, M; Gathe, J; Horban, A; Nelson, M; Nguyen, T; Podzamczer, D; Quinson, AM; Santiago, S; Spencer, D; Yong, CL; Zhang, W, 2011)	0.68
"NVP XR in combination with TDF and emtricitabine was shown to be non-inferior in efficacy to NVP IR with a similar safety and adverse event profile, with the potential for the added convenience of once-daily dosing."	( Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients. Andrade-Villanueva, J; Bogner, J; Cahn, P; Drulak, M; Gathe, J; Horban, A; Nelson, M; Nguyen, T; Podzamczer, D; Quinson, AM; Santiago, S; Spencer, D; Yong, CL; Zhang, W, 2011)	0.68
" Similarly, the proportion of serious adverse events in the HIVIGLOB/sdNVP and sdNVP arms, respectively, for mothers (18."	( Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). Antelman, G; Falksveden, L; Fowler, MG; Guay, L; Jackson, JB; Mmiro, F; Moulton, LH; Mubiru, M; Musoke, P; Nakabiito, C; Omer, SB; Onyango-Makumbi, C; Wahren, B; Wigzell, H; Zwerski, S, 2011)	0.37
"Giving mother-infant pairs an infusion of peripartum HIV hyperimmune globulin in addition to sdNVP for preventing maternal-to-child transmission was as safe as sdNVP alone but was no more effective than sdNVP alone in preventing HIV transmission."	( Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). Antelman, G; Falksveden, L; Fowler, MG; Guay, L; Jackson, JB; Mmiro, F; Moulton, LH; Mubiru, M; Musoke, P; Nakabiito, C; Omer, SB; Onyango-Makumbi, C; Wahren, B; Wigzell, H; Zwerski, S, 2011)	0.37
" Primary outcome was a composite of death, virological failure, default, or serious adverse event (SAE) at 24 weeks."	( Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Bhavani, PK; Dilip, M; Iliayas, S; Menon, PA; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Pooranagangadevi, NP; Ramachandran, R; Ramesh Kumar, S; Selvaraju, S; Swaminathan, S; Venkatesan, P, 2011)	0.65
" Frequency of adverse events (AEs) was similar between arms, with 88."	( A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients. Bhatti, L; Conner, C; Dejesus, E; Mills, A; Storfer, S, 2011)	0.62
" Adverse events (AEs) were recorded."	( Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION). Arasteh, K; Cordes, C; Guo, J; Livrozet, JM; Orkin, C; Plettenberg, A; Quinson, A; Robinson, P; Wang, E; Ward, D; Yong, CL, 2012)	0.59
" The primary efficacy endpoint was HIV-1 infection in infants at 6 months and safety endpoints were adverse reactions in both groups."	( Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Andrew, P; Brown, ER; Chetty, V; Chipato, T; Coovadia, HM; Eshleman, SH; Fawzi, W; Fowler, MG; George, K; Guay, L; Kisenge, R; Lynn, DJ; Maldonado, Y; Manji, K; Mofenson, LM; Moodley, D; Msweli, L; Musoke, P; Mwatha, A; Nakabiito, C; Richardson, P; Stranix-Chibanda, L; Zwerski, S, 2012)	0.66
" 125 (16%) of 758 infants given extended nevirapine and 116 (15%) of 761 controls had serious adverse events, but frequency of adverse events, serious adverse events, and deaths did not differ significantly between treatment groups."	( Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Andrew, P; Brown, ER; Chetty, V; Chipato, T; Coovadia, HM; Eshleman, SH; Fawzi, W; Fowler, MG; George, K; Guay, L; Kisenge, R; Lynn, DJ; Maldonado, Y; Manji, K; Mofenson, LM; Moodley, D; Msweli, L; Musoke, P; Mwatha, A; Nakabiito, C; Richardson, P; Stranix-Chibanda, L; Zwerski, S, 2012)	0.92
" The ultimate goal is to develop diagnostic methods for predicting the onset of nevirapine-induced toxic reactions."	( Evidence for nevirapine bioactivation in man: searching for the first step in the mechanism of nevirapine toxicity. Antunes, AM; Branco, T; Caixas, U; Godinho, AL; Grilo, NM; Marinho, AT; Marques, MM; Monteiro, EC; Oliveira, MC; Pereira, SA, 2012)	0.98
"We compared adverse events among breast-feeding neonates born to Kenyan mothers receiving triple-antiretroviral therapy, including either nevirapine or nelfinavir."	( Rash, hepatotoxicity and hyperbilirubinemia among Kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission. Akoth, B; Angira, F; Masaba, R; Mills, LA; Minniear, TD; Ndivo, R; Oyaro, B; Peters, PJ; Polle, N; Thomas, TK; Zeh, C, 2012)	0.58
"Hepatotoxicity was a common adverse effect of NVP among men and women with CD4 >250 cells per microliter."	( The interaction of CD4 T-cell count and nevirapine hepatotoxicity in China: a change in national treatment guidelines may be warranted. Ghanem, KG; Guo, F; Han, Y; Li, T; Li, Y; Qiu, Z; Wang, H; Wang, W; Xie, J; Zhang, C; Zhou, M, 2013)	0.66
"The risk of adverse drug events associated with nevirapine (NVP) is suggested to be greater in pregnant women."	( Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis. Andrieux-Meyer, I; Calmy, A; Ford, N; Hargreaves, S; Mills, EJ; Shubber, Z, 2013)	0.93
"We searched six databases for studies reporting adverse events among HIV-positive pregnant women who had received NVP-based antiretroviral therapy for at least 7 days."	( Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis. Andrieux-Meyer, I; Calmy, A; Ford, N; Hargreaves, S; Mills, EJ; Shubber, Z, 2013)	0.68
"3%) of patients discontinued NVP due to an adverse event."	( Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis. Andrieux-Meyer, I; Calmy, A; Ford, N; Hargreaves, S; Mills, EJ; Shubber, Z, 2013)	0.68
"These results suggest that the frequency of adverse events associated with NVP use in pregnant women, although high, is no higher than reported for NVP in the general adult population."	( Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis. Andrieux-Meyer, I; Calmy, A; Ford, N; Hargreaves, S; Mills, EJ; Shubber, Z, 2013)	0.68
"We systematically reviewed adverse events among treatment-naive HIV-positive adults and children receiving either NVP or EFV as part of first-line antiretroviral therapy."	( Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. Andrieux-Meyer, I; Calmy, A; Ford, N; Hargreaves, S; Mills, EJ; Renaud-Théry, F; Shaffer, N; Shubber, Z; Vitoria, M, 2013)	0.68
"Compared to NVP, EFV is associated with a lower frequency of severe adverse events, in particular treatment discontinuations."	( Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. Andrieux-Meyer, I; Calmy, A; Ford, N; Hargreaves, S; Mills, EJ; Renaud-Théry, F; Shaffer, N; Shubber, Z; Vitoria, M, 2013)	0.68
" Pressure of work and insufficient perceived benefit of side-effect recording are suspected causes."	( Underreporting of side effects of standard first-line ART in the routine setting in Blantyre, Malawi. Lungu, M; Mathews, T; Tapsfield, J; van Oosterhout, JJ, 2011)	0.37
"Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used in the treatment of HIV infections and has been reported to be toxic to the male reproductive system."	( Nevirapine induces testicular toxicity in Wistar rats: reversal effect of kolaviron (biflavonoid from Garcinia kola seeds). Adaramoye, OA; Akanni, OO; Farombi, EO, 2013)	3.28
" In contrast, NVP-2T did not produce an adverse effect on the biochemical indices studied in testes and sperm of rats."	( Nevirapine induces testicular toxicity in Wistar rats: reversal effect of kolaviron (biflavonoid from Garcinia kola seeds). Adaramoye, OA; Akanni, OO; Farombi, EO, 2013)	1.83
"Taken together, KV reversed the adverse effects of NVP-4T on testicular antioxidant enzymes and markers of oxidative stress in the rats."	( Nevirapine induces testicular toxicity in Wistar rats: reversal effect of kolaviron (biflavonoid from Garcinia kola seeds). Adaramoye, OA; Akanni, OO; Farombi, EO, 2013)	1.83
" There were no differences in adverse events between study arms."	( Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial. Aizire, J; Allen, M; Andrew, P; Brown, E; Chetty, V; Chipato, T; Coovadia, H; Eshleman, SH; Fawzi, W; Fowler, MG; George, K; Herron, CM; Jackson, JB; Kisenge, R; Maldonado, Y; Manji, K; Mofenson, LM; Moodley, D; Msweli, L; Musoke, P; Mwatha, A; Richardson, P; Stranix-Chibanda, L; Zwerski, S, 2014)	0.68
" At week 48, the most common treatment-related grade ≥ 2 adverse event (AE) was rash (13%); 12% experienced grade 3 AEs."	( Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study. Cahn, P; Chokephaibulkit, K; Dincq, S; Fourie, J; Kakuda, TN; Karatzios, C; Nijs, S; Opsomer, M; Tambuyzer, L; Tomaka, FL; Tudor-Williams, G, 2014)	0.4
" Both ACT regimens were safe and well tolerated."	( Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. Achan, J; Arinaitwe, E; Charlebois, E; Clark, TD; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, MR; Muhindo, MK; Mwangwa, F; Rosenthal, PJ; Ruel, T; Tappero, JW, 2014)	0.4
"Treatment of uncomplicated malaria with AL or DP was efficacious and safe in HIV-infected children taking ART."	( Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. Achan, J; Arinaitwe, E; Charlebois, E; Clark, TD; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, MR; Muhindo, MK; Mwangwa, F; Rosenthal, PJ; Ruel, T; Tappero, JW, 2014)	0.4
" Hepatotoxicity was rated according to the AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS)."	( [Hepatotoxicity in healthy infants exposed to nevirapine during pregnancy]. Figueras-Nadal, C; Fortuny-Guasch, C; Iveli, P; Martín-Nalda, A; Noguera-Julian, A; Rovira-Girabal, N; Soler-Palacín, P, 2016)	0.69
" We investigated the frequency and severity of adverse events (AE) in infants receiving multiple drug prophylaxis compared to ZDV alone."	( Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis: a retrospective case review. Barr, E; Davies, J; Forster, JE; Kinzie, K; Levin, MJ; McFarland, EJ; Pappas, J; Paul, S; Smith, C; Weinberg, A, 2015)	0.42
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."	( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016)	0.43
" The aim of this study was to compare the rate of any discontinuation of antiretroviral (ARV) regimen because of virologic failure (VF), and/or adverse drug reaction (ADR) among patients receiving stable ARV regimens for at least 6 months."	( Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study. Bani-Sadr, F; Cabie, A; Cotte, L; de Boissieu, P; Delobel, P; Dramé, M; Garraffo, R; Huleux, T; Poizot-Martin, I; Raffi, F; Rey, D, 2016)	0.68
" The most common adverse events potentially attributable to combination antiretroviral therapy were transient asymptomatic hyperlactatemia (26%), anemia (24."	( Nevirapine Pharmacokinetics and Safety in Neonates Receiving Combination Antiretroviral Therapy for Prevention of Vertical HIV Transmission. Bitnun, A; Brophy, J; Campbell, DM; Colantonio, D; Kakkar, F; Lau, E; Murphy, K; Read, SE; Samson, L; Seto, W; Yudin, MH, 2017)	1.9
" Secondary endpoints were time to loss of virological response and adverse events."	( Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan. Chang, HM; Chen, YS; Kunin, CM; Lee, CY; Lee, SS; Tsai, HC, 2017)	0.73
" Furthermore, there were no significant differences in adverse events between these two groups."	( Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan. Chang, HM; Chen, YS; Kunin, CM; Lee, CY; Lee, SS; Tsai, HC, 2017)	0.73
" The form is designed to obtain information on the demographics of the patients, WHO clinical stage of their HIV infection, HAART regimen for the patients, and suspected adverse events associated with the antiretroviral drugs used by the patients."	( A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria. Awodele, O; Oshikoya, KA; Popoola, TD, 2016)	0.43
" About half (57%) of the participants reported clinical adverse events; 92% of which were reported within two weeks of HAART initiation."	( A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria. Awodele, O; Oshikoya, KA; Popoola, TD, 2016)	0.43
"Antiretroviral drugs exposure often presents with adverse events, an observation similar to other studies."	( A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria. Awodele, O; Oshikoya, KA; Popoola, TD, 2016)	0.43
"Our findings suggest that ART drugs are not associated with an increased risk of CMs, yet some may increase adverse birth events."	( Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs. Antony, J; Ashoor, HM; Blondal, E; Finkelstein, Y; Ghassemi, M; Gough, K; Hemmelgarn, BR; Hutton, B; Ivory, JD; Khan, PA; Lillie, E; Straus, SE; Tricco, AC; Vafaei, A; Veroniki, AA, 2018)	0.48
" This antiretroviral is one of the scarce examples of drugs with prescription criteria based on sex, in order to prevent adverse reactions."	( Singularities of nevirapine metabolism: from sex-dependent differences to idiosyncratic toxicity. Antunes, AMM; Caixas, U; Charneira, C; Gonçalves-Dias, C; Marinho, AT; Marques, MM; Miranda, JP; Monteiro, EC; Pereira, SA, 2019)	0.85
" We evaluated the adverse events associated with the use of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP) for neonatal PEP during the first 6 weeks of life."	( Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants. Anugulruengkitt, S; Chokephaibulkit, K; Cressey, TR; Jantarabenjakul, W; Ounchanum, P; Pancharoen, C; Punnahitanon, S; Puthanakit, T; Sophonphan, J; Srirompotong, U; Suntarattiwong, P, 2019)	0.73
" They received a directly-observed 3-day standard treatment of DPQ and were followed up until day 63 for malaria infection and adverse events."	( Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial. Banda, CG; Kalilani-Phiri, L; Khoo, SH; Lalloo, DG; Macuacua, S; Maculuve, S; Mallewa, J; Mukaka, M; Mwapasa, V; Piqueras, M; Sevene, E; Terlouw, DJ; Vala, A, 2019)	0.51
"DPQ was highly efficacious and safe for the treatment of malaria in HIV-infected patients concurrently taking efavirenz- or nevirapine-based ART, despite known pharmacokinetic interactions between dihydroartemisinin-piperaquine and efavirenz- or nevirapine-based ART regimens."	( Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial. Banda, CG; Kalilani-Phiri, L; Khoo, SH; Lalloo, DG; Macuacua, S; Maculuve, S; Mallewa, J; Mukaka, M; Mwapasa, V; Piqueras, M; Sevene, E; Terlouw, DJ; Vala, A, 2019)	0.72
"NVP/ZDV/3TC started in the first week of life was safe and effective, even when trough NVP levels were below target."	( Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life. Ajibola, G; Batlang, O; Bennett, K; Capparelli, EV; Hughes, MD; Jean-Philippe, P; Kuritzkes, DR; Lichterfeld, M; Lockman, S; Makhema, J; Maswabi, K; Mohammed, T; Moyo, S; Sakoi, M; Shapiro, RL, 2021)	0.62
" There were no clinically relevant toxicities nor adverse events in both control and test arms."	( Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria. Abideen, G; Adeniji, H; Adeuja, O; Agbaje, EO; Akanmu, AS; Akinleye, MO; Akinyede, AA; Busari, AW; Hassan, OO; Ken-Owotor, C; Kogbe, S; Ogunfowokan, T; Onwujuobi, AG; Oreagba, IA; Owolabi, ET; Usman, SO, 2020)	0.96
" DAIDS grade 3 or 4 adverse events at least possibly related to antiretrovirals occurred in 30 (7%, 95% CI 5-10) of 438 infants but did not lead to nevirapine cessation in any neonates; neutropenia (25 [6%] neonates) and anaemia (six [1%]) were most common."	( Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. Bryson, Y; Bwakura-Dangarembizi, M; Capparelli, EV; Chadwick, EG; Coletti, A; Cotton, MF; Hazra, R; Jean-Philippe, P; LeBlanc, R; Mirochnick, M; Naidoo, KL; Nelson, BS; Persaud, D; Reding, C; Ruel, TD; Spector, SA; Tierney, C; Zimmer, B, 2021)	1.09
"Nevirapine at the dose studied was confirmed to be safe and provides therapeutic exposure concentrations."	( Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. Bryson, Y; Bwakura-Dangarembizi, M; Capparelli, EV; Chadwick, EG; Coletti, A; Cotton, MF; Hazra, R; Jean-Philippe, P; LeBlanc, R; Mirochnick, M; Naidoo, KL; Nelson, BS; Persaud, D; Reding, C; Ruel, TD; Spector, SA; Tierney, C; Zimmer, B, 2021)	2.34

Excerpt	Reference	Relevance
" The terminal half-life and mean residence time exceeded 24 h in all but one subject, indicating a prolonged disposition time in this population."	( Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Andrews, C; Bova, CA; Cheeseman, SH; Hattox, SE; Keirns, JJ; Koup, RA; McLaughlin, MM; Pav, JW; Roy, T; Sullivan, JL, 1993)	0.61
" Nevirapine significantly reduced median indinavir Cmin (47."	( Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. Dusek, A; Hall, DB; Lamson, M; Murphy, RL; Myers, M; Sommadossi, JP, 1999)	1.46
" The median half-life in women was 61."	( A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). Allen, M; Bagenda, D; Dransfield, K; Elliott, T; Fleming, T; Fowler, MG; Guay, LA; Hom, D; Horton, S; Jackson, JB; Mirochnick, M; Mmiro, F; Mofenson, L; Murarka, A; Musoke, P; Nakabiito, C; Pav, JW, 1999)	0.55
" Overall, comparison of the pharmacokinetic parameters between the 50 and 200 mg doses indicates that nevirapine is well absorbed at clinically relevant doses."	( Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Cappola, M; Hawi, A; Lamson, MJ; MacGregor, TR; Pav, JW; Robinson, P; Rowland, L; Sabo, JP, 1999)	0.77
"The dNN study evaluated the safety, efficacy and pharmacokinetic interactions of the combination of stavudine (2',3'-didehydro-2',3'-dideoxythymidine; D4T), nelfinavir and nevirapine in 25 HIV-infected subjects who received treatment for up to 29 weeks."	( dNN study: stavudine, nelfinavir and nevirapine. Preliminary safety, activity and pharmacokinetic interactions. Skowron, G, 1998)	0.77
" Non-compartmental methods were used to calculate the area under the plasma concentration versus time curve (AUC[24h]), and the maximal (Cmax) and minimal plasma concentration (Cmin), the time to Cmax (t(max)), the plasma elimination half-life (t1/2), the apparent oral clearance (Cl/F) and the apparent volume of distribution (V/F)."	( The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. Beijnen, JH; Danner, SA; Foudraine, NA; Hoetelmans, RM; Kwakkelstein, MO; Lange, JM; Meenhorst, PL; Mulder, JW; Reiss, P; van Heeswijk, RP; Veldkamp, AI; Wit, FW, 2000)	0.58
" However, Cmax and Cmin were higher and lower, respectively, when nevirapine was used in the once daily regimen as compared with the twice daily regimen."	( The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. Beijnen, JH; Danner, SA; Foudraine, NA; Hoetelmans, RM; Kwakkelstein, MO; Lange, JM; Meenhorst, PL; Mulder, JW; Reiss, P; van Heeswijk, RP; Veldkamp, AI; Wit, FW, 2000)	0.82
" However, Cmax and Cmin are higher and lower, respectively, for the once daily regimen as compared with the twice daily regimen."	( The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. Beijnen, JH; Danner, SA; Foudraine, NA; Hoetelmans, RM; Kwakkelstein, MO; Lange, JM; Meenhorst, PL; Mulder, JW; Reiss, P; van Heeswijk, RP; Veldkamp, AI; Wit, FW, 2000)	0.58
" The differences between the pharmacokinetic parameters of efavirenz with and without nevirapine were analyzed, and the pharmacokinetics of nevirapine were compared with those in historical control patients."	( The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. Beijnen, JH; Carlier, H; Gazzard, B; Harris, M; Hoetelmans, RM; Johnson, M; Kwakkelstein, MO; Lange, JM; Montaner, JS; Moyle, G; Reiss, P; van Leeuwen, R; Veldkamp, AI; Youle, M, 2001)	0.79
" Initial dose pharmacokinetic profiles in the pregnant women were similar to those seen in nonpregnant adults."	( Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Fenton, T; Lugo, M; Mirochnick, M; Siminski, S; Sullivan, JL, 2001)	1.75
" Although possessing a common mechanism of action, these agents can be differentiated by both molecular and pharmacokinetic characteristics."	( Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. DiCenzo, R; Morse, GD; Smith, PF, 2001)	0.31
" This pharmacokinetic interaction study was nested within a larger Phase III clinical trial conducted to characterize the safety and efficacy of coadministered nevirapine and lamivudine."	( Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. Lamson, MJ; Leitz, G; MacGregor, TR; Sabo, JP; Yong, CL, 2000)	0.83
"Concomitant administration of NVP at steady state with EE/NET resulted in a significant (29%) median reduction in the area under the plasma concentration time curve (AUC(infinity)) and a significant reduction in mean residence time (MRT) and half-life (t(1/2)) of EE."	( Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. Hutman, HW; Lamson, M; Marshak, A; McDonough, M; Mildvan, D; Robinson, P; Yarrish, R, 2002)	0.59
" Population pharmacokinetic parameters (apparent clearance (CL/F), volume of distribution (V/F), absorption rate constant (k a)) were estimated, as were interindividual, interoccasion, and residual variability in the pharmacokinetics."	( Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Beijnen, JH; de Maat, MM; Huitema, AD; Meenhorst, PL; Mulder, JW; van Gorp, EC, 2002)	0.6
"From 173 outpatients a total number of 757 nevirapine plasma concentrations at a single random time point and full pharmacokinetic curves for 13 patients were available resulting in a database of 1329 nevirapine plasma concentrations."	( Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Beijnen, JH; de Maat, MM; Huitema, AD; Meenhorst, PL; Mulder, JW; van Gorp, EC, 2002)	0.86
"The pharmacokinetics of nevirapine were adequately described by our population pharmacokinetic model."	( Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Beijnen, JH; de Maat, MM; Huitema, AD; Meenhorst, PL; Mulder, JW; van Gorp, EC, 2002)	0.91
" The objective of this study was to assess the impact of body weight on the pharmacokinetic disposition of nelfinavir (NFV) in the absence and presence of nevirapine (NVP) and compare the pharmacokinetic profiles of twice-daily (BID) and three-times-daily (TID) NFV regimens."	( Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. Aweeka, FT; Floren, LC; Hayashi, S; Jayewardene, A; Johnson, G; Krogstad, P; Nachman, S; Stanley, K; Wiznia, A, 2003)	0.52
"This was an intensive pharmacokinetic substudy nested in a phase II, multicenter, randomized, open-label trial."	( Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. Aweeka, FT; Floren, LC; Hayashi, S; Jayewardene, A; Johnson, G; Krogstad, P; Nachman, S; Stanley, K; Wiznia, A, 2003)	0.32
"Evaluate pharmacokinetic interaction, short-term safety, and antiretroviral activity of stavudine (d4T), nevirapine (NVP), and nelfinavir (NFV) as combination HIV-1 therapy."	( Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults. Fisher, A; Grosso, R; Hall, DB; Jacobs, M; Kerr, B; Leoung, G; Lewis, R; MacGregor, T; Odgen, R; Robinson, P; Skowron, G; Stevens, M; Yen-Lieberman, B, 2004)	0.78
"Prospective, open-label study investigating the pharmacokinetic interactions between d4T, NVP, and NFV and documenting short-term tolerability and virologic and immunologic activity."	( Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults. Fisher, A; Grosso, R; Hall, DB; Jacobs, M; Kerr, B; Leoung, G; Lewis, R; MacGregor, T; Odgen, R; Robinson, P; Skowron, G; Stevens, M; Yen-Lieberman, B, 2004)	0.56
" Steady-state pharmacokinetic parameters of NFV, AG1402 (metabolite of NFV), and d4T were compared before and after the addition of NVP."	( Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults. Fisher, A; Grosso, R; Hall, DB; Jacobs, M; Kerr, B; Leoung, G; Lewis, R; MacGregor, T; Odgen, R; Robinson, P; Skowron, G; Stevens, M; Yen-Lieberman, B, 2004)	0.56
"NVP administration did not significantly affect the steady-state pharmacokinetic parameters of NFV or d4T."	( Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults. Fisher, A; Grosso, R; Hall, DB; Jacobs, M; Kerr, B; Leoung, G; Lewis, R; MacGregor, T; Odgen, R; Robinson, P; Skowron, G; Stevens, M; Yen-Lieberman, B, 2004)	0.56
"The prolonged elimination half-life of NVP compared with NRTIs, which persists even after 20 weeks of therapy, raises concern over the development of NNRTI resistance if all three drugs are stopped together."	( Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance. Back, D; Clarke, JR; Fidler, S; Mackie, NE; Tamm, N; Taylor, GP; Weber, JN, 2004)	0.6
" Population pharmacokinetic parameters [clearance (CL/F), volume of distribution (V/F), absorption rate constant (ka)] and interindividual (IIV) and interoccasion variability (IOV) were estimated."	( Race is not associated with nevirapine pharmacokinetics. Beijnen, JH; de Maat, MM; Huitema, AD; Mulder, JW; Nellen, JF; Prins, JM; Wit, FW, 2004)	0.62
"The aim of this 2NN pharmacokinetic substudy was to investigate the population pharmacokinetics of nevirapine and efavirenz."	( Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, J; MacGregor, TR; van Leth, F, 2005)	1.99
"We have investigated the pharmacokinetics of nevirapine and paclitaxel in a patient who used both drugs concomitantly, as there are strong theoretical indications for a potential pharmacokinetic drug-drug interaction."	( No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel. Beijnen, JH; Huitema, AD; Kappelhoff, BS; Mairuhu, AT; Schellens, JH, 2005)	0.84
" Intensive pharmacokinetic sampling occurred after 4 weeks of therapy."	( Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403. Acosta, EP; Aldrovandi, G; Chen, J; Damle, B; Hodge, J; Hughes, MD; King, JR; Nachman, S; Wiznia, A; Yogev, R, 2005)	0.33
" NFV pharmacokinetic measurements were not statistically different between the treatment groups, yet exposure to the NFV metabolite, M8, was significantly higher in subjects receiving RTV."	( Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403. Acosta, EP; Aldrovandi, G; Chen, J; Damle, B; Hodge, J; Hughes, MD; King, JR; Nachman, S; Wiznia, A; Yogev, R, 2005)	0.33
" A randomized, two-way, crossover study was conducted in 24 fasting, healthy, Indian male subjects to compare plasma pharmacokinetic profile and single-dose tolerability of a new nevirapine tablet formulation (test, T) with that of a reference (R) tablet."	( Pharmacokinetic profiling and bioequivalence assessment of two marketed brands of nevirapine tablets in healthy Indian volunteers. Lulla, A; Malhotra, G; Narang, VS; Purandare, S, 2005)	0.75
" Dosage and dosing frequency did not influence clearance or volume of distribution of nevirapine, indicating linear pharmacokinetic behavior of nevirapine whether given as a single daily dose or as divided doses over 24 hours."	( Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Robinson, PA; van Leth, F, )	0.68
" The Cmin of nevirapine is lower and the Cmax of nevirapine is higher for the once-daily regimen as compared to the twice-daily regimen."	( Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Robinson, PA; van Leth, F, )	0.82
" The objective was to find cutoff values of the Cmin and AUC24 below which the risk of virologic failure increased."	( Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. Beijnen, JH; Boron-Kaczmarska, A; Hall, DB; Huitema, AD; Johnson, D; Kappelhoff, BS; Lange, JM; Leith, J; Leth, FV; Livrozet, JM; Losso, MH; Saag, MS; Wit, FW, 2006)	0.62
"A population pharmacokinetic analysis was performed in the context of therapeutic drug monitoring (87 patients, 121 samples)."	( Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O, 2006)	0.64
" A pre-dose to 6 h post-dose steady-state pharmacokinetic analysis (n = 35) of the drugs on the day of the scheduled Caesarean section was performed."	( Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. Belohradsky, BH; Eberle, J; Friese, K; Gingelmaier, A; Grubert, TA; Kästner, R; Kurowski, M; Mylonas, I, 2006)	0.55
" The influence of gender, age, body weight and comedication on minimum and maximum concentrations (C(min), C(max)), area under the concentration-time curve (AUC), total clearance (CL(tot)), half-life (t(1/2)) and volume of distribution (V(d)) was analysed by multivariate techniques."	( A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Carlebach, A; Gute, P; Haberl, A; Harder, S; Klauke, S; Knecht, G; Kurowski, M; Rohrbacher, M; Staszewski, S; Stocker, H; von Hentig, N, 2006)	0.58
" We determined the pharmacokinetic profiles of stavudine, lamivudine and nevirapine in Pedimune and compared these with the branded products."	( Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults. Burger, DM; Dijkema, T; Gibb, DM; L'homme, RF; van der Ven, AJ; Warris, A, 2007)	0.57
" An 8 h pharmacokinetic curve was recorded at day 1 of every cycle after medication intake."	( Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults. Burger, DM; Dijkema, T; Gibb, DM; L'homme, RF; van der Ven, AJ; Warris, A, 2007)	0.34
"Non-parametric statistical tests revealed no statistically significant differences in Cmax (0."	( Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults. Burger, DM; Dijkema, T; Gibb, DM; L'homme, RF; van der Ven, AJ; Warris, A, 2007)	0.34
"The pharmacokinetic profiles of stavudine, lamivudine and nevirapine in Pedimune Baby and Junior are comparable to the branded products."	( Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults. Burger, DM; Dijkema, T; Gibb, DM; L'homme, RF; van der Ven, AJ; Warris, A, 2007)	0.58
" Patients taking Triomune had notably higher stavudine Cmax values."	( Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults. Corbett, AH; Hosseinipour, MC; Kanyama, C; Kashuba, AD; Mshali, I; Phakati, S; Rezk, NL; van der Horst, C, 2007)	0.56
" Both drugs have demonstrated interindividual pharmacokinetic variability."	( Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring? Dahri, K; Ensom, MH, 2007)	0.7
" Nevirapine has a long half-life and achieves high steady-state plasma concentrations relative to the concentration required to inhibit 50% viral replication in vitro (IC(50)) in patients."	( Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. Cooper, CL; van Heeswijk, RP, 2007)	1.64
" Nevirapine pharmacokinetic studies were carried out starting with the seventh dose of nevirapine in the nevirapine regimen (on days 7-10 or 28-31) and the combination regimen (on days 49-52)."	( Pharmacokinetic study of the interaction between itraconazole and nevirapine. Jaruratanasirikul, S; Sriwiriyajan, S, 2007)	1.49
"There was no significant difference in nevirapine pharmacokinetic parameters between the nevirapine and combination regimens."	( Pharmacokinetic study of the interaction between itraconazole and nevirapine. Jaruratanasirikul, S; Sriwiriyajan, S, 2007)	0.85
" Noncompartmental pharmacokinetic analysis was performed."	( Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily. Arroyo, E; Climent-Grana, E; Merino, E; Pérez-Ruixo, JJ; Portilla, J; Valenzuela, B, 2007)	0.56
" Pharmacokinetic parameters were calculated using noncompartmental methods, and bioequivalence was assessed using an analysis of variance model."	( Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products. Dimarco, M; Dodard, C; Guilbaud, R; Marier, JF; Monif, T; Morelli, G; Singla, AK; Thudi, NR; Tippabhotla, SK, 2007)	0.6
" Blood samples were collected from 1 to 144 hours post-dose for pharmacokinetic analysis."	( Influence of piperine on the pharmacokinetics of nevirapine under fasting conditions: a randomised, crossover, placebo-controlled study. Kasibhatta, R; Naidu, MU, 2007)	0.59
" Pharmacokinetic variables were compared between patients divided based on CD4 cell counts, sex, and BMI."	( Steady-State Pharmacokinetics of Nevirapine in HIV-1 Infected Adults in India. Anitha, S; Hemanthkumar, AK; Kumaraswami, V; Narendran, G; Padmapriyadarsini, C; Rajasekaran, S; Ramachandran, G; Subramanyam, S; Swaminathan, S, 2007)	0.62
"Patients with higher BMI had lower peak and trough concentration and exposure of nevirapine than those with lower BMI; none of the differences in the pharmacokinetic variables of nevirapine between the various patient groups was statistically significant."	( Steady-State Pharmacokinetics of Nevirapine in HIV-1 Infected Adults in India. Anitha, S; Hemanthkumar, AK; Kumaraswami, V; Narendran, G; Padmapriyadarsini, C; Rajasekaran, S; Ramachandran, G; Subramanyam, S; Swaminathan, S, 2007)	0.85
"The influence of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics was investigated in HIV-infected patients with a population pharmacokinetic approach."	( Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients. Allavena, C; Biron, C; Dailly, E; Jolliet, P; Raffi, F, 2008)	1.09
" After 4 weeks or more, a 12-h pharmacokinetic curve was recorded."	( Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. Burger, DM; Chintu, C; Ewings, FM; Gibb, DM; Kabamba, D; Kankasa, C; L'homme, RF; Mulenga, V; Thomason, MJ; Walker, AS, 2008)	1.79
"Nevirapine concentrations were higher but more variable than in adults; the pharmacokinetic parameters of stavudine and lamivudine were comparable to adults."	( Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. Burger, DM; Chintu, C; Ewings, FM; Gibb, DM; Kabamba, D; Kankasa, C; L'homme, RF; Mulenga, V; Thomason, MJ; Walker, AS, 2008)	3.23
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"The aim of this study was to develop and validate a population pharmacokinetic model for nevirapine in a population of HIV-infected adults and to evaluate the influence of nevirapine dosing regimen and patient characteristics on nevirapine trough concentration."	( Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach. Cedeño, S; Clotet, B; Costa, J; Miranda, C; Miranda, J; Moltó, J; Negredo, E; Santos, JR; Valle, M; Vilaró, J, 2008)	0.85
" Pharmacokinetic parameters, inter-individual variability and residual error were estimated using non-linear mixed effects modelling."	( Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach. Cedeño, S; Clotet, B; Costa, J; Miranda, C; Miranda, J; Moltó, J; Negredo, E; Santos, JR; Valle, M; Vilaró, J, 2008)	0.63
"We aimed to compare the steady-state pharmacokinetic parameters and tolerability of Triomune 40 (stavudine 40 mg, lamivudine 150 mg and nevirapine 200 mg) and branded formulations of these drugs in HIV-infected Ugandans."	( Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults. Back, D; Boffito, M; Byakika-Kibwika, P; D'Avolio, A; Di Perri, G; Kalemeera, F; Khoo, S; Lamorde, M; Mauro, S; Mayanja-Kizza, H; Merry, C; Ryan, M, 2008)	0.76
" Similarity between steady-state pharmacokinetic parameters was assessed using the US Food and Drug Administration standards for bioequivalency testing."	( Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults. Back, D; Boffito, M; Byakika-Kibwika, P; D'Avolio, A; Di Perri, G; Kalemeera, F; Khoo, S; Lamorde, M; Mauro, S; Mayanja-Kizza, H; Merry, C; Ryan, M, 2008)	0.56
" Pharmacokinetic parameter inter-individual variability ranged from 29% to 99%."	( Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults. Back, D; Boffito, M; Byakika-Kibwika, P; D'Avolio, A; Di Perri, G; Kalemeera, F; Khoo, S; Lamorde, M; Mauro, S; Mayanja-Kizza, H; Merry, C; Ryan, M, 2008)	0.56
" Capacity building for pharmacokinetic research in resource-limited settings is a priority."	( Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults. Back, D; Boffito, M; Byakika-Kibwika, P; D'Avolio, A; Di Perri, G; Kalemeera, F; Khoo, S; Lamorde, M; Mauro, S; Mayanja-Kizza, H; Merry, C; Ryan, M, 2008)	0.56
" The effect of three routinely prescribed antiretroviral (ARV) drugs on the pharmacokinetic profile of an antidiabetic drug, chlorpropamide, was investigated in 18 human subjects, who had recently been diagnosed positive for human immunodeficiency virus (HIV) infection."	( The influence of lamivudine, stavudine and nevirapine on the pharmacokinetics of chlorpropamide in human subjects. Bakare-Odunola, MT; Enemali, I; Garba, M; Mustapha, KB; Obodozie, OO, )	0.39
" A 600-mg oral dose of efavirenz was subsequently administered, and pharmacokinetic sampling was repeated."	( Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. Acosta, EP; Floyd, M; Gebretsadik, T; Haas, DW; Mayo, G; Menon, UN; Shintani, A; Stein, CM; Wilkinson, GR, 2009)	0.58
"A 12 h pharmacokinetic analysis was performed in 18 patients: 7 HIV/HCV-coinfected and 11 HIV-monoinfected."	( Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals. Bertram, N; Fätkenheuer, G; Reichel, C; Rockstroh, JK; Schwarze-Zander, C; Sudhop, T; Vogel, M; Voigt, E; Wasmuth, JC; Wyen, C, 2009)	1.8
"Small intensive pharmacokinetic (PK) studies of medications in early-phase trials cannot identify the range of factors that influence drug exposure in heterogenous populations."	( Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. Anastos, K; Bacchetti, P; Benet, LZ; Cohen, M; Gandhi, M; Gange, SJ; Greenblatt, RM; Kalinowski, A; Minkoff, H; Wolfe, AR; Young, M, 2009)	0.35
"To investigate the pharmacokinetic interaction between darunavir/ritonavir (DRV/r) and nevirapine (NVP) in 19 HIV-infected patients."	( Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients. De Pauw, M; Hoetelmans, RM; Lefebvre, E; Mariën, K; Pozniak, A; Sekar, V; Vangeneugden, T, 2009)	0.85
"A highly sensitive and specific LC-MS/MS assay was developed and validated to quantify nevirapine (NVP) and its five metabolites [2-, 3-, 8-, 12-hydroxyl NVP (OHNVP) and 4-carboxyl NVP (CANVP)] simultaneously in baboon serum and the assay was used to characterize their pharmacokinetic studies of an oral-dose escalation study in baboon."	( A sensitive and specific liquid chromatography/tandem mass spectrometry method for quantification of nevirapine and its five metabolites and their pharmacokinetics in baboons. Chan, KK; Fan-Havard, P; Ling, Y; Liu, Z; Ren, C; Schlabritz-Loutsevitch, N, 2010)	0.8
" The method has been successfully applied to the pharmacokinetic study of a combination treatment of 300 mg lamivudine, 30 mg stavudine and 200 mg nevirapine in 22 healthy male volunteers under fasting conditions."	( Simultaneous determination of lamivudine, stavudine and nevirapine in human plasma by LC-MS/MS and its application to pharmacokinetic study in clinic. Ding, C; Ge, Q; Li, Z; Liu, X; Zhi, X; Zhou, Z, 2010)	0.81
" After 10 days of one formulation, 6-h pharmacokinetic sampling was performed, and patients were crossed over to subsequent formulations."	( Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children. Corbett, AH; Hosseinipour, MC; Kanyama, C; Kashuba, AD; Kazembe, P; Mkupani, P; Mwansambo, C; Nyirenda, J; Rezk, NL; Sichali, D; Tien, H; Weigel, R, 2010)	0.59
"Full 12-hour pharmacokinetic profiles of nevirapine, stavudine, and lamivudine in HIV-infected children taking fixed-dose combination antiretroviral tablets have been reported previously by us."	( Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets. Burger, D; Chintu, C; Ewings, F; Gibb, DM; Kabamba, D; Kankasa, C; L'homme, R; Mulenga, V; Thomason, M; Walker, AS, 2010)	0.87
" Six-point pharmacokinetic sampling (0, 2, 4, 6, 8, and 12 h) was undertaken after observed intake with a standardized breakfast."	( Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults. Dickinson, L; Gibb, DM; Gilks, CF; Kayiwa, J; Khoo, S; Kityo, C; Lutwama, F; Munderi, P; Nalumenya, R; Reid, A; Ssali, F; Tumukunde, D; Walker, AS, 2010)	0.36
"The International Maternal Pediatric Adolescent AIDS Clinical Trials group (IMPAACT) P1056 study was a phase I/II, 2-arm, randomized, open-label, multidose pharmacokinetic cross-over study."	( A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand. Capparelli, E; Chokephaibulkit, K; Chotpitayasunondh, T; Cressey, TR; Eksaengsri, A; Hongsiriwan, S; McIntosh, K; Muresan, P; Plipat, N; Prasitsuebsai, W; Sirisanthana, V; Smith, ME; Toye, M; Vanprapar, N; Yogev, R, 2010)	0.59
" The developed assay method was successfully applied to a pharmacokinetic study in human male volunteers."	( Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Inamadugu, JK; Karra, VK; Mullangi, R; Pilli, NR; Rao, JV; Vaidya, JR, 2011)	0.37
"The aims of this ANRS12154 open-label, single-center, multiple-dose pharmacokinetic study were to characterize nevirapine pharmacokinetics in a Cambodian population of HIV-infected patients and to identify environmental and genetic factors of variability, focusing on the CYP2B6, CYP3A5, and ABCB1 (MDR1) genes."	( Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Becquemont, L; Bertrand, J; Borand, L; Chou, M; Comets, E; Le Tiec, C; Mentre, F; Ouk, V; Segeral, O; Taburet, AM; Verstuyft, C, 2010)	0.82
" The method was sensitive, specific, precise, accurate and suitable for bioequivalence and pharmacokinetic studies."	( Simultaneous determination of niacin and its metabolites--nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide--in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Damaramadugu, R; Inamadugu, JK; Mullangi, R; Ponneri, V, 2010)	0.36
" Subjects underwent 12 h intensive pharmacokinetic sampling on Days 7, 14 and 21 of nevirapine treatment."	( Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. Back, D; Boffito, M; Byakika-Kibwika, P; Coakley, P; Colebunders, R; Kalemeera, F; Khoo, S; Lamorde, M; Merry, C; Namakula, R; Okaba-Kayom, V; Ryan, M, 2011)	2.04
"Non-linear mixed-effects modelling was used to estimate pharmacokinetic parameters from 275 patients."	( Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. Back, DJ; Brockmeyer, NH; Davies, G; Egan, D; Fätkenheuer, G; Hendra, H; Johnson, MA; Khoo, S; Mahungu, T; Owen, A; Rockstroh, J; Schipani, A; Siccardi, M; Wyen, C; Youle, M, 2011)	0.59
" No significant difference in the pharmacokinetic parameters of NVP was found upon short-term co-administration of Sutherlandia."	( Effect of short term and chronic administration of Sutherlandia frutescens on pharmacokinetics of nevirapine in rats. Earla, R; Folk, WR; Kwatra, D; Mandava, NK; Minocha, M; Mitra, AK; Pal, D, 2011)	0.59
"Patients, who participated in the 2NN pharmacokinetic sub study, were reconsented and reenrolled into a clinical trial for genotyping analysis."	( Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine. Hall, D; Jayadev, S; Lehr, T; MacGregor, TR; Schaefer, HG; Staab, A; Yuan, J; Zimdahl-Gelling, H, 2011)	0.57
" Pharmacokinetic parameter estimates and model-predicted HIV-1 transmission rates were very consistent with other studies."	( Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes. Frank, M; Harms, G; Kloft, C; Kunz, A; Schütte, C; von Kleist, M, 2011)	0.67
" More comprehensive in vivo pharmacokinetic data are required to justify the potential use of these agents as safe and effective options during pregnancy."	( Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). Back, DJ; Else, LJ; Khoo, SH; Taylor, S, 2011)	0.37
"In this Phase I/II open-label pharmacokinetic study, 42 children weighing 6-30 kg treated with NVP-based HAART for ≥4 weeks were randomized to receive the FDC tablets (GPO-VIR Z30) or the liquid formulations."	( Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. Aurpibul, L; Capparelli, E; Chokephaibulkit, K; Cressey, TR; Eksaengsri, A; Hongsiriwon, S; Kabat, B; Limwongse, C; McIntosh, K; Muresan, P; Ngampiyaskul, C; Sirisanthana, V; Smith, ME; Toye, M; Wittawatmongkol, O; Yogev, R, 2011)	0.59
"To propose a modelling strategy to efficiently integrate data from different sources in one simultaneous analysis, using nevirapine population pharmacokinetic data as an example."	( Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. Barnes, KI; Cohen, K; Denti, P; Huitema, A; Karlsson, MO; Kredo, T; Nachega, JB; Svensson, E; van der Walt, JS, 2012)	0.81
"NVP pharmacokinetics were modeled by population pharmacokinetic analysis."	( Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. Aweeka, FT; Currier, JS; Dong, BJ; Frymoyer, A; Hughes, MD; Lizak, P; Lockman, S; Sawe, F; Verotta, D; Zheng, Y, 2012)	1.82
" The method was successfully applied to quantify them in a rat pharmacokinetic study in whole blood, plasma and DBS cards after a single oral co-administration at the dose of 10, 2 and 13 mg/kg for lamivudine, stavudine and nevirapine, respectively, to male Wistar rats."	( Exploring dried blood spot sampling technique for simultaneous quantification of antiretrovirals: lamivudine, stavudine and nevirapine in a rodent pharmacokinetic study. Aleti, R; Bhyrapuneni, G; Kalaikadhiban, I; Kandikere, V; Komarneni, P; Muddana, N; Nirogi, R; Padala, N, 2012)	0.77
" The developed and validated method was successfully applied to quantitative determination of the three analytes in plasma for pharmacokinetic study in 12 healthy human volunteers."	( Development and validation of an HPLC-UV method for simultaneous determination of zidovudine, lamivudine, and nevirapine in human plasma and its application to pharmacokinetic study in human volunteers. Choudhury, H; Das, A; Gorain, B; Nandi, U; Pal, TK; Roy, B, 2013)	0.6
" The developed assay method was successfully applied to a pharmacokinetic study in humans."	( Simultaneous determination of atorvastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study. Gajula, R; Inamadugu, JK; Mullangi, R; Pilli, NR; Ponneri, V; Ravi, VB, 2012)	0.38
"Twenty-two children received antituberculosis and antiretroviral therapy (ART) concurrently for 4 weeks before pharmacokinetic sampling."	( Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. Burger, DM; Chintu, C; Cook, A; Gibb, DM; McIlleron, H; Merry, C; Mulenga, V; Oudijk, JM; Walker, AS, 2012)	0.7
"Co-administration of artemether/lumefantrine with antiretroviral therapy has potential for pharmacokinetic drug interactions."	( Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. Back, D; Byakika-Kibwika, P; de Vries, PJ; Hanpithakpong, W; Katabira, E; Khoo, S; Lamorde, M; Lindegardh, N; Mayanja-Kizza, H; Mayito, J; Merry, C; Nabukeera, L; Namakula, R; Ntale, M; Pakker, N; Ryan, M; Tarning, J, 2012)	0.6
" Clinical data from population pharmacokinetic and pharmacodynamic trials evaluating the impact of these drug interactions are urgently needed."	( Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. Back, D; Byakika-Kibwika, P; de Vries, PJ; Hanpithakpong, W; Katabira, E; Khoo, S; Lamorde, M; Lindegardh, N; Mayanja-Kizza, H; Mayito, J; Merry, C; Nabukeera, L; Namakula, R; Ntale, M; Pakker, N; Ryan, M; Tarning, J, 2012)	0.6
" The population pharmacokinetic approach represents a very useful tool for the description of the dose-concentration relationship, the quantification of variability in the target population of patients and the identification of influencing factors."	( Dosage optimization of treatments using population pharmacokinetic modeling and simulation. Aouri, M; Arab-Alameddine, M; Buclin, T; Csajka, C; Decosterd, LA; Guidi, M; Rotger, M; Telenti, A, 2012)	0.38
" NVP pharmacokinetic data were combined from eight pediatric clinical trials (Pediatric AIDS Clinical Trials Group [PACTG] studies 245, 356, 366, 377, 403, 1056, and 1069 and Children with HIV in Africa Pharmacokinetics and Adherence of Simple Antiretroviral Regimens [CHAPAS]) representing subjects from multiple continents and across the pediatric age continuum."	( Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Acosta, EP; Aweeka, FT; Burger, D; Capparelli, EV; Cressey, TR; Kabamba, D; Nikanjam, M; Spector, SA, 2012)	1.82
" In a pharmacokinetic investigation, breast milk and plasma samples of mothers and newborns were collected."	( Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns. Frank, M; Harms, G; Kloft, C; Kunz, A, 2013)	0.66
" Pharmacokinetic parameters were calculated by noncompartmental analysis."	( Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state. Barrail-Tran, A; Chou, M; Fan-Havard, P; Haas, DW; Ling, Y; Liu, Z; Taburet, AM, 2013)	0.68
" Median distribution half-life was 24 min (range 6-42 min) and 39 min (range 33."	( Pharmacokinetics of midazolam after intravenous administration to horses. Aarnes, TK; Bednarski, RM; Hubbell, JA; Kelly, EM; Lakritz, J; Lerche, P; Liu, Z, 2013)	0.39
" We conducted a cross-sectional study of HIV-positive women to determine if protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) C(min) and Cmax values were significantly different than historical general population (predominantly male) averages and to evaluate correlates of higher concentrations."	( Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study. Angel, JB; Blitz, SL; Burdge, D; Cohen, J; Conway, B; de Pokomandy, A; Gough, K; Haase, D; Klein, MB; la Porte, CJ; Loemba, H; Loutfy, MR; Pick, N; Raboud, J; Rachlis, AR; Smaill, FM; Trottier, S; Tseng, AL; Walmsley, SL, 2013)	0.39
" Timed blood samples for C(min) and Cmax were drawn weekly for 3 weeks."	( Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study. Angel, JB; Blitz, SL; Burdge, D; Cohen, J; Conway, B; de Pokomandy, A; Gough, K; Haase, D; Klein, MB; la Porte, CJ; Loemba, H; Loutfy, MR; Pick, N; Raboud, J; Rachlis, AR; Smaill, FM; Trottier, S; Tseng, AL; Walmsley, SL, 2013)	0.39
"Compared to historical control data, C(min) in the women enrolled was significantly higher whereas Cmax was significantly lower."	( Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study. Angel, JB; Blitz, SL; Burdge, D; Cohen, J; Conway, B; de Pokomandy, A; Gough, K; Haase, D; Klein, MB; la Porte, CJ; Loemba, H; Loutfy, MR; Pick, N; Raboud, J; Rachlis, AR; Smaill, FM; Trottier, S; Tseng, AL; Walmsley, SL, 2013)	0.39
"To confirm whether 7 days of phenytoin, an enzyme inducer, would decrease the elimination half-life of single-dose nevirapine and to investigate its effect on the development of nevirapine resistance in pregnant, HIV-infected women."	( Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. Aitken, S; Burger, DM; Chunda, C; Fillekes, Q; Gibb, DM; Kankasa, C; Kisanga, ER; Muro, EP; Thomason, MJ; Walker, AS, 2013)	0.81
"In a pharmacokinetic pilot trial (NCT01187719), HIV-infected, antiretroviral (ARV)-naive pregnant women ≥18 years old from Zambia and Tanzania and with CD4 cell counts >350 cells/mm(3) were randomized 1 : 1 to a control (zidovudine pre-delivery, single-dose nevirapine/zidovudine/lamivudine at delivery and zidovudine/lamivudine for 7 days post-delivery) or an intervention (control plus 184 mg of phenytoin once daily for 7 days post-delivery) group."	( Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. Aitken, S; Burger, DM; Chunda, C; Fillekes, Q; Gibb, DM; Kankasa, C; Kisanga, ER; Muro, EP; Thomason, MJ; Walker, AS, 2013)	0.78
" The GM (95% CI) half-life of nevirapine was 63."	( Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. Aitken, S; Burger, DM; Chunda, C; Fillekes, Q; Gibb, DM; Kankasa, C; Kisanga, ER; Muro, EP; Thomason, MJ; Walker, AS, 2013)	0.89
"Adding 7 days of an enzyme inducer to single-dose nevirapine to prevent mother-to-child transmission of HIV significantly reduced subtherapeutic nevirapine levels by shortening the half-life of nevirapine."	( Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. Aitken, S; Burger, DM; Chunda, C; Fillekes, Q; Gibb, DM; Kankasa, C; Kisanga, ER; Muro, EP; Thomason, MJ; Walker, AS, 2013)	0.86
"To compare steady-state (ss) pharmacokinetic targets of nevirapine extended-release (NVP-XR) tablets once-daily (QD) with immediate-release (NVP-IR) tablet or oral suspension twice-daily in HIV-1-infected children and adolescents."	( Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study. Anabwani, G; Feiterna-Sperling, C; Giaquinto, C; Königs, C; MacGregor, TR; Mensa, FJ; Mompati, K; Nguyen, T; Nuttall, J; Quinson, AM; Sabo, JP; Yong, CL, 2014)	0.93
" Cpre,ss (steady-state, predose concentrations) was obtained from all, and 12-hour NVP-IR and 24-hour NVP-XR steady-state pharmacokinetic profiles were obtained in the pharmacokinetic substudy."	( Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study. Anabwani, G; Feiterna-Sperling, C; Giaquinto, C; Königs, C; MacGregor, TR; Mensa, FJ; Mompati, K; Nguyen, T; Nuttall, J; Quinson, AM; Sabo, JP; Yong, CL, 2014)	0.68
" The purpose of the current study was to determine the population mean pharmacokinetic parameters and identify factors that influence pharmacokinetic parameters of nevirapine in Thai HIV-infected patients."	( Population pharmacokinetics of nevirapine in Thai HIV-infected patients. Avihingsanon, A; Manosuthi, W; Punyawudho, B; Wattanakul, T, 2014)	0.88
"This population-based pharmacokinetic model can be used for optimizing nevirapine dosage regimens for individual patients to improve efficacy and safety of nevirapine therapy in this population."	( Population pharmacokinetics of nevirapine in Thai HIV-infected patients. Avihingsanon, A; Manosuthi, W; Punyawudho, B; Wattanakul, T, 2014)	0.92
"Nevirapine (NVP) extensive data obtained after oral single dose administration of 200 mg in a crossover study involving 16 healthy subjects was used to develop a descriptive population pharmacokinetic model including drug recirculation, since secondary peaks were observed in plasma concentration-time profiles for all subjects."	( Population pharmacokinetic model to analyze nevirapine multiple-peaks profile after a single oral dose. Fagiolino, P; Ibarra, M; Vázquez, M, 2014)	2.11
" Therefore, it was decided to study a potential pharmacokinetic interaction between the nonnucleoside reverse transcriptase inhibitor nevirapine (NVP) and the tricyclic antidepressant nortriptyline (NT)."	( Pharmacokinetic interaction between nevirapine and nortriptyline in rats: inhibition of nevirapine metabolism by nortriptyline. Gandía, P; Melis, V; Peris, JE; Usach, I, 2014)	0.88
" Substituting nevirapine for rilpivirine resulted in ongoing virological suppression and did not have clinically relevant pharmacokinetic effects by cytochrome P450 interactions."	( The efficacy, pharmacokinetics, and safety of a nevirapine to rilpivirine switch in virologically suppressed HIV-1-infected patients. Blonk, M; Burger, D; Rijnders, BJ; Rokx, C; Verbon, A, 2015)	1.03
" Pharmacokinetic analysis of the rat plasma NVP concentration-time data allowed absorption rate constants to be calculated."	( Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants. Baum, MM; Beliveau, M; Cortez, JM; Moss, JA; Quintero, R; Smith, TJ, 2015)	0.68
" The effect of EFV and/or NVP on lumefantrine pharmacokinetic profile among HIV-malaria co-infected patients on ART and treated with AL was investigated."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	0.76
" Pharmacokinetic analysis of lumefantrine was done using non-linear mixed effect modelling."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	0.76
"Of the evaluated models, a two-compartment pharmacokinetic model with first order absorption and lag-time described well lumefantrine plasma concentrations time profile."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	0.76
"The metabolic pathways of dolutegravir and nevirapine suggest a potential pharmacokinetic interaction between these drugs."	( Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1. Allavena, C; Billaud, E; Bouchez, S; Bouquié, R; Dailly, E; Deslandes, G; Grégoire, M; Hall, N; Hernando, H; Jolliet, P; Raffi, F; Reliquet, V, 2015)	1.05
" Full pharmacokinetic profiles were assessed on the day of nevirapine discontinuation and 2 weeks after discontinuation of nevirapine."	( Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1. Allavena, C; Billaud, E; Bouchez, S; Bouquié, R; Dailly, E; Deslandes, G; Grégoire, M; Hall, N; Hernando, H; Jolliet, P; Raffi, F; Reliquet, V, 2015)	1.03
"018) and terminal half-life (-15%, P = 0."	( Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1. Allavena, C; Billaud, E; Bouchez, S; Bouquié, R; Dailly, E; Deslandes, G; Grégoire, M; Hall, N; Hernando, H; Jolliet, P; Raffi, F; Reliquet, V, 2015)	0.79
" Plasma concentrations were measured as therapeutic drug monitoring while a subset of patients underwent intensive 12-hour pharmacokinetic evaluation."	( Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics. Bonora, S; Calcagno, A; Calza, L; Capetti, A; Cenderello, G; D'Avolio, A; Di Perri, G; Guaraldi, G; Lanzafame, M; Marinaro, L; Montrucchio, C; Tettoni, MC; Trentini, L, 2016)	0.77
" Median trough raltegravir and nevirapine concentrations were 83 ng/ml (32-227) and 5460 ng/ml (4037-7221); intensive 12-hours pharmacokinetic parameters (n=7) were similar to published data."	( Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics. Bonora, S; Calcagno, A; Calza, L; Capetti, A; Cenderello, G; D'Avolio, A; Di Perri, G; Guaraldi, G; Lanzafame, M; Marinaro, L; Montrucchio, C; Tettoni, MC; Trentini, L, 2016)	1.06
"This nonrandomized, parallel group, pharmacokinetic evaluation was conducted in three groups of human immunodeficiency virus-infected Ugandan women: ART-naive (n = 17), efavirenz-based ART (n = 20), and nevirapine-based ART (n = 20)."	( Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks. Back, DJ; Buzibye, A; Byakika-Kibwika, P; Cohn, SE; Darin, KM; Dilly Penchala, S; Else, LJ; Lamorde, M; Merry, C; Nakalema, S; Scarsi, KK, 2016)	0.62
" Hence, this study was aimed to determine population pharmacokinetic parameters in Malaysian HIV-infected patients with a non-parametric approach which allows detection of outliers or non-normal distribution contrary to the parametric approach."	( Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach. Choon, TS; Hassan, NB; Mustafa, S; Woillard, JB; Yusuf, WN, 2016)	0.72
" In the intensive pharmacokinetic phase, apparent clearance (CL/F) was higher in pregnant (n=31) than postpartum (n=28) women (P=0."	( Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study. Back, D; Bolaji, O; Khoo, S; Neary, M; Olagunju, A; Owen, A, 2016)	0.77
" The pharmacodynamic consequences in patients at risk of suboptimal exposure and potential dose optimization strategies warrant further investigation."	( Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study. Back, D; Bolaji, O; Khoo, S; Neary, M; Olagunju, A; Owen, A, 2016)	0.77
"A physiologically-based pharmacokinetic (PBPK) model for nevirapine, which is metabolized by the cytochrome P450 (CYP) 3A4, 2B6 and 2D6 pathways, was developed to predict maternal and fetal pharmacokinetics (PK)."	( A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways. Benaboud, S; Blanche, S; Bouazza, N; De Sousa Mendes, M; Foissac, F; Hirt, D; Lui, G; Pressiat, C; Treluyer, JM; Urien, S; Valade, E; Zheng, Y, 2017)	0.7
" Here we aimed to quantify nevirapine and LPV/r drug-drug interaction effects on bedaquiline and M2 in patients co-infected with HIV and multidrug-resistant tuberculosis (MDR-TB) using population pharmacokinetic (PK) analysis and compare these with model-based predictions from single-dose studies in subjects without TB."	( Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. Brill, MJ; Karlsson, MO; Maartens, G; Pandie, M; Svensson, EM, 2017)	0.97
"Traditional medication adherence measures do not account for the pharmacokinetic (PK) properties of the drugs, potentially misrepresenting true therapeutic exposure."	( Pharmacokinetics-based adherence measures for antiretroviral therapy in HIV-infected Kenyan children. Ayaya, SO; Liu, H; Nyandiko, WM; Scanlon, ML; Slaven, JE; Tu, W; Vreeman, RC, 2017)	0.46
"Sparse pharmacokinetic sampling of ENG, NVP, or EFV were performed at screening, entry, and then 1, 4, 12, and 24-week postimplant insertion."	( Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy. Achilles, SL; Chappell, CA; Chen, BA; Cohn, SE; Darin, KM; Lamorde, M; Mackline, H; Nakalema, S; Riddler, SA; Scarsi, KK, 2017)	0.46
" Pharmacokinetic parameters (area under the plasma concentration vs."	( Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children. Aweeka, FT; Barlow-Mosha, L; Carey, V; Gingrich, D; Graham, B; Huang, L; Kamthunzi, P; Lindsey, JC; Marzan, F; Nachman, S; Parikh, S; Ssemambo, PK, 2017)	0.83
" Fifteen of the 16 (aged 4 to 11 years) on nevirapine-based ART were included in the pharmacokinetic analysis."	( Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children. Aweeka, FT; Barlow-Mosha, L; Carey, V; Gingrich, D; Graham, B; Huang, L; Kamthunzi, P; Lindsey, JC; Marzan, F; Nachman, S; Parikh, S; Ssemambo, PK, 2017)	1.1
" NVP was administered orally to male and female rats and sex differences in plasma levels and pharmacokinetic parameters were analysed."	( Sex-dependent metabolism of nevirapine in rats: impact on plasma levels, pharmacokinetics and interaction with nortriptyline. Compañ, P; Peris, JE; Usach, I, 2018)	0.77
" Associations between patient genotype and etonogestrel pharmacokinetic parameters were determined through univariate and multivariate linear regression."	( Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. Achilles, SL; Chappell, CA; Chen, BA; Lamorde, M; Matovu, J; Nakalema, S; Neary, M; Owen, A; Scarsi, KK; Siccardi, M, 2019)	0.73
"Within the control group, CYP2B6 983 T>C was associated with 27% higher etonogestrel Cmax and 28% higher AUC0-24weeks."	( Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. Achilles, SL; Chappell, CA; Chen, BA; Lamorde, M; Matovu, J; Nakalema, S; Neary, M; Owen, A; Scarsi, KK; Siccardi, M, 2019)	0.73
" Participants provided sparse pharmacokinetic (PK) sampling at baseline and weeks 2 and 4 for trough nevirapine determination."	( Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Hakim, J; Kanyama, C; Langat, D; Leon-Cruz, J; Mwelase, N; Omoz-Oarhe, A; Podany, AT; Supparatpinyo, K; Swindells, S, 2021)	2.28
" However, pharmacokinetic knowledge is lacking for specific populations, especially patients with neglected tropical diseases and severe malnutrition."	( Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review. Beijnen, JH; Dorlo, TPC; Huitema, ADR; Verrest, L; Wilthagen, EA, 2021)	0.62
" A linear one-compartment population pharmacokinetic model with first-order conditional estimation with interaction was used to evaluate methadone clearance (CL/F) and volume of distribution (V/F)."	( Effect of HIV, antiretrovirals, and genetics on methadone pharmacokinetics: Results from the methadone antiretroviral pharmacokinetics study. Bart, G; Brundage, RC; Giang, LM; Hodges, JS; Yen, H, 2021)	0.62
" This study aimed to develop a population pharmacokinetic model to characterize the disposition of maraviroc in neonates to inform dosing regimens and expand available options."	( Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K, 2022)	0.72
"Using maraviroc concentrations from neonates who received either a single dose or multiple doses of 8 mg/kg of maraviroc in the first 6 weeks of life, a population pharmacokinetic model was developed to determine the effects of age, sex, maternal efavirenz exposure and concomitant ARV therapy on maraviroc disposition."	( Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K, 2022)	0.72
" There are few pharmacokinetic models of buprenorphine across diverse populations."	( Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability. Bart, G; Brundage, RC; Giang, LM; Jaber, M; Korthuis, PT, 2022)	0.72

Excerpt	Reference	Relevance
"5, 50, and 200 mg/day, alone or in combination with zidovudine, 200 mg q8h."	( Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. Cheeseman, SH; Greenough, TC; Hall, D; Hattox, SE; Havlir, D; McLaughlin, MM; Myers, M; Spector, SA; Stein, DS; Sullivan, JL, 1995)	0.59
" MKC-442 was evaluated in combination with the nucleoside analogues AZT, ddI and ddC, the non-nucleoside RT inhibitor nevirapine, the HIV-1 proteinase inhibitor Ro-31-8959, and the alpha-glucosidase 1 inhibitor, MDL-28,574, using a cell viability assay."	( The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds. Brennan, TM; Bridges, CG; Leyda, JP; Taylor, DL; Tyms, AS, 1995)	0.5
"To determine whether synergistic inhibition of HIV-1 replication would result from the in vitro use of nevirapine in combination with zidovudine, interferon (IFN)-alpha 2C, and CD4 immunoadhesin."	( Nevirapine synergistically inhibits HIV-1 replication in combination with zidovudine, interferon or CD4 immunoadhesin. Brewster, F; Grob, P; Koup, RA; Sullivan, JL, 1993)	1.94
"The non-nucleoside reverse transcriptase inhibitor nevirapine (formerly BI-RG-587) was tested in combination with the other antiretrovial agents."	( Nevirapine synergistically inhibits HIV-1 replication in combination with zidovudine, interferon or CD4 immunoadhesin. Brewster, F; Grob, P; Koup, RA; Sullivan, JL, 1993)	1.98
"Zidovudine, IFN-alpha 2C and CD4 immunoadhesin, when used in combination with nevirapine, synergistically inhibited HIV-1 replication in human peripheral blood lymphocytes compared with each agent used alone."	( Nevirapine synergistically inhibits HIV-1 replication in combination with zidovudine, interferon or CD4 immunoadhesin. Brewster, F; Grob, P; Koup, RA; Sullivan, JL, 1993)	1.96
"Antiretroviral therapy including zidovudine may yield replicating viruses with a two amino-acid insertion in RT in combination with amino-acid changes at codons 67 and 215, which are highly resistant to lamivudine and stavudine on top of zidovudine and have unpredictable susceptibility to didanosine and zalcitabine despite lack of previously reported corresponding resistance-associated amino-acid changes."	( Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. Baan, E; Danner, SA; de Jong, JJ; de Wolf, F; Goudsmit, J; Hillebrand, ME; Huismans, R; Jurriaans, S; Lukashov, VV; ten Veen, JH, 1999)	0.3
"The purpose of the current study was to determine the efficacy and safety of nevirapine combined with nelfinavir and two nucleoside reverse transcriptase inhibitors (NRTIs) in patients previously exposed to highly active antiretroviral therapy (HAART)."	( The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study. Black, FT; Jensen-Fangel, S; Larsen, L; Obel, N; Thomsen, HF, 2001)	0.9
" Efavirenz, DPC082, DPC083, DPC961, and DPC963 used in combination with the NRTIs zidovudine and lamivudine acted synergistically to inhibit RT activity in the HIV-1 RT enzyme assay and additively to slightly synergistically to inhibit HIV-1 (RF) replication in the yield reduction assay."	( Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. Erickson-Viitanen, SK; King, RW; Klabe, RM; Reid, CD, 2002)	0.31
"To evaluate the sustained efficacy of nevirapine in combination with two nucleoside analogues in the treatment of HIV-infected patients in routine clinical practice."	( Sustained efficacy of nevirapine in combination with two nucleoside analogues in the treatment of HIV-infected patients: a 48-week retrospective multicenter study. Allan, PS; Arumainayagam, J; Browning, M; Das, S; Harindra, V; Tobin, J; Wade, A; Yoganathan, K, )	0.72
" To have any understanding of drug-drug interactions in HIV treatment we need to appreciate the importance of key pharmacological areas including: 1) how each drug in a regimen is eliminated; 2) the potential for a drug to either induce or inhibit metabolic enzymes and/or transporters; 3) the therapeutic index of each drug."	( Pharmacokinetic drug interactions with nevirapine. Back, D; Gibbons, S; Khoo, S, 2003)	0.59
"Randomized, controlled, open-label trial of 233 protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-naive HIV-infected patients allocated to a regimen of nelfinavir and nevirapine (1250/200 mg twice daily; n = 118) or ritonavir and saquinavir (400/400 mg twice daily; n = 115), both in combination with two nucleoside reverse transcriptase inhibitors."	( A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors. Gerstoft, J; Katzenstein, TL; Kirk, O; Lundgren, JD; Mathiesen, LR; Nielsen, H; Obel, N; Pedersen, C, 2003)	0.75
"A regimen of nelfinavir/nevirapine had a favourable virological effect and tolerability over a 48-week period compared with ritonavir/saquinavir, when administered in combination with two nucleoside reverse transcriptase inhibitors."	( A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors. Gerstoft, J; Katzenstein, TL; Kirk, O; Lundgren, JD; Mathiesen, LR; Nielsen, H; Obel, N; Pedersen, C, 2003)	0.86
"We have investigated the pharmacokinetics of nevirapine and paclitaxel in a patient who used both drugs concomitantly, as there are strong theoretical indications for a potential pharmacokinetic drug-drug interaction."	( No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel. Beijnen, JH; Huitema, AD; Kappelhoff, BS; Mairuhu, AT; Schellens, JH, 2005)	0.84
"Tenofovir disoproxil fumarate (DF) has been studied in combination with efavirenz in healthy volunteers and no interaction was found."	( Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. Burger, DM; Droste, JA; Hekster, YA; Kearney, BP, 2006)	0.54
" Six different groups were studied: 200 mg nevirapine twice daily, 400 mg nevirapine once daily, 600 mg efavirenz once daily, all without tenofovir DF (groups 1, 2, and 3, respectively), and the same groups with the drugs combined with tenofovir 300 mg once daily (groups 4, 5, and 6, respectively)."	( Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. Burger, DM; Droste, JA; Hekster, YA; Kearney, BP, 2006)	0.8
"We assessed the 18-month effectiveness of short-course (sc) antiretroviral peripartum regimens combined with alternatives to prolonged breastfeeding to prevent mother-to-child transmission (MTCT) of HIV-1 in Abidjan, Côte d'Ivoire."	( 18-month effectiveness of short-course antiretroviral regimens combined with alternatives to breastfeeding to prevent HIV mother-to-child transmission. Becquet, R; Dabis, F; Dequae-Merchadou, L; Ekouevi, DK; Horo, A; Leroy, V; Rouet, F; Rouzioux, C; Sakarovitch, C; Timité-Konan, M; Tonwe-Gold, B; Viho, I, 2008)	0.35
" Patients with HIV may also have simultaneous chronic medical conditions, resulting in the possibility of complex drug-drug interactions."	( Possible antiretroviral therapy-warfarin drug interaction. Fulco, PP; Higginson, RT; Zingone, MM, 2008)	0.35
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."	( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009)	0.35
"To determine which NNRTI, EFV or NVP, is more efficacious when given in combination with two NRTIs as part of initial ART for HIV infection in adults and children."	( Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Irlam, JH; Mbuagbaw, LC; Rutherford, GW; Siegfried, N; Spaulding, A, 2010)	0.73
"Both drugs have equivalent efficacies in initial treatment of HIV infection when combined with two NRTIs, but different side effects."	( Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Irlam, JH; Mbuagbaw, LC; Rutherford, GW; Siegfried, N; Spaulding, A, 2010)	0.73
"We retrospectively evaluated the durability and reasons for discontinuation of nevirapine (NVP) in combination with a tenofovir (TDF) and emtricitabine (FTC) or lamivudine (3TC)-containing antiretroviral therapy (ART) regimen in an Australian outpatient setting."	( Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects. Chan, DJ; Jeganathan, S; Maruszak, H; Smith, DE, 2011)	0.9
" nevirapine on the same background, in naïve HIV-1-infected patients) study compared prospectively ritonavir-boosted atazanavir (ATZ/r) 300 mg/100 mg once daily (qd) with immediate release nevirapine (NVP) 200 mg twice daily or 400 mg qd, each combined with fixed-dose tenofovir 300 mg/emtricitabine 200 mg qd in 569 ARV-naïve HIV-1-infected patients."	( Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). Andrade-Villanueva, J; Cairns, V; Clotet, B; de Rossi, L; Domingo, P; Gellermann, HJ; Podzamczer, D; Reiss, P; Rockstroh, JK; Soriano, V; Taylor, S, 2011)	1.61
"ARTEN is a randomized, open-label, non-inferiority trial that compares nevirapine (NVP) 200 mg twice daily or 400 mg once daily to atazanavir/ritonavir (ATZ/r) 300 mg/100 mg once daily, each combined with fixed-dose tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg once daily, in antiretroviral-naive HIV-1 patients with CD4(+) T-cell counts <400 (men) and <250 cells/mm(3) (women)."	( Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Andrade-Villanueva, J; Antunes, F; Arastéh, K; de Rossi, L; Di Perri, G; Domingo, P; Gellermann, H; Lutz, T; Migrone, H; Opravil, M; Podzamczer, D; Soriano, V; Taylor, S, 2011)	2.05
"NVP demonstrated at week 48 non-inferior antiviral efficacy compared with ATZ/r when given along with TDF/FTC, despite more drug-related discontinuations with NVP than ATZ/r."	( Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Andrade-Villanueva, J; Antunes, F; Arastéh, K; de Rossi, L; Di Perri, G; Domingo, P; Gellermann, H; Lutz, T; Migrone, H; Opravil, M; Podzamczer, D; Soriano, V; Taylor, S, 2011)	1.81
"Efficacy results were consistent with the ARTEN study demonstrating that NVP was non-inferior to ATV/r when taken in combination with TDF/FTC."	( A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients. Bhatti, L; Conner, C; Dejesus, E; Mills, A; Storfer, S, 2011)	0.62
"Drugs most likely to interact with combined oral contraceptives, transdermal and implant contraceptives include protease inhibitors, the NNRTIs efavirenz and nevirapine, and cobicistat-boosted elvitegravir."	( Drug interactions between antiretrovirals and hormonal contraceptives. Hills-Nieminen, C; Tseng, A, 2013)	0.59
"Compared with zidovudine-lamivudine, the use of tenofovir-lamivudine or emtricitabine in combination with nevirapine was a strong predictor of virologic failure in our cohort, which was not explained by other risk factors or criteria for regimen selection."	( Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort. Agbaji, OO; Darin, KM; Eisen, G; Gashau, W; Kanki, PJ; Meloni, ST; Murphy, RL; Nkado, R; Okonkwo, P; Onwujekwe, DI; Rawizza, HE; Scarsi, KK; Tchetgen Tchetgen, EJ, 2016)	0.87
" Single-dose drug-drug interaction studies found no significant interactions with nevirapine or lopinavir/ritonavir, but these findings could be misleading, especially because of bedaquiline's long terminal t1/2."	( Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. Conradie, F; Hughes, J; Maartens, G; McIlleron, H; Pandie, M; Siwendu, S; Variava, E; Wiesner, L, 2016)	0.88
"To determine which non-nucleoside reverse transcriptase inhibitor, either EFV or NVP, is more effective in suppressing viral load when given in combination with two nucleoside reverse transcriptase inhibitors as part of initial antiretroviral therapy for HIV infection in adults and children."	( Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Irlam, JH; Mbuagbaw, L; Mursleen, S; Rutherford, GW; Siegfried, N; Spaulding, AB, 2016)	0.8
"Both drugs have similar benefits in initial treatment of HIV infection when combined with two NRTIs."	( Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Irlam, JH; Mbuagbaw, L; Mursleen, S; Rutherford, GW; Siegfried, N; Spaulding, AB, 2016)	0.8
"To investigate the genetic contribution to this previously observed drug-drug interaction through studying SNPs in genes known to be involved in efavirenz, nevirapine or etonogestrel metabolism in the same group of women."	( Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. Achilles, SL; Chappell, CA; Chen, BA; Lamorde, M; Matovu, J; Nakalema, S; Neary, M; Owen, A; Scarsi, KK; Siccardi, M, 2019)	0.93
"This study demonstrates the influence of pharmacogenetics on the extent of drug-drug interactions between etonogestrel and efavirenz- or nevirapine-based ART."	( Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. Achilles, SL; Chappell, CA; Chen, BA; Lamorde, M; Matovu, J; Nakalema, S; Neary, M; Owen, A; Scarsi, KK; Siccardi, M, 2019)	0.94

Excerpt	Reference	Relevance
" Good oral bioavailability was observed in rhesus monkeys upon oral dosing of 1 as a suspension in methocel."	( 5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase. Balani, SK; Ciccarone, TM; Condra, JH; Emini, EA; Goldman, ME; Greenlee, WJ; Kauffman, LR; MacTough, SC; Rooney, CS; Williams, TM, 1993)	0.29
" The relative bioavailability (F) of ZDV and ddI in the triple combination compared to that in the double combination was also evaluated."	( Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. D'Aquila, RT; Fischl, MA; Hirsch, MS; Hughes, MD; Johnson, VA; Myers, M; Sheiner, LB; Sommadossi, JP; Zhou, XJ, 1999)	0.59
" Preliminary pharmacokinetics in rats showed that compound 18 is orally bioavailable and penetrates well into the brain."	( Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues. Bäckbro, K; Engelhardt, P; Fridborg, K; Högberg, M; Johansson, NG; Kangasmetsä, J; Lövgren, S; Noréen, R; Oberg, B; Sahlberg, BL; Sahlberg, C; Unge, T; Vrang, L; Zhang, H, 1999)	0.3
"The results of two randomized, single-dose, crossover bioavailability studies are presented which describe the pharmacokinetics and oral bioavailability of nevirapine, a novel nonnucleoside antiretroviral drug."	( Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Cappola, M; Hawi, A; Lamson, MJ; MacGregor, TR; Pav, JW; Robinson, P; Rowland, L; Sabo, JP, 1999)	0.75
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."	( QSAR model for drug human oral bioavailability. Topliss, JG; Yoshida, F, 2000)	0.31
" Nevirapine is well absorbed during labor, and sufficient drug for prophylaxis against perinatal transmission crosses the placenta if an oral dose is administered to the mother at least 1 hour before delivery."	( Antiretroviral pharmacology in pregnant women and their newborns. Mirochnick, M, 2000)	1.22
" Through an integrated effort involving synthesis, docking studies, and biological and pharmacokinetic evaluation, we investigated the structural dependence of the poor bioavailability and rapid clearance within the thioureidic series of antivirals."	( Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent. Aiello, F; Armaroli, S; Bergamini, A; Bolacchi, F; Bongiovanni, B; Caccia, S; Campiani, G; Capozzi, M; Coletta, M; Fabbrini, M; Garofalo, A; Greco, G; Guiso, G; Maga, G; Marini, S; Morelli, E; Nacci, V; Novellino, E; Ramunno, A; Spadari, S; Ventura, L, 2001)	0.31
" Population pharmacokinetic parameters (apparent clearance (CL/F), volume of distribution (V/F), absorption rate constant (k a)) were estimated, as were interindividual, interoccasion, and residual variability in the pharmacokinetics."	( Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Beijnen, JH; de Maat, MM; Huitema, AD; Meenhorst, PL; Mulder, JW; van Gorp, EC, 2002)	0.6
" Population pharmacokinetic parameters [clearance (CL/F), volume of distribution (V/F), absorption rate constant (ka)] and interindividual (IIV) and interoccasion variability (IOV) were estimated."	( Race is not associated with nevirapine pharmacokinetics. Beijnen, JH; de Maat, MM; Huitema, AD; Mulder, JW; Nellen, JF; Prins, JM; Wit, FW, 2004)	0.62
" Volume of distribution and absorption rate constant were 77."	( Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, J; MacGregor, TR; van Leth, F, 2005)	1.77
"Ideally, an anti-HIV drug should (1) be highly active against wild-type and mutant HIV without allowing breakthrough; (2) have high oral bioavailability and long elimination half-life, allowing once-daily oral treatment at low doses; (3) have minimal adverse effects; and (4) be easy to synthesize and formulate."	( In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). Andries, K; Arnold, E; Bohets, H; Clark, AD; Daeyaert, F; Das, K; de Béthune, MP; De Clerck, F; de Jonge, M; De Knaep, F; Frenkel, YV; Guillemont, J; Heeres, J; Hughes, SH; Janssen, PA; Koymans, L; Kukla, M; Lampo, A; Lewi, PJ; Ludovici, D; Medaer, B; Pasquier, E; Pauwels, R; Stoffels, P; Vinkers, M; Williams, P, 2005)	0.33
" Our findings suggest that decreased bioavailability of nevirapine because of rifampicin coadministration could be overcome by increasing the dose of nevirapine from 200 to 300 mg twice daily without short-term adverse events."	( Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. Hemanthkumar, AK; Kumaraswami, V; Narendran, G; Padmapriyadarsini, C; Raja, K; Rajasekaran, S; Ramachandran, G; Sathishnarayan, S; Sukumar, B; Swaminathan, S, 2006)	0.97
"An open-label, balanced, randomized, 2-treatment, 2-period, 2-sequence, single-dose, crossover bioavailability study was conducted in 40 subjects with 21-day washout period between each treatment."	( Nevirapine/lamivudine/stavudine as a combined-formulation tablet: bioequivalence study compared with each component administered concurrently under fasting condition. Garg, M; Monif, T; Singla, AK; Tippabhotla, SK; Vijan, T, 2006)	1.78
"Nevirapine has been widely used in pregnancy for its efficacy, low pill burden, bioavailability and rapid transplacental transfer."	( Safety of nevirapine in pregnancy. Anderson, J; de Ruiter, A; Edwards, SG; Hay, P; McDonald, C; Natarajan, U; Pym, A; Taylor, GP; Velisetty, P; Welch, J, 2007)	2.18
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34
" There are indications that piperine inhibits, rather than stimulates, drug metabolism in most cases, thus increasing the bioavailability and effect of some drugs."	( Influence of piperine on the pharmacokinetics of nevirapine under fasting conditions: a randomised, crossover, placebo-controlled study. Kasibhatta, R; Naidu, MU, 2007)	0.59
"This pilot study provided evidence for enhanced bioavailability of nevirapine when administered with piperine."	( Influence of piperine on the pharmacokinetics of nevirapine under fasting conditions: a randomised, crossover, placebo-controlled study. Kasibhatta, R; Naidu, MU, 2007)	0.83
"Hypoxis hemerocallidea and l-canavanine interact with the efflux of nevirapine across intestinal epithelial cells and therefore can potentially increase the bioavailability of this antiretroviral drug when taken concomitantly."	( Impact of traditional medicinal plant extracts on antiretroviral drug absorption. Brown, D; Brown, L; Hamman, JH; Heyneke, O; van Wyk, JP, 2008)	0.58
"4% and reduced the absorption rate constant (k(a)) by almost sixfold."	( Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. Cohen, K; Elsherbiny, D; Jansson, B; McIlleron, H; Simonsson, US; Smith, P, 2009)	0.64
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."	( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010)	0.36
"This study compared the pharmacokinetics and relative bioavailability of a test and reference formulation of nevirapine 200-mg tablets after single oral doses in healthy Chinese men to meet regulatory criteria for marketing of the new generic formulation."	( Relative bioavailability of two formulations of nevirapine 200-mg tablets in healthy Chinese male volunteers: a single-dose, randomized-sequence, open-label, two-way crossover study. Hu, Y; Yang, X; Yu, C; Zhang, Q; Zhu, Y; Zou, J, 2010)	0.83
" Mean relative bioavailability was 103."	( Relative bioavailability of two formulations of nevirapine 200-mg tablets in healthy Chinese male volunteers: a single-dose, randomized-sequence, open-label, two-way crossover study. Hu, Y; Yang, X; Yu, C; Zhang, Q; Zhu, Y; Zou, J, 2010)	0.62
" Therefore, this investigation aimed at screening the effects of short term and chronic exposure of sutherlandia on oral bioavailability and pharmacokinetics of nevirapine (NVP), a non-nucleoside reverse transcriptase inhibitor, in Sprague Dawley rats."	( Effect of short term and chronic administration of Sutherlandia frutescens on pharmacokinetics of nevirapine in rats. Earla, R; Folk, WR; Kwatra, D; Mandava, NK; Minocha, M; Mitra, AK; Pal, D, 2011)	0.78
" However, there are no studies about its bioavailability in rats and hardly any about its pharmacokinetic."	( Bioavailability of nevirapine in rats after oral and subcutaneous administration, in vivo absorption from gastrointestinal segments and effect of bile on its absorption from duodenum. Peris, JE; Usach, I, 2011)	0.7
"The aim of this study was to investigate the steady-state bioavailability of 2 once-daily tablet formulations of NVP XR (containing 25% or 20% hypromellose; NVP XR25 and NVP XR20, respectively) in 400- or 300-mg tablets compared with twice-daily immediate-release (IR) NVP 200-mg tablets."	( Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study. Arasteh, K; Battegay, M; Berger, F; Bogner, JR; Livrozet, JM; Macha, S; Mossdorf, E; Plettenberg, A; Quinson, AM; Robinson, P; Stern, J; Witt, MD; Yong, CL; Zhang, W, 2011)	0.64
" The relative bioavailability of NVP XR25 was greater compared with that of NVP XR20."	( Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study. Arasteh, K; Battegay, M; Berger, F; Bogner, JR; Livrozet, JM; Macha, S; Mossdorf, E; Plettenberg, A; Quinson, AM; Robinson, P; Stern, J; Witt, MD; Yong, CL; Zhang, W, 2011)	0.64
"Extent of bioavailability was lower and t(max,ss) was delayed with all NVP XR formulations compared with NVP IR."	( Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study. Arasteh, K; Battegay, M; Berger, F; Bogner, JR; Livrozet, JM; Macha, S; Mossdorf, E; Plettenberg, A; Quinson, AM; Robinson, P; Stern, J; Witt, MD; Yong, CL; Zhang, W, 2011)	0.64
" Higher MRT values of surface coated nanosuspension in brain, liver and spleen as compared to pure drug solution ensured enhanced bioavailability and prolonged residence of the drug at the target site."	( Surface modified nevirapine nanosuspensions for viral reservoir targeting: In vitro and in vivo evaluation. Shegokar, R; Singh, KK, 2011)	0.71
" We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP; 30/15/28 mg) in HIV-infected children."	( Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. Aurpibul, L; Capparelli, E; Chokephaibulkit, K; Cressey, TR; Eksaengsri, A; Hongsiriwon, S; Kabat, B; Limwongse, C; McIntosh, K; Muresan, P; Ngampiyaskul, C; Sirisanthana, V; Smith, ME; Toye, M; Wittawatmongkol, O; Yogev, R, 2011)	0.79
" Concomitant antitubercular treatment including rifampicin typically decreased bioavailability by 39%, with significant between-subject variability."	( Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. Barnes, KI; Cohen, K; Denti, P; Huitema, A; Karlsson, MO; Kredo, T; Nachega, JB; Svensson, E; van der Walt, JS, 2012)	0.6
" The Triomune fixed-dose tablet was an independent predictor of bioavailability compared to the liquid and other tablet formulations."	( Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Acosta, EP; Aweeka, FT; Burger, D; Capparelli, EV; Cressey, TR; Kabamba, D; Nikanjam, M; Spector, SA, 2012)	1.82
" Subjects taking concomitant PIs exhibited increases in CsA and TAC exposure (AUC/dose) due to the increased apparent oral bioavailability and decreased apparent oral clearance."	( Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients. Barin, B; Benet, L; Browne, M; Carlson, L; Christians, U; Floren, L; Frassetto, L; Roland, M; Stock, P; Wolfe, A, 2013)	0.39
" Oral bioavailability of nevirapine SEDDS was checked by using rat model."	( Role of lipid-based excipients and their composition on the bioavailability of antiretroviral self-emulsifying formulations. Chudasama, A; Nivsarkar, M; Patel, V; Shishoo, C; Vasu, K, 2015)	0.72
" Finally, oral bioavailability of the NVP-loaded micellar systems (2mg/mL) was assessed in male Wistar rats (8mg/kg) and compared with a pediatric commercially available formulation (Viramune(®))."	( Enhanced oral bioavailability of nevirapine within micellar nanocarriers compared with Viramune(®). Bernabeu, E; Chiappetta, DA; Cohen, L; Höcht, C; Lepera, L; Moretton, MA; Taira, C, 2014)	0.68
" Pharmacokinetic analysis of the rat plasma NVP concentration-time data allowed absorption rate constants to be calculated."	( Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants. Baum, MM; Beliveau, M; Cortez, JM; Moss, JA; Quintero, R; Smith, TJ, 2015)	0.68
" However, the data obtained from IDR testing indicate that dissolution is the critical factor for the bioavailability of this drug."	( Compatibility studies of nevirapine in physical mixtures with excipients for oral HAART. de Oliveira, GG; Ferraz, HG; Severino, P; Souto, EB, 2013)	0.69
" Compared to RRC, Ugandan children exhibited reduced bioavailability of EFV and LPV; 11% (P=0."	( The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda. Achan, J; Aweeka, F; Bartelink, IH; Capparelli, E; Charlebois, E; Dorsey, G; Gingrich, D; Havlir, D; Jullien, V; Kamya, M; Plenty, A; Ruel, T; Savic, RM; Scherpbier, HJ; Young, SL, 2015)	0.63
" Patients in the EFV-arm but not in the NVP-arm had significantly lower lumefantrine bioavailability compared to that in the control-arm."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	0.76
"Co-treatment of AL with EFV-based ART but not NVP-based ART significantly reduces lumefantrine bioavailability and consequently total exposure."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	0.76
"It was concluded that the concept of mixed hydrotropic solid dispersion is a safe, novel and cost-effective technique for enhancing the bioavailability of poorly water-soluble drugs by dissolving the drug in a nonionized form."	( Improving the solubility of nevirapine using A hydrotropy and mixed hydrotropy based solid dispersion approach. Awasthi, R; Dua, K; Kamate, VJ; Madan, JR, )	0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"Nevirapine (NVP) is used for the management of HIV/AIDS but must be dosed frequently, exhibits unpredictable bioavailability and a side effect profile that includes hepato- and dermo-toxicity."	( Preformulation characterization and identification of excipients for nevirapine loaded niosomes. Walker, RB; Witika, BA, 2021)	2.3
" Bioavailability of lumefantrine, sulfadoxine, pyrimethamine, lopinavir, and efavirenz was decreased in severely malnourished patients, but increased for the P-glycoprotein substrates abacavir, saquinavir, nevirapine, and ivermectin."	( Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review. Beijnen, JH; Dorlo, TPC; Huitema, ADR; Verrest, L; Wilthagen, EA, 2021)	0.81
" Proportionate changes in CL/F and V/F might indicate a primary effect on bioavailability (F) rather than two separate effects."	( Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability. Bart, G; Brundage, RC; Giang, LM; Jaber, M; Korthuis, PT, 2022)	0.72

Excerpt	Relevance	Reference
" Good oral bioavailability was observed in rhesus monkeys upon oral dosing of 1 as a suspension in methocel."	( 5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase. Balani, SK; Ciccarone, TM; Condra, JH; Emini, EA; Goldman, ME; Greenlee, WJ; Kauffman, LR; MacTough, SC; Rooney, CS; Williams, TM, 1993)	0.29
" Clearance was more rapid in chronic dosing studies than predicted by single-dose studies and was more rapid in younger children than in adolescent children."	( Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. Bryson, Y; Cort, S; Lamson, M; Luzuriaga, K; McSherry, G; Robinson, J; Scott, G; Stechenberg, B; Sullivan, JL, 1996)	0.56
" This small-animal model should be particularly useful in the preclinical prioritization of lead compounds within a common chemical class, in the evaluation of alternative in vivo dosing regimens, and in the determination of appropriate combination therapy in vivo."	( Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds. Charpiot, B; Datema, R; Hincenbergs, M; Kaneshima, H; Linquist, V; McCune, JM; Moreno, MB; Rabin, L; Seifert, J; Warren, S, 1996)	0.29
"Blood samples were obtained at 0, 1, 2, 3, 4, 6 and 8 h after dosing on both study days."	( The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. Back, DJ; Barry, MG; Breckenridge, AM; Halifax, KL; Merry, C; Mulcahy, F; Ryan, M; Tjia, JF, 1998)	0.54
" In the absence of therapeutic drug monitoring we suggest that an increase in the standard NFV dosage of 750 mg three times daily will be required to ensure satisfactory NFV plasma concentrations, thereby maintaining antiviral efficacy."	( The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. Back, DJ; Barry, MG; Breckenridge, AM; Halifax, KL; Merry, C; Mulcahy, F; Ryan, M; Tjia, JF, 1998)	0.54
" Following maternal dosing with 200 mg during labor, concentrations exceeding 100 ng/mL (10 times the in vitro IC50) were achieved in the newborns."	( Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. Beckerman, K; Fenton, T; Gagnier, P; Gwynne, M; Jimenez, E; Mirochnick, M; Pav, J; Siminski, S; Spector, SA; Sperling, RS; Sullivan, JL; Yogev, R, 1998)	0.62
" These data suggest that indinavir dosing should be dependent on drug exposure and not on cotherapy with nevirapine."	( Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. Dusek, A; Hall, DB; Lamson, M; Murphy, RL; Myers, M; Sommadossi, JP, 1999)	0.76
"The administration of a single dose of nevirapine to women during labor and to their newborns at 72 h was well tolerated and showed potent antiretroviral activity in the women at 1 week after dosing without rebound above baseline 6 weeks after a single dose."	( A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). Allen, M; Bagenda, D; Dransfield, K; Elliott, T; Fleming, T; Fowler, MG; Guay, LA; Hom, D; Horton, S; Jackson, JB; Mirochnick, M; Mmiro, F; Mofenson, L; Murarka, A; Musoke, P; Nakabiito, C; Pav, JW, 1999)	0.82
" Although the currently used protease inhibitors (PIs) may undergo more rapid rates of metabolism because NVP induces CYP3A, No dosage adjustments are required when NVP is taken in combination with PIs so far."	( [Antiretroviral agent nevirapine: its pharmacological action and potential for clinical use]. Osugi, T; Takeuchi, S, 1999)	0.62
"To investigate and to compare the steady-state plasma pharmacokinetics of nevirapine in a dosing regimen of 400 mg once daily versus 200 mg twice daily in HIV-1-infected individuals."	( The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. Beijnen, JH; Danner, SA; Foudraine, NA; Hoetelmans, RM; Kwakkelstein, MO; Lange, JM; Meenhorst, PL; Mulder, JW; Reiss, P; van Heeswijk, RP; Veldkamp, AI; Wit, FW, 2000)	0.81
" Differences in these pharmacokinetic parameters for the two dosing regimens were tested using ANOVA."	( The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. Beijnen, JH; Danner, SA; Foudraine, NA; Hoetelmans, RM; Kwakkelstein, MO; Lange, JM; Meenhorst, PL; Mulder, JW; Reiss, P; van Heeswijk, RP; Veldkamp, AI; Wit, FW, 2000)	0.58
"These data show that the daily exposure to nevirapine, as measured by the plasma AUC[24h], is not different between a 400 mg once daily and a 200 mg twice daily dosing regimen."	( The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. Beijnen, JH; Danner, SA; Foudraine, NA; Hoetelmans, RM; Kwakkelstein, MO; Lange, JM; Meenhorst, PL; Mulder, JW; Reiss, P; van Heeswijk, RP; Veldkamp, AI; Wit, FW, 2000)	0.84
" Oral dosing is administered three times daily for delavirdine (DLV), twice daily for nevirapine (NVP), and once daily for efavirenz (EFV)."	( Clinical uses of non-nucleoside reverse transcriptase inhibitors. Harris, M; Montaner, JS, )	0.35
" RT sequences from plasma collected prior to NVP dosing were also analyzed."	( Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. Becker-Pergola, G; Eshleman, SH; Fowler, MG; Guay, LA; Jackson, JB; Mirochnick, M; Mmiro, F; Mofenson, LM; Mracna, M; Musoke, P, 2000)	0.54
" Pharmacokinetic data suggested that a more prolonged exposure to NVP after dosing may favor selection of NVP-resistant HIV-1."	( Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. Becker-Pergola, G; Eshleman, SH; Fowler, MG; Guay, LA; Jackson, JB; Mirochnick, M; Mmiro, F; Mofenson, LM; Mracna, M; Musoke, P, 2000)	0.54
"NVP reaches concentrations in the semen approximately 60% of those in the blood plasma throughout the 12 h dosing period."	( Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. Drake, SM; Hoetelmans, RM; Pillay, D; Taylor, S; van Heeswijk, RP; White, DJ; Workman, J, 2000)	0.64
" Dosing regimens must take into account developmental changes in clearance and appropriate scaling for size."	( Antiretroviral pharmacology in pregnant women and their newborns. Mirochnick, M, 2000)	0.31
" Plasma trough levels of nelfinavir (NFV) and saquinavir (SQV), in a twice daily dosing regimen, were above the protein-corrected IC(95) in most patients despite the addition of an enzymatic inducer such as nevirapine, and peak levels were 2- and 5-fold increased with respect to standard doses."	( Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure. Antela, A; Casado, JL; Dehertogh, P; Dronda, F; Hertogs, K; Martí-Belda, P; Moreno, S; Sabido, R, 2001)	0.73
" Clinicians should use recommended PEP guidelines and dosing instructions to reduce the risk for serious adverse events."	( Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000. , 2001)	0.58
" The pharmacokinetics of nevirapine in plasma and saliva during a dosing interval was assessed in HIV-1-infected patients taking nevirapine (200 mg twice daily) to explore the relation between the concentration of nevirapine in plasma and saliva."	( Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapine. Beijnen, JH; Hoetelmans, RM; Lange, JM; Meenhorst, PL; Mulder, JW; van Heeswijk, RP; Veldkamp, AI, 2001)	0.82
" Information on each drug, such as the name of the drug, the dosage normally prescribed, and cost of treatment is listed."	( What they say about: non-nucleoside drugs. , )	0.13
" Several studies of regimens that include protease inhibitors compare dosing twice daily to three times a day."	( Antivirals update. , 1998)	0.3
" Dosage and cost data are included."	( What they say about non-nucleoside drugs. , )	0.13
" Finally, nevirapine-containing regimens have a simpler dosing schedule, and this facilitates high adherence and improves QOL."	( Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. Balagué, M; Bonjoch, A; Clotet, B; Domingo, P; Francia, E; Fumaz, CR; Gel, S; Johnston, S; Lange, J; Negredo, E; Paredes, R; Romeu, J; Ruiz, L, 2001)	0.97
"Limited data are available on antiretroviral drug concentrations in seminal plasma during a dosing interval."	( Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma. de Vries, JW; Hoetelmans, RM; Lange, JM; Prins, JM; Repping, S; van Praag, RM, 2001)	0.6
" Given that the lowest trough serum concentration of nevirapine exceeded by more than 40 times the protein binding adjusted median infective dose (IC(50)) of wild-type HIV in all patients, we suggest that there is no need to increase nevirapine dosage when it is given with rifampicin."	( Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. Crespo, M; Falco, V; Lopez, RM; Ocaña, I; Pahissa, A; Pou, L; Ribera, E; Ruiz, I, 2001)	0.84
"The objective of this study was to develop and validate a limited sampling strategy (LSS) that allows accurate and precise estimation of the area under the plasma concentration versus time curve (AUC) of nevirapine, when used in the licensed dosage of 200 mg twice daily."	( Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine. Beijnen, JH; Hoetelmans, RM; Lange, JM; Meenhorst, PL; Mulder, JW; van Heeswijk, RP; Veldkamp, AI, 2001)	0.7
"As part of an on-going clinical trial in Malawi, infants born to women who received (early presenters) or did not receive (late presenters) standard intrapartum nevirapine (NVP) dosing were randomized to receive orally either single dose NVP alone or NVP plus zidovudine (twice daily for 1 week)."	( Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants. Broadhead, R; Fiscus, S; Gibbons, A; Hoover, D; Kumwenda, N; Lema, V; Liomba, G; Mukiibi, J; Taha, TE, 2002)	0.51
"The complexity of highly active antiretroviral therapy (HAART), with multiple medications, formulations, and dosing intervals, makes adherence challenging."	( Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Johnson, GM; Krogstad, PA; Lee, S; Mohan, K; Morse, EV; Nachman, S; Stanley, K; Van Dyke, RB; Wiznia, A, 2002)	0.31
" Nevirapine was administered at the lead-in dosage of 200 mg once daily."	( Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. Cahn, P; Casssetti, LI; Gigliotti, M; Hall, DB; Losso, M; McDonough, M; Montaner, JS; Robinson, PA; Wruck, J; Zala, C, 2003)	1.44
" Lower predose nevirapine concentrations were associated with lower cord blood concentrations and a shorter interval between maternal dosing and delivery."	( Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. Blanchard, S; Culnane, M; Cunningham, CK; Dorenbaum, A; Gelber, RD; Mirochnick, M; Mofenson, L; Sullivan, JL, 2003)	1.02
"Infants born less than 2 hours after maternal nevirapine dosing during labor should receive a dose of nevirapine immediately after birth in addition to the standard infant dose at 48 to 72 hours."	( Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. Blanchard, S; Culnane, M; Cunningham, CK; Dorenbaum, A; Gelber, RD; Mirochnick, M; Mofenson, L; Sullivan, JL, 2003)	0.93
" Nevirapine was dosed according to the manufacturer's guidelines."	( Nevirapine use in HIV-1-infected children. Ball, C; Dumont, G; Gibb, DM; Lyall, H; Novelli, V; Sharland, M; Tudor-Williams, G; Verweel, G; Walters, S; Wilkins, E, 2003)	2.67
" NFV dosed at 55 mg/kg BID in children who are <30 kg provides comparable exposure to that measured in children who are >25 kg and receiving NFV 30 mg/kg TID."	( Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. Aweeka, FT; Floren, LC; Hayashi, S; Jayewardene, A; Johnson, G; Krogstad, P; Nachman, S; Stanley, K; Wiznia, A, 2003)	0.32
" Using the recommended lead-in dosing schedule in conjunction with good health care management, this adverse event can be controlled in the vast majority of patients."	( Defining the toxicity profile of nevirapine and other antiretroviral drugs. Murphy, RL, 2003)	0.6
" Following maternal dosing with 200 mg NVP orally at onset of labor, breast-feeding infants were randomized within 48 hours of birth to 1 of 3 regimens: arm 1, NVP given OW (4 mg/kg from birth to 14 days, upward arrow to 8 mg/kg from 15 days to 24 weeks), arm 2, NVP given TW (4 mg/kg from birth to 14 days, upward arrow to 8 mg/kg from 15 days to 24 weeks), and arm 3, NVP given OD (2 mg/kg from birth to 14 days, upward arrow to 4 mg/kg from 15 days to 24 weeks)."	( Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. Abdool Karim, SS; Bassett, MT; Coovadia, HM; Emel, L; Eshleman, SH; Fleming, T; George, K; Jones, SA; Katzenstein, DA; Maldonado, Y; Maponga, CC; Mirochnick, MM; Mofenson, LM; Mwatha, A; Shetty, AK; Wells, J, 2003)	0.59
" Labor ward dosing to enhance nevirapine coverage should be considered as an adjunct to antenatal nevirapine administration for prevention of mother-to-child transmission of HIV."	( Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings. Acosta, EP; Aldrovandi, GM; Goldenberg, RL; Kumwenda, R; Sinkala, M; Stout, JP; Stringer, JS; Vermund, SH, 2004)	1.01
" PI-based therapies often fail due to poor adherence caused by heavy pill burden, complex dosing schedules and undesirable side effects."	( Clinical utility of current NNRTIs and perspectives of new agents in this class under development. Hamatake, R; Hong, Z; Zhang, Z, 2004)	0.32
" Adjusting dosage by means of therapeutic drug monitoring would appear to be a reasonable way of maximising patient benefit from treatment."	( Follow-up measurements of Nevirapine plasma levels over a prolonged period. Ebigbo, A; Klinker, H; Knipper, A; Langmann, P; Sienz, M; Winzer, R; Zilly, M, 2004)	0.62
"In antiretroviral-experienced subjects with sustained viral suppression, dual therapy with NVP plus LPV/rtv at standard dosage was as potent and safe as standard-of-care HAART at 48 weeks of follow-up."	( Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study). Burger, D; Clotet, B; Côté, H; López, S; Martínez, E; Miró, O; Moltó, J; Montaner, J; Negredo, E; Puig, J; Rey-Joly, C; Ribalta, J; Ruiz, L; Salazar, J, 2005)	0.63
"The median NVP level fell to 68 ng/mL (range: <50-228, n = 43) 8 to 14 days after dosing and to 51 ng/mL (range: <50-166, n = 25) between 15 and 21 days."	( Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. Capparelli, E; Cressey, TR; Jackson, JB; Jourdain, G; Kunkeaw, S; Lallemant, MJ; Mirochnick, M; Musoke, P, 2005)	0.68
" Our objective was to determine intracellular (or cell-associated) nevirapine concentrations over the full dosing interval and to relate protein binding and P-glycoprotein (P-gp) expression to intracellular exposure."	( Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Almond, LM; Back, DJ; Bonington, A; Dalton, M; Edirisinghe, D; Khoo, SH, 2005)	0.82
"054) and remained unchanged over the dosing interval."	( Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Almond, LM; Back, DJ; Bonington, A; Dalton, M; Edirisinghe, D; Khoo, SH, 2005)	0.59
"The intracellular accumulation of nevirapine was low, did not change over the dosing interval, and was not related to protein binding."	( Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Almond, LM; Back, DJ; Bonington, A; Dalton, M; Edirisinghe, D; Khoo, SH, 2005)	0.87
" The method has been successfully used to analyze commercial solid dosage form to assess the chromatographic performance of SFC system."	( Effect of system variables involved in packed column SFC of nevirapine as model analyte using response surface methodology: application to retention thermodynamics, solute transfer kinetic study and binary diffusion coefficient determination. Agrawal, H; Kaul, N; Mahadik, KR; Paradkar, AR, 2005)	0.57
" Daily drug dosage was 250 or 400 mg didanosine, 300mg lamivudine and 400 mg nevirapine."	( Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients. Blanco, JL; Crespo, M; Deig, E; Falcó, V; González, A; Miró, JM; Ocaña, I; Pahissa, A; Pedrol, E; Ribera, E; Rodríguez-Pardo, D; Rubio, M; Soler, A, 2005)	0.78
" One patient erroneously took double dosing of nevirapine, while the other patient did not attend the scheduled laboratory control two weeks after the initiation of nevirapine treatment."	( [Hepatic failure due to nevirapine treatment for HIV infection]. Katzenstein, TL; Mens, H, 2005)	0.89
"To improve the dosing frequency and pill burden of antiretroviral therapy, we compared two once-daily dosed regimens to a twice-daily dosed regimen."	( Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES). Borleffs, JC; Hassink, EA; Juttmann, JR; Koopmans, PP; Lange, JM; Lowe, SH; Richter, C; Schreij, G; ten Kate, RW; van der Tweel, I; Wensing, AM, )	0.13
"HIV-1-infected, antiretroviral drug-naïve adults were randomized to either twice-daily nelfinavir and stavudine and once-daily didanosine (regimen A) or simplified once-daily dosed antiretroviral regimens consisting of nevirapine, didanosine, and lamivudine (regimen B) or saquinavir, ritonavir, didanosine, and lamivudine (regimen C)."	( Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES). Borleffs, JC; Hassink, EA; Juttmann, JR; Koopmans, PP; Lange, JM; Lowe, SH; Richter, C; Schreij, G; ten Kate, RW; van der Tweel, I; Wensing, AM, )	0.32
"No statistically significant difference in efficacy was found between the two investigated once-daily dosed treatment regimens (B and C) and the reference (A)."	( Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES). Borleffs, JC; Hassink, EA; Juttmann, JR; Koopmans, PP; Lange, JM; Lowe, SH; Richter, C; Schreij, G; ten Kate, RW; van der Tweel, I; Wensing, AM, )	0.13
"As part of the large international, randomized 2NN trial, the pharmacokinetics of nevirapine in once-daily 400 mg and twice-daily 200 mg dosing regimens were investigated."	( Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Robinson, PA; van Leth, F, )	0.68
" Differences in pharmacokinetics between once- versus twice-daily dosing were investigated with nonlinear mixed effects modelling (NONMEM)."	( Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Robinson, PA; van Leth, F, )	0.45
" Dosage and dosing frequency did not influence clearance or volume of distribution of nevirapine, indicating linear pharmacokinetic behavior of nevirapine whether given as a single daily dose or as divided doses over 24 hours."	( Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Robinson, PA; van Leth, F, )	0.68
"The daily exposure to nevirapine (AUC24h) was similar for the 400 mg once-daily and the 200 mg twice-daily dosing regimens."	( Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Robinson, PA; van Leth, F, )	0.77
" To minimize toxicity, clinicians must adhere to dosing guidelines, avoid prescribing the drug in patients with known increased risk of toxicity, and promptly recognize toxicities, which are mainly cutaneous and hepatic."	( Nevirapine toxicity. Taiwo, BO, 2006)	1.78
" In a multivariate model, K103N detection was associated with HIV-1 subtype (C > A), after adjusting for log10 delivery viral load, the number of days between NVP dosing and sample collection, age, and parity."	( Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. Chen, S; Church, JD; Eshleman, SH; Fiscus, SA; Flys, TS; Guay, LA; Hoover, DR; Jackson, JB; Jones, DC; Kumwenda, N; Mmiro, F; Musoke, P; Mwatha, A; Taha, TE, 2006)	0.55
"To reduce mother-to-child transmission (MTCT) of HIV, we assessed the stability of nevirapine suspension in an oral dosing syringe over a range of storage conditions."	( Stability of nevirapine suspension in prefilled oral syringes used for reduction of mother-to-child HIV transmission. Dreyfuss, ML; Gray, RH; Hamzeh, FM; Li, X; Parsons, TL; Rexroad, VE; Stamper, PD, 2006)	0.93
"A mother-to-child transmission dosing kit, containing a maternal nevirapine tablet and infant nevirapine suspension in an oral syringe that can be dispensed to the pregnant woman to use at delivery."	( Stability of nevirapine suspension in prefilled oral syringes used for reduction of mother-to-child HIV transmission. Dreyfuss, ML; Gray, RH; Hamzeh, FM; Li, X; Parsons, TL; Rexroad, VE; Stamper, PD, 2006)	0.94
" Based on these results, it is acceptable to test the pharmacokinetics and dosing requirements of Pedimune in HIV-infected children."	( Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults. Burger, DM; Dijkema, T; Gibb, DM; L'homme, RF; van der Ven, AJ; Warris, A, 2007)	0.34
"Despite the benefits of protease inhibitor (PI)-based HIV treatment, issues of tolerability, dosing frequency, pill count and long-term metabolic complications necessitate evaluation of alternate treatment strategies."	( Evaluation of nevirapine-switch strategies for HIV treatment. Cooper, CL, 2006)	0.69
" The first trial began in April 1991 and assessed zidovudine (ZDV) versus placebo and since then, the type, dosage and duration of drugs to be compared has been modified in each subsequent trial."	( Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Brocklehurst, P; Siegfried, NL; van der Merwe, L; Volmink, J, 2007)	0.34
"0001 in both cases) influenced by the patient's status (mean KM estimate of 812 days for virological failures, 1294 for naive patients and 1657 for treatment simplifications) and by the dosing schedule (once-daily 1315 days; twice-daily 1198 days)."	( Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort. Airoldi, M; Arici, C; Bombana, E; Gregis, G; Maggiolo, F; Quinzan, G; Ravasio, V; Ripamonti, D; Suter, F, 2007)	0.63
"In the context of attempts to simplify treatment regimens and enhance adherence, there is great interest in once-daily dosing regimens for the treatment of HIV-1 infection."	( Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. Cooper, CL; van Heeswijk, RP, 2007)	0.73
"Most antiretrovirals are metabolized in the liver, and lower dosing could be advisable in patients with severe liver insufficiency."	( Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. Barreiro, P; Gonzalez-Lahoz, J; Jiménez-Nácher, I; Labarga, P; Martín-Carbonero, L; Rodríguez-Novoa, S; Ruiz, A; Soriano, V, 2007)	0.34
" However, a higher daily dosage of itraconazole might have an inhibitory effect."	( Pharmacokinetic study of the interaction between itraconazole and nevirapine. Jaruratanasirikul, S; Sriwiriyajan, S, 2007)	0.58
"Co-administration of NVP and daily dosage of FLU (200 mg/day and 400 mg/day) results in markedly increased trough plasma NVP level when compared to the administration of NVP alone."	( Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. Athichathanabadi, C; Manosuthi, W; Phoorisri, T; Sungkanuparph, S; Uttayamakul, S, 2007)	0.79
"The effect of nevirapine once-daily dosing on the pharmacokinetics of methadone and its main metabolite, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, was evaluated in ten HIV positive patients on stable methadone therapy."	( Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily. Arroyo, E; Climent-Grana, E; Merino, E; Pérez-Ruixo, JJ; Portilla, J; Valenzuela, B, 2007)	0.92
" In conclusion, with the persistence of 4'-Ed4TTP and persistent anti-HIV activity in cells, we anticipate less frequent dosing and fewer patient compliance issues than for D4T."	( Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog. Baba, M; Cheng, YC; Dutschman, GE; Grill, SP; Hu, R; Lam, W; Paintsil, E; Tanaka, H, 2007)	0.34
" Further in-depth studies in a large number of patients receiving different dosage regimens are required to confirm these results and further our understanding of a possible clinical advantage arising from the bioenhancement capabilities of piperine in the treatment of HIV infection."	( Influence of piperine on the pharmacokinetics of nevirapine under fasting conditions: a randomised, crossover, placebo-controlled study. Kasibhatta, R; Naidu, MU, 2007)	0.59
" Simplification of dosing schedules has prompted investigations into once-daily dosing regimens; nevirapine once-daily dosing strategies are currently under investigation."	( Once-daily dosing of nevirapine in HAART. Clotet, B, 2008)	0.88
"For optimal adherence, once-daily dosing is best."	( Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study. Arvieux, C; Chaillot, F; Le Moal, G; Massari, V; Parienti, JJ; Reliquet, V; Vabret, A; Verdon, R, 2007)	0.65
" Newer HAART regimens have less toxicity and better dosing characteristics than first-generation regimens, but it is not known whether they are associated with improved clinical outcomes."	( Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine. Crane, HM; Kitahata, MM; Van Rompaey, SE, 2007)	0.53
" The results of the calculations revealed that the variant that survives in patients dosed with either nevirapine or efavirenz had a more positive Delta Delta G value than other variants that were not observed in patients."	( Energetic effects for observed and unobserved HIV-1 reverse transcriptase mutations of residues L100, V106, and Y181 in the presence of nevirapine and efavirenz. Franklin, AM; Jorgensen, WL; Rader, LH; Smith, KD; Smith, MB; Smith, RH; Taylor, EV; Tirado-Rives, J, 2008)	0.76
" TDM is useful to determine the best dosage regimen adapted to each patient."	( Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF. Alonzi, T; Ascenzi, P; Mancone, C; Narciso, P; Notari, S; Tripodi, M, 2008)	0.59
"Seventy-one Zambian children were treated with Triomune Baby or Junior dosed according to weight bands."	( Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. Burger, DM; Chintu, C; Ewings, FM; Gibb, DM; Kabamba, D; Kankasa, C; L'homme, RF; Mulenga, V; Thomason, MJ; Walker, AS, 2008)	1.79
"To determine the impact of pregnancy on the pharmacokinetics (PK) of nevirapine (NVP) during chronic dosing in HIV-infected women and appropriate NVP dosing in this population."	( Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. Aweeka, F; Best, B; Burchett, SK; Capparelli, EV; Foca, M; Hitti, J; Hu, C; Jimenez, E; Mirochnick, M; Nachman, S; Read, JS; Shearer, WT; Smith, E; Spector, SA; Stek, A; Thorpe, EM; Watts, H, 2008)	0.88
"The aim of this study was to develop and validate a population pharmacokinetic model for nevirapine in a population of HIV-infected adults and to evaluate the influence of nevirapine dosing regimen and patient characteristics on nevirapine trough concentration."	( Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach. Cedeño, S; Clotet, B; Costa, J; Miranda, C; Miranda, J; Moltó, J; Negredo, E; Santos, JR; Valle, M; Vilaró, J, 2008)	0.85
"0 mg/L when nevirapine was dosed once daily."	( Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach. Cedeño, S; Clotet, B; Costa, J; Miranda, C; Miranda, J; Moltó, J; Negredo, E; Santos, JR; Valle, M; Vilaró, J, 2008)	1.01
" The latter association was maintained with both 200 mg twice daily (bid) and 400 mg once daily (qd) dosing [GG, 3527 ng/mL (n=30); GT, 4525 ng/mL (n=32); TT, 7020 ng/mL (n=2); P(anova)=0."	( Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. Back, Dj; Egan, D; Johnson, M; Khoo, S; Mahungu, T; Owen, A; Smith, C; Turner, F; Youle, M, 2009)	0.58
"01) in the total area under the concentration-time curve (AUC(T)), maximum plasma concentration (C(max)) and terminal elimination half-life (T((1/2)beta)) of quinine compared with values with quinine dosing alone (AUC: 53."	( Effects of concurrent administration of nevirapine on the disposition of quinine in healthy volunteers. Cook, JM; Omoruyi, SI; Onyeji, CO; Owolabi, AR; Sarma, PV; Soyinka, JO, 2009)	0.62
" Efavirenz and nevirapine concentrations at 12 h after dosing (C12) were monitored at weeks 6 and 12."	( A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Burapatarawong, S; Likanonsakul, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Prasithsirskul, W; Prommool, V; Ruxrungtham, K; Sungkanuparph, S; Tantanathip, P; Thawornwa, U; Thongyen, S, 2009)	0.71
" Significant autoinduction of cytochrome P450 3A4 and 2B6 following multiple dosing prompted an assessment of the metabolic profiles in patients with liver disease receiving chronic nevirapine therapy."	( Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis. Cammett, AM; Felizarta, F; MacGregor, TR; Mallolas, J; Miailhes, P; Piliero, PJ; Wruck, JM, 2009)	0.83
"Children were recruited in weight-based dosage bands and nutritional status classified according to weight for height."	( Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets. Back, D; Else, L; Fraser, W; Khoo, S; Molyneux, E; Moons, P; Poerksen, G; Pollock, L; Walker, S, 2009)	0.68
" We investigated the relationship of NVP dosing with safety and efficacy."	( Safety and efficacy of once-daily nevirapine dosing: a multicohort study. Battegay, M; Calmy, A; de Wolf, F; Hirschel, B; Hogg, RS; Lange, JM; Lima, VD; Montaner, JS; Nguyen, A; Reiss, P; Vallier, N; Wit, FW; Yip, B, 2009)	0.63
" Daily drug dosage was 300 mg Tenofovir, 200mg Emtricitabine and 400 mg Nevirapine once daily."	( Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial). Flux, K; Gholam, P; Hartmann, M; Hueter, E; Weberschock, T, 2009)	0.85
" These data suggest that 2 tablets of lopinavir-ritonavir BD may be inadequate when dosed with NNRTIs in Ugandan adults, and the dosage should be increased by the addition of an additional adult tablet or a half-dose tablet (100/25 mg), where available."	( Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults. Dickinson, L; Gibb, DM; Gilks, CF; Kayiwa, J; Khoo, S; Kityo, C; Lutwama, F; Munderi, P; Nalumenya, R; Reid, A; Ssali, F; Tumukunde, D; Walker, AS, 2010)	0.36
" Children were stratified by weight and dosing was weight-based."	( A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand. Capparelli, E; Chokephaibulkit, K; Chotpitayasunondh, T; Cressey, TR; Eksaengsri, A; Hongsiriwan, S; McIntosh, K; Muresan, P; Plipat, N; Prasitsuebsai, W; Sirisanthana, V; Smith, ME; Toye, M; Vanprapar, N; Yogev, R, 2010)	0.59
"CHAP2 (Children with HIV Antibiotic Prophylaxis 2) is a prospective cohort of Zambian children using d4T/3TC/NVP adult Triomune30 dosed according to WHO guidelines."	( Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine. Chintu, C; Ferrier, A; Ford, D; Gibb, DM; Grant, PR; Gupta, RK; Kabamba, D; Kalumbi, M; Mulenga, V; Pillay, D; Walker, AS, 2010)	0.56
" Children taking T30 for > 6 weeks from each dosing weight band (<5, 5-<8, 8-<12, 12-<14, 14-<19, 19-<26, 26-<30 and > or = 30 kg) were recruited."	( Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets. Burger, D; Chesshyre, E; Khoo, S; Molyneux, E; Moons, P; Poerksen, G; Pollock, L, 2010)	0.73
" Nevirapine trough concentrations were measured after 18 and 36 months of starting antiretroviral treatment and in samples drawn during a dosing interval in a subset of 10 patients."	( Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Becquemont, L; Bertrand, J; Borand, L; Chou, M; Comets, E; Le Tiec, C; Mentre, F; Ouk, V; Segeral, O; Taburet, AM; Verstuyft, C, 2010)	1.52
"Children were randomized to initiate antiretroviral therapy with full-dose (FD) nevirapine (Triomune Baby or Junior in the morning and evening) versus DE (half-dose nevirapine for 14 days [Triomune in the morning and stavudine-lamivudine {Lamivir-S} in the evening], then FD), in accordance with World Health Organization weight-band dosing tables."	( Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial. Burger, D; Chijoka, C; Chintu, C; Cook, A; Ferrier, A; Gibb, DM; Kabamba, D; Kalengo, C; Kankasa, C; Kityo, C; Mulenga, V; Thomason, M; Walker, AS, 2010)	0.94
"This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment."	( Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. Biwolé-Sida, M; Bork, K; Coudray, M; Cournil, A; Delaporte, E; Essomba, CN; Kouanfack, C; Laurent, C; Tonfack, CA, 2010)	0.36
"The use of d4T at a lower dosage might increase safety with regard to its effect on lipoatrophy."	( Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. Biwolé-Sida, M; Bork, K; Coudray, M; Cournil, A; Delaporte, E; Essomba, CN; Kouanfack, C; Laurent, C; Tonfack, CA, 2010)	0.36
" A minimum effective concentration (MEC) of 3000 ng/mL was used to interpret nevirapine concentrations 12 h after dosing (C(12))."	( Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. Back, D; Boffito, M; Byakika-Kibwika, P; Coakley, P; Colebunders, R; Kalemeera, F; Khoo, S; Lamorde, M; Merry, C; Namakula, R; Okaba-Kayom, V; Ryan, M, 2011)	2.04
"All randomised controlled trials comparing EFV to NVP in HIV-infected individuals without prior exposure to ART, irrespective of the dosage or NRTI backbone."	( Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Irlam, JH; Mbuagbaw, LC; Rutherford, GW; Siegfried, N; Spaulding, A, 2010)	0.73
" Data were analysed on an intention-to-treat basis and reported as per dosage of NVP."	( Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Irlam, JH; Mbuagbaw, LC; Rutherford, GW; Siegfried, N; Spaulding, A, 2010)	0.73
"The trials were pooled as per dosage of NVP."	( Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Irlam, JH; Mbuagbaw, LC; Rutherford, GW; Siegfried, N; Spaulding, A, 2010)	0.73
" For analysis of nevirapine pharmacokinetic parameters, blood samples were obtained before dosing and at regularly scheduled intervals over 168 hours after administration."	( Relative bioavailability of two formulations of nevirapine 200-mg tablets in healthy Chinese male volunteers: a single-dose, randomized-sequence, open-label, two-way crossover study. Hu, Y; Yang, X; Yu, C; Zhang, Q; Zhu, Y; Zou, J, 2010)	0.96
" Dosing recommendations for children should be reviewed in the light of these findings."	( Factors influencing plasma nevirapine levels: a study in HIV-infected children on generic antiretroviral treatment in India. Agibothu Kupparam, HK; Karunaianandham, R; Mahalingam, V; Navaneethapandian, PG; Perumal Kannabiran, B; Ramachandran, G; Shah, I; Sikhamani, R; Soundararajan, L; Swaminathan, S, 2011)	0.67
" Currently, twice-a-day dosing is required for the successful application of NVP immediate release (IR), but there is potential for a more convenient once-a-day antiretroviral combination."	( Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation. Parienti, JJ; Peytavin, G, 2011)	1.81
" Simulations of the nevirapine concentration profile were performed with dosing regimens of 200 mg twice daily and 400 mg once daily for individuals with body weights of 50, 70 and 90 kg in combination with CYP2B6 genetic variation."	( Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. Back, DJ; Brockmeyer, NH; Davies, G; Egan, D; Fätkenheuer, G; Hendra, H; Johnson, MA; Khoo, S; Mahungu, T; Owen, A; Rockstroh, J; Schipani, A; Siccardi, M; Wyen, C; Youle, M, 2011)	0.92
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."	( FDA-approved drug labeling for the study of drug-induced liver injury. Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)	0.37
" The first trial began in April 1991 and assessed zidovudine (ZDV) versus placebo and since then, the type, dosage and duration of drugs to be compared has been modified in each subsequent trial."	( Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Brocklehurst, P; Siegfried, N; Sint, TT; van der Merwe, L, 2011)	0.37
"This study (VERxVE) compared the efficacy and safety of the new nevirapine extended-release (NVP XR) formulation dosed once daily with NVP immediate release (IR) twice daily in treatment-naive patients."	( Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients. Andrade-Villanueva, J; Bogner, J; Cahn, P; Drulak, M; Gathe, J; Horban, A; Nelson, M; Nguyen, T; Podzamczer, D; Quinson, AM; Santiago, S; Spencer, D; Yong, CL; Zhang, W, 2011)	0.92
" The usual dosing regimen is 200 mg twice/day."	( Bioavailability of nevirapine in rats after oral and subcutaneous administration, in vivo absorption from gastrointestinal segments and effect of bile on its absorption from duodenum. Peris, JE; Usach, I, 2011)	0.7
" Lopinavir was active at levels well below those achieved with standard dosing of coformulated lopinavir-ritonavir."	( In vitro activity of antiretroviral drugs against Plasmodium falciparum. Nsanzabana, C; Rosenthal, PJ, 2011)	0.37
" Our study suggests that NVP dosing of preterm infants as soon as possible after birth without maternal intrapartum dosing may be as effective as combined maternal and infant dosing."	( Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1. Cotton, MF; Els, I; Hall, D; Madsen, R; Mirochnick, M; Mugabo, P; Rabie, H; Smith, J; Smith, P; Steyn, W, 2011)	1.81
" It is expected that patients who are on NVP IR at present will consider switching to NVP XR to achieve regimen simplification by reducing their daily dosing and pill burden."	( Guidelines for the use of extended-release nevirapine in HIV-infected patients. Corbett, AH; Heil, EL, 2011)	0.63
" The correlation between nevirapine concentrations, efficacy and hepatotoxicity suggests the benefit of dosage adjustment based on therapeutic drug monitoring among Chinese HIV-infected patients to optimize nevirapine containing antiretroviral therapy."	( Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection. Fu, Q; Han, Y; Kou, H; Li, T; Li, Y; Ma, Q; Qiu, Z; Wang, J; Ye, M; Zhu, Z; Zuo, L, 2011)	2.12
" Dosing was weight-based."	( Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. Aurpibul, L; Capparelli, E; Chokephaibulkit, K; Cressey, TR; Eksaengsri, A; Hongsiriwon, S; Kabat, B; Limwongse, C; McIntosh, K; Muresan, P; Ngampiyaskul, C; Sirisanthana, V; Smith, ME; Toye, M; Wittawatmongkol, O; Yogev, R, 2011)	0.59
" Factors that may have contributed to the suboptimal results with nevirapine include elevated viral load at baseline, selection for nevirapine resistance, background regimen of nucleoside reverse-transcriptase inhibitors, and the standard ramp-up dosing strategy."	( Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. Abrams, EJ; Barlow-Mosha, L; Bobat, R; Chi, BH; Cotton, MF; Eshleman, SH; Hughes, MD; Jean-Philippe, P; Kamthunzi, P; Khadse, S; Lindsey, JC; Millar, L; Mofenson, LM; Moultrie, H; Mujuru, HA; Palumbo, P; Petzold, E; Purdue, L; Schimana, W; Violari, A, 2012)	2.06
" However, there are challenges to initiate ART in early life, including the possibility of drug resistance in the context of prevention of mother-to-child transmission (PMTCT) programs, a paucity of drug choices , uncertain dosing for some medications and long-term toxicities."	( Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age. Cotton, M; Gibb, D; Penazzato, M; Prendergast, A; Tierney, J, 2012)	0.38
" Male Cbl-b(-/-) mice dosed with NVP had an increase in ALT of >200 U/L, which also resolved despite continued treatment."	( Bioactivation of nevirapine to a reactive quinone methide: implications for liver injury. Hayes, MA; Li, Y; Novalen, M; Sharma, AM; Uetrecht, J, 2012)	0.72
" It can thus be used to make predictions and dosage adjustment optimization based on Bayesian therapeutic drug monitoring (TDM)."	( Dosage optimization of treatments using population pharmacokinetic modeling and simulation. Aouri, M; Arab-Alameddine, M; Buclin, T; Csajka, C; Decosterd, LA; Guidi, M; Rotger, M; Telenti, A, 2012)	0.38
" An extended-release (XR) formulation of NVP was developed since QD dosing and reduced pill burdens have been shown to improve regimen adherence."	( Once-daily nevirapine XR: a brief overview of the safety and efficacy of a new formulation. Bhatti, L; Gladstein, J, )	0.52
"In this highly adherent population, the number of daily pills was related to self-reported health status but not to self-reported adherence, whereas the dosing interval did not influence self-reported adherence or health status."	( Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy. Bocchiola, B; Cahua, T; Castagna, A; Danise, A; Galli, L; Gianotti, N; Lazzarin, A; Maillard, M; Panzini, P; Pazzi, A; Salpietro, S; Zandonà, D, 2013)	0.39
" Through dose-response experiments, we established relative inhibitory potencies of NRTIs on in vitro telomerase activity as compared to the inhibitory potencies of the corresponding dideoxynucleotide triphosphates."	( In vitro and ex vivo inhibition of human telomerase by anti-HIV nucleoside reverse transcriptase inhibitors (NRTIs) but not by non-NRTIs. Côté, HC; Hukezalie, KR; Thumati, NR; Wong, JM, 2012)	0.38
"Standard LPV dosing achieved therapeutic levels in pregnancy and no appreciable concentrations in breast milk."	( Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. Capparelli, E; Essex, M; Leidner, J; Lockman, S; Makhema, J; Moffat, C; Moss, M; Moyo, S; Ogwu, A; Rossi, S; Shapiro, RL, 2013)	0.39
" The aims of this study were to investigate the population pharmacokinetics of NVP in children, establish factors that influence NVP pharmacokinetics and evaluate the current dosing recommendations."	( Evaluation of nevirapine dosing recommendations in HIV-infected children. Benaboud, S; Blanche, S; Bouazza, N; Dollfus, C; Faye, A; Foissac, F; Frange, P; Hirt, D; Lachassinne, E; Treluyer, JM; Urien, S, 2013)	0.75
" Based on simulations of European Medicines Agency (EMA) and World Health Organization (WHO) dosing recommendations, the probability of observing minimal concentrations below the efficacy target of 3 mg l(-1) is higher following the EMA recommendations than the WHO recommendations."	( Evaluation of nevirapine dosing recommendations in HIV-infected children. Benaboud, S; Blanche, S; Bouazza, N; Dollfus, C; Faye, A; Foissac, F; Frange, P; Hirt, D; Lachassinne, E; Treluyer, JM; Urien, S, 2013)	0.75
" Simulations revealed that newborns born early (<1 hour) after maternal nevirapine intake would benefit from a 3-fold higher nevirapine dosage (6 mg/kg) after birth for analogous protective plasma concentrations over the first 2 weeks."	( Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns. Frank, M; Harms, G; Kloft, C; Kunz, A, 2013)	0.89
" Formulations allowing once-daily dosing of antiretrovirals can significantly improve regimen adherence, which is important for maintaining virologic control, especially for NNRTI-based regimens with low barriers for genetic resistance."	( Considerations on the new nevirapine: switching patients from twice-daily to once-daily. Slim, J; Ward, D, )	0.43
" Fixed-dose combination anti-retroviral therapy provides adequate suppression of HIV-1 replication, provides barrier to the development of resistance, simplifies dosage regimen and improves adherence."	( A randomized pahse I bioequivalence clinincal trial of a paediatric fixed-dose combination antiretroviral reconstitutable suspension in healthy adult volunteers. Adeyeye, M; Edowhorhu, G; Esseku, F; Gbadero, D; Joshi, A; Oyegbile, Y, 2013)	0.39
" A total of 15 blood samples were collected before dosing and up to 96 h post dosing."	( A randomized pahse I bioequivalence clinincal trial of a paediatric fixed-dose combination antiretroviral reconstitutable suspension in healthy adult volunteers. Adeyeye, M; Edowhorhu, G; Esseku, F; Gbadero, D; Joshi, A; Oyegbile, Y, 2013)	0.39
"Regimen simplification can be defined as a change in established effective therapy to reduce pill burden and dosing frequency, to enhance tolerability, or to decrease specific food and fluid requirements."	( Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV. Bosco, O; Cruciani, M; Malena, M; Mengoli, C; Parisi, SG; Serpelloni, G, 2013)	0.39
" SJS can occur in children at any age, with any level of immunosuppression, and can occur during the lead-in dosing period of NVP."	( Stevens-Johnson syndrome and HIV in children in Swaziland. Blank, DA; Draper, HR; Dziuban, EJ; Hughey, AB; Kochelani, D; Schutze, GE; Stewart, DA, 2013)	0.39
" As prolonged subtherapeutic nevirapine dosage leads to the emergence of resistance, single-dose nevirapine could be used with phenytoin as an alternative if other ARVs were unavailable."	( Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. Aitken, S; Burger, DM; Chunda, C; Fillekes, Q; Gibb, DM; Kankasa, C; Kisanga, ER; Muro, EP; Thomason, MJ; Walker, AS, 2013)	0.89
" Our results demonstrate that the HIV PI lopinavir inhibits liver stage parasites at clinically relevant concentrations, that is, at drug levels achieved in HIV-infected patients on standard dosing regimens."	( The effect of antiretrovirals on Plasmodium falciparum liver stages. Borkowsky, W; De La Vega, P; Duffy, PE; Hobbs, CV; Krzych, U; Penzak, SR; Sinnis, P; Van Vliet, J, 2013)	0.39
" We set out to demonstrate that in-home HIV testing and NVP dosing by traditional birth attendants (TBAs) is feasible and acceptable by women in rural Zambia."	( In-home HIV testing and nevirapine dosing by traditional birth attendants in rural Zambia: a feasibility study. Botha, B; Brennan, AT; Goggin, C; Hamomba, L; Mazimba, A; Pilingana, P; Scott, N; Seidenberg, P; Semrau, K; Thea, DM, )	0.44
"3%) took single-dose NVP administered by a TBA between 1 and 24 hours prior to birth and 100% of exposed newborns (16 of 16) received NVP syrup within 72 hours after birth, 80% of whom were dosed in the first 24 hours of life."	( In-home HIV testing and nevirapine dosing by traditional birth attendants in rural Zambia: a feasibility study. Botha, B; Brennan, AT; Goggin, C; Hamomba, L; Mazimba, A; Pilingana, P; Scott, N; Seidenberg, P; Semrau, K; Thea, DM, )	0.44
" Mice were dosed twice daily until PND 28."	( Toxicology and Carcinogenesis Studies of Mixtures of 3'-Azido-3'-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CAS Nos. 30516-87-1, 134678-17-4, 129618-40-2) in Genetically Modified C3B6.129F1-Trp53(tm1Brd) N12 Haploinsufficient Mice (in u , 2013)	0.6
" Additionally, nevirapine plasma concentrations of 200 mg twice daily (NVPBID) and 400 mg once daily (NVPOD) were simulated using the final model to investigate the impact of the covariates and different dosage regimens on nevirapine steady state concentrations."	( Population pharmacokinetics of nevirapine in Thai HIV-infected patients. Avihingsanon, A; Manosuthi, W; Punyawudho, B; Wattanakul, T, 2014)	1.04
"This population-based pharmacokinetic model can be used for optimizing nevirapine dosage regimens for individual patients to improve efficacy and safety of nevirapine therapy in this population."	( Population pharmacokinetics of nevirapine in Thai HIV-infected patients. Avihingsanon, A; Manosuthi, W; Punyawudho, B; Wattanakul, T, 2014)	0.92
" However, there are challenges to initiation of ART in early life, including the possibility of drug resistance in the context of prevention of mother-to-child transmission (PMTCT) programs, a paucity of drug choices , uncertain dosing for some medications and long-term toxicities."	( Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age. Abrams, E; Muhe, LM; Penazzato, M; Prendergast, AJ; Tindyebwa, D, 2014)	0.4
"The aim of the present research work was to formulate and evaluate the extended release matrix pellets of nevirapine using extrusion and spheronization technique which will be an alternative technique for making extended release dosage forms and to compare the drug release profiles of the formulations with the reference product."	( Effect of combination of acrylic polymers on the release of nevirapine formulated as extended release matrix pellets using extrusion and spheronization technique. Dua, K; Prasad, A; Sharma, A; Singh, G, 2014)	0.86
" Efficacious, safe bedaquiline dosing for MDR-TB patients receiving antiretrovirals is important."	( Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. Dooley, KE; Karlsson, MO; Svensson, EM, 2014)	0.68
" This modelling technique is able to inform the design of clinical studies, and allows assessment of pragmatic dosing strategies under complex therapeutic scenarios."	( Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine. Back, D; Davies, G; Khoo, S; Owen, A; Schipani, A; Siccardi, M, 2015)	0.62
"We document our experience with therapeutic drug monitoring (TDM) of antiretroviral agents (1807 determinations) carried out as day-by-day clinical practice for the optimization of drug dosing in HIV-infected patients."	( Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint. Baldelli, S; Castoldi, S; Cattaneo, D; Charbe, N; Clementi, E; Cozzi, V; Fucile, S, 2014)	0.4
" Nevirapine has low solubility, an acid medium being the most appropriate medium for assessing the release of the drug from dosage forms."	( Compatibility studies of nevirapine in physical mixtures with excipients for oral HAART. de Oliveira, GG; Ferraz, HG; Severino, P; Souto, EB, 2013)	1.6
" In conclusion, this genotypic resistance analysis strongly suggests that the latest NNRTI, rilpivirine, may retain activity in a large proportion of HIV-1 patients in whom resistance failed while they were on an efavirenz- or nevirapine-containing regimen, and may present an attractive option for second-line treatment given its good safety profile and dosing convenience."	( Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine. Camacho, RJ; Gomes, P; Rhee, SY; Theys, K; Vandamme, AM, 2015)	0.81
" Optimal lumefantrine dosage regimen for patients on EFV-based ART was determined by population pharmacokinetics and simulation."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	0.76
" The predictive model through simulation of lumefantrine exposure at different dosage regimen scenarios for patients on EFV-based ART, suggest that AL taken twice daily for five days using the current dose could improve lumefantrine exposure and consequently malaria treatment outcomes."	( The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015)	0.76
" Stavudine and lamivudine are administered as fixed combination while nevirapine as separate dosage form which often results in poor compliance and adherence to therapy by patients and therefore, there is a need to develop dosage forms that can overcome the problems of currently available dosage forms for treatment of HIV infection."	( Simultaneous And Extended Delivery Of Stavudine, Lamivudine And Nevirapine In Fixed Dose Combination Using Sandwiched Osmotic Tablets For Hiv Therapy. Priya, MR; Rajendran, NN, 2015)	0.89
"05) in the area under the plasma concentration-time curve for dolutegravir from the time the dose was administered until the end of the dosing interval (-19%, P = 0."	( Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1. Allavena, C; Billaud, E; Bouchez, S; Bouquié, R; Dailly, E; Deslandes, G; Grégoire, M; Hall, N; Hernando, H; Jolliet, P; Raffi, F; Reliquet, V, 2015)	0.79
" According to therapeutic drug monitoring for dolutegravir, some patients may need a higher dose than 50 mg of dolutegravir once daily to maintain the therapeutic plasma concentration throughout the dosing interval."	( Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1. Allavena, C; Billaud, E; Bouchez, S; Bouquié, R; Dailly, E; Deslandes, G; Grégoire, M; Hall, N; Hernando, H; Jolliet, P; Raffi, F; Reliquet, V, 2015)	0.79
" Absence of hypersensitivity reactions, superior resistance profile and once-daily dosing favours abacavir for African children, supporting WHO 2013 guidelines."	( Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. Abongomera, G; Asiimwe, A; Burger, D; Chabala, C; Chintu, C; Cook, AD; Gibb, DM; Kekitiinwa, A; Kenny, J; Kityo, C; Klein, N; McIlleron, H; Mirembe, G; Mulenga, V; Musiime, V; Owen-Powell, E; Thomason, MJ; Walker, AS, 2016)	0.43
" Only zidovudine has adequate dosing recommendations for treating term and preterm infants and has an intravenous formulation, essential if feeding intolerance occurs."	( The last and first frontier--emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants. Cotton, MF; Holgate, S; Mirochnick, M; Nelson, A; Rabie, H; Wedderburn, C, 2015)	0.42
" In an effort to understand whether NVP is metabolized differently in a transiently inflamed liver and whether a heightened immune response alters NVP-induced hepatic responses, female brown Norway rats were dosed with either vehicle or NVP alone (75 mg/kg/day for 15 days) or galactosamine alone (single intraperitoneal [ip] injection on day 7 to mimic viral hepatitis) or a combination of NVP (75/100/150 mg/kg/day for 15 days) and galactosamine (single 750 mg/kg ip on day 7)."	( Drug-induced Liver Fibrosis: Testing Nevirapine in a Viral-like Liver Setting Using Histopathology, MALDI IMS, and Gene Expression. Arrington-Brown, L; Bailey, D; Brown, HR; Cariello, NF; Castellino, S; Elangbam, CS; Fowler, S; Gates, LD; Groseclose, MR; Krull, DL; Mellon-Kusibab, K; Miller, RT; Shah, V; Tillman, T; Yoon, LW, 2016)	0.71
"The PBPK approach is a useful tool for quantifying a priori the drug exposure of metabolized drugs during pregnancy, and can be applied to evaluate alternative dosing regimens to optimize drug therapy."	( A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways. Benaboud, S; Blanche, S; Bouazza, N; De Sousa Mendes, M; Foissac, F; Hirt, D; Lui, G; Pressiat, C; Treluyer, JM; Urien, S; Valade, E; Zheng, Y, 2017)	0.46
"We included all randomized controlled trials (RCTs) that compared EFV to NVP in people with HIV without prior exposure to ART, irrespective of the dosage or NRTI's given in combination."	( Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Irlam, JH; Mbuagbaw, L; Mursleen, S; Rutherford, GW; Siegfried, N; Spaulding, AB, 2016)	0.8
" We performed subgroup analyses for concurrent treatment for tuberculosis and dosage of NVP."	( Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Irlam, JH; Mbuagbaw, L; Mursleen, S; Rutherford, GW; Siegfried, N; Spaulding, AB, 2016)	0.8
" To normalise bedaquiline exposure in patients with concomitant LPV/r therapy, an adjusted bedaquiline dosing regimen is proposed for further study."	( Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. Brill, MJ; Karlsson, MO; Maartens, G; Pandie, M; Svensson, EM, 2017)	0.67
" NVP was dosed at 150 mg/m daily for 14 days, then twice daily for 14 days."	( Nevirapine Pharmacokinetics and Safety in Neonates Receiving Combination Antiretroviral Therapy for Prevention of Vertical HIV Transmission. Bitnun, A; Brophy, J; Campbell, DM; Colantonio, D; Kakkar, F; Lau, E; Murphy, K; Read, SE; Samson, L; Seto, W; Yudin, MH, 2017)	1.9
" Lower empiric dosing is recommended for infants <34 weeks of GA."	( Nevirapine Pharmacokinetics and Safety in Neonates Receiving Combination Antiretroviral Therapy for Prevention of Vertical HIV Transmission. Bitnun, A; Brophy, J; Campbell, DM; Colantonio, D; Kakkar, F; Lau, E; Murphy, K; Read, SE; Samson, L; Seto, W; Yudin, MH, 2017)	1.9
" Blood plasma was collected at 1, 4 and 24 hours post-ART dosing from 58 subjects receiving NVP-containing ART and used to determine cNVP and viral load (VL)."	( Plasma nevirapine concentrations predict virological and adherence failure in Kenyan HIV-1 infected patients with extensive antiretroviral treatment exposure. Aman, RA; Kimulwo, MJ; Kokwaro, GO; Muigai, AW; Ochieng, DJ; Ochieng, W; Ogutu, BR; Okendo, J; Oloo, FA, 2017)	0.91
" We evaluated current World Health Organization (WHO) weight-band NVP prophylactic dosing recommendations and investigated optimal therapeutic NVP dosing for neonates."	( Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates. Aarons, L; Borkird, T; Capparelli, EV; Cressey, TR; Jittayanun, K; Jourdain, G; Lallemant, M; Le Coeur, S; Luvira, A; Phanomcheong, S; Puangsombat, A; Punyawudho, B; Saenjum, C; Sukrakanchana, PO; Urien, S, 2017)	0.82
"0 mg/L) using different infant dosing strategies."	( Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates. Aarons, L; Borkird, T; Capparelli, EV; Cressey, TR; Jittayanun, K; Jourdain, G; Lallemant, M; Le Coeur, S; Luvira, A; Phanomcheong, S; Puangsombat, A; Punyawudho, B; Saenjum, C; Sukrakanchana, PO; Urien, S, 2017)	0.82
"In a population of HIV-infected Kenyan children on antiretroviral therapy including nevirapine (NVP), we used a one-compartment model with previously established PK parameters and Medication Event Monitoring Systems (MEMS®)-recorded dosing times to estimate the mean plasma concentration of NVP (Cp) in individual patients during 1 month of follow-up."	( Pharmacokinetics-based adherence measures for antiretroviral therapy in HIV-infected Kenyan children. Ayaya, SO; Liu, H; Nyandiko, WM; Scanlon, ML; Slaven, JE; Tu, W; Vreeman, RC, 2017)	0.68
" However, studies have shown that this dosing strategy based on adult studies may not be appropriate in children, given that younger children have higher drug clearance rates."	( Sub-therapeutic nevirapine concentration during antiretroviral treatment initiation among children living with HIV: Implications for therapeutic drug monitoring. A K, HK; D'souza, RR; Gopalan, BP; Mehta, K; Rajnala, N; Ramachandran, G; Shet, A, 2017)	0.8
" However, the reduction in artemisinin exposure may warrant further study, and suggests that dosage adjustment of artemether-lumefantrine with nevirapine-based ART in children is likely warranted."	( Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children. Aweeka, FT; Barlow-Mosha, L; Carey, V; Gingrich, D; Graham, B; Huang, L; Kamthunzi, P; Lindsey, JC; Marzan, F; Nachman, S; Parikh, S; Ssemambo, PK, 2017)	1.03
"The development of antiretroviral associations in a single dosage form aims to ensure improved efficacy, low costs and better adherence to treatment."	( Formulation, Development and Scale-Up of Fixed-Dose Combination Tablets Containing Zidovudine, Lamivudine and Nevirapine. Barros Silva, LCPB; da Silva, RMF; de Lima, LG; de Medeiros, FPM; de Sousa, ALMD; Lavra, ZMM; Neto, PJR; Rolim, LA; Rosa, TA; Wanderley Sales, VA, 2019)	0.73
" Lopinavir TDM excluded pharmacokinetic reasons for failure in patients failing treatment when lopinavir dosing was supervised."	( Pediatric Antiretroviral Therapeutic Drug Monitoring: A Five and a Half Year Experience from a South African Tertiary Hospital. Decloedt, EH; Engelbrecht, AE; Norman, J; Rabie, H; Wiesner, L, 2020)	0.56
" This study aims to establish dosing of nevirapine for very early treatment of HIV-exposed neonates at high risk of HIV acquisition."	( Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. Bryson, Y; Bwakura-Dangarembizi, M; Capparelli, EV; Chadwick, EG; Coletti, A; Cotton, MF; Hazra, R; Jean-Philippe, P; LeBlanc, R; Mirochnick, M; Naidoo, KL; Nelson, BS; Persaud, D; Reding, C; Ruel, TD; Spector, SA; Tierney, C; Zimmer, B, 2021)	1.16
" The regimen consisted of two nucleoside reverse transcriptase inhibitors plus nevirapine dosed at 6 mg/kg twice daily for term neonates (≥37 weeks gestational age) or 4 mg/kg twice daily for 1 week and 6 mg/kg twice daily thereafter for preterm neonates (34 to <37 weeks gestational age)."	( Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. Bryson, Y; Bwakura-Dangarembizi, M; Capparelli, EV; Chadwick, EG; Coletti, A; Cotton, MF; Hazra, R; Jean-Philippe, P; LeBlanc, R; Mirochnick, M; Naidoo, KL; Nelson, BS; Persaud, D; Reding, C; Ruel, TD; Spector, SA; Tierney, C; Zimmer, B, 2021)	1.12
"Nevirapine (NVP) is used for the management of HIV/AIDS but must be dosed frequently, exhibits unpredictable bioavailability and a side effect profile that includes hepato- and dermo-toxicity."	( Preformulation characterization and identification of excipients for nevirapine loaded niosomes. Walker, RB; Witika, BA, 2021)	2.3
"2% (30/185) with improper dosage or prescription errors."	( Adverse Reactions to Antiretrovirals in Cuban Patients Living with HIV/AIDS. Morales-Pérez, M, 2021)	0.62
" This study aimed to develop a population pharmacokinetic model to characterize the disposition of maraviroc in neonates to inform dosing regimens and expand available options."	( Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K, 2022)	0.72
" The final model was used in Monte Carlo simulations to generate expected exposures with recommended dosing regimens."	( Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K, 2022)	0.72
" Monte Carlo simulations with FDA-approved weight band dosing resulted in the majority of simulated patients (84."	( Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K, 2022)	0.72
"While maraviroc apparent clearance is decreased in the first few days of life, the current FDA-approved maraviroc weight band dosing provides maraviroc exposures for neonates in the first 6 weeks of life, which were consistent with adult maraviroc exposure range."	( Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K, 2022)	0.72

Role	Description
antiviral drug	A substance used in the prophylaxis or therapy of virus diseases.
HIV-1 reverse transcriptase inhibitor	An entity which inhibits the activity of HIV-1 reverse transcriptase.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
dipyridodiazepine	An organic heterotricyclic compound whose skeleton consists of a diazepine ring which is fused to two pyridine rings.
cyclopropanes	Cyclopropane and its derivatives formed by substitution.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Nevirapine Metabolism Pathway	8	21

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	47.3935	0.0032	45.4673	12,589.2998	AID2517
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	0.4507	0.0060	38.0041	19,952.5996	AID1159521
USP1 protein, partial	Homo sapiens (human)	Potency	0.6310	0.0316	37.5844	354.8130	AID743255
TDP1 protein	Homo sapiens (human)	Potency	7.3563	0.0008	11.3822	44.6684	AID686978; AID686979
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	35.4813	0.0112	12.4002	100.0000	AID1030
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	31.9093	0.0030	41.6115	22,387.1992	AID1159552
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	16.2595	0.0008	17.5051	59.3239	AID1159527; AID1159531
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	63.6675	0.0015	30.6073	15,848.9004	AID1224848; AID1224849
pregnane X nuclear receptor	Homo sapiens (human)	Potency	63.6675	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	15.9926	0.0002	29.3054	16,493.5996	AID743080
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	50.1187	0.0010	19.4141	70.9645	AID588537
importin subunit beta-1 isoform 1	Homo sapiens (human)	Potency	5.6234	5.8048	36.1306	65.1308	AID540263
DNA polymerase beta	Homo sapiens (human)	Potency	35.4813	0.0224	21.0102	89.1251	AID485314
mitogen-activated protein kinase 1	Homo sapiens (human)	Potency	6.2303	0.0398	16.7842	39.8107	AID1454
snurportin-1	Homo sapiens (human)	Potency	5.6234	5.8048	36.1306	65.1308	AID540263
geminin	Homo sapiens (human)	Potency	23.7246	0.0046	11.3741	33.4983	AID624296; AID624297
lamin isoform A-delta10	Homo sapiens (human)	Potency	0.0355	0.8913	12.0676	28.1838	AID1487
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain B, Hiv-1 Reverse Transcriptase	Human immunodeficiency virus 1	IC50 (µMol)	0.0800	0.0800	8.5400	17.0000	AID977608
Chain A, Hiv-1 Reverse Transcriptase	Human immunodeficiency virus 1	IC50 (µMol)	0.0800	0.0800	8.5400	17.0000	AID977608
Chain A, Hiv-1 Reverse Transcriptase	Human immunodeficiency virus 1	IC50 (µMol)	0.0800	0.0800	8.5400	17.0000	AID977608
Chain A, Hiv-1 Reverse Transcriptase	Human immunodeficiency virus 1	IC50 (µMol)	0.0800	0.0800	8.5400	17.0000	AID977608
Chain B, Hiv-1 Reverse Transcriptase	Human immunodeficiency virus 1	IC50 (µMol)	0.0800	0.0800	8.5400	17.0000	AID977608
Chain A, Reverse transcriptase/ribonuclease H	Human immunodeficiency virus 1	IC50 (µMol)	1.1650	1.1650	1.1650	1.1650	AID977608
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	187.5333	0.1100	7.1903	10.0000	AID1443980; AID1449628; AID1473738
Prothrombin	Bos taurus (cattle)	IC50 (µMol)	1.1500	0.0089	0.8857	6.0000	AID1191671
Renin	Homo sapiens (human)	Ki	7.0000	0.0000	1.8078	7.4000	AID198779
Gag-Pol polyprotein	Human immunodeficiency virus type 1 BH10	IC50 (µMol)	17.2958	0.0800	1.7128	3.9300	AID1795322; AID1795327; AID1795330; AID1795355; AID1795358; AID1797479
Gag-Pol polyprotein	Human immunodeficiency virus type 2 (ISOLATE ROD)	IC50 (µMol)	11.0250	0.0026	1.4352	3.5000	AID1795385
Gag-Pol polyprotein	HIV-1 M:B_HXB2R	IC50 (µMol)	19.1534	0.0006	0.9141	8.3200	AID1795311; AID1795346; AID1795349; AID1795367; AID1795381; AID1795382; AID1795384; AID1795385; AID1795386; AID1795388; AID1795390; AID1795394; AID1795395; AID1795423; AID1795433; AID1795743; AID1796564; AID1796846; AID1802330; AID1802585; AID1803151
Gag-Pol polyprotein	HIV-1 M:B_HXB2R	Ki	11.7714	0.0000	0.5144	9.0000	AID1798816
Imidazoleglycerol-phosphate dehydratase	Saccharomyces cerevisiae S288C	IC50 (µMol)	59.6333	1.7000	1.7000	1.7000	AID1797479
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	0.1810	0.0001	1.7536	10.0000	AID1583030
Cytochrome P450 2C9	Homo sapiens (human)	IC50 (µMol)	0.1810	0.0000	2.8005	10.0000	AID1583030
Gag-Pol polyprotein	Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE)	IC50 (µMol)	0.6900	0.0002	0.1042	1.7000	AID1801807
Ryanodine receptor 1	Homo sapiens (human)	Ki	7.0000	7.0000	7.0000	7.0000	AID198779
Kappa-type opioid receptor	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	0.7000	0.0003	0.7123	7.0700	AID573468
Cannabinoid receptor 1	Mus musculus (house mouse)	Ki	7.2000	0.0006	0.7246	7.2000	AID736440
Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)	IC50 (µMol)	5.7500	0.0000	0.7263	5.7500	AID266346
Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)	IC50 (µMol)	0.1800	0.0002	1.0140	10.0000	AID299022
Exoribonuclease H	Human immunodeficiency virus 2	IC50 (µMol)	20.0000	0.0005	0.0152	0.0300	AID199097
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	IC50 (µMol)	32.3710	0.0001	1.0768	10.0000	AID104448; AID1057035; AID1059142; AID1060625; AID1069710; AID1072797; AID1124998; AID1126511; AID1141975; AID1141976; AID1141978; AID1161108; AID1165079; AID1171593; AID1171594; AID1171595; AID1171596; AID1171598; AID1175435; AID1187998; AID1191404; AID1191671; AID1197835; AID1200848; AID1206939; AID1231487; AID1235381; AID1248227; AID1249724; AID1275539; AID1290408; AID1292014; AID1292366; AID1298247; AID1298248; AID1298249; AID1298250; AID1298251; AID1298253; AID1304407; AID1320869; AID1352323; AID1373153; AID1379964; AID1391076; AID1410405; AID1410486; AID1418468; AID143385; AID143387; AID1457063; AID1457064; AID1457065; AID1485966; AID1485969; AID1485970; AID1485971; AID1485972; AID1485973; AID1485974; AID1485975; AID1504705; AID1520066; AID1535529; AID1537494; AID1558858; AID1565088; AID1572530; AID1583030; AID1594863; AID1596756; AID1609110; AID1627029; AID1636131; AID1637387; AID1655526; AID1657475; AID1685253; AID1705194; AID1705195; AID1729163; AID1731753; AID1750722; AID1769793; AID1773463; AID1775803; AID1811038; AID1815396; AID1819220; AID1822283; AID1877036; AID1880369; AID1884494; AID197775; AID197776; AID197779; AID197780; AID197782; AID197787; AID197788; AID197792; AID197794; AID197795; AID197796; AID197797; AID197798; AID197799; AID197800; AID197803; AID197807; AID197925; AID197931; AID197932; AID197933; AID197934; AID197941; AID197943; AID197944; AID197946; AID197948; AID198067; AID198068; AID198073; AID198074; AID198075; AID198077; AID198078; AID198080; AID198086; AID198094; AID198228; AID198229; AID198231; AID198234; AID198235; AID198236; AID198239; AID198247; AID198257; AID198258; AID198259; AID198260; AID198396; AID198400; AID198409; AID198410; AID198411; AID198563; AID199102; AID199242; AID199243; AID199521; AID200150; AID200161; AID240924; AID241996; AID242064; AID242248; AID242545; AID266345; AID266346; AID266347; AID266348; AID279321; AID279324; AID279325; AID282736; AID282737; AID282738; AID282739; AID282740; AID286999; AID287002; AID294633; AID294634; AID299022; AID301928; AID317728; AID318120; AID342718; AID360704; AID360705; AID360706; AID360707; AID360708; AID360709; AID360710; AID360711; AID391687; AID391688; AID391690; AID430054; AID457955; AID457959; AID457960; AID457961; AID479214; AID481177; AID510360; AID518734; AID518735; AID518737; AID518738; AID557019; AID557043; AID557044; AID566904; AID573464; AID573465; AID573466; AID573468; AID573469; AID573470; AID606671; AID606672; AID606673; AID606674; AID607877; AID608390; AID619628; AID648425; AID666410; AID698144; AID698145; AID698146; AID717253; AID718366; AID734270; AID735329; AID738336; AID757621; AID779524; AID781021
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	Ki	348.4432	0.0003	1.5523	10.0000	AID198779; AID198906; AID198907; AID198908; AID198909; AID198910; AID198911; AID198912; AID198913; AID198915; AID198916; AID198917; AID302259; AID302260; AID302261; AID302262; AID302263; AID302265; AID368564; AID368565; AID368566; AID368567; AID368568; AID368569; AID370724; AID370725; AID370726; AID370727; AID622047; AID622049; AID622052; AID736038; AID736040; AID736041; AID736438; AID736439; AID736440
Protease	Human immunodeficiency virus 1	IC50 (µMol)	23.1003	0.0001	0.2248	7.3200	AID200169; AID200170; AID200171
Cardiac ryanodine receptor 2	Canis lupus familiaris (dog)	Ki	7.0000	7.0000	7.0000	7.0000	AID198779
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Reverse transcriptase	Human immunodeficiency virus 1	IC50 (µMol)	198.6700	0.0100	0.5356	7.1300	AID1815391; AID1815397; AID1815398; AID1815399; AID1815400; AID1815401; AID1815402
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	EC50 (µMol)	5.9505	0.0004	0.6153	9.7000	AID1056583; AID1373152; AID1373158; AID1373159; AID1373160; AID1373161; AID1373162; AID1373163; AID1410481; AID1410482; AID1456307; AID1456308; AID1483271; AID1483272; AID1483273; AID1483274; AID1483275; AID1483276; AID1483277; AID1750717; AID1750718; AID1750719; AID199992; AID199993; AID199994; AID199995; AID199997; AID199998; AID199999; AID200000; AID240140; AID267854; AID267855; AID267856; AID267858; AID460296; AID757627
Reverse transcriptase	Human immunodeficiency virus 1	EC50 (µMol)	247.8373	0.0002	1.1683	9.0740	AID1731746; AID1731747; AID1731749; AID1731750; AID1731751; AID1741393; AID1741394; AID1741395; AID1741396; AID1741397
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
5-hydroxytryptamine receptor 1A	Rattus norvegicus (Norway rat)	ID50	20.0000	0.4000	0.4000	0.4000	AID298089
Acetylcholinesterase	Rattus norvegicus (Norway rat)	ID50	35.0000	0.0800	0.0800	0.0800	AID650690
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	Activity	3.2650	0.0009	1.3073	8.0000	AID199980; AID279322
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	ED50	3.0652	0.0002	0.9935	9.8000	AID105522; AID105535; AID105537; AID105539; AID105543
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	ID50	11.6821	0.0060	2.1898	9.0000	AID1155813; AID1155814; AID1155815; AID1155816; AID1574384; AID1574385; AID1574386; AID1574387; AID242820; AID253490; AID253492; AID253493; AID253494; AID253495; AID257163; AID257164; AID257165; AID267851; AID267862; AID267863; AID298087; AID298088; AID298089; AID298090; AID366526; AID366527; AID366529; AID366531; AID368555; AID368556; AID368557; AID650688; AID650689; AID650690; AID650691; AID650692; AID663305; AID663306; AID663308
Fructose-1,6-bisphosphatase 1	Mus musculus (house mouse)	ID50	8.0000	0.4000	4.2000	8.0000	AID368556
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
proteolysis	Prothrombin	Bos taurus (cattle)
acute-phase response	Prothrombin	Bos taurus (cattle)
positive regulation of blood coagulation	Prothrombin	Bos taurus (cattle)
protein polymerization	Prothrombin	Bos taurus (cattle)
kidney development	Renin	Homo sapiens (human)
mesonephros development	Renin	Homo sapiens (human)
angiotensin maturation	Renin	Homo sapiens (human)
renin-angiotensin regulation of aldosterone production	Renin	Homo sapiens (human)
proteolysis	Renin	Homo sapiens (human)
regulation of blood pressure	Renin	Homo sapiens (human)
male gonad development	Renin	Homo sapiens (human)
hormone-mediated signaling pathway	Renin	Homo sapiens (human)
response to lipopolysaccharide	Renin	Homo sapiens (human)
response to immobilization stress	Renin	Homo sapiens (human)
drinking behavior	Renin	Homo sapiens (human)
regulation of MAPK cascade	Renin	Homo sapiens (human)
cell maturation	Renin	Homo sapiens (human)
amyloid-beta metabolic process	Renin	Homo sapiens (human)
response to cAMP	Renin	Homo sapiens (human)
response to cGMP	Renin	Homo sapiens (human)
cellular response to xenobiotic stimulus	Renin	Homo sapiens (human)
juxtaglomerular apparatus development	Renin	Homo sapiens (human)
viral life cycle	Gag-Pol polyprotein	HIV-1 M:B_HXB2R
establishment of integrated proviral latency	Gag-Pol polyprotein	HIV-1 M:B_HXB2R
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
response to hypoxia	Ryanodine receptor 1	Homo sapiens (human)
outflow tract morphogenesis	Ryanodine receptor 1	Homo sapiens (human)
calcium ion transport	Ryanodine receptor 1	Homo sapiens (human)
muscle contraction	Ryanodine receptor 1	Homo sapiens (human)
release of sequestered calcium ion into cytosol by sarcoplasmic reticulum	Ryanodine receptor 1	Homo sapiens (human)
calcium-mediated signaling	Ryanodine receptor 1	Homo sapiens (human)
response to caffeine	Ryanodine receptor 1	Homo sapiens (human)
skin development	Ryanodine receptor 1	Homo sapiens (human)
ossification involved in bone maturation	Ryanodine receptor 1	Homo sapiens (human)
skeletal muscle fiber development	Ryanodine receptor 1	Homo sapiens (human)
release of sequestered calcium ion into cytosol	Ryanodine receptor 1	Homo sapiens (human)
protein homotetramerization	Ryanodine receptor 1	Homo sapiens (human)
regulation of cytosolic calcium ion concentration	Ryanodine receptor 1	Homo sapiens (human)
cellular response to calcium ion	Ryanodine receptor 1	Homo sapiens (human)
cellular response to caffeine	Ryanodine receptor 1	Homo sapiens (human)
striated muscle contraction	Ryanodine receptor 1	Homo sapiens (human)
lipid metabolic process	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
triglyceride metabolic process	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
circadian rhythm	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
protein secretion	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
phospholipid transport	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
sterol transport	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
triglyceride transport	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
low-density lipoprotein particle remodeling	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
plasma lipoprotein particle assembly	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
chylomicron assembly	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
very-low-density lipoprotein particle assembly	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
lipoprotein transport	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
response to calcium ion	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
establishment of localization in cell	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
intermembrane lipid transfer	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
ceramide 1-phosphate transport	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
lipoprotein metabolic process	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
cholesterol homeostasis	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
response to hypoxia	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
neutrophil mediated immunity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
germinal center formation	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of leukocyte chemotaxis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
proteolysis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
membrane protein ectodomain proteolysis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell adhesion	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Notch receptor processing	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of cell population proliferation	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
response to xenobiotic stimulus	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of T cell chemotaxis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
protein processing	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
signal release	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
B cell differentiation	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of cell growth	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of cell migration	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
response to lipopolysaccharide	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of chemokine production	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
regulation of mast cell apoptotic process	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
T cell differentiation in thymus	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell adhesion mediated by integrin	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
wound healing, spreading of epidermal cells	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
amyloid precursor protein catabolic process	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
spleen development	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell motility	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
defense response to Gram-positive bacterium	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cellular response to high density lipoprotein particle stimulus	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
commissural neuron axon guidance	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycle	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
positive regulation of vascular endothelial cell proliferation	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Notch signaling pathway	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
serine-type endopeptidase activity	Prothrombin	Bos taurus (cattle)
calcium ion binding	Prothrombin	Bos taurus (cattle)
protein binding	Prothrombin	Bos taurus (cattle)
fibrinogen binding	Prothrombin	Bos taurus (cattle)
aspartic-type endopeptidase activity	Renin	Homo sapiens (human)
signaling receptor binding	Renin	Homo sapiens (human)
insulin-like growth factor receptor binding	Renin	Homo sapiens (human)
protein binding	Renin	Homo sapiens (human)
peptidase activity	Renin	Homo sapiens (human)
peptidase activity	Gag-Pol polyprotein	HIV-1 M:B_HXB2R
integrase activity	Gag-Pol polyprotein	HIV-1 M:B_HXB2R
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
ryanodine-sensitive calcium-release channel activity	Ryanodine receptor 1	Homo sapiens (human)
voltage-gated calcium channel activity	Ryanodine receptor 1	Homo sapiens (human)
calcium channel activity	Ryanodine receptor 1	Homo sapiens (human)
calcium ion binding	Ryanodine receptor 1	Homo sapiens (human)
calmodulin binding	Ryanodine receptor 1	Homo sapiens (human)
ATP binding	Ryanodine receptor 1	Homo sapiens (human)
intracellularly gated calcium channel activity	Ryanodine receptor 1	Homo sapiens (human)
calcium-induced calcium release activity	Ryanodine receptor 1	Homo sapiens (human)
lipid transporter activity	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
protein binding	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
lipid binding	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
apolipoprotein binding	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
protein-containing complex binding	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
protein heterodimerization activity	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
phospholipid transfer activity	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
phosphatidylcholine transfer activity	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
cholesterol transfer activity	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
triglyceride transfer activity	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
ceramide 1-phosphate transfer activity	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
phosphatidylethanolamine transfer activity	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
phospholipid transporter activity	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
endopeptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metalloendopeptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Notch binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
interleukin-6 receptor binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
integrin binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
protein binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
peptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metallopeptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
SH3 domain binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cytokine binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
PDZ domain binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
tumor necrosis factor binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metal ion binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic process	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular region	Renin	Homo sapiens (human)
extracellular space	Renin	Homo sapiens (human)
plasma membrane	Renin	Homo sapiens (human)
apical part of cell	Renin	Homo sapiens (human)
extracellular space	Renin	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Ryanodine receptor 1	Homo sapiens (human)
plasma membrane	Ryanodine receptor 1	Homo sapiens (human)
cell cortex	Ryanodine receptor 1	Homo sapiens (human)
junctional sarcoplasmic reticulum membrane	Ryanodine receptor 1	Homo sapiens (human)
terminal cisterna	Ryanodine receptor 1	Homo sapiens (human)
sarcoplasmic reticulum	Ryanodine receptor 1	Homo sapiens (human)
organelle membrane	Ryanodine receptor 1	Homo sapiens (human)
I band	Ryanodine receptor 1	Homo sapiens (human)
sarcoplasmic reticulum membrane	Ryanodine receptor 1	Homo sapiens (human)
extracellular exosome	Ryanodine receptor 1	Homo sapiens (human)
ryanodine receptor complex	Ryanodine receptor 1	Homo sapiens (human)
Z disc	Ryanodine receptor 1	Homo sapiens (human)
sarcolemma	Ryanodine receptor 1	Homo sapiens (human)
smooth endoplasmic reticulum	Ryanodine receptor 1	Homo sapiens (human)
sarcoplasmic reticulum membrane	Ryanodine receptor 1	Homo sapiens (human)
calcium channel complex	Ryanodine receptor 1	Homo sapiens (human)
endoplasmic reticulum	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
endoplasmic reticulum lumen	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
Golgi apparatus	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
cytosol	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
brush border membrane	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
microvillus membrane	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
vesicle	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
receptor complex	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
Golgi apparatus	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
endoplasmic reticulum	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
basolateral plasma membrane	Microsomal triglyceride transfer protein large subunit	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
cell-cell junction	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
focal adhesion	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
ruffle membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Golgi membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cytoplasm	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
endoplasmic reticulum lumen	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cytosol	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
plasma membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell surface	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
actin cytoskeleton	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
apical plasma membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
membrane raft	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
plasma membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2791)

Assay ID	Title	Year	Journal	Article
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID622057	Ratio of Ki for HIV1 RT p66/p66 homodimer G190A mutant to Ki for wild-type HIV1 RT p66/p66 homodimer	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID106053	Inhibitory activity against 100I strain of HIV-I in MT-4 cells	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
AID82462	Antiviral activity against K103N/P225H strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID248264	In vitro inhibitory concentration against HIV Y188L mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID279480	Antiviral activity against HIV1 isolate with RT 100F mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID279463	Antiviral activity against HIV1 isolate with RT 108I, 181C, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1574373	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID1637393	Antiviral activity against human HIV-1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection from virus-induced cytopathic effect measured 5 days post infection by MTT assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID557045	Antiviral activity against HIV1 CRF17_BF harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID440071	Antiviral activity against HIV-1 LAI harboring wild type reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID1574390	Resistance index, ratio of ID50 for recombinant HIV-1 His-tagged reverse transcriptase p66/p51 L100I mutant to ID50 for recombinant wild type HIV-1 reverse transcriptase His-tagged p66/p51	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID508644	Antiviral activity against Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1161105	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.
AID226239	Fold resistance (L100I/ WT) (as per ref 7 in the article)	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID632800	Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral infection	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
AID1654213	Drug metabolism in human primary hepatocytes assessed as Cytochrome P450-mediated formation of 2-OHNVP at 10 uM incubated for 24 to 48 hrs by uHPLC-MS analysis	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death.
AID302267	Resistance index, ratio of Ki for HIV1 reverse transcriptase L100I mutant to Ki for wild type HIV1 3B reverse transcriptase	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID248880	Inhibitory concentration against human immunodeficiency virus type 1 (with K103N/Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID298079	Antiviral activity against HIV1 RT 112 mutant in lymphocytes assessed as reduction of p24 antigen production	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID106769	Cytotoxic dose required to reduce the viability of normal uninfected MT-4 cells by 50%	2002	Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.
AID499278	Selectivity index, ratio of CC50 for human MT4 cells to IC50 for HIV1 3B	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Anti-HIV and antiplasmodial activity of original flavonoid derivatives.
AID1197831	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
AID523356	Antiviral activity against HIV1 with RT connection domain Y181C/T369I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID279411	Antiviral activity against HIV1 isolate with RT 103N, 108I, 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID248846	Inhibitory concentration against human immunodeficiency virus type 1 (with Y188C resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID573475	Antiviral activity of wild-type Human immunodeficiency virus 1 isolate 5331 by cell based assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID1335201	Ratio of IC50 for HIV-1 NL4-3 harboring RT-K103N/V108I double mutant infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein to IC50 for wild-type HIV-1 NL4-3 infected in HEK293T cells co-expressing vesicular stomatitis virus glyco	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID279437	Antiviral activity against HIV1 isolate with RT 103N, 108I, 225H mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID557047	Antiviral activity against HIV1 clade D harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID1750722	Inhibition of recombinant wild type p66/p51 HIV1 reverse transcriptase incubated for 40 mins by picogreen dye-based spectrofluorometric analysis	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID1457066	Inhibition of HIV1 reverse transcriptase p66 K103N/Y1881C double mutant associated RNA dependent DNA polymerase activity expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer by scintilla	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID1565095	Antiviral activity against drug resistant HIV-1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID361906	Antiviral activity against wild type HIV1 in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1574378	Antiviral activity against HIV-1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID82460	Antiviral activity against K103N/G190A strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID198911	Inhibition of HIV-1 Mutant HIV-1 RT enzymes containing the single amino acid substitution K103N	2001	Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3	Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.
AID1124992	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives.
AID105716	Antiviral activity against HIV-1 (strain RF) infected MT-4 cells	1995	Journal of medicinal chemistry, May-12, Volume: 38, Issue:10	Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
AID1223490	Apparent permeability across human differentiated Caco2 cells	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID244633	Selective index value (ratio of CC50 to IC50 value)against HIV LAI cell line	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID1729156	Antiviral activity against HIV1 harboring L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID1729152	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV 3B infected in human MT4 cells	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID1249715	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID269798	Antiviral activity against HIV1 K103N mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269798	Antiviral activity against HIV1 K103N mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269798	Antiviral activity against HIV1 K103N mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1485973	Inhibition of HIV-1 reverse transcriptase Y181C mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID1773455	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring E138K mutant infected in human MT4 cells
AID297137	Antiviral activity against wild type HIV1 NL4-3 by cytopathic cell killing assay	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme.
AID666414	Antiviral activity against NNRTI-resistant HIV1 A17 expressing reverse transcriptase K103N and Y181C mutant infected in human MT4 cells assessed as inhibition of viral p24 antigen production after 7 days by ELISA	2012	Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5	Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.
AID1163254	Antileishmanial activity against Leishmania infantum MHOM/MA (BE)/67 infected in primary peritoneal mouse macrophages assessed as reduction in parasite burdun	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID1303216	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenic effect after 5 days by MTT assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and anti-HIV activity of novel quinoxaline derivatives.
AID198078	Inhibitory activity against HIV-1 Mutant Reverse transcriptase P236L	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones.
AID725390	Cytotoxicity against human CEmx174 cells expressing LTR-GFP	2013	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1	Synthesis and biological evaluation of triazolothienopyrimidine derivatives as novel HIV-1 replication inhibitors.
AID1141978	Inhibition of HIV1 wild-type reverse transcriptase L1001 mutant using [3H]dTTP by scintillation counting	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID299022	Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
AID105693	Anti-HIV-1 activity against K1001 strain was determined in MT-4 cells by the MTT method	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID257917	Antiviral activity against HIV1 Y181C mutant using HeLa MAGI assay	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.
AID1357783	Antiviral activity against wild-type HIV-1 3B infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID1485974	Inhibition of HIV-1 reverse transcriptase Y188L mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID1391081	Antiviral activity against HIV1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
AID226240	Fold resistance (L100I/ WT) (as per ref 8 in the article)	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.
AID342721	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors.
AID522377	Resistance index, ratio of EC50 for recombinant HIV1 harboring reverse transcriptase V106A/V179D mutant clone to EC50 for wild type HIV1	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID1761020	Antiviral activity against HIV-1 harboring reverse transcriptase RES056 mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect measured after 5 days by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID198247	Inhibitory concentration against HIV-1 wild type Reverse transcriptase (RT)	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse transcriptase enzymes.
AID279396	Antiviral activity against HIV1 isolate with RT 103N, 225H mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1443668	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
AID297141	Antiviral activity against HIV1 with RT V108I mutation by cytopathic cell killing assay	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme.
AID413566	Ratio of EC50 for multidrug-resistant HIV1with reverse transcriptase clone 7324-1 to EC50 for wild type HIV1 3B	2008	Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24	Development and preclinical studies of broad-spectrum anti-HIV agent (3'R,4'R)-3-cyanomethyl-4-methyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (3-cyanomethyl-4-methyl-DCK).
AID1200845	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
AID248841	Inhibitory concentration against human immunodeficiency virus type 1 (with G190A resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID322392	Antiviral activity against HIV1 3B assessed as inhibition of virus-induced cytopathogenicity in MT4 cells after 4 days by MTT assay	2008	Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1	Synthesis and anti-HIV evaluation of novel 1,3-disubstituted thieno[3,2-c][1,2,6]thiadiazin-4(3H)-one 2,2-dioxides(TTDDs).
AID1171598	Inhibition of wild type HIV1 reverse transcriptase Y181I mutant assessed as reduction in enzyme activity	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID586904	Activity at BCRP	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID1191403	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID281489	Selectivity index, CC50 for MT4 cells/IC50 for HIV1 3B	2007	Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8	Synthesis and anti-HIV-1 activity evaluation of 5-alkyl-2-alkylthio-6-(arylcarbonyl or alpha-cyanoarylmethyl)-3,4-dihydropyrimidin-4(3H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID298078	Antiviral activity against wild type HIV1 3B in lymphocytes assessed as reduction of p24 antigen production	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID1637404	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for human HIV-1 3B harboring F227L/V106A double mutant infected in human MT4 cells	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID1741400	Inhibition of recombinant HIV-1 reverse transcriptase p66/p51 incubated for 40 mins by picogreen dye based fluorescence assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID492287	Antiviral activity against HIV1 with reverse transcriptase F227L, V106A mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID573480	Fold resistance, ratio of EC50 for Human immunodeficiency virus 1 isolate 8116 harboring A98S, G190A mutation in reverse transcriptase to wild-type	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID282738	Inhibition of HIV1 RT V106A mutant	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
AID1171588	Resistance index, ratio of EC50 for HIV1 NL4-3 expressing reverse transcriptase K103N mutant to EC50 for wild type HIV1 NL4-3	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1292366	Inhibition of HIV1 reverse transcriptase using 234-nt long RNA/18-mer DNA oligonucleotide as template/primer preincubated for 15 mins followed by incubation with template/primer for 40 mins by liquid scintillation counting in presence of alpha[P33]-dCTP	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Design, discovery, modelling, synthesis, and biological evaluation of novel and small, low toxicity s-triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1483281	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for reverse transcriptase K103N mutant in human MT4 cells infected HIV1 3B	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID1565099	Antiviral activity against drug resistant HIV-1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID322394	Selectivity index, Ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2008	Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1	Synthesis and anti-HIV evaluation of novel 1,3-disubstituted thieno[3,2-c][1,2,6]thiadiazin-4(3H)-one 2,2-dioxides(TTDDs).
AID508783	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase E138K mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1736356	Antiviral activity against VSVG/HIV-1 harboring reverse transcriptase Y181C mutant infected in human HEK 293T cells assessed as inhibition of virus replication preincubated with cells for 15 mins prior to viral infection and measured at 48 hrs post-infect
AID650693	Ratio of ID50 for HIV 1 reverse transcriptase Y188L mutant to ID50 for wild type HIV 1 NL4-3 reverse transcriptase	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID1610053	Antiviral activity against HIV1 NARI-DR infected in human TZM-bl cells incubated for 48 hrs by bright Glo-luciferase reporter gene assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.
AID1357793	Antiviral activity against HIV1 harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID361905	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/P225H mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID726437	Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase K103N and Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4	Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.
AID279430	Antiviral activity against HIV1 isolate with RT 103N, 106I mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1320864	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
AID28979	Delta logD (logD6.5 - logD7.4)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID1290408	Inhibition of recombinant HIV1 His-tagged p66/p51 reverse transcriptase expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)-oligo(dT) (12 to 18 bp) as template/primer incubated for 20 mins by scintillation counting	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the N-Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family.
AID1056578	Antiviral activity against HIV-1 expressing reverse transcriptase K103N/P225H double mutant infected in human 293T cells co-transfected with VSVG protein assessed as inhibition of viral-replication incubated 15 mins prior to viral-infection measured after	2013	Journal of natural products, Dec-27, Volume: 76, Issue:12	Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73.
AID1636135	Inhibition of Escherichia coli RNA polymerase	2016	Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15	Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1637388	Antiviral activity against human HIV-1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathic effect measured 5 days post infection by MTT assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID607875	Cytotoxic activity against human MT4 cells assessed as viability of mock-infected cells after 5 days by MTT assay	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1316806	Selectivity index, ratio of CC50 for human MT-4 cells to IC50 for HIV-1 3B infected in human MT-4 cells	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Synthesis of arylated coumarins by Suzuki-Miyaura cross-coupling. Reactions and anti-HIV activity.
AID443757	Antiviral activity against HIV1 with reverse transcriptase Y181L mutation	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile.
AID247496	Inhibitory activity against HIV-1 mutant strain 101E	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID1059146	Antiviral activity against HIV1 3B infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24	Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID476469	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus replication by MTT assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.
AID246153	Concentration required to achieve 50% protection of infected MT-4 cells from K103N-Y181C	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID717257	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
AID1574384	Inhibition of recombinant wild type HIV-1 His-tagged reverse transcriptase p66/p51 expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer after 20 mins by scintillation counting analysis	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID263153	Cytotoxicity against HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID263153	Cytotoxicity against HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID263153	Cytotoxicity against HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID391991	Inhibition of HIV1 reverse transcriptase at 100 ug/ml after 1 hr by microtiter plate ELISA	2008	European journal of medicinal chemistry, Dec, Volume: 43, Issue:12	Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.
AID735329	Inhibition of HIV-1 reverse transcriptase assessed as decrease in incorporation of [3H]TTP into polyA template	2013	Journal of natural products, Apr-26, Volume: 76, Issue:4	Cytotoxic, antitopoisomerase IIα, and anti-HIV-1 activities of triterpenoids isolated from leaves and twigs of Gardenia carinata.
AID105540	Inhibitory activity against HIV-1 Wild Type in MT-4 cell culture (human T-cell line with 50% human AB serum)	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
AID1558853	Antiviral activity against HIV1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
AID1483269	Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID573474	Antiviral activity of wild-type Human immunodeficiency virus 1 isolate 5269 by cell based assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID518742	Selectivity ratio of EC50 for antiviral activity against HIV 1 subtype B harboring reverse transcriptase M230L mutant to EC50 for antiviral activity against HIV 1 subtype B harboring wild type reverse transcriptase	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
AID666413	Antiviral activity against HIV1 SF33 infected in human MT4 cells assessed as inhibition of viral p24 antigen production after 7 days by ELISA	2012	Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5	Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.
AID587747	Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as level of infection using human HeLaT4 cells pretreated for 24 hrs followed by exposed to vi	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID587755	Antiviral activity against HIV1 NL4-3.Luc in human MDM assessed as infectivity treated for 24 hrs by luciferase assay	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID246786	Concentration required to reduce the amount of p24 by 90% in C8166 cells infected with an efavirenz-resistant strain EFVR	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1077220	Cytotoxicity against human MT4 cells assessed as growth inhibition after 5 days by MTT assay	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.
AID508795	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V090I mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID197933	HIV-1 reverse transcriptase inhibitory activity against Ile 100 mutant using (poly)rC600*(oligo)dGT as template primer.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
AID1880372	Antiviral activity against wild type HIV-1 IIIB infected in human MT4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2022	Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12	Structure-Based Discovery of Novel NH
AID632804	Cytotoxicity against human MT2 cells infected with HIV1 NL4.3 by MTT assay	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
AID1637401	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for human HIV-1 3B harboring Y181C mutant infected in human MT4 cells	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID405582	Cytotoxicity against human 293T cells assessed as inhibition of cell proliferation by tetrazolium dye method	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates.
AID571978	Antiviral activity against HIV-1 subtype B V022810 harboring NNRTI A98S andK101R mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID46376	Antiviral activity against site directed resistant isolate HIV-1 K101E in CEM cells	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID663306	Inhibition of HIV1 recombinant reverse transcriptase K103N mutant assessed as [3H]dTTP incorporation into poly(rA)/oligo(dT)	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID496616	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase V90I/V35T, T39M, K46Q, V60I, S68G, D123E, I135V, S162A, K173A, Q174K,D177E, T200A, Q207E, R211K mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID1687687	Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells reduction in cell viability by MTT assay to EC50 for antiviral activity against wild type HIV-1 strain IIIB infected in human MT4 cells assessed as reduction in virus-induced cytopa	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
AID734261	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for Human immunodeficiency virus 1 A17 infected in human MT4 cells	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID1822273	Antiviral activity against wild type HIV-1 IIIB infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID293562	Antiviral activity against HIV1 LAI with RT F227C mutation in MT4 cells by EGFP based replication assay	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID1565100	Antiviral activity against drug resistant HIV-1 harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID1877038	Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability measured after 3 days by XTT assay	2021	Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22	HIV-1 gp120 Antagonists Also Inhibit HIV-1 Reverse Transcriptase by Bridging the NNRTI and NRTI Sites.
AID508655	Selectivity index, ratio of CC50 human MT4 cells to EC50 for Human immunodeficiency virus 1	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID525105	Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID287003	Inhibition of drug-resistant reverse transcriptase T181C mutant	2007	Journal of medicinal chemistry, May-17, Volume: 50, Issue:10	De novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variants.
AID82465	Antiviral activity against L100I strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1171590	Resistance index, ratio of EC50 for HIV1 NL4-3 expressing reverse transcriptase Y188L mutant to EC50 for wild type HIV1 NL4-3	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1743637	Resistance index, ratio of EC50 for antiviral activity against HIV1 expressing RT Y188L mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID395597	Selectivity index, ratio of CC50 for human CEM cells to EC50 for HIV1 3B	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	Synthesis and anti-HIV studies of 2- and 3-adamantyl-substituted thiazolidin-4-ones.
AID257918	Antiviral activity against HIV1 V106A mutant using HeLa MAGI assay	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.
AID492282	Antiviral activity against HIV1 with reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID279426	Antiviral activity against HIV1 isolate with RT 227L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID368559	Antiviral activity against HIV1 reverse transcriptase K103N mutant infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID293563	Antiviral activity against HIV1 LAI with RT L100I and K103N mutation in MT4 cells by EGFP based replication assay	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID232981	Selectivity index; ND = Not determined	2001	Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4	Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds.
AID1435517	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 expressing reverse transcriptase F227L/V106A double mutant
AID1316344	Selectivity index, ratio of CC50 for human mock-infected MT4 cells to EC50 for HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID481177	Inhibition of HIV1 reverse transcriptase by ELISA	2010	Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9	Synthesis and biological evaluation of novel C5 halogen-functionalized S-DABO as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID197800	Compound was tested for inhibitory activity against HIV-1 wild type reverse transcriptase	1998	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16	A dipyrido [2,3-b:3',2'-f]azepine analog of the HIV-1 reverse transcriptase inhibitor nevirapine.
AID1460929	Antiviral activity against HIV-1 Bal infected in human MAGI-CCR5 cells assessed as reduction in viral infection after 48 hrs by fluorescence based beta-galactosidase reporter gene assay	2017	Bioorganic & medicinal chemistry, 12-01, Volume: 25, Issue:23	An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors.
AID571971	Antiviral activity against HIV-1 subtype CRF01_AE V022820 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID391678	Antiviral activity against HIV1 infected in human 293T cells assessed as inhibition of pseudovirus infection	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.
AID650694	Ratio of ID50 for HIV 1 reverse transcriptase Y181I mutant to ID50 for wild type HIV 1 NL4-3 reverse transcriptase	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID1069707	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 3B	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design and synthesis of N₁-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID248316	In vitro inhibitory concentration against HIV-1 Y181C mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID527562	Antiviral activity against HIV1 NL4-3 containing reverse transcriptase K103N mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Discovery and SAR of a series of 4,6-diamino-1,3,5-triazin-2-ol as novel non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID279412	Antiviral activity against HIV1 isolate with RT 103N, 188L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID279403	Antiviral activity against HIV1 isolate with RT 108I mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1316336	Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID1565097	Antiviral activity against drug resistant HIV-1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID361917	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1303215	Cytotoxicity against human MT4 cells infected with HIV1 3B assessed as cell growth inhibition after 5 days by MTT assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and anti-HIV activity of novel quinoxaline derivatives.
AID257165	Inhibition of Y181I mutant HIV1 reverse transcriptase by [3H]-dTTP poly(rA)/oligo(dT) incorporation	2005	Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25	Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.
AID279418	Antiviral activity against HIV1 isolate with RT 98G, 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID619641	Ratio of EC50 for HIV-1 3B harboring RT K103N mutant infected in human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID1483278	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID573470	Inhibition of DNA-dependent DNA polymerase activity of wild-type Human immunodeficiency virus 1 subtype B reverse transcriptase Y181C mutant by filter-based filtration assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID698294	Antiviral activity against HIV1 IRLL98 containing reverse transcriptase K101Q, Y181C and G190A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID299023	Antiviral activity against HIV1 assessed as reduction of virus-induced cytopathic effect in MT4 cells	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
AID1880377	Antiviral activity against HIV-1 IIIB harboring reverse transcriptase K103N mutant infected in human MT4 cells by MTT assay	2022	Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12	Structure-Based Discovery of Novel NH
AID267648	Antiviral activity against HIV1 Y181C mutant	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID370725	Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 L100I mutant expressed in Escherichia coli JM109	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
AID558379	Drug level in HIV-infected pregnant woman cord blood plasma at 200 mg, po BID by HPLC/UV analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.
AID1162261	Antiviral activity against X4 tropic HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathic effect after 2 to 3 days by MTT assay	2014	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18	Semi-synthesis of oxygenated dolabellane diterpenes with highly in vitro anti-HIV-1 activity.
AID1171586	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1282049	Cytotoxicity against human U2OS cells assessed as cell viability at highest non-toxic concentration	2016	Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8	Antiretroviral (HIV-1) activity of azulene derivatives.
AID348907	Ratio of ED50 for drug resistant HIV1 with reverse transcriptase K103N mutant to wild type HIV1 NL4-3	2008	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21	Towards novel S-DABOC inhibitors: synthesis, biological investigation, and molecular modeling studies.
AID105123	Dose required to achieve 50% protection of MT-4 cells from the HIV-1 induced cytopathogenicity in mock-infected MT-4 cells	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.
AID586319	Antiviral activity against Human T-cell leukemia/lymphoma virus type 1 infected in human PBMC assessed as inhibition of tax/rex gene expression after 3 weeks post infection by quantitative real time RT-PCR	2011	Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6	Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID1627026	Cytotoxicity against HIV1 infected human PBMC cells assessed as reduction in cell viability after 7 days by MTT assay	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1591876	Solubility of the compound in water at pH 7	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase.
AID1636929	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection against viral infection by MTT method	2016	Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20	Computer-aided discovery of anti-HIV agents.
AID718369	Selectivity index, ratio of CC50 for HIV1 3B infected in human MT4 cells to EC50 for HIV1 3B	2012	Bioorganic & medicinal chemistry, Dec-01, Volume: 20, Issue:23	Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
AID1754639	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for Antiviral activity against HIV-1 IIIB infected in human MT4 cells	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID1185993	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay relative HIV1	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID1186004	Antiviral activity against HIV1 harboring reverse transcriptase K103N/V108I double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID226238	Fold resistance (L100I/ WT) (as per ref 6 in the article)	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.
AID1197830	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
AID1316342	Selectivity index, ratio of CC50 for human mock-infected MT4 cells to EC50 for HIV1 3B harboring reverse transcriptase L100I mutant infected in human MT4 cells	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID1736364	Selectivity index, ratio of EC50 for antiviral activity against VSVG/HIV-1 harboring reverse transcriptase K103N/Y181C double mutant infected in human HEK 293T cells to EC50 for antiviral activity against VSVG/wild type HIV-1 infected in human HEK293T cel
AID443755	Antiviral activity against HIV1 with reverse transcriptase K103N mutation	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile.
AID443756	Antiviral activity against HIV1 with reverse transcriptase Y181C mutation	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile.
AID234267	Selectivity index, ratio of CC50 to EC50	2000	Journal of medicinal chemistry, May-04, Volume: 43, Issue:9	Structure-based design, synthesis, and biological evaluation of novel pyrrolyl aryl sulfones: HIV-1 non-nucleoside reverse transcriptase inhibitors active at nanomolar concentrations.
AID557039	Antiviral activity against HIV1 isolate R8 harboring reverse transcriptase K103N and Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs in presence of 10% FBS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID279322	Inhibition of reverse transcriptase in HIV1 Z6gpt assessed as inhibition of ssDNA synthesis	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID508642	Antiviral activity against Human immunodeficiency virus 1 subtype AE infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID551464	Antiviral activity against HIV1 3B infected in human C8166 cells assessed as protection against virus-induced cytopathogenicity after 3 days	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	Synthesis and biological evaluation of novel dihydro-aryl/alkylsulfanyl-cyclohexylmethyl-oxopyrimidines (S-DACOs) as high active anti-HIV agents.
AID566899	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by microtiter plate analysis	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection.
AID1457054	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 NL4-3 infected in human MT4 cells	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID1072802	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2014	Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6	Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
AID1483276	Inhibition of HIV1 3B reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID371909	Antiviral activity against HIV1 NL4-3 with L100I mutant in human TZM-b1 cells assessed as beta-galactosidase activity after 48 hrs by single round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID368567	Inhibition of HIV1 recombinant free reverse transcriptase K103N mutant expressed in Escherichia coli BL21	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID1357789	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID1862267	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Design, synthesis, and biological evaluation of novel double-winged galloyl derivatives as HIV-1 RNase H inhibitors.
AID1754641	Antiviral activity against HIV1 harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID650544	Antiviral activity against HIV 1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID1072801	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2014	Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6	Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
AID508654	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V179F, Y181C, F227C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID391992	Antiviral activity against HIV1 3B replication in human CEM cells assessed as inhibition of virus-induced cytopathic effect after 5 days by tetrazolium-based colorimetric assay	2008	European journal of medicinal chemistry, Dec, Volume: 43, Issue:12	Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.
AID650541	Resistance ratio of EC50 for multidrug-resistant HIV 1 IRLL98 harboring reverse transcriptase K101Q/Y181C/G190a mutant to EC50 for wild type HIV 1 NL4-3 infected in human MT4 cells	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID572175	Antiviral activity against HIV-1 subtype F V029522 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID371904	Antiviral activity against HIV1 NL4-3 with K103N/L100I double mutant in human TZM-b1 cells assessed as beta-galactosidase activity after 48 hrs by single round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID363038	Selectivity index, ratio of CC50 for human MT4 cells to IC50 for HIV1 3B	2008	European journal of medicinal chemistry, Jun, Volume: 43, Issue:6	Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 11: structural modulations of diaryltriazines with potent anti-HIV activity.
AID1248227	Inhibition of recombinant HIV1 Reverse transcriptase p66/p51 using poly (rA)-oligo (dT) as template primer after 40 mins by spectrofluorometric analysis	2015	Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20	A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities.
AID1888700	Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT K103N mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells
AID666973	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 NL4-3	2012	European journal of medicinal chemistry, Aug, Volume: 54	Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors.
AID1460943	Antiviral activity against HIV-1 NL4-3 harboring reverse transcriptase Y181C mutant infected in human MAGI-CCR5 cells assessed as reduction in viral infection after 48 hrs by fluorescence based beta-galactosidase reporter gene assay	2017	Bioorganic & medicinal chemistry, 12-01, Volume: 25, Issue:23	An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors.
AID1443980	Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch	2010	Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1446814	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild-type HIV1 3B infected in human MT4 cells	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID104944	Concentration which reduced the viability of the HIV-1 infected MT-4 cells to 50% compared to untreated control cells	1995	Journal of medicinal chemistry, Dec-08, Volume: 38, Issue:25	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs.
AID198746	In vitro inhibitory activity against human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) at a concentration of 10 ug/mL.	1991	Journal of medicinal chemistry, Jul, Volume: 34, Issue:7	Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones.
AID373574	Half life in plasma of HIV1-infected patient administered as single dose	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID279478	Antiviral activity against HIV1 isolate with RT 106L, 188L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1773459	Resistance factor, ratio of EC50 for HIV1 harboring Y18IC mutant infected in human MT4 cells to EC50 for HIV1 3B infected in MT4 cells
AID508761	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K103N, F227L mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1443664	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 3B	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
AID246266	Effective concentration against human immunodeficiency virus type 1 K103N mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
AID293564	Antiviral activity against HIV1 LAI with RT K103N and Y181C mutation in MT4 cells by EGFP based replication assay	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID1743627	Antiviral activity against HIV1 harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID346973	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV 3B	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Studies on anti-HIV quinolones: new insights on the C-6 position.
AID88364	Antiviral activity against E138K mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID630953	Selectivity index, ratio of CC50 for human TZM-bl cells to EC50 for R5 tropic Human immunodeficiency virus 1 subtype B-ADA5	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1352315	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 3B	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID698300	Selectivity index, ratio of EC50 for HIV1 containing reverse transcriptase Y181C mutant to EC50 for wild type HIV1 NL4-3	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID391995	Antiviral activity against HIV2 ROD replication in human CEM cells assessed as inhibition of virus-induced cytopathic effect at subtoxic concentration after 5 days by tetrazolium-based colorimetric assay	2008	European journal of medicinal chemistry, Dec, Volume: 43, Issue:12	Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.
AID1443660	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
AID279457	Antiviral activity against HIV1 isolate with RT 98G, 101E, 181C, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1155814	Inhibition of HIV-1 recombinant NNTRI-resistant reverse transcriptase K103N mutant assessed as incorporation of [3H]dTTP into poly(rA)/oligo(dT)10:1	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID1654219	Drug metabolism in C57BL/6J mouse primary hepatocytes assessed as 12-O-GlucD2NVP metabolite formation at 10 uM incubated for 24 hrs by uHPLC-MS analysis	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death.
AID1815393	Resistance fold, ratio of EC50 for HIV1 harboring reverse transcriptase E138K mutant infected MV4 cells to EC50 for wild type HIV1 infected MV4 cells	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID263516	Antiviral activity against HIV1 I135V mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID1357792	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID571977	Antiviral activity against HIV-1 subtype B V022809 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1610045	Antiviral activity against HIV1 NL4.3 infected in human TZM-bl cells measured upto 24 hrs by bright Glo-luciferase reporter gene assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.
AID269796	Antiviral activity against HIV1 F227L mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269796	Antiviral activity against HIV1 F227L mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269796	Antiviral activity against HIV1 F227L mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1298251	Inhibition of HIV1 reverse transcriptase p66/p51 Y181C mutant using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID1811039	Anti-viral activity against HIV1 harboring RT L100I mutant infected MV4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
AID1729151	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID1304407	Inhibition of HIV-1 BH10 recombinant reverse transcriptase K103N mutant expressed in Escherichia coli assessed as incorporation of [32P]GTP into poly(rA)/oligo(dT) as template primer	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID282737	Inhibition of HIV1 RT K103N mutant	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
AID430055	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Design, synthesis, and structure-activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents.
AID1457056	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human ML4 cells assessed as protection against virus-induced cytopathic effect measured on day 5 post infection by MTT assay	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID587754	Antiviral activity against HIV1 NL4-3.Luc in human PBMC assessed as infectivity treated for 24 hrs by luciferase assay	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID105572	Antiviral activity was determined against wild type HIV-1 in MT-4 cells infected with HIV-1 IIIB using an XTT assay	1998	Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12	Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1217706	Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1163255	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human O positive erythrocyte assessed as reduction in parasitemia after 72 hrs	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID82458	Antiviral activity against K101E strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID779524	Inhibition of recombinant wild type HIV-1 reverse transcriptase p66/p51 expressed in Escherichia coli JM109 using poly(rA)/oligo(dT)16 (1:1.2) as template/primer after 40 mins by spectrofluorometric analysis	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
AID508765	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase M236L mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1217709	Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID279470	Antiviral activity against HIV1 isolate with RT 238T mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1316328	Selectivity index, ratio of CC50 for human mock-infected MT4 cells to EC50 for HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID105547	Tested for the inhibition of wild type HIV-1 (IIIB) replication in MT-4 cells	1996	Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21	Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.
AID1574388	Resistance index, ratio of ID50 for recombinant HIV-1 His-tagged reverse transcriptase p66/p51 K103N mutant to ID50 for recombinant wild type HIV-1 reverse transcriptase His-tagged p66/p51	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID1460931	Antiviral activity against HIV-1 Bal infected in human PBMC by MTS assay	2017	Bioorganic & medicinal chemistry, 12-01, Volume: 25, Issue:23	An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors.
AID248354	Concentration required to inhibit 50% viral production of human immunodeficiency virus type 1 (HIV-1-IIIB)	2005	Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7	Hierarchical database screenings for HIV-1 reverse transcriptase using a pharmacophore model, rigid docking, solvation docking, and MM-PB/SA.
AID269794	Cytotoxicity against HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269794	Cytotoxicity against HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269794	Cytotoxicity against HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID734267	Cytotoxicity against human MT4 cells after 3 days by XTT assay	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID1435503	Antiviral activity against HIV1 expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
AID199242	Inhibitory effect on recombinant HIV- 1 reverse transcriptase which has a mutation Leu 100 to Ile 100 (clone 118)	1998	Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12	Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID496618	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase V90I/V35T, E36D, V60I, K122E, D123S, I135V, E138D, S162A, K173T,Q174S, D177E, I178M, V189I, T200A, I202V, Q207E, F214L, V245Q mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID523486	Antiviral activity against HIV1 with RT connection domain L100I/T369I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID587757	Ratio of EC50 for HIV1 NL4-3.Luc assessed as infectivity using human MDM pretreated for 24 hrs followed by exposed to virus after compound washout to standard EC50 for HIV1 NL4-3.Luc	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID1267611	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Design and Synthesis of DiselenoBisBenzamides (DISeBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity.
AID1057036	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.
AID248261	In vitro inhibitory concentration against HIV L100I mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID253493	Dose required to inhibit HIV-1 reverse transcriptase activity (Y181I mutant) by 50%	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure-activity relationship investigation.
AID779527	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
AID257166	Antiviral activity against wild type HIV1 NL4-3 infected MT4 cells by MTT method	2005	Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25	Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.
AID1069708	Cytotoxicity against human MT4 cells assessed as cell viability	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design and synthesis of N₁-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID248260	In vitro inhibitory concentration against HIV K103N mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID1457057	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human ML4 cells assessed as protection against virus-induced cytopathic effect measured on day 5 post infection by MTT assay	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID1298245	Cytotoxicity against human MT4 cells after 5 days MTT assay	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID1815384	Antiviral activity against HIV1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID1736368	Selectivity index, ratio of EC50 for antiviral activity against VSVG/HIV-1 harboring reverse transcriptase V108I/K103N double mutant infected in human HEK 293T cells to EC50 for antiviral activity against VSVG/wild type HIV-1 infected in human HEK293T cel
AID1390713	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells	2018	Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.
AID1056577	Ratio of EC50 for HIV-1 expressing reverse transcriptase K103N mutant to EC50 for wild-type HIV-1	2013	Journal of natural products, Dec-27, Volume: 76, Issue:12	Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73.
AID1391077	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
AID247619	Inhibitory activity against HIV-1 double mutants strain 103N and 181C	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID279451	Antiviral activity against HIV1 isolate with RT 101E, 108I, 181C, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID395594	Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	Synthesis and anti-HIV studies of 2- and 3-adamantyl-substituted thiazolidin-4-ones.
AID482695	Antiviral activity against HIV1 NL4-3 infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID279325	Inhibition of reverse transcriptase activity in HIV1 NL4-3 infected MT4 cells before dialysis	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification.
AID584081	Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase V108I, H221Y, F227F/L, M230M/I mutant infected in human SupT1 cells derived from 11 viral passages with lersivirine assessed as inhibition of viral replication after 21 days relative to	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID199992	Effective concentration required against L100I mutant HIV-1 reverse transcriptase (as per ref 12 in the article)	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.
AID106609	Cytotoxic concentration that reduces the MT-4 cell viability by 50%	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.
AID1249721	Antiviral activity against HIV1 expressing reverse transcriptase Y181C mutant	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID571984	Antiviral activity against HIV-1 subtype C V022816 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID361922	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188C mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID198231	Inhibition of purified recombinant HIV-1 reverse transcriptase	1999	Bioorganic & medicinal chemistry letters, Jun-07, Volume: 9, Issue:11	Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
AID29361	Dissociation constant (pKa)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID1157587	Antiviral activity against saquinavir-resistant HIV1 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID294631	Cytotoxicity against CEM cells	2007	European journal of medicinal chemistry, Jul, Volume: 42, Issue:7	Synthesis and anti-HIV studies of 2-adamantyl-substituted thiazolidin-4-ones.
AID267862	Inhibition of HIV1 reverse transcriptase K103N mutant	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
AID1186685	Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection from viral cytopathicity after 5 days by MTT assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID440638	Antiviral activity against NNRTI-resistant HIV1 NL4-3 with reverse transcriptase K103N mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20	Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase.
AID1822277	Antiviral activity against HIV-1 harboring K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID1773444	Selectivity ratio of CC50 for human MT4 cells to IC50 for HIV1 RES056 infected in MT4 cells
AID523484	Antiviral activity against HIV1 with RT connection domain L100I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID106065	Inhibitory activity against 181C strain of HIV-I in MT-4 cells	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
AID1520037	Antiviral activity against VSV-G pseudotyped HIV1 transfected in human 293T cells co-transfected with NL4-3 HIV1 supernatant infected in human SupT1 cells treated with compound for 48 hrs assessed as inhibition of viral infection at 100 nM after 48 hrs by	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Preliminary SAR and biological evaluation of potent HIV-1 protease inhibitors with pyrimidine bases as novel P2 ligands to enhance activity against DRV-resistant HIV-1 variants.
AID1815386	Resistance fold, ratio of EC50 for HIV1 harboring reverse transcriptase Y181C mutant infected MV4 cells to EC50 for wild type HIV1 infected MV4 cells	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1435502	Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
AID650689	Inhibition of HIV 1 reverse transcriptase K103N mutant assessed as inhibition of time-dependent incorporation of [3H]dTTP into poly(rA)n.oligo(dT)	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID523347	Antiviral activity against HIV1 with RT connection domain N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID82470	Antiviral activity against V106I strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1729149	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID267859	Cytotoxicity against MT4 cells by MTT assay	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
AID302254	Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID449491	Cytotoxicity against human MT4 cells as reduction in cell viability after 5 days by MTT assay	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID198235	Inhibitory activity against HIV rRT activity in mutant HIV-1 strain resistant to Nevirapine (Y181C)	1996	Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2	2-Sulfonyl-4-chloroanilino moiety: a potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones.
AID1373152	Inhibition of reverse transcriptase Y181C mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID361928	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I/Y181C mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1157582	Antiviral activity against efavirenz-resistant HIV1 harboring RT 100I, 103R, 179D, 225H mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID660088	Inhibition of HIV-1 reverse transcriptase at 20 ug after 1 hr by colorimetry	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis, biological activity and docking study of imidazol-5-one as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID508785	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase E138A mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1186002	Antiviral activity against HIV1 harboring reverse transcriptase K103N/G190A double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID1565093	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV IIIB
AID734256	Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 harboring reverse transcriptase Y181C mutation infected in human TZM-bl cells assessed decrease in p24 level after 7 days by ELISA	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID246359	Protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID226250	Y181C/WTIIIB ratio of the compound	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1410488	Inhibition of HIV1 reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity by MTT assay	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.
AID263522	Antiviral activity against HIV1 F227L mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID698145	Inhibition of HIV1 reverse transcriptase K103N mutant RNA-dependent DNA polymerase activity using poly(rA)/oligo(dT)10:1 and [3H]-dTTP substrate	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID82474	Antiviral activity against Y181C strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID279472	Antiviral activity against HIV1 isolate with RT 103S mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID302621	Cytotoxicity against human MT2 cells by MTT assay	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	From docking false-positive to active anti-HIV agent.
AID1743630	Antiviral activity against HIV1 harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID371907	Antiviral activity against HIV1 NL4-3 with Y181L mutant in human TZM-b1 cells assessed as beta-galactosidase activity after 48 hrs by single round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID198094	Inhibitory activity against HIV-1 recombinant reverse transcriptase.	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID443758	Antiviral activity against HIV1 with reverse transcriptase G190A mutation	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile.
AID440084	Antiviral activity against HIV1 HXB2 harboring 100I and K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID1572530	Inhibition of HIV1 reverse transcriptase p66/p51 using poly(rA)/oligo(dT)16 as template/primer measured after 40 mins by pico-green based spectrofluorometric analysis
AID1574387	Inhibition of recombinant HIV-1 His-tagged reverse transcriptase p66/p51 L100I mutant expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer after 20 mins by scintillation counting analysi	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID1175436	Antiviral activity against wild-type HIV-1 SF33 infected in human TZM-bl cells after 7 days by ELISA	2015	Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1	Synthesis and biological evaluation of pyridinone analogues as novel potent HIV-1 NNRTIs.
AID298074	Antiviral activity against HIV1 3B in MT4 cells by MTT assay	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID246274	Effective concentration against rhuman immunodeficiency virus type 1 L100I mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
AID508787	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V106M mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID491827	Antiviral activity against HIV1 with reverse transcriptase 8605MR mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	2010	Journal of medicinal chemistry, Jul-08, Volume: 53, Issue:13	Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1418464	Antiviral activity against HIV1 RES056 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 4 days by MTT assay	2018	Bioorganic & medicinal chemistry letters, 12-01, Volume: 28, Issue:22	Design and synthesis of a novel series of non-nucleoside HIV-1 inhibitors bearing pyrimidine and N-substituted aromatic piperazine.
AID246481	Effective concentration against human immunodeficiency virus type 1 mutated at 227C; ND:Not determined	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID1483280	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for reverse transcriptase L100I mutant in human MT4 cells infected HIV1 3B	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID360706	Inhibition of HIV1 RT K103N mutant mediated DNA-dependent DNA polymerization using RNA/DNAM duplex primed substrate by scintillation proximity assay	2007	The Journal of biological chemistry, Mar-16, Volume: 282, Issue:11	HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.
AID46377	Antiviral activity against site directed resistant isolate HIV-1 K103N in CEM cells	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID1636146	Antiviral activity against wild type HIV1 NL4-3	2016	Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15	Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
AID1304401	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID248843	Inhibitory concentration against human immunodeficiency virus type 1 (with V106A resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID1591874	Antiviral activity against HIV1 NL4-3 harboring Y181C mutant infected in human MT2 cells measured 48 hrs post-infection by MTT assay	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase.
AID105143	Concentration required to achieve 50% protection of MT-4 cells from HIV-1-induced cytopathogenicity.	1999	Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4	5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1736154	Inhibition of wild type recombinant HIV-1 subtype B BH10 p66/p51 reverse transcriptase heterodimer expressed in Escherichia coli BL21 (DE3) assessed as inhibition of dTTP incorporation on poly(rA)-oligo(dT) template primer duplex at 100 uM preincubated wi	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Design, synthesis and biological evaluation of quinoxaline compounds as anti-HIV agents targeting reverse transcriptase enzyme.
AID404304	Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID735082	Antiviral activity against wild type HIV by cell based assay	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Synthesis and biological evaluation of phosphonate analogues of nevirapine.
AID1443666	Antiviral activity against HIV1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
AID246779	Concentration required to reduce the amount of p24 by 90% in wtIIIB-HIV-1-infected C8166 cells	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID371896	Antiviral activity against wild type HIV1 NL4-3 in human TZM-b1 cells assessed as beta-galactosidase activity after 48 hrs	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID1884541	Fold resistance, ratio of EC50 for antiviral activity against drug-resistant HIV-1 Y188L mutant infected in human MT4 cells to EC50 for antiviral activity against NNRTI resistant wild type HIV-1 infected in human MT4 cells	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID1442776	Inhibition of HIV1 reverse transcriptase by colorimetric assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
AID248842	Inhibitory concentration against human immunodeficiency virus type 1 (with K103N resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID1888701	Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT Y181C mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells
AID1357785	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID1637390	Cytotoxicity against mock-infected human MT4 cells assessed as reduction of cell viability after 5 days by MTT assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID522373	Antiviral activity against recombinant HIV1 harboring reverse transcriptase V106I/V179D mutant clone infected in MAGIC-5 cells using 5-bromo4-chloro-3-indolyl-beta-D-galactopyranoside staining based light microscopy	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID443754	Antiviral activity against HIV1 PNL4-3	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile.
AID1155809	Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID346972	Cytotoxicity against mock-infected human MT4 cells by MTT assay	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Studies on anti-HIV quinolones: new insights on the C-6 position.
AID1880376	Antiviral activity against HIV-1 IIIB harboring reverse transcriptase L1001 mutant infected in human MT4 cells by MTT assay	2022	Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12	Structure-Based Discovery of Novel NH
AID496622	Antiviral activity against HIV-1 subtype CRF06_cpx ontaining reverse transcriptase V106I/V21I, V35T, V60I, K122T, D123R, I135V, S162A, K173T, Q174K, D177E, I178L, T200A, Q207D, R211K, V245Q, E248D mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID269801	Antiviral activity against HIV1 Y181C mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269801	Antiviral activity against HIV1 Y181C mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269801	Antiviral activity against HIV1 Y181C mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1056575	Ratio of EC50 for HIV-1 expressing reverse transcriptase K103N/V108I double mutant to EC50 for wild-type HIV-1	2013	Journal of natural products, Dec-27, Volume: 76, Issue:12	Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73.
AID586321	Inhibition of HIV1 3B reverse transcriptase activity infected in human H9 cells assessed as level of p24 antigen	2011	Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6	Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID1884488	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against NNRTI resistant HIV-1 infected in human MT4 cells	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID1485967	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID614141	Antiviral activity against wild type Human immunodeficiency virus 1 3B bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2011	Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17	Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
AID1418466	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	2018	Bioorganic & medicinal chemistry letters, 12-01, Volume: 28, Issue:22	Design and synthesis of a novel series of non-nucleoside HIV-1 inhibitors bearing pyrimidine and N-substituted aromatic piperazine.
AID279417	Antiviral activity against HIV1 isolate with RT 106A, F227L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID305057	Antiviral activity against HIV in HEK293T cells after 48 hrs	2007	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1	4-Aminopyrimidines as novel HIV-1 inhibitors.
AID718368	Cytotoxicity against HIV2 ROD infected in human MT4 cells by MTT assay	2012	Bioorganic & medicinal chemistry, Dec-01, Volume: 20, Issue:23	Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
AID199997	Effective concentration required against wild type HIV-1 reverse transcriptase (as per ref 12 in the article)	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.
AID440075	Antiviral activity against HIV1 HXB2 harboring Y188L mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID269689	Antiviral activity against HIV1 NNTRI resistant L100I mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269689	Antiviral activity against HIV1 NNTRI resistant L100I mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269689	Antiviral activity against HIV1 NNTRI resistant L100I mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1057037	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild-type HIV1 3B infected in MT4 cells	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.
AID508786	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V108I mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1191400	Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID199995	Effective concentration required against L100I mutant HIV-1 reverse transcriptase (as per ref 8 in the article)	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.
AID478386	Inhibition of HIV1 RT after 1 hr by ELISA relative to control	2010	Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9	Design of potential reverse transcriptase inhibitor containing Isatin nucleus using molecular modeling studies.
AID1249723	Antiviral activity against HIV1 expressing reverse transcriptase F227L + V106A mutant	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID361908	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID518735	Inhibition of RNA-dependent DNA polymerase activity of HIV1 subtype B reverse transcriptase M230L mutant by filter-based filtration assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
AID371897	Selectivity index, ratio of CC50 for human TZM-b1 cells to EC50 for HIV1 NL4-3	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID361924	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/V108I mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID440074	Antiviral activity against HIV1 HXB2 harboring Y181C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID508778	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V179E mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID197779	Ability to inhibit HIV-1 Reverse Transcriptase (RT) using an rC-dG template/primer	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	Synthesis of a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID606674	Inhibition of HIV1 reverse transcriptase V179D mutant	2011	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13	Enantioselective binding of second generation pyrrolobenzoxazepinones to the catalytic ternary complex of HIV-1 RT wild-type and L100I and K103N drug resistant mutants.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID496620	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase K101E/K30E, I31P, V35Q, T39S, E44G, E53G, A62G, N81H, Q91H,I135V,S162A, K173S, Q174R, D177E, V179I, T200I, Q207N, R211K, F214L mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID198228	Inhibitory activity against recombinant HIV-1 reverse transcriptase (rRT)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
AID279467	Antiviral activity against HIV1 isolate with RT 106A, 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID263517	Antiviral activity against HIV1 E138K mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID198411	Tested for the inhibition of wild type HIV-1 (IIIB) RT	1996	Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21	Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.
AID1267612	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-2 ROD	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Design and Synthesis of DiselenoBisBenzamides (DISeBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity.
AID1517761	Inhibition of HIV-1 reverse transcriptase RNA-dependent DNA polymerase activity assessed as reduction in biotin-dUTP incorporation at 500 nM using poly(A)/oligo (dT)15 as template/primer by ELISA	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Discovery of 2-isoxazol-3-yl-acetamide analogues as heat shock protein 90 (HSP90) inhibitors with significant anti-HIV activity.
AID1882468	Antiviral activity against wild type HIV-1 IIIB infected in human MT2 cells assessed as protection against virus-induced cytopathicity by MTT assay	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
AID248844	Inhibitory concentration against human immunodeficiency virus type 1 (with V108I resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID267863	Inhibition of HIV1 reverse transcriptase Y181I mutant	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
AID265467	Antiviral activity against HIV1 3B in MT4 cell line	2006	Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11	Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide.
AID366524	Antiviral activity against HIV1 isolates with reverse transcriptase Y188L mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID371911	Antiviral activity against HIV1 NL4-3 with Y181C mutant in human TZM-b1 cells assessed as beta-galactosidase activity after 48 hrs by single round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID738335	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
AID1483277	Inhibition of HIV1 3B reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID248493	In vitro inhibitory concentration value against HIV K103N and Y181C mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID1171585	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID757625	Antiviral activity against HIV1 RES056 expressing RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2013	European journal of medicinal chemistry, Jul, Volume: 65	Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID373561	Half life in plasma of HIV1-infected patient	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID508764	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase L100I, K101E mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1773452	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring K103N mutant infected in human MT4 cells
AID198236	Inhibitory activity against HIV rRT activity in wild type IIIB strain	1996	Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2	2-Sulfonyl-4-chloroanilino moiety: a potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones.
AID1304403	Cytotoxicity against mock-infected human MT4 cells	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID1373156	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B expressing wild type reverse transcriptase	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID663299	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID685331	Antiviral activity against HIV-1 3B infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay	2012	Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
AID693583	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	European journal of medicinal chemistry, Dec, Volume: 58	Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors.
AID522372	Antiviral activity against recombinant HIV1 harboring reverse transcriptase V106A/V179D mutant clone infected in MAGIC-5 cells using 5-bromo4-chloro-3-indolyl-beta-D-galactopyranoside staining based light microscopy	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID1743629	Antiviral activity against HIV1 harboring RT Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID82463	Antiviral activity against K103N/V108I strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1235381	Inhibition of HIV1 recombinant wild type reverse transcriptase p66/p51 assessed as reduction in biotin deoxyuridine triphosphate (biotin-dUTP) incorporation using poly(rA)/oligo (dT)16 template and primer by spectrofluorometry	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Hybrid chemistry. Part 4: Discovery of etravirine-VRX-480773 hybrids as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID106967	Concentration required to inhibit HIV-1 induced cytopathicity in MT-4 cells by 50%	1992	Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16	TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro -5''- (4''-amino-1'',2''-oxathiole 2'',2''-dioxide) pyrimidine and pyrimidine-modified nucleosides.
AID1763904	Antiviral activity against HIV-1 RES056 infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
AID1304408	Antiviral activity against HIV-1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID1729150	Antiviral activity against HIV1 RES056 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID592540	Cytotoxicity against human CEM cells by coulter counter analysis	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide.
AID247502	Inhibitory activity against HIV-1 mutant strain 188L	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID613685	Induction of human A375 cell differentiation assessed as formation of vimentin intermediate filament at 20 uM after 96 hrs by immunofluorescence analysis	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitors.
AID734265	Antiviral activity against Human immunodeficiency virus 1 SF33 infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID1561720	Resistance index, ratio of EC50 for antiviral activity against HIV1 3B infected in human MT4 cells grown under 30 passages in presence of (E)-4-((4-((4-(4-(2-Cyanovinyl)-2,6-dimethylphenoxy)thieno[2,3- d]pyrimidin-2-yl)amino)piperidin-1-yl)methyl)benzenes
AID584082	Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase L100I, K103Q, H221H/Y mutant infected in human SupT1 cells derived from 11 viral passages with efavirenz assessed as inhibition of viral replication after 21 days relative to drug sensi	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID1822278	Antiviral activity against HIV-1 harboring Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID614139	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 IIIB infected in human MT4 cells	2011	Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17	Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
AID106977	Effective concentration against HIV-1 induced cytopathicity in MT-4 cells using MTT method	2000	Journal of medicinal chemistry, May-04, Volume: 43, Issue:9	Structure-based design, synthesis, and biological evaluation of novel pyrrolyl aryl sulfones: HIV-1 non-nucleoside reverse transcriptase inhibitors active at nanomolar concentrations.
AID1390712	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.
AID1056576	Ratio of EC50 for HIV-1 expressing reverse transcriptase L100I/K103N double mutant to EC50 for wild-type HIV-1	2013	Journal of natural products, Dec-27, Volume: 76, Issue:12	Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73.
AID1627027	Cytotoxicity against HIV1 infected human CEM cells assessed as reduction in cell viability after 7 days by MTT assay	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1609104	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 4 days by MTT assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1059145	Antiviral activity against drug-resistant HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT-4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24	Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1761008	Selectivity index, ratio of CC50 for human TZM-bl cells to EC50 for wild type HIV1 NL4-3 infected in human TZM-bl cells	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID1165076	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
AID351446	Antiviral activity against HIV2 ROD in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by MTT assay	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Synthesis of alkenyldiarylmethanes (ADAMs) containing benzo[d]isoxazole and oxazolidin-2-one rings, a new series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1357791	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID1884539	Fold resistance, ratio of EC50 for antiviral activity against drug-resistant HIV-1 K103 N mutant infected in human MT4 cells to EC50 for antiviral activity against NNRTI resistant wild type HIV-1 infected in human MT4 cells	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID523348	Antiviral activity against HIV1 with RT connection domain T369I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID94314	Antiviral activity against HIV-1 K103N mutant virus.	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID198563	The compound was evaluated for the inhibition of HIV-1 reverse transcriptase	2000	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2	Novel 2,2-dioxide-4,4-disubstituted-1,3-H-2,1,3-benzothiadiazines as non-nucleoside reverse transcriptase inhibitors.
AID1171584	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID297134	Inhibition of HIV1 NL4-3 reverse transcriptase	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme.
AID279466	Antiviral activity against HIV1 isolate with RT 103N, 190S mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID508638	Antiviral activity against Human immunodeficiency virus 1 subtype F1 infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID279458	Antiviral activity against HIV1 isolate with RT 103Q mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID571972	Antiviral activity against HIV-1 subtype CRF01_AE V022821 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID457960	Inhibition of HIV1 reverse transcriptase Y181I mutant by RNA-dependent DNA polymerase activity assay	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID279432	Antiviral activity against HIV1 isolate with RT 181I mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID572184	Antiviral activity against HIV-1 SM026 harboring NNTRI 103N and 181C mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID781026	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against viral-induced cytotoxicity after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs.
AID607873	Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1574377	Antiviral activity against HIV-1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID279454	Antiviral activity against HIV1 isolate with RT 100I, 103N, 108I mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID302253	Antiviral activity against HIV1 with reverse transcriptase K103N mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID265472	Activity against HIV-112 assessed by inhibition of p24 production in human lymphocytes	2006	Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11	Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide.
AID263518	Antiviral activity against HIV1 V179E mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID619636	Antiviral activity against HIV-1 3B harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID572183	Antiviral activity against HIV-1 SM024 harboring NNTRI 190A mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID622048	Inhibition of DNA-dependent DNA polymerase activity of HIV1 reverse transcriptase p66/p66 homodimer V106A mutant using activated DNA and [alpha-32P]dATP after 30 mins by liquid scintillation counting	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID1235383	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity added 3 to 5 hrs post infection and measured 31 hrs post infection by p24 enzyme-linked immunosorbent assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Hybrid chemistry. Part 4: Discovery of etravirine-VRX-480773 hybrids as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1811035	Anti-viral activity against HIV1 harboring RT Y188L mutant infected MV4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
AID440632	Antiviral activity against HIV1 RF infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20	Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase.
AID734258	Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 harboring reverse transcriptase K103N mutation infected in human TZM-bl cells assessed decrease in p24 level after 7 days by ELISA	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID1691437	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	2020	European journal of medicinal chemistry, May-01, Volume: 193	In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP.
AID734264	Selectivity index, ratio of CC50 for human TZM-bl cells to EC50 for Human immunodeficiency virus 1 SF33 infected in human TZM-bl cells	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID1316346	Selectivity index, ratio of CC50 for human mock-infected MT4 cells to EC50 for HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID1888689	Antiviral activity against HIV1 with RT F227L + V106A mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay
AID298077	Cytotoxicity against lymphocytes	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID88367	Antiviral activity against K103N/L100I mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID622050	Inhibition of DNA-dependent DNA polymerase activity of HIV1 reverse transcriptase p66/p66 homodimer Y188L mutant using activated DNA and [alpha-32P]dATP after 30 mins by liquid scintillation counting	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID88368	Antiviral activity against K103N/P225H mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1636131	Inhibition of HIV1 reverse transcriptase using T19-Cy5 labeled 23-mer DNA/T2-TAMRA labeled 63-mer DNA as primer/template assessed as inhibition of dNTP incorporation into primer/template	2016	Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15	Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
AID1754643	Antiviral activity against HIV1 harboring RT Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID586325	Cytotoxicity against human MOLT3 cells after 24 hrs by MTS assay	2011	Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6	Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID368566	Inhibition of wild type HIV1 reverse transcriptase-DNA-dNTP ternary complex	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID619638	Antiviral activity against HIV-1 3B harboring RT Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID279439	Antiviral activity against HIV1 isolate with RT 101P, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1558855	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
AID1811034	Anti-viral activity against HIV1 harboring RT E138K mutant infected MV4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
AID440670	Antiviral activity against NNRTI-resistant HIV1 N119 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Activity and molecular modeling of a new small molecule active against NNRTI-resistant HIV-1 mutants.
AID523345	Antiviral activity against HIV1 with RT connection domain T369I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID591356	Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide.
AID1736357	Antiviral activity against VSVG/HIV-1 harboring reverse transcriptase K103N/Y181C double mutant infected in human HEK 293T cells assessed as inhibition of virus replication preincubated with cells for 15 mins prior to viral infection and measured at 48 hr
AID606671	Inhibition of HIV1 wild type reverse transcriptase	2011	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13	Enantioselective binding of second generation pyrrolobenzoxazepinones to the catalytic ternary complex of HIV-1 RT wild-type and L100I and K103N drug resistant mutants.
AID1126511	Inhibition of wild-type HIV1 reverse transcriptase p66/p51 after 40 mins by spectrophotometry	2014	Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8	Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID650542	Antiviral activity against multidrug-resistant HIV 1 IRLL98 harboring reverse transcriptase K101Q/Y181C/G190a mutant infected in human MT4 cells assessed as virus-induced cytopathic effect after 5 days by MTT assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID155278	Anti-HIV activity by its ability to inhibit the replication of HIV-1 strain HTLV IIIB in peripheral blood mononuclear cells (PBMC)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
AID83547	Potency evaluated against NNRTI-Resistant HIV-1 strain Gly190Ala	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 varian
AID1504705	Inhibition of recombinant wild type HIV1 reverse transcriptase using DIG-labeled dUTP/biotin-labeled dUTP and dTTP as template and viral nucleotides assessed as decrease in biotin-dUTP incorporation after 1 hr by ELISA	2017	ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11	Discovery of Thiophene[3,2-
AID440072	Selectivity index, ratio of CC50 for human MT4 cells to IC50 for HIV-1 LAI harboring wild type reverse transcriptase infected in human MT4 cells	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID361911	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase L100I mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID46383	Antiviral activity against site directed resistant isolate HIV-1 Y188C in CEM cells	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID1163230	Antitrypanocidal activity against suramin-sensitive Trypanosoma brucei brucei Squib427 assessed as reduction in parasite growth after 72 hrs	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID302269	Resistance index, ratio of Ki for NNRTI-resistant HIV1 reverse transcriptase V179D mutant to Ki for wild type HIV1 3B reverse transcriptase	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID1249713	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID88370	Antiviral activity against K103N/Y181C mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID623212	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID1248223	Cytotoxicity against uninfected human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20	A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities.
AID235446	Selective index (CD50 compared to ED50 against HIV-1 IIIB strain).	2002	Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.
AID1743631	Antiviral activity against HIV1 harboring RT F227L/V106Amutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID269800	Antiviral activity against HIV1 V106A mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269800	Antiviral activity against HIV1 V106A mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269800	Antiviral activity against HIV1 V106A mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID200000	Effective concentration required against wild type HIV-1 reverse transcriptase (as per ref 8 in the article)	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.
AID298088	Inhibition of HIV1 RT K103N mutant	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID1880374	Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells to EC50 for antiviral activity against wild type HIV-1 IIIB infected in human MT4 cells	2022	Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12	Structure-Based Discovery of Novel NH
AID248255	In vitro inhibitory concentration against HIV E138K mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID279462	Antiviral activity against HIV1 isolate with RT 103N, 108I, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1446818	Antiviral activity against HIV1 harboring Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID1155818	Fold resistance, ratio of ID50 for HIV-1 recombinant NNTRI-resistant reverse transcriptase Y181I mutant to ID50 for wild type HIV-1 recombinant reverse transcriptase	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID551465	Cytotoxicity against human C1866 cells after 72 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	Synthesis and biological evaluation of novel dihydro-aryl/alkylsulfanyl-cyclohexylmethyl-oxopyrimidines (S-DACOs) as high active anti-HIV agents.
AID1736352	Cytotoxicity against human HEK 293T cells assessed as cell viability at 30 uM measured after 48 hrs by Celltiter-glo assay
AID1152242	Selectivity index, ratio of CC50 for human TZM-bl cells to EC50 for X4 tropic Human immunodeficiency virus 1 3B subtype B	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID198258	Inhibitory concentration against mutant reverse transcriptase of K103N was determined which is in turn resistant to pyridinones	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse transcriptase enzymes.
AID106978	Effective concentration against HIV-1 induced cytopathogenicity in MT-4 cells	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1815398	Inhibition of HIV1 reverse transcriptase K103N mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID46205	Tested for the inhibitory activity of virus induced giant cell formation in HIV-2 infected CEM cells	1994	Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24	1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole 2",2"-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity.
AID1380570	Resistance index, ratio of IC50 for antiviral activity against HIV1 virions containing reverse transcriptase K103N mutant derived from HIV/VSG-G or HIV/HA virions infected 293T cells using human A549 cells as target cells to IC50 for antiviral activity ag	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and biological evaluation of substituted (+)-SG-1 derivatives as novel anti-HIV agents.
AID510359	Inhibition of HIV1 recombinant protease	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents.
AID1729153	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV HIV1 RES056 harboring K103N/Y181C double mutant infected in human MT4 cells	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID279413	Antiviral activity against HIV1 isolate with RT 106A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID279424	Antiviral activity against HIV1 isolate with RT 103N, 106A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID655386	Antiviral activity against HIV1 LAI infected in CEMx174 cells coexpressing GFP after 5 days by fluorimetry	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	A novel 3,4-dihydropyrimidin-2(1H)-one: HIV-1 replication inhibitors with improved metabolic stability.
AID279438	Antiviral activity against HIV1 isolate with RT 98G, 103N, 108I mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID279456	Antiviral activity against HIV1 isolate with RT 188H mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1657475	Inhibition of wild type recombinant HIV1 reverse transcriptase p66/p51 using poly(rA)/oligo(dT)16 as template/primer measured after 40 mins by picogreen dye-based spectrofluorometric method	2020	Bioorganic & medicinal chemistry, 04-15, Volume: 28, Issue:8	Inhibition of HIV-1 RT activity by a new series of 3-(1,3,4-thiadiazol-2-yl)thiazolidin-4-one derivatives.
AID28681	Partition coefficient (logD6.5)	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID1267619	Cytotoxicity against human HUT78 cells assessed as reduction in cell viability after 5 days by MTT assay	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Design and Synthesis of DiselenoBisBenzamides (DISeBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity.
AID1443662	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
AID1292375	Cytotoxicity against human U2OS cells assessed as cell viability at 50 uM after 48 hrs relative to control	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Design, discovery, modelling, synthesis, and biological evaluation of novel and small, low toxicity s-triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1446811	Antiviral activity against HIV1 RES056 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID1657477	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity againstHIV1 infected in human MT4 cells	2020	Bioorganic & medicinal chemistry, 04-15, Volume: 28, Issue:8	Inhibition of HIV-1 RT activity by a new series of 3-(1,3,4-thiadiazol-2-yl)thiazolidin-4-one derivatives.
AID508636	Antiviral activity against Human immunodeficiency virus 1 subtype G infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1815399	Inhibition of HIV1 reverse transcriptase Y181C mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID587738	Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef infected in human HeLa-T4 cells assessed as luciferase activity after 48 hrs by exogenous RT assay	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID1267618	Antiviral activity against HIV1 3B persistently infected in HUT78 cells assessed as reduction of p24 production after 43 hrs by ELISA	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Design and Synthesis of DiselenoBisBenzamides (DISeBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity.
AID293560	Antiviral activity against HIV1 LAI with RT K103N mutation in MT4 cells by EGFP based replication assay	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID491826	Antiviral activity against HIV1 with reverse transcriptase 6005MR mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	2010	Journal of medicinal chemistry, Jul-08, Volume: 53, Issue:13	Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID431622	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1884225	Antiviral activity against HIV-1 harboring K103N mutant infected in human MT4 cells assessed as reduction in virus induced cytotoxicity incubated for 5 to 7 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID298075	Antiviral activity against HIV1 RT Y181C mutant in MT4 cells by MTT assay	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID1290399	Antiviral activity against HIV1 NL4.3 infected in human TZM-bl cells incubated for 30 mins prior to infection measured after 48 hrs by luciferase assay	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the N-Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family.
AID1275548	Antiviral activity against HIV1 3B expressing reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
AID1298249	Inhibition of HIV1 reverse transcriptase p66/p51 K103N mutant using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID522374	Resistance index, ratio of EC50 for recombinant HIV1 harboring reverse transcriptase V106A mutant clone to EC50 for wild type HIV1	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID1057040	Antiviral activity against wild-type HIV1 3B infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.
AID1705183	Antiviral activity against HIV-1 NL4-3 infected in human MT-4 cells assessed as virus induced cytopathic effect by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID318122	Antiviral activity against HIV1 3B in MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2008	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4	Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
AID767499	Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.
AID198229	Inhibition of recombinant reverse transcriptase (RT) in cell-free Quan-T-RT assay system	1999	Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24	N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
AID105526	Inhibition of HIV-1(IIIB) variants (Ile100/Cys181) in HIV-1 MT-4 cells	1996	Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21	Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.
AID1754646	Antiviral activity against HIV1 harboring RT F227L/V106A mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID1761007	Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability measured after 1 day by CytoTox-Glo assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID1636140	Binding affinity to bodipy-labeled HIV1 reverse transcriptase p66 W24C/K287C double mutant assessed as induction of p66 thumb and finger domain open conformation by measuring increase in bodipy fluorescence at 10 uM by stopped flow kinetic analysis	2016	Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15	Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
AID1882469	Antiviral activity against HIV-1 harboring Y181C mutant infected in human MT2 cells assessed as protection against virus-induced cytopathicity by MTT assay	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
AID279397	Antiviral activity against HIV1 isolate with RT 188L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID302620	Antiviral activity against HIV1 3B in human MT2 cells by MTT assay	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	From docking false-positive to active anti-HIV agent.
AID279431	Antiviral activity against HIV1 isolate with RT 103S, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1754645	Antiviral activity against HIV1 harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID525111	Antiviral activity against HIV 1 NL4.3 assessed as inhibition of virus-induced cytopathic effect by MTT assay	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID1391080	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 3B infected in human MT4 cells	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
AID1687682	Antiviral activity against HIV-1 Y181C mutant strain infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
AID246482	Effective concentration for the inhibition of wild type human immunodeficiency virus type 1 LAI strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID508788	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V106A mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID587748	Ratio of EC50 for single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as level of infection using human HeLaT4 cells pretreated for 24 hrs followed by exposed to virus immed	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID1191971	Antiviral activity against HIV1 3B infected infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6	Design, synthesis of new β-carboline derivatives and their selective anti-HIV-2 activity.
AID1574371	Therapeutic index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 NL4-3 infected in human MT4 cells	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID104602	Concentration which inhibited >95% spread of HIV-1 strain IIIb infection in susceptible MT-4 cell culture	1991	Journal of medicinal chemistry, Sep, Volume: 34, Issue:9	2-Pyridinone derivatives: a new class of nonnucleoside, HIV-1-specific reverse transcriptase inhibitors.
AID1811037	Anti-viral activity against HIV1 harboring RT K103N mutant infected MV4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
AID557043	Inhibition of HIV1 isolate R8 reverse transcriptase Y181C mutant after 90 mins by electrochemiluminescence analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID1561716	Antiviral activity against HIV1 3B infected in human MT4 cells grown under 30 passages in absence of test compound assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay
AID1750725	Selectivity index, ratio of CC50 for cytotoxicity against human MT-4 cells to EC50 for inhibition of HIV-1 p66/51 reverse transcriptase Y181C mutant	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1743638	Resistance index, ratio of EC50 for antiviral activity against HIV1 expressing RT E138K mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID279414	Antiviral activity against HIV1 isolate with RT 108I, 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID779525	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
AID297140	Antiviral activity against HIV1 with RT K103N mutation by cytopathic cell killing assay	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme.
AID199521	In vitro for inhibitory activity against HIV-1 Reverse Transcriptase	1993	Journal of medicinal chemistry, Mar-19, Volume: 36, Issue:6	Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations.
AID613683	Induction of apoptosis in human A375 cells seeded as low density at 20 uM after 96 hrs by DAPI staining-based FACS analysis	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitors.
AID155270	Ability to inhibit the replication of A17 variant (Y181C,K103N) strain of HIV-1 p24 antigen production in PBMC	1999	Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24	N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
AID279324	Inhibition of reverse transcriptase activity in HIV1 NL4-3 infected MT4 cells after dialysis	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification.
AID1456310	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8	Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR.
AID440664	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Activity and molecular modeling of a new small molecule active against NNRTI-resistant HIV-1 mutants.
AID1754637	Antiviral activity against wild type HIV-1 IIIB infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect measured after 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID197788	In vitro ability to inhibit wild type resistant (WT) reverse transcriptase	2000	Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5	Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: lead identification and SAR of 3- and 4-substituted derivatives.
AID105205	Potency against non nucleoside reverse transcriptor was determined in MT-4 cells	2004	Bioorganic & medicinal chemistry letters, May-17, Volume: 14, Issue:10	Threshold interaction energy of NRTI's (2'-deoxy 3'-substituted nucleosidic analogs of reverse transcriptase inhibitors) to undergo competitive inhibition.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1572554	Solubility in water at pH 7
AID373390	Antiviral activity against 0.1 MOI HIV1 3B infected in human TZM-b1 cells assessed as inhibition of viral replication at 0.14 uM after 24 hrs by luciferase assay	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID1574375	Antiviral activity against HIV 1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID232750	Selectivity index is the ratio between CC50 for MT-4 cells and IC50 against HIV-1 infection	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.
AID413564	Ratio of EC50 for multidrug-resistant HIV1 with reverse transcriptase 41 L, 67N, 210W, 215Y, 184V, 103N mutation to EC50 for wild type HIV1 3B	2008	Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24	Development and preclinical studies of broad-spectrum anti-HIV agent (3'R,4'R)-3-cyanomethyl-4-methyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (3-cyanomethyl-4-methyl-DCK).
AID82456	Antiviral activity against E138K strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1316338	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID105349	Tested for the inhibitory activity of HIV-2 infected MT-4 cells	1994	Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24	1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole 2",2"-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity.
AID1705195	Inhibition of RNA-dependent DNA polymerase activity of recombinant HIV-1 p66/p51 reverse transcriptase K103N mutant assessed as inhibition of [3H]dTTP incorporation using poly(rA)/oligo(dT) as templates incubated for 15 mins by MicroBeta scintillation cou	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID298059	Inhibition of HIV1 reverse transcriptase	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID305058	Cytotoxicity against HEK293T cells after 48 hrs	2007	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1	4-Aminopyrimidines as novel HIV-1 inhibitors.
AID430054	Inhibition of HIV1 recombinant RNA-dependent DNA polymerase activity of reverse transcriptase assessed as incorporation of radioactive dTTP into poly(rA)/oligo(dT)	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Design, synthesis, and structure-activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents.
AID1410482	Inhibition of HIV1 RES056 reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity by MTT assay	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.
AID1773463	Inhibition of wild type HIV1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation into protein incubated for 1 hrs by ELISA
AID522378	Resistance index, ratio of EC50 for recombinant HIV1 harboring reverse transcriptase V106I/V179D mutant clone to EC50 for wild type HIV1	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID734260	Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 A17 double mutant infected in human TZM-bl cells assessed decrease in p24 level after 7 days by ELISA	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID1460937	Antiviral activity against wild type HIV-1 NL4-3 infected in human MAGI-CCR5 cells assessed as reduction in viral infection after 48 hrs by fluorescence based beta-galactosidase reporter gene assay	2017	Bioorganic & medicinal chemistry, 12-01, Volume: 25, Issue:23	An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors.
AID1290401	Cytotoxicity against human TZM-bl cells assessed as reduction in cell viability after 2 days by WST-1 assay	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the N-Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family.
AID279449	Antiviral activity against HIV1 isolate with RT 98G, 188L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID299026	Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of virus-induced giant cell formation	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
AID231368	Ratio of wild type IIIB to that of Y181C HIV-1 induced cytopathogenicity	2004	Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4	Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C varia
AID1594862	Lipophilicity, log P of the compound	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
AID1373154	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID527563	Antiviral activity against HIV1 NL4-3 containing reverse transcriptase Y181C mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Discovery and SAR of a series of 4,6-diamino-1,3,5-triazin-2-ol as novel non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID106589	Concentration required to reduce human MT-4 cell viability by 50%.	1992	Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15	3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2'-5'-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranose]-3'-spiro-5"-[4"-amino-1",2"-oxathiole 2",2"-dioxide] (
AID297136	Toxicity against CEM cells	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme.
AID586901	Activity at MRP1	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID571983	Antiviral activity against HIV-1 subtype B V022815 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID247501	Inhibitory activity against HIV-1 mutant strain 181C	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID265473	Activity against HIV-AB1 assessed by inhibition of p24 production in human lymphocytes	2006	Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11	Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide.
AID1446815	Antiviral activity against HIV1 harboring L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID328843	Inhibition of human MRP3 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID556527	Antiviral activity against Human immunodeficiency virus 1 clone 14682 harboring 122E, 135V, Q145V, 200A mutation in reverse transcriptase by phenosense assay relative to wild type	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
AID482691	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as time-of-addition prolongation at 2 ug/ml after 31 hrs post infection by ELISA	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID1884486	Antiviral activity against NNRTI resistant wild type HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID1769793	Inhibition of recombinant HIV1 reverse transcriptase by colorimetric assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design of gp120 HIV-1 entry inhibitors by scaffold hopping via isosteric replacements.
AID248881	Inhibitory concentration against human immunodeficiency virus type 1 (with V106A/Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID279469	Antiviral activity against HIV1 isolate with RT 238N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID279465	Antiviral activity against HIV1 isolate with RT 98G, 103N, 181C, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID82467	Antiviral activity against P236L strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID525107	Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID266348	Inhibition of HIV1 reverse transcriptase Y188C mutant in 293T cells	2006	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11	New HIV-1 reverse transcriptase inhibitors based on a tricyclic benzothiophene scaffold: synthesis, resolution, and inhibitory activity.
AID198239	Inhibitory activity against HIV-1 reverse transcriptase	1996	Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8	All-atom models for the non-nucleoside binding site of HIV-1 reverse transcriptase complexed with inhibitors: a 3D QSAR approach.
AID328881	Toxicity in mouse fibroblast cells assessed as accumulation of prelamin A at 200 uM after 10 days by Western blot	2007	Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33	HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells.
AID1357784	Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID1248225	Antiviral activity against HIV 1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20	A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities.
AID360708	Inhibition of HIV1 RT K103N mutant mediated DNA-dependent DNA polymerization using DNA PPT primed substrate by scintillation proximity assay	2007	The Journal of biological chemistry, Mar-16, Volume: 282, Issue:11	HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.
AID1171581	Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID689697	Antiviral activity against wild type HIV1 LAI infected in human CEM174 cells assessed as inhibition of viral replication preincubated for 1 hr prior to viral infection measured after 5 days	2012	ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8	Discovery of Phenylaminopyridine Derivatives as Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
AID431621	Cytotoxicity against human MT4 cells by MTT assay	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1736345	Cytotoxicity against human HEK 293T cells assessed as reduction in cell viability measured after 48 hrs by Celltiter-glo assay
AID1654238	Drug metabolism in human liver microsomes assessed as Cytochrome P450-mediated formation of 12-OHNVP by measuring Kcat/Km ratio in presence of NADPH regenerating reagents by uHPLC-MS/MS analysis	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death.
AID267649	Antiviral activity against HIV1 L100I mutant	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID304872	Antiviral activity against HIV1 with reverse transcriptase IRLL98 mutation in MT4 cells after 5 days by MTT method relative to wild type NL4-3	2007	Journal of medicinal chemistry, Dec-27, Volume: 50, Issue:26	Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants.
AID510361	Inhibition of HIV1 integrase after 1 hr	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents.
AID105906	Effective dose required to achieve protection of MT-4 cells from wild type IIIB HIV-1 induced cytopathogenicity	2004	Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4	Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C varia
AID1244339	Spermicidal activity in liquefied human semen assessed as reduction in motile spermatozoa incubated at 37 degC for 30 mins	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	N-Alkyl/aryl-4-(3-substituted-3-phenylpropyl)piperazine-1-carbothioamide as dual-action vaginal microbicides with reverse transcriptase inhibition.
AID1691436	Antiviral activity against HIV1 RES056 infected in human MT4 cells assessed as reduction in virus-induced cell death incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, May-01, Volume: 193	In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP.
AID561949	Antibacterial activity against Staphylococcus aureus after 18 to 24 hrs by agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Lack of antimicrobial activity by the antiretroviral drug nevirapine against common bacterial pathogens.
AID198234	Inhibitory activity against HIV rRT activity in HIV-1 mutant resistant to TIBO(L100I) strain	1996	Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2	2-Sulfonyl-4-chloroanilino moiety: a potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones.
AID1155804	Antiviral activity against wild type HIV-1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID1884229	Antiviral activity against HIV-1 RES056 infected in human MT4 cells assessed as reduction in virus induced cytotoxicity incubated for 5 to 7 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID279434	Antiviral activity against HIV1 isolate with RT 101E, 181C, 190S mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1373163	Inhibition of reverse transcriptase K103N/Y181C double mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID1763898	Antiviral activity against HIV-1 IIIB harboring RT L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
AID302271	Resistance index, ratio of Ki for HIV1 reverse transcriptase Y188L mutant to Ki for wild type HIV1 3B reverse transcriptase	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID1380567	Antiviral activity against HIV1 virions derived from HIV/VSG-G or HIV/HA virions infected 293T cells using human A549 cells as target cells assessed as inhibition of viral replication using compound pre-mixed virions followed by incubation with target cel	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and biological evaluation of substituted (+)-SG-1 derivatives as novel anti-HIV agents.
AID1157583	Antiviral activity against N119-sensitive HIV1 harboring Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID82472	Antiviral activity against V108I strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID82471	Antiviral activity against V106I/Y181C strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1141959	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID443752	Selectivity index, ratio of IC50 for African green monkey Vero cells to EC50 for HIV1	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile.
AID1888696	Antiviral activity against HIV1 with RT Y181C mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID83549	Potency evaluated against NNRTI-Resistant HIV-1 strain Leu100Ile	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 varian
AID1558849	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells incubated for 5 days by MTT assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
AID318126	Inhibition of PDE4B2 expressed in COS7 cells assessed as cAMP hydrolysis at 100 uM	2008	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4	Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
AID1743639	Resistance index, ratio of EC50 for antiviral activity against HIV1 expressing RT F227L/V106A mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID1763899	Antiviral activity against HIV-1 IIIB harboring RT K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
AID606673	Inhibition of HIV1 reverse transcriptase L100I mutant	2011	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13	Enantioselective binding of second generation pyrrolobenzoxazepinones to the catalytic ternary complex of HIV-1 RT wild-type and L100I and K103N drug resistant mutants.
AID279390	Antiviral activity against HIV1 isolate with RT 103N, 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1884222	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 to 7 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID1773440	Antiviral activity against HIV1 RES056 infected in human MT4 cells assessed as reduction in virus-induced cytopathogenic effect by MTT assay
AID279416	Antiviral activity against HIV1 isolate with RT 179A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1457060	Ratio of EC50 for HIV-1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells to EC50 for HIV1 NL4-3 infected in human MT4 cells	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID650687	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV 1 NL4-3	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID734255	Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 harboring reverse transcriptase Y181C mutation infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID279445	Antiviral activity against HIV1 isolate with RT 101E, 103N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID317733	Cytotoxicity against mock-infected human MT4 cells by MTT assay	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID1292009	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
AID1157593	Antiviral activity against MC1220-resistant HIV1 harboring RT 100I, 179D, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID267851	Inhibition of wild type HIV1 reverse transcriptase	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
AID1275547	Antiviral activity against HIV1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
AID1610041	Therapeutic index, ratio of CC50 for human TZM-bl cells to IC50 for antiviral activity against HIV1 N119 infected in human TZM-bl cells	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.
AID1654239	Drug metabolism in human liver microsomes assessed as Cytochrome P450-mediated formation of 3-OHNVP formation at 5 to 400 uM in presence of NADPH regenerating reagents by uHPLC-MS/MS analysis	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death.
AID105341	Inhibitory activity against resistant HIV-1 strain MC639r was determined.	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.
AID373565	Antiviral activity against 0.1 MOI HIV1 3B in 24 hrs pretreated human TZM-b1 cells infected 24 hrs post drug removal assessed as inhibition of viral replication at 0.04 to 0.18 uM measured 24 hrs postinfection by luciferase assay	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID1535529	Inhibition of recombinant wild type HIV1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation using poly(A)/oligo(dT)15 as template/primer after 1 hr by ELISA	2019	Bioorganic & medicinal chemistry, 02-01, Volume: 27, Issue:3	Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs.
AID1822283	Inhibition of recombinant wild type p66/p51 HIV1 reverse transcriptase incubated for 40 mins by picogreen dye-based spectrofluorometric analysis	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID1056581	Antiviral activity against HIV-1 expressing reverse transcriptase L100I/K103N double mutant infected in human 293T cells co-transfected with VSVG protein assessed as inhibition of viral-replication incubated 15 mins prior to viral-infection measured after	2013	Journal of natural products, Dec-27, Volume: 76, Issue:12	Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73.
AID198770	Binding affinity against HIV reverse transcriptase (Estimated Ki)	2000	Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18	Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID508650	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase L100I, K103N, Y181C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID573465	Inhibition of Human immunodeficiency virus 1 subtype B reverse transcriptase G190A mutant by filter-based filtration assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID508791	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K101Q mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID287005	Inhibition of DNA polymerase activity of reverse transcriptase pre-incubated with drug assessed as impairment of primer elongation by DNA polymerase primer-extension assay	2007	Journal of medicinal chemistry, May-17, Volume: 50, Issue:10	De novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variants.
AID622055	Ratio of Ki for HIV1 RT p66/p66 homodimer Y181C mutant to Ki for wild-type HIV1 RT p66/p66 homodimer	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID279474	Antiviral activity against HIV1 isolate with RT 101R, 103N, 181C, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID635345	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.
AID1654199	Drug metabolism in C57BL/6J mouse primary hepatocytes assessed as Cytochrome P450-mediated formation of 2-OHNVP at 10 uM incubated for 24 hrs by uHPLC-MS analysis	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death.
AID198067	Inhibition of HIV-1 reverse transcriptase at 37 degree Centigrade	2001	Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2	Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations.
AID298064	Cytotoxicity against human MT4 cells by MTT assay	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID1171594	Inhibition of wild type HIV1 reverse transcriptase K103N mutant assessed as reduction in enzyme activity	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID738334	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
AID198077	Inhibitory activity against HIV-1 Mutant Reverse transcriptase P236L	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 7. 8-Arylethyldipyridodiazepinones as potent broad-spectrum inhibitors of wild-type and mutant enzymes.
AID508781	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase E138R mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1736157	Selectivity index, ratio of CC50 for human MT2 cells to EC50 for anti-HIV-1 activity against HTLV-3B infected in human MT2 cells	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Design, synthesis and biological evaluation of quinoxaline compounds as anti-HIV agents targeting reverse transcriptase enzyme.
AID508763	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase L100I, K103N mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1323001	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV2 ROD	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells.
AID1320868	Solubility of the compound	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
AID1335206	Ratio of IC50 for HIV-1 NL4-3 harboring RT-Y181C mutant infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein to IC50 for wild-type HIV-1 NL4-3 infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID106579	50% cytotoxic concentration against mock-infected MT-4 cells using MTT method	2000	Journal of medicinal chemistry, May-04, Volume: 43, Issue:9	Structure-based design, synthesis, and biological evaluation of novel pyrrolyl aryl sulfones: HIV-1 non-nucleoside reverse transcriptase inhibitors active at nanomolar concentrations.
AID1304409	Antiviral activity against HIV-1 3B expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID228281	Compound was evaluated for the cytotoxic activity by using Microculture Tetrazolium assay (MTA)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
AID1736366	Selectivity index, ratio of EC50 for antiviral activity against VSVG/HIV-1 harboring reverse transcriptase Y188L mutant infected in human HEK 293T cells to EC50 for antiviral activity against VSVG/wild type HIV-1 infected in human HEK293T cells
AID1267628	Antiviral activity against nevirapine-resistant SIV mac251 infected in human MT4 cells	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Design and Synthesis of DiselenoBisBenzamides (DISeBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity.
AID1435512	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 expressing reverse transcriptase L100I mutant
AID267647	Antiviral activity against HIV1 K103N mutant	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID508647	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase L100I, K103N, E138G mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID302263	Inhibition of HIV1 reverse transcriptase V179D mutant	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID253490	Dose required to inhibit HIV-1 reverse transcriptase activity (K103N mutant) by 50%	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure-activity relationship investigation.
AID1141962	Antiviral activity against HIV1 3B infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID82272	Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in MT-4-infected wild type cells	2002	Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.
AID1773441	Antiviral activity against wild type HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathogenic effect by MTT assay
AID240140	Concentration required to inhibit HIV-1 reverse transcriptase activity (wild-type) by 50%	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure-activity relationship investigation.
AID342720	Cytotoxicity against human MT4 cells	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors.
AID1457053	Antiviral activity against HIV1 NL4-3 infected in human ML4 cells assessed as protection against virus-induced cytopathic effect measured on day 5 post infection by MTT assay	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID508767	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase M230L mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1275539	Inhibition of HIV1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation using poly(rA)-oligo(dT) as template/primer and digoxigenin-dUTP/biotin-dUTP/dTTP nucleotides incubated for 1 hr by ELISA	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
AID1418463	Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 4 days by MTT assay	2018	Bioorganic & medicinal chemistry letters, 12-01, Volume: 28, Issue:22	Design and synthesis of a novel series of non-nucleoside HIV-1 inhibitors bearing pyrimidine and N-substituted aromatic piperazine.
AID232055	Selectivity index (Ratio of CC50/EC50).	2004	Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15	Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID279443	Antiviral activity against HIV1 isolate with RT 106A, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID199097	Inhibitory activity against HIV rRT activity in HIV-2	1996	Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2	2-Sulfonyl-4-chloroanilino moiety: a potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones.
AID1141976	Inhibition of HIV1 wild-type reverse transcriptase K103N mutant using [3H]dTTP by scintillation counting	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1884494	Inhibition of recombinant wild-type p66/p51 HIV-1 reverse transcriptase incubated for 40 mins by picogreen dye-based spectrofluorometric analysis	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID1410481	Inhibition of wild-type HIV1 3B reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytotoxicity by MTT assay	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.
AID1877040	Potency index, ratio of test compound EC50 to NBD-14189 EC50 for antiviral activity against HIV1 pseudovirus infected in human TZM-bl cells preincubated with virus for 30 mins followed by cell infection and measured after 3 days by luciferase assay	2021	Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22	HIV-1 gp120 Antagonists Also Inhibit HIV-1 Reverse Transcriptase by Bridging the NNRTI and NRTI Sites.
AID508753	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V179F, Y181I mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1155819	Fold resistance, ratio of ID50 for HIV-1 recombinant NNTRI-resistant reverse transcriptase L100I mutant to ID50 for wild type HIV-1 recombinant reverse transcriptase	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID105325	Inhibition of Efavirenz resistant HIV-1 (Y181C) induced cytopathicity in MT-4 cells.	2004	Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15	Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID197944	In vitro inhibition of recombinant reverse transcriptase (WT) of HIV-1 IIIB	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors.
AID572180	Antiviral activity against HIV-1 SM002 harboring NNTRI 181C mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1185995	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay relative HIV1	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID1636440	Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1743636	Resistance index, ratio of EC50 for antiviral activity against HIV1 expressing RT Y181C mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID572187	Antiviral activity against HIV-1 SM051 harboring NNTRI 100I and 103N mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1077223	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.
AID82271	Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in MT-4-infected Y181C strain	2002	Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.
AID1687685	Antiviral activity against HIV-2 ROD strain infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
AID1736155	Anti-HIV-1 activity against HTLV-3B infected in human MT2 cells assessed as reduction in syncytium formation by measuring reduction in p24 antigen production measured after 4 days by ELISA method	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Design, synthesis and biological evaluation of quinoxaline compounds as anti-HIV agents targeting reverse transcriptase enzyme.
AID279444	Antiviral activity against HIV1 isolate with RT 101Q, 181C, 190S mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID263514	Antiviral activity against HIV1 V106A mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID1217704	Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1574376	Antiviral activity against HIV-1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID88377	Antiviral activity against V106A mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1155805	Cytotoxicity against human MT4 cells assessed as induction of cell death by MTT method	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID210590	In vitro metabolism in human liver microsomes	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones.
AID518738	Inhibition of DNA-dependent DNA polymerase activity of HIV1 subtype B reverse transcriptase M230L mutant by gel-based primer extension assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
AID1687684	Antiviral activity against HIV-1 RES056 mutant strain infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
AID635302	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.
AID88371	Antiviral activity against P236L mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID152641	Cytotoxic concentration was evaluated against human peripheral blood mononuclear cells (PBMC); ND = Not determined	2001	Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4	Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds.
AID105858	Compound was tested for potency to achieve protection of MT-4 cells from 100I strain of HIV-1 virus	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).
AID302248	Cytotoxicity against MT4 cells after 4 days by MTT method	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID572172	Antiviral activity against HIV-1 subtype CRF05_DF V022823 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1173646	Therapeutic index, ratio of CC50 for human CEmx174 cells expressing GFP to IC50 for HIV-1 LAI infected in human CEMx174-LTR-GFP CG8 cells	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Serendipitous discovery of 2-((phenylsulfonyl)methyl)-thieno[3,2-d]pyrimidine derivatives as novel HIV-1 replication inhibitors.
AID736040	Inhibition of HIV1 reverse transcriptase p66/p51 Y181C mutant after 30 mins by liquid scintillation counting	2013	Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID561946	Antibacterial activity against Streptococcus pneumoniae after 18 to 24 hrs by agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Lack of antimicrobial activity by the antiretroviral drug nevirapine against common bacterial pathogens.
AID248494	In vitro inhibitory concentration against HIV L100I and K103N mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID294634	Inhibition of HIV1 reverse transcriptase using Poly rA.dT template	2007	European journal of medicinal chemistry, Jul, Volume: 42, Issue:7	Synthesis and anti-HIV studies of 2-adamantyl-substituted thiazolidin-4-ones.
AID1228841	Selectivity index, ratio of CC50 against human MT4 cells to EC50 for HIV1 NL4-3 infected in human MT4 cells	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Limonoids with Anti-HIV Activity from Cipadessa cinerascens.
AID247617	Inhibitory activity against HIV-1 double mutants strain 100I and 103N	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID342719	Antiviral activity against HIV1 3B in human MT4 cells assessed as virus-induced cytopathogenicity after 5 days	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors.
AID298089	Inhibition of HIV1 RT Y181I mutant	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID361923	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/G190A mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID523477	Antiviral activity against HIV1 with RT connection domain G190A/T369I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID294629	Antiviral activity against HIV1 3B in CEM cells	2007	European journal of medicinal chemistry, Jul, Volume: 42, Issue:7	Synthesis and anti-HIV studies of 2-adamantyl-substituted thiazolidin-4-ones.
AID1231489	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action.
AID106745	Cytotoxicity against MT-4 cells.	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID561947	Antibacterial activity against Haemophilus influenzae after 18 to 24 hrs by agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Lack of antimicrobial activity by the antiretroviral drug nevirapine against common bacterial pathogens.
AID1882471	Cytotoxicity against human MT2 cells assessed as cell viability by MTT assay	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
AID1157592	Antiviral activity against 6-[(3,5-Dimethylphenyl)fluoromethyl]-5-ethyl-1-{[[4-(3-hydroxyprop-1-ynyl)benzyl]oxy]methyl}pyrimidine-2,4(1H,3H)-dione-resistant HIV1 harboring RT 106I, 181C mutant infected in human MT4 cells assessed as inhibition of virus-in	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID1316335	Selectivity index, ratio of CC50 for human mock-infected MT4 cells to EC50 for HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID246511	Compound concentration required to achieve 50% protection of infected MT-4 cells from K103N-Y181C strain was determined by the MTT method	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID566904	Inhibition of HIV1 reverse transcriptase	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection.
AID1335218	Antiviral activity against wild-type HIV-1 NL4-3 harboring vesicular stomatitis virus glycoprotein infected in HEK293T cells pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene assay	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1141966	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID328844	Inhibition of human MRP2 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence at 10 uM by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID366530	Resistance index, ratio of ID50 for reverse transcriptase Y181I mutant to IC50 for wild-type HIV1 reverse transcriptase	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID413267	Antiviral activity against multidrug-resistant HIV1 with reverse transcriptase clone 7324-1 infected human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	2008	Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24	Development and preclinical studies of broad-spectrum anti-HIV agent (3'R,4'R)-3-cyanomethyl-4-methyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (3-cyanomethyl-4-methyl-DCK).
AID1457052	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID1558857	Antiviral activity against HIV1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
AID1610043	Antiviral activity against HIV1 VB51 infected in human PBMC cells incubated for 5 days by bright Glo-luciferase reporter gene assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.
AID232053	Selectivity index is the ratio of CC50 to EC50	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.
AID1335205	Ratio of IC50 for HIV-1 NL4-3 harboring RT-L100I/K103N double mutant infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein to IC50 for wild-type HIV-1 NL4-3 infected in HEK293T cells co-expressing vesicular stomatitis virus glyco	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID389380	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID525109	Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID619630	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID106074	Inhibitory activity against LAI strain of HIV-I in MT-4 cells	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
AID1152241	Cytotoxicity against human TZM-bl cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID247504	Inhibitory activity against HIV-1 mutant strain 190S	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID1156485	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
AID1773443	Selectivity ratio of CC50 for human MT4 cells to IC50 for HIV-1 3B infected in MT4 cells
AID1352317	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 4 days by MTT assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID1561719	Antiviral activity against HIV1 3B infected in human MT4 cells grown under 30 passages in presence of 4-[[4-[[4-[4-[2-cyanovinyl]-2,6-dimethylphenoxy]thieno[3,2-d]pyrimidin-2-yl]amino]-1-piperidyl]methyl]benzenesulfonamide assessed as protection against v
AID736442	Cytotoxicity against human MT4 cells after 4 days by MTT assay	2013	Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID496621	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase K101E/V35T, E36D, K49R, V60I, K122P, I135R, S162A, E169R, K173T, Q174E,D177E, V189I, T200A, I202V, Q207E, R211K, V245Q mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID279326	Decrease in reverse transcriptase activity in HIV1 infected HeLa MAGI cells assessed as decrease in number of blue foci after dialysis	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification.
AID82461	Antiviral activity against K103N/L100I strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1141963	Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as protection of cells monitored by giant cell formation by microscopy	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID248882	Inhibitory concentration against human immunodeficiency virus type 1 (with V108I/Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID767496	Solubility of the compound in water by HPLC analysis	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.
AID1155808	Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID104800	Dose required to reduce the viability of mock-infected cells by 50%, determined by MTT method.	1998	Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21	Novel 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit human immunodeficiency virus type 1 replication.
AID1124991	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives.
AID88382	Antiviral activity against Y188C mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID294632	Selectivity index, ratio of CC50 for CEM cells to EC50 for HIV1 infected CEM cells	2007	European journal of medicinal chemistry, Jul, Volume: 42, Issue:7	Synthesis and anti-HIV studies of 2-adamantyl-substituted thiazolidin-4-ones.
AID371905	Antiviral activity against HIV1 NL4-3 with K103N/Y181C double mutant in human TZM-b1 cells assessed as beta-galactosidase activity after 48 hrs by single round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID246283	Effective concentration of the compound to inhibit HIV-1 mutant LAI replication in HIV-infected MT-4 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID88378	Antiviral activity against V106A/Y181C mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID558393	Ratio of drug level in HIV-infected pregnant woman cord blood plasma to maternal blood plasma at 200 mg, po BID by HPLC/UV analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.
AID663298	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID1901048	Inhibition of HIV-1 reverse transcriptase RNA-dependent DNA polymerase activity assessed as reduction in biotin-dUTP incorporation at 500 nM using poly(A)/oligo (dT)15 as template/primer by ELISA relative to control	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and anti-HIV activity of a new isoxazole containing disubstituted 1,2,4-oxadiazoles analogs.
AID698304	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 NL4-3 infected in human MT4 cells	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1077222	Antiviral activity against HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.
AID523357	Antiviral activity against HIV1 with RT connection domain G190A mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID525106	Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID1736151	Inhibition of wild type recombinant HIV-1 subtype B BH10 p66/p51 reverse transcriptase heterodimer expressed in Escherichia coli BL21 (DE3) assessed as inhibition of dTTP incorporation on poly(rA)-oligo(dT) template primer duplex preincubated with enzyme	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Design, synthesis and biological evaluation of quinoxaline compounds as anti-HIV agents targeting reverse transcriptase enzyme.
AID1750716	Selectivity index, ratio of CC50 for human MT-4 cells to EC50 for HIV-1 infected in MT-4 cells	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID557040	Antiviral activity against HIV1 isolate R8 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs in presence of 10% FBS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID104757	Compound dose required to reduce the viability of mock-infected cells by 50%	1995	Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17	Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzyloxopyrimidines.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID198915	Inhibition of HIV-1 Mutant HIV-1 RT enzymes containing the single amino acid substitution Y181I	2001	Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3	Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.
AID1654218	Drug metabolism in C57BL/6J mouse primary hepatocytes assessed as O-GlucNVP metabolite formation at 10 uM incubated for 24 hrs by uHPLC-MS analysis	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death.
AID1594863	Inhibition of HIV1 reverse transcriptase derived from HIV patient plasma by LC/MS/MS analysis	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
AID247499	Inhibitory activity against HIV-1 mutant strain 138K	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID573464	Inhibition of RNA-dependent DNA polymerase activity of wild-type Human immunodeficiency virus 1 subtype B reverse transcriptase by filter-based filtration assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID1152372	Antiviral activity against HIV1 RES056 harboring RT K103N,Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID523355	Antiviral activity against HIV1 with RT connection domain Y181C/T369I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID82473	Antiviral activity against V108I/Y181C strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1884542	Fold resistance, ratio of EC50 for antiviral activity against drug-resistant HIV-1 E138K mutant infected in human MT4 cells to EC50 for antiviral activity against NNRTI resistant wild type HIV-1 infected in human MT4 cells	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID527376	Toxicity in human CEM-SS cells	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Discovery and SAR of a series of 4,6-diamino-1,3,5-triazin-2-ol as novel non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID650696	Ratio of ID50 for HIV 1 reverse transcriptase K103N mutant to ID50 for wild type HIV 1 NL4-3 reverse transcriptase	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID1126508	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	2014	Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8	Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1185997	Antiviral activity against HIV1 harboring reverse transcriptase L1001/K103N double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay r	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID572188	Antiviral activity against HIV-1 SM052 harboring NNTRI 101E and 103N mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID279419	Antiviral activity against HIV1 isolate with RT 101Q, 181C, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID496619	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase A98G/V35T, V60I, I135L, S162A, K173A, Q174K, D177E, I178M, T200A,Q207E, R211K, V245Q, D250E mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID252950	Selectivity index of cytotoxic activity (CC50) to inhibitory activity (IC50) relative to LAI cell line	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID666410	Inhibition of HIV1 reverse transcriptase using poly(ra)/oligo(dT)15 homopolymer template as substrate after 1 hr	2012	Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5	Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.
AID698146	Inhibition of wild type HIV1 reverse transcriptase RNA-dependent DNA polymerase activity using poly(rA)/oligo(dT)10:1 and [3H]-dTTP substrate	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1059141	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for drug-resistant HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant	2013	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24	Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID665547	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
AID571980	Antiviral activity against HIV-1 subtype B V022812 harboring NNRTI V179I mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID263508	Cytotoxicity against HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID666971	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days	2012	European journal of medicinal chemistry, Aug, Volume: 54	Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID198260	Inhibitory concentration against mutant reverse transcriptase of P236L was determined which is in turn resistant to BHAP	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse transcriptase enzymes.
AID718370	Cytotoxicity against HIV1 3B infected in human MT4 cells by MTT assay	2012	Bioorganic & medicinal chemistry, Dec-01, Volume: 20, Issue:23	Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
AID197925	Concentration required to inhibit the HIV-1 reverse transcriptase activity by 50%.	1999	Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4	5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives.
AID1171595	Inhibition of wild type HIV1 reverse transcriptase Y181I/Y181C mutant assessed as reduction in enzyme activity	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1223488	1-Octanol-water distribution coefficient, log D of the compound at pH 7.4	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID1446813	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID1636138	Binding affinity to bodipy-labeled HIV1 reverse transcriptase p66 W24C/K287C double mutant assessed as induction of p66 thumb and finger domain open conformation by measuring increase in bodipy fluorescence at 10 uM by fluorescence spectroscopic analysis	2016	Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15	Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
AID1822332	Antiviral activity against HIV-1 harboring Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity at 2 uM incubated for 5 days by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID361927	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106I/Y181C mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID363036	Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of viral replication by MTT assay	2008	European journal of medicinal chemistry, Jun, Volume: 43, Issue:6	Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 11: structural modulations of diaryltriazines with potent anti-HIV activity.
AID279476	Antiviral activity against HIV1 isolate with RT 101N, 103N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1056574	Ratio of EC50 for HIV-1 expressing reverse transcriptase K103N/G190A double mutant to EC50 for wild-type HIV-1	2013	Journal of natural products, Dec-27, Volume: 76, Issue:12	Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73.
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID717258	Cytotoxicity against human MT4 cells by MTT assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
AID1761009	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect measured after 5 days by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID648421	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2012	European journal of medicinal chemistry, May, Volume: 51	Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1565090	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID586322	Inhibition of Human T-cell leukemia/lymphoma virus type 1 reverse transcriptase activity infected in human MT2 cells assessed as level of p19 antigen	2011	Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6	Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID648420	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	2012	European journal of medicinal chemistry, May, Volume: 51	Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1292367	Antiviral activity against HIV1 virion infected in human TZM-bl cells after 48 hrs by firefly luciferase assay	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Design, discovery, modelling, synthesis, and biological evaluation of novel and small, low toxicity s-triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1888692	Selectivity index, ratio of CC50 for toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells cells assessed as protection against viral-induc
AID1435513	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 expressing reverse transcriptase K103N mutant
AID523353	Antiviral activity against HIV1 with RT connection domain Y181C mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID1763900	Antiviral activity against HIV-1 IIIB harboring RT Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
AID395596	Cytotoxicity against HIV-infected human CEM cells	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	Synthesis and anti-HIV studies of 2- and 3-adamantyl-substituted thiazolidin-4-ones.
AID678715	Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID583848	Antiviral activity against HIV1 NL4-3 infected in human SupT1 cells derived from 11 viral passages assessed as inhibition of viral replication after 21 days relative to drug sensitive HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID1057038	Antiviral activity against HIV2 ROD infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.
AID556524	Antiviral activity against Human immunodeficiency virus 1 clone pNL4-3-Q145M harboring K102Q, Q145M, S162C, K277R, I293V mutation in reverse transcriptase by phenosense assay relative to wild type	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
AID104804	Tested for the cytotoxic concentration required to reduce the number of viable mock infected MT-4 cells	1994	Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24	1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole 2",2"-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity.
AID370729	Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 V179D mutant expressed in Escherichia coli JM109	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
AID298080	Antiviral activity against HIV1 RT AB1 mutant in lymphocytes assessed as reduction of p24 antigen production	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID557042	Antiviral activity against HIV1 isolate R8 harboring wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs in presence of 10% FBS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID608393	Selectivity index, ratio of CC50 for MAGI-CCR5 cells to IC50 for HIV13B infected in human MAGI-CCR5 cells	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Imidazo[1,2-a]pyridin-3-amines as potential HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID366526	Inhibition of RNA dependent DNA polymerase activity of wild-type HIV1 reverse transcriptase	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID1705194	Inhibition of RNA-dependent DNA polymerase activity of wild type recombinant HIV-1 His-tagged p66/p51 reverse transcriptase assessed as inhibition of [3H]dTTP incorporation using poly(rA)/oligo(dT) as templates incubated for 15 mins by MicroBeta scintilla	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID242820	Dose required to inhibit HIV-1 reverse transcriptase activity (wild-type) by 50%	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure-activity relationship investigation.
AID1162263	Selectivity index, ratio of CC50 for human MT2 cells to EC50 for X4 tropic HIV1 3B infected in human MT2 cells	2014	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18	Semi-synthesis of oxygenated dolabellane diterpenes with highly in vitro anti-HIV-1 activity.
AID1485968	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID557044	Inhibition of HIV1 isolate R8 reverse transcriptase K103N mutant after 90 mins by electrochemiluminescence analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID1197832	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
AID1162262	Cytotoxicity against human MT2 cells after 4 to 5 days by MTT assay	2014	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18	Semi-synthesis of oxygenated dolabellane diterpenes with highly in vitro anti-HIV-1 activity.
AID630957	Selectivity index, ratio of CC50 for human TZM-bl cells to EC50 for R5 tropic Human immunodeficiency virus 1 subtype C-VB59	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID279391	Antiviral activity against HIV1 isolate with RT 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1141968	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID573478	Antiviral activity of Human immunodeficiency virus 1 isolate 8117 harboring A98S, G190A mutation in reverse transcriptase by cell based assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID269804	Antiviral activity against HIV1 Y181H mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269804	Antiviral activity against HIV1 Y181H mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269804	Antiviral activity against HIV1 Y181H mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1761018	Antiviral activity against HIV-1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect measured after 5 days by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID246301	Effective concentration of the compound to inhibit HIV-1 mutant Y188L replication in HIV-infected MT-4 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID391676	Inhibition of RNA dependent DNA polymerase activity of HIV1 BH10 recombinant reverse transcriptase p66/p51 assessed as residual enzyme activity at 50 ug/ml relative to control	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.
AID88365	Antiviral activity against G190A mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID523350	Antiviral activity against HIV1 with RT connection domain K103N/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID248263	In vitro inhibitory concentration against HIV V179E mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID360704	Inhibition of HIV1 RT mediated DNA-dependent DNA synthesis initiation using RNA/DNAM duplex primed substrate by scintillation proximity assay	2007	The Journal of biological chemistry, Mar-16, Volume: 282, Issue:11	HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.
AID1171597	Inhibition of wild type HIV1 reverse transcriptase V106A mutant assessed as reduction in enzyme activity	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1206939	Inhibition of HIV1 recombinant wild type reverse transcriptase p66/p51 assessed as reduction in biotin-labeled dUTP incorporation into DNA using polyr(A) x oligo(dT)16 template/primer hybrid	2015	European journal of medicinal chemistry, Jun-05, Volume: 97	Discovery of piperidin-4-yl-aminopyrimidine derivatives as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1731743	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID279402	Antiviral activity against HIV1 isolate with RT 103N, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1320867	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
AID197796	Compound was tested for inhibitory activity against HIV-1 mutant type reverse transcriptase (K103N)	1998	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16	A dipyrido [2,3-b:3',2'-f]azepine analog of the HIV-1 reverse transcriptase inhibitor nevirapine.
AID279415	Antiviral activity against HIV1 isolate with RT 101E, 181C, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1072799	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES056	2014	Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6	Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
AID228280	Compound dose required to reduce viability of mock infected cells using MTT method	2000	Bioorganic & medicinal chemistry letters, Feb-07, Volume: 10, Issue:3	1-[2-(Diphenylmethoxy)ethyl]-2-methyl-5-nitroimidazole: a potent lead for the design of novel NNRTIs.
AID361920	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P225H mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID105535	Inhibitory activity against HIV-1 Asn 103 mutant in MT-4 cells.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
AID1705186	Antiviral activity against HIV1 harboring RT K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID293565	Antiviral activity against HIV1 LAI with RT F227C and V106A mutation in MT4 cells by EGFP based replication assay	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID665273	Antiviral activity against HIV2 ROD mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	European journal of medicinal chemistry, Jul, Volume: 53	Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID302266	Resistance index, ratio of Ki for HIV1 RT K103N mutant to Ki for wild type HIV1 3B reverse transcriptase	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1228736	Antiviral activity against HIV2-ROD infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay	2015	Journal of natural products, May-22, Volume: 78, Issue:5	Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata.
AID247620	Inhibitory activity against HIV-1 double mutants strain 227L and 106A	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID104448	Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.
AID591355	Antiviral activity against HIV2 isolate ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days by microscopic analysis	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide.
AID1784207	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Discovery, optimization, and target identification of novel coumarin derivatives as HIV-1 reverse transcriptase-associated ribonuclease H inhibitors.
AID607877	Inhibition of HIV1 wild type RT using poly(rA)/oligo(dT)15 homopolymer template after 1 hrs by ELISA	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1815390	Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells to EC50 of Anti-HIV activity against HIV-1 IIIB infected in human MT4	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID1750723	Selectivity index, ratio of CC50 for cytotoxicity against human MT-4 cells to EC50 for inhibition of HIV-1 p66/51 reverse transcriptase L100I mutant	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID267855	Antiviral activity against HIV1 IRLL98 in MT4 cells by MTT assay	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
AID105155	Effective concentration against HIV-1 induced cytopathogenicity in MT-4 cells	1996	Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2	2-Sulfonyl-4-chloroanilino moiety: a potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones.
AID650691	Inhibition of wild type HIV1 NL4-3 reverse transcriptase assessed as inhibition of time-dependent incorporation of [3H]dTTP into poly(rA)n.oligo(dT)	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID1435507	Antiviral activity against HIV1 expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
AID232050	Selectivity index expressed as the ratio of CC50/ EC50	1996	Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2	2-Sulfonyl-4-chloroanilino moiety: a potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones.
AID368568	Inhibition of HIV1 recombinant reverse transcriptase K103N mutant-DNA binary complex expressed in Escherichia coli BL21	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID1352323	Inhibition of recombinant wild type HIV1 reverse transcriptase p66/p51 using poly (rA)/anoligo (dT)16 as template/primer assessed as inhibition of biotin-dUTP incorporation after 40 mins by Pico-Green staining based fluorescence assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID301928	Inhibition of HIV1 reverse transcriptase by ELISA	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	The design and synthesis of N-1-alkylated-5-aminoarylalkylsubstituted-6-methyluracils as potential non-nucleoside HIV-1 RT inhibitors.
AID1072800	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2014	Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6	Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
AID508779	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V179D mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1249722	Antiviral activity against HIV1 expressing reverse transcriptase Y188L mutant	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID155276	Anti-HIV activity by its ability to inhibit the replication of HIV-1 strain A17 variant (Y181C,K103N) in peripheral blood mononuclear cells (PBMC)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
AID1888691	Toxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay
AID1435504	Antiviral activity against HIV1 expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
AID1316345	Selectivity index, ratio of CC50 for human mock-infected MT4 cells to EC50 for HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID1322999	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells.
AID678717	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1888704	Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT F227L + V106A mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells
AID46381	Antiviral activity against site directed resistant isolate HIV-1 V179D in CEM cells	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID508649	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase L100I, K103N, V179L mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID391687	Inhibition of RNA dependent DNA polymerase activity of HIV1 BH10 recombinant reverse transcriptase p66/p51 assessed as residual enzyme activity	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.
AID1155813	Inhibition of wild type HIV-1 recombinant reverse transcriptase assessed as incorporation of [3H]dTTP into poly(rA)/oligo(dT)10:1	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID240924	Inhibitory concentration against HIV-Reverse transcriptase	2005	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4	Human immunodeficiency virus-reverse transcriptase inhibition and hepatitis C virus RNA-dependent RNA polymerase inhibition activities of fullerene derivatives.
AID198068	Inhibition of reverse transcriptase activity of HIV-1 in the presence of [alpha35 S] TTP as cosubstrate	1993	Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24	Synthesis and anti-HIV-1 activity of a series of imidazo[1,5-b]pyridazines.
AID557048	Antiviral activity against HIV1 clade F1 harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID717261	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
AID508640	Antiviral activity against Human immunodeficiency virus 1 subtype BG infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1191974	Selectivity index, ratio of CC50 for mock-infected human HeLa cells to EC50 for HIV2 ROD infected in human MT4 cells	2015	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6	Design, synthesis of new β-carboline derivatives and their selective anti-HIV-2 activity.
AID247498	Inhibitory activity against HIV-1 mutant strain 106A	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID391690	Inhibition of DNA dependent DNA polymerase activity of HIV1 reverse transcriptase Y181C mutant expressed in Escherichia coli BL21	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.
AID1888694	Antiviral activity against HIV1 with RT L100I mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay
AID106949	Anti-HIV-1 activity against WTIIIB HIV-1 strain in MT-4 cells	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1446819	Antiviral activity against HIV1 harboring E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID698301	Antiviral activity against HIV1 containing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1446817	Antiviral activity against HIV1 harboring Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID1446826	Inhibition of wild-type HIV1 reverse transcriptase assessed as decrease in biotin-dUTP incorporation using poly(A)/oligo(dT)15 as template/primer after 1 hr by ELISA	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID299025	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
AID619629	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID1249720	Antiviral activity against HIV1 expressing reverse transcriptase E138K mutant	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID1483273	Inhibition of HIV1 3B reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID1731749	Inhibition of reverse transcriptase Y188L mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID508641	Antiviral activity against Human immunodeficiency virus 1 subtype AG infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID253492	Dose required to inhibit HIV-1 reverse transcriptase activity (V179D mutant) by 50%	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure-activity relationship investigation.
AID1418467	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild-type HIV1 3B infected in human MT4 cells	2018	Bioorganic & medicinal chemistry letters, 12-01, Volume: 28, Issue:22	Design and synthesis of a novel series of non-nucleoside HIV-1 inhibitors bearing pyrimidine and N-substituted aromatic piperazine.
AID1822274	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID1485966	Inhibition of recombinant wild-type HIV-1 reverse transcriptase p66/p51 RNA-dependent DNA polymerase activity expressed in Escherichia coli JM109 assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by Pi	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID246351	Effective concentration against human immunodeficiency virus type 1 mutated at 188L	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID1056579	Antiviral activity against HIV-1 expressing reverse transcriptase K103N/G190A double mutant infected in human 293T cells co-transfected with VSVG protein assessed as inhibition of viral-replication incubated 15 mins prior to viral-infection measured after	2013	Journal of natural products, Dec-27, Volume: 76, Issue:12	Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73.
AID1877036	Inhibition of recombinant HIV-1 reverse transcriptase incubated for 2 hrs by colorimetric assay	2021	Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22	HIV-1 gp120 Antagonists Also Inhibit HIV-1 Reverse Transcriptase by Bridging the NNRTI and NRTI Sites.
AID1731744	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
AID1654236	Drug metabolism in human liver microsomes assessed as Cytochrome P450-mediated formation of 12-OHNVP at 1 to 400 uM in presence of NADPH regenerating reagents by uHPLC-MS/MS analysis	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death.
AID635301	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity after 5 days by MTT assay	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID518740	Antiviral activity against HIV 1 subtype B harboring wild type reverse transcriptase infected in human TZM-bl cells assessed as inhibition of viral growth by luciferase reporter gene assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
AID523354	Antiviral activity against HIV1 with RT connection domain Y181C/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID265474	Selectivity index, TC50 for human lymphocytes/EC50 for HIV1 3B	2006	Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11	Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide.
AID1316805	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Synthesis of arylated coumarins by Suzuki-Miyaura cross-coupling. Reactions and anti-HIV activity.
AID673926	Antiviral activity against Human immunodeficiency virus 1 infected in human 293T cells assessed as inhibition of viral replication after 48 hrs by luminescence analysis	2012	ACS medicinal chemistry letters, Jun-14, Volume: 3, Issue:6	Novel Cyclopropyl-Indole Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.
AID1572527	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytotoxicity after 5 days by MTT assay
AID253495	Dose required to inhibit HIV-1 reverse transcriptase activity ( L100I mutant) by 50%	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure-activity relationship investigation.
AID1561717	Antiviral activity against HIV1 3B infected in human MT4 cells grown under 30 passages in presence of (E)-4-((4-((4-(4-(2-Cyanovinyl)-2,6-dimethylphenoxy)thieno[2,3- d]pyrimidin-2-yl)amino)piperidin-1-yl)methyl)benzenesulfonamide assessed as protection ag
AID523358	Antiviral activity against HIV1 with RT connection domain G190A/N348Ib mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID105522	Concentration which reduced the cytopathic effect of HIV-1 in MT-4 infected cells	1995	Journal of medicinal chemistry, Dec-08, Volume: 38, Issue:25	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs.
AID198259	Inhibitory concentration against mutant reverse transcriptase of L100I was determined which is in turn resistant TIBO	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse transcriptase enzymes.
AID1565091	Antiviral activity against drug resistant HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID1457058	Antiviral activity against HIV1 harboring reverse transcriptase K103N /Y1881C double mutant infected in human ML4 cells assessed as protection against virus-induced cytopathic effect measured on day 5 post infection by MTT assay	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID282740	Inhibition of HIV1 RT Y188L mutant	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
AID342718	Inhibition of HIV1 reverse transcriptase RNA-dependent DNA polymerase activity assessed as incorporation of radioactive dTTP into poly(rA)/oligo(DT)	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors.
AID1298243	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID46204	Tested for the inhibitory activity of virus induced giant cell formation in HIV-1 infected CEM cells	1994	Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24	1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole 2",2"-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity.
AID1072798	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV2 ROD	2014	Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6	Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
AID1155806	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV-1 NL4-3 infected in human MT4 cells	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID1435509	Antiviral activity against HIV1 RES056 expressing reverse transcriptase mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
AID1185998	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID1784213	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Discovery, optimization, and target identification of novel coumarin derivatives as HIV-1 reverse transcriptase-associated ribonuclease H inhibitors.
AID299029	Antiviral activity against HIV1 with reverse transcriptase E138K mutation in CEM cells assessed as inhibition of virus-induced giant cell formation	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
AID508774	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase Y181I mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1565088	Inhibition of HIV1 reverse transcriptase assessed as inhibition of biotin-dUTP incorporation into template incubated for 1 hr by ELISA
AID287001	Cytotoxicity against Jurkat cells by XTT assay	2007	Journal of medicinal chemistry, May-17, Volume: 50, Issue:10	De novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variants.
AID1217712	Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1731751	Inhibition of reverse transcriptase F227L/V106A double mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID586908	Induction of MRP1 activity	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID665553	Fold resistance, ratio of EC50 for HIV1 RES056 harboring reverse transcriptase K103N/Y181C RT mutant to EC50 for wild type HIV1 3B	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
AID248259	In vitro inhibitory concentration against HIV K101E mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID276232	Cytotoxicity against MT2 cells	2006	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21	Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1244338	Inhibition of HIV1 reverse transcriptase at 100 ug/ml incubated for 1 hr by ELISA method	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	N-Alkyl/aryl-4-(3-substituted-3-phenylpropyl)piperazine-1-carbothioamide as dual-action vaginal microbicides with reverse transcriptase inhibition.
AID279392	Antiviral activity against HIV1 isolate with RT 100I, 103N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1357795	Resistance factor, ratio of EC50 for HIV1 harboring reverse transcriptase K103N mutant to EC50 for wild-type HIV-1 3B	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID1565096	Antiviral activity against drug resistant HIV-1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID473117	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV.
AID1152245	Antiviral activity against X4 tropic Human immunodeficiency virus 1 UG070 subtype D infected in human TZM-bl cells assessed as reduction in virus-induced cytopathic effect after 48 hrs by luminescence assay	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID449489	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus induced cytotoxicity after 5 days by MTT assay	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID621978	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID1636149	Ratio of IC50 for NNRTI resistant HIV1 harboring reverse transcriptase K103N/V179F/Y181C mutant infected in human TZM-bl cells to IC50 for wild type HIV1 NL4-3 infected in human TZM-bl cells	2016	Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15	Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
AID557036	Antiviral activity against HIV1 isolate R8 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs in presence of 50% human serum	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID269803	Antiviral activity against HIV1 V179E mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269803	Antiviral activity against HIV1 V179E mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269803	Antiviral activity against HIV1 V179E mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1191404	Inhibition of wild type HIV1 p66/p51 reverse transcriptase by spectrofluorometry	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID104802	In vitro cytotoxicity against mock infected MT-4 cells.	2004	Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15	Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID256329	Percentage inhibition of proliferation against alive human A-375 cells treated with DMSO (control) at a concentration of 350 uM	2005	Journal of medicinal chemistry, Nov-03, Volume: 48, Issue:22	6-[1-(2,6-difluorophenyl)ethyl]pyrimidinones antagonize cell proliferation and induce cell differentiation by inhibiting (a nontelomeric) endogenous reverse transcriptase.
AID361909	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID443759	Antiviral activity against HIV1 with reverse transcriptase G139I mutation	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile.
AID106956	Compound dose required to achieve protection of MT-4 cells from HIV-1 induced cytopathicity using MTT method	2000	Bioorganic & medicinal chemistry letters, Feb-07, Volume: 10, Issue:3	1-[2-(Diphenylmethoxy)ethyl]-2-methyl-5-nitroimidazole: a potent lead for the design of novel NNRTIs.
AID1572528	Antiviral activity against HIV1 harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytotoxicity after 5 days by MTT assay
AID663307	Inhibition of HIV1 recombinant reverse transcriptase L100I mutant assessed as [3H]dTTP incorporation into poly(rA)/oligo(dT)	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID572185	Antiviral activity against HIV-1 SM030 harboring NNTRI 100I mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID293557	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 LAI	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID1822275	Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells to EC50 for antiviral activity against HIV-1 IIIB infected in human MT4 cells	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID222294	Effect of human plasma protein binding on antiviral efficacy.	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID1815387	Resistance fold, ratio of EC50 for HIV1 harboring reverse transcriptase L100I mutant infected MV4 cells to EC50 for wild type HIV1 infected MV4 cells	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID297135	Antiviral activity against HIV1 infected CEM cells	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme.
AID105700	Anti-HIV-1 activity against K103N+Y181C strain was determined in MT-4 cells by the MTT method	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1446816	Antiviral activity against HIV1 harboring K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID391683	Antiviral activity against HIV1 infected in 8186 T cells	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.
AID1761017	Antiviral activity against HIV-1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect measured after 5 days by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID1141972	Ratio of EC50 for HIV1 harboring reverse transcriptase Y188L mutant to EC50 for wild type HIV1 NL4.3	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1443670	Antiviral activity against HIV1 harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
AID693584	Antiviral activity against HIV1 RES056 harbouring RT K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	European journal of medicinal chemistry, Dec, Volume: 58	Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors.
AID279433	Antiviral activity against HIV1 isolate with RT 179T mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID449492	Selective index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2009	European journal of medicinal chemistry, Nov, Volume: 44, Issue:11	Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID19262	Aqueous solubility	2000	Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11	Prediction of drug solubility from Monte Carlo simulations.
AID198909	In vitro inhibitory activity against HIV-1 mutant Reverse transcriptase containing the single amino acid substitution Y188L	1999	Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21	Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: further structure-activity relationship studies and identification of more potent broad-spectrum HIV-1 RT inhibitors with antiviral activity.
AID1155817	Fold resistance, ratio of ID50 for HIV-1 recombinant NNTRI-resistant reverse transcriptase K103N mutant to ID50 for wild type HIV-1 recombinant reverse transcriptase	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID1591873	Antiviral activity against wild-type HIV1 NL4-3 infected in human MT2 cells measured 48 hrs post-infection by MTT assay	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase.
AID299030	Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in CEM cells assessed as inhibition of virus-induced giant cell formation	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
AID1815400	Inhibition of HIV1 reverse transcriptase Y188L mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID1173644	Antiviral activity against HIV-1 LAI infected in human CEMx174-LTR-GFP CG8 cells assessed as inhibition of viral replication after 5 days	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Serendipitous discovery of 2-((phenylsulfonyl)methyl)-thieno[3,2-d]pyrimidine derivatives as novel HIV-1 replication inhibitors.
AID557035	Antiviral activity against HIV1 isolate R8 harboring reverse transcriptase K103N and Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs in presence of 50% human serum	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID757623	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2013	European journal of medicinal chemistry, Jul, Volume: 65	Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1171582	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as protection against virus-induced cytopathicity by giant cell formation assay	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID460296	Inhibition of HIV1 reverse transcriptase by EIA	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Biomimetic synthesis and anti-HIV activity of dimeric phloroglucinols.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1275552	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 3B infected in human MT4 cells	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
AID1637398	Antiviral activity against human HIV-1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection from virus-induced cytopathic effect measured 5 days post infection by MTT assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID621980	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B expressing reverse transcriptase K103N/Y181C double mutant	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID1750717	Inhibition of HIV-1 p66/p51 reverse transcriptase L100I mutant incubated for 40 mins by picogreen dye-based spectrofluorometric analysis	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID361914	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190E mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1654201	Drug metabolism in C57BL/6J mouse primary hepatocytes assessed as Cytochrome P450-mediated formation of 12-OHNVP at 10 uM incubated for 24 hrs by uHPLC-MS analysis	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death.
AID82276	Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in MT-4-infected Y181C+K103N strain	2002	Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.
AID492286	Antiviral activity against HIV1 with reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID767501	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.
AID1379964	Inhibition of recombinant wild type HIV1 reverse transcriptase p66/p51 assessed as reduction in biotin-dUTP incorporation incubated for 40 mins using poly(rA) template and oligo(dT)16 primer by picogreen dye based spectrofluorometry	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.
AID655387	Cytotoxicity against human CEmx174 cells	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	A novel 3,4-dihydropyrimidin-2(1H)-one: HIV-1 replication inhibitors with improved metabolic stability.
AID197780	Compound was evaluated for its inhibitory activity against recombinant HIV-1 Reverse transcriptase using cell free RT inhibition assay	2000	Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18	Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID1784214	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Discovery, optimization, and target identification of novel coumarin derivatives as HIV-1 reverse transcriptase-associated ribonuclease H inhibitors.
AID1267625	Antiviral activity against NRTI/NNRTI-resistant HIV1 L6 harboring reverse transcriptase V75I/F77L/K103N/F116Y/Q151M/M184V mutant infected in human MT4 cells	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Design and Synthesis of DiselenoBisBenzamides (DISeBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity.
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID1152246	Antiviral activity against R5 tropic Human immunodeficiency virus 1 VB59 subtype C infected in human TZM-bl cells assessed as reduction in virus-induced cytopathic effect after 48 hrs by luminescence assay	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1357798	Resistance factor, ratio of EC50 for HIV1 harboring reverse transcriptase Y188L mutant to EC50 for wild-type HIV-1 3B	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID279323	Inhibition of reverse transcriptase RTY18C mutant in HIV1 Z6gpt assessed as inhibition of ssDNA synthesis	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification.
AID267856	Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
AID571968	Antiviral activity against HIV-1 subtype CRF02_AG V022825 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1352319	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 4 days by MTT assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID82606	The effect of protein binding on the antiviral activity versus wild type virus strain K103N was tested in the presence of acid glycoprotein in HeLa MAGI assay	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID105859	Compound was tested for potency to achieve protection of MT-4 cells from 101E strain of HIV-1 virus	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).
AID1773457	Resistance factor, ratio of EC50 for HIV1 harboring L1001 mutant infected in human MT4 cells to EC50 for HIV1 3B infected in MT4 cells
AID1884491	Antiviral activity against drug-resistant HIV-1 Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID572169	Antiviral activity against HIV-1 subtype D V022832 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID557052	Antiviral activity against NRTI-resistant HIV1 harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID82476	Antiviral activity against wild-type HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1157595	Antiviral activity against TMC125-resistant HIV1 harboring RT 109M, 138K, 190E mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID1483272	Inhibition of HIV1 3B reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID779529	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
AID1141977	Inhibition of HIV1 wild-type reverse transcriptase Y181I/Y181C mutant using [3H]dTTP by scintillation counting	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1390711	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.
AID561944	Antibacterial activity against Shigella sonnei ATCC 111060 after 18 to 24 hrs by agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Lack of antimicrobial activity by the antiretroviral drug nevirapine against common bacterial pathogens.
AID1565092	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay
AID1685255	Cytotoxicity against human MT2 cells assessed as cell growth inhibition after 5 days by MTT assay	2021	ACS medicinal chemistry letters, Feb-11, Volume: 12, Issue:2	Covalent Inhibition of Wild-Type HIV-1 Reverse Transcriptase Using a Fluorosulfate Warhead.
AID1705193	Resistance index, ratio of EC50 for antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 NL4-3 infected in human MT4 cells	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID395595	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	2009	European journal of medicinal chemistry, Jan, Volume: 44, Issue:1	Synthesis and anti-HIV studies of 2- and 3-adamantyl-substituted thiazolidin-4-ones.
AID1157581	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID571986	Antiviral activity against HIV-1 subtype C V022829 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID735081	Antiviral activity against HIV harboring reverse transcriptase Y181C mutant by cell based assay	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Synthesis and biological evaluation of phosphonate analogues of nevirapine.
AID1316337	Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID508752	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V179I, Y181C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID619643	Ratio of EC50 for HIV-1 3B harboring RT L100I mutant infected in human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID1729160	Antiviral activity against HIV1 harboring E138K mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID317734	Inhibition of tubulin polymerization after 20 mins	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID346970	Antiviral activity against HIV 3B in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Studies on anti-HIV quinolones: new insights on the C-6 position.
AID368558	Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID198913	Inhibition of HIV-1 Mutant HIV-1 RT enzymes containing the single amino acid substitution V106A	2001	Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3	Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.
AID1636932	Aqueous solubility of compound in water at pH 7 by HPLC analysis	2016	Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20	Computer-aided discovery of anti-HIV agents.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID416759	Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in human CEM cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID391996	Antiviral activity against HIV2 ROD replication in human MT4 cells assessed as inhibition of virus-induced cytopathic effect at subtoxic concentration after 5 days by tetrazolium-based colorimetric assay	2008	European journal of medicinal chemistry, Dec, Volume: 43, Issue:12	Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.
AID105546	Inhibition of mutant type (Ile100) HIV-1 (IIIB) replication in MT-4 cells	1996	Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21	Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.
AID1888703	Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT E138K mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells
AID1862268	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Design, synthesis, and biological evaluation of novel double-winged galloyl derivatives as HIV-1 RNase H inhibitors.
AID1186005	Antiviral activity against HIV1 harboring reverse transcriptase K103N/V108I double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay r	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID226237	Fold resistance (L100I/ WT) (as per ref 12 in the article)	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.
AID689698	Cytotoxicity against human CEM174 cells assessed as cell viability	2012	ACS medicinal chemistry letters, Aug-09, Volume: 3, Issue:8	Discovery of Phenylaminopyridine Derivatives as Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
AID391677	Inhibition of DNA dependent DNA polymerase activity of HIV1 BH10 recombinant reverse transcriptase p66/p51 assessed as residual enzyme activity at 50 ug/ml relative to control	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.
AID360707	Inhibition of HIV1 RT K103N mutant mediated DNA-dependent DNA polymerization using RNA PPT primed substrate by scintillation proximity assay	2007	The Journal of biological chemistry, Mar-16, Volume: 282, Issue:11	HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.
AID83554	Potency evaluated against wild type HIV-1 strain IIIB	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 varian
AID571985	Antiviral activity against HIV-1 subtype C V022817 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID348906	Antiviral activity against drug-resistant HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method	2008	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21	Towards novel S-DABOC inhibitors: synthesis, biological investigation, and molecular modeling studies.
AID1763901	Antiviral activity against HIV-1 IIIB harboring RT Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
AID572179	Antiviral activity against HIV-1 subtype O V029524 harboring NNRTI A98G, V179E and Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID666412	Cytotoxicity against human MT4 cells after 3 days by XTT assay	2012	Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5	Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.
AID1729159	Antiviral activity against HIV1 harboring Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID572177	Antiviral activity against HIV-1 subtype H V022828 harboring NNRTI K101Q and V179I mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID104980	Dose required to achieve 50% protection of MT-4 cells from HIV-1 induced cytopathogenicity	1995	Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17	Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzyloxopyrimidines.
AID586320	Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of gag gene expression after 5 days post infection by quantitative real time RT-PCR	2011	Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6	Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID260237	Antiviral activity against HIV1 3B in MT2 cells by MTT assay	2006	Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3	Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1609109	Antiviral activity against HIV-1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 4 days by MTT assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID198906	In vitro inhibitory activity against HIV-1 mutant Reverse transcriptase containing the single amino acid substitution L100I	1999	Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21	Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: further structure-activity relationship studies and identification of more potent broad-spectrum HIV-1 RT inhibitors with antiviral activity.
AID266346	Inhibition of HIV1 reverse transcriptase K103N mutant in 293T cells	2006	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11	New HIV-1 reverse transcriptase inhibitors based on a tricyclic benzothiophene scaffold: synthesis, resolution, and inhibitory activity.
AID368561	Antiviral activity against HIV1 reverse transcriptase Y188L mutant infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID1292363	Antiviral activity against HIV1 virus-like particles harboring wild type reverse transcriptase infected in human U2OS cells assessed as remaining viral activity at 5 uM after 24 hrs by Renilla luciferase assay relative to control	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Design, discovery, modelling, synthesis, and biological evaluation of novel and small, low toxicity s-triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID391692	Inhibition of DNA dependent DNA polymerase activity of HIV2 recombinant reverse transcriptase at 140 uM	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.
AID586902	Activity at MRP2	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID1773442	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
AID557038	Antiviral activity against HIV1 isolate R8 harboring wild type reverse transcriptase infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs in presence of 50% human serum	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID1591875	Cytotoxicity against human MT2 cells infected with wild-type HIV1 NL4-3 measured 48 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16	Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase.
AID197932	HIV-1 reverse transcriptase inhibitory activity against Cys181 mutant using (poly)rC600*(oligo)dGT as template primer.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
AID198409	Tested for the inhibition of mutant type (Cys181) HIV-1 (IIIB) RT	1996	Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21	Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.
AID1380573	Antiviral activity against HIV1 virions containing reverse transcriptase E138K/M184V mutant derived from HIV/VSG-G or HIV/HA virions infected 293T cells using human A549 cells as target cells assessed as inhibition of viral replication using compound pre-	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and biological evaluation of substituted (+)-SG-1 derivatives as novel anti-HIV agents.
AID1059142	Inhibition of recombinant HIV1 reverse transcriptase using poly rA:dT as template/primer after 1 hr by ELISA	2013	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24	Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1877039	Potency index, ratio of test compound IC50 to NBD-14189 IC50 for inhibition of recombinant HIV-1 reverse transcriptase incubated for 2 hrs by colorimetric assay	2021	Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22	HIV-1 gp120 Antagonists Also Inhibit HIV-1 Reverse Transcriptase by Bridging the NNRTI and NRTI Sites.
AID1884227	Antiviral activity against HIV-1 harboring Y188L mutant infected in human MT4 cells assessed as reduction in virus induced cytotoxicity incubated for 5 to 7 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID556525	Antiviral activity against Human immunodeficiency virus 1 clone 38086 harboring K49R, V60I, I135V, Q145M, Q174H, G196E, Q207E, R211K, V245K mutation in reverse transcriptase by phenosense assay relative to wild type	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
AID279477	Antiviral activity against HIV1 isolate with RT 181V mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID460295	Inhibition of HIV1 reverse transcriptase at 20 ug/mL by EIA	2010	Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5	Biomimetic synthesis and anti-HIV activity of dimeric phloroglucinols.
AID279319	Inhibition of reverse transcriptase assessed as decrease in ssDNA level in cell free virion HIV1 by NERT-based real-time PCR at 10 uM	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification.
AID83552	Potency evaluated against NNRTI-Resistant HIV-1 strain Tyr188Leu	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 varian
AID1231487	Inhibition of wild-type HIV1 Reverse transcriptase p66/p51 assessed as relative fluorescence signal after 40 mins	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action.
AID287004	Inhibition of drug-resistant reverse transcriptase L100I-K103 mutant	2007	Journal of medicinal chemistry, May-17, Volume: 50, Issue:10	De novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variants.
AID1736363	Selectivity index, ratio of EC50 for antiviral activity against VSVG/HIV-1 harboring reverse transcriptase Y181C mutant infected in human HEK 293T cells to EC50 for antiviral activity against VSVG/wild type HIV-1 infected in human HEK293T cells
AID317729	Antiviral activity against HIV1RF infected in human CEM-SS cells	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID1316333	Cytotoxicity against human mock-infected MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID81255	Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells.	1992	Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15	3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2'-5'-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranose]-3'-spiro-5"-[4"-amino-1",2"-oxathiole 2",2"-dioxide] (
AID263507	Antiviral activity against HIV1 in HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID665272	Antiviral activity against HIV1 RES056 harboring K103N/Y181C RT mutant infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	European journal of medicinal chemistry, Jul, Volume: 53	Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID1609103	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID244306	Fold increase in inhibitory concentration against HIV 1 reverse transcriptase mutant type Cys181 over wild type HIV 1 reverse transcriptase	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
AID586900	Activity at ABCB1	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID263521	Antiviral activity against HIV1 F227C mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID482696	Antiviral activity against AZT-resistant HIV infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID294630	Antiviral activity against HIV2 ROD in CEM cells	2007	European journal of medicinal chemistry, Jul, Volume: 42, Issue:7	Synthesis and anti-HIV studies of 2-adamantyl-substituted thiazolidin-4-ones.
AID265471	Activity against HIV1 3B assessed by inhibition of p24 production in human lymphocytes	2006	Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11	Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide.
AID281485	Antiviral activity against wild type HIV1 3B in MT4 cells after 4 days by MTT method	2007	Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8	Synthesis and anti-HIV-1 activity evaluation of 5-alkyl-2-alkylthio-6-(arylcarbonyl or alpha-cyanoarylmethyl)-3,4-dihydropyrimidin-4(3H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1298253	Inhibition of HIV1 3B reverse transcriptase p66/p51 K103N/Y181C mutant using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID648422	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2012	European journal of medicinal chemistry, May, Volume: 51	Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1373158	Inhibition of reverse transcriptase L100I mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID1379963	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.
AID1292376	Cytotoxicity against human U2OS cells assessed as cell viability at 5 uM after 48 hrs relative to control	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Design, discovery, modelling, synthesis, and biological evaluation of novel and small, low toxicity s-triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1657476	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	2020	Bioorganic & medicinal chemistry, 04-15, Volume: 28, Issue:8	Inhibition of HIV-1 RT activity by a new series of 3-(1,3,4-thiadiazol-2-yl)thiazolidin-4-one derivatives.
AID1199054	Antiviral activity against Human immunodeficiency virus type 2 ROD infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay	2014	Journal of natural products, Jun-27, Volume: 77, Issue:6	Jatrophane diterpenes as inhibitors of chikungunya virus replication: structure-activity relationship and discovery of a potent lead.
AID318121	Antiviral activity against HIV1 RF in CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay	2008	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4	Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
AID366532	Resistance index, ratio of ID50 for reverse transcriptase L100I mutant to IC50 for wild-type HIV1 reverse transcriptase	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID282735	Inhibition of HIV1 RT	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
AID608389	Inhibition of HIV1 reverse transcriptase assessed as residual enzyme activity at 50 uM after 1 hr by ELISA relative to control	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Imidazo[1,2-a]pyridin-3-amines as potential HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID299028	Antiviral activity against HIV1 with reverse transcriptase K103N mutation in CEM cells assessed as inhibition of virus-induced giant cell formation	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
AID557022	Antiviral activity against HIV1 CRF01_AE harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID263152	Antiviral activity against HIV1 in HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID263152	Antiviral activity against HIV1 in HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID263152	Antiviral activity against HIV1 in HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1335207	Ratio of IC50 for HIV-1 NL4-3 harboring RT-K103N mutant infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein to IC50 for wild-type HIV-1 NL4-3 infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID614142	Antiviral activity against wild type Human immunodeficiency virus 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2011	Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17	Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
AID1596756	Inhibition of recombinant wild-type HIV1 3B reverse transcriptase assessed as reduction in biotin-dUTP incorporation using poly(rA)/oligo(dT)16 as template primer incubated for 1 hr followed by the addition of (DIG)-dUTP and biotin-labeled dNTPs by ELISA	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Synthesis and biological evaluation of dihydroquinazoline-2-amines as potent non-nucleoside reverse transcriptase inhibitors of wild-type and mutant HIV-1 strains.
AID366517	Antiviral activity against HIV1 NL4-3 in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID413265	Antiviral activity against multidrug-resistant HIV1 with reverse transcriptase 41L, 67N, 210W, 215Y, 184V, 103N mutation infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	2008	Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24	Development and preclinical studies of broad-spectrum anti-HIV agent (3'R,4'R)-3-cyanomethyl-4-methyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (3-cyanomethyl-4-methyl-DCK).
AID1077218	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.
AID391691	Inhibition of DNA dependent DNA polymerase activity of HIV1 reverse transcriptase L100I/K103N mutant expressed in Escherichia coli DH5alpha	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.
AID328845	Inhibition of human MRP3 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence at 10 uM by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID263515	Antiviral activity against HIV1 I135T mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID1152247	Selectivity index, ratio of CC50 for human TZM-bl cells to EC50 for X4 tropic Human immunodeficiency virus 1 UG070 subtype D	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID246275	Effective concentration against rhuman immunodeficiency virus type 1 Y181C mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
AID1761015	Antiviral activity against HIV-1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect measured after 5 days by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID1357797	Resistance factor, ratio of EC50 for HIV1 harboring reverse transcriptase Y181C mutant to EC50 for wild-type HIV-1 3B	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID573481	Fold resistance, ratio of EC50 for Human immunodeficiency virus 1 isolate 8117 harboring A98S, G190A mutation in reverse transcriptase to wild-type	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID1197833	Resistance index, ratio of EC50 for HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant to EC50 for wild type HIV1 3B	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
AID1574386	Inhibition of recombinant HIV-1 His-tagged reverse transcriptase p66/p51 Y181I mutant expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer after 20 mins by scintillation counting analysi	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID1316341	Antiviral activity against HIV1 3B harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID302252	Resistance index, Ratio of EC50 for drug-resistant HIV1 with RT IRLL98 mutation in MT3 cells to EC50 for HIV1 NL43 in MT3 cells	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID650540	Antiviral activity against wild type HIV 1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID586326	Cytotoxicity against PHA-stimutated human PBMC after 24 hrs by MTS assay	2011	Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6	Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID105539	Inhibitory activity against HIV-1 Ile 100 mutant in MT-4 cells.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
AID523349	Antiviral activity against HIV1 with RT connection domain K103N mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID508643	Antiviral activity against Human immunodeficiency virus 1 subtype A1 infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID197795	Inhibition of HIV-1 reverse transcriptase using rCdG as template and dGTP as substrate	1995	Journal of medicinal chemistry, Dec-08, Volume: 38, Issue:25	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs.
AID1161104	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.
AID1736152	Selectivity for inhibition of wild type recombinant HIV-1 subtype B BH10 p66/p51 reverse transcriptase heterodimer expressed in Escherichia coli BL21 (DE3) at 50 uM over inhibition of recombinant HIV-1 subtype B BH10 p66/p51 reverse transcriptase heterodi	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Design, synthesis and biological evaluation of quinoxaline compounds as anti-HIV agents targeting reverse transcriptase enzyme.
AID246799	Compound concentration required to reduce the amount of p24 by 90% in C8166 cells infected with an efavirenz-resistant strain EFVR carrying mutations K103R, V179D, and P225H	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID522371	Antiviral activity against recombinant HIV1 harboring reverse transcriptase V179D mutant clone infected in MAGIC-5 cells using 5-bromo4-chloro-3-indolyl-beta-D-galactopyranoside staining based light microscopy	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID82275	Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in MT-4-infected Y181C strain	2002	Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.
AID1175438	Selectivity index, ratio of CC50 for human TZM-bl cells to EC50 for wild-type HIV-1 SF33	2015	Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1	Synthesis and biological evaluation of pyridinone analogues as novel potent HIV-1 NNRTIs.
AID299027	Antiviral activity against HIV1 with reverse transcriptase L100I mutation in CEM cells assessed as inhibition of virus-induced giant cell formation	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
AID152657	Inhibitory activity of compound on p24 production in peripheral blood mononuclear cells infected with HIV strain A17 variant.	1999	Bioorganic & medicinal chemistry letters, Jun-07, Volume: 9, Issue:11	Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
AID391689	Inhibition of HIV1 BH10 recombinant reverse transcriptase p66/p51 RNase H activity assessed as residual enzyme activity	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.
AID1884221	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction in virus induced cytotoxicity incubated for 5 to 7 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1460940	Therapeutic index, ratio of TC50 for human MAGI-CCR5 cells to IC50 for HIV-1 A17 harboring reverse transcriptase K103N/Y181C double mutant infected in MAGI-CCR5 cells	2017	Bioorganic & medicinal chemistry, 12-01, Volume: 25, Issue:23	An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors.
AID361910	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y188L mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID586905	Inhibition of ABCB1 activity	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID650543	Cytotoxicity against human MT4 cells assessed as cell viability by MTT assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID557051	Antiviral activity against PI-resistant HIV1 harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID1191973	Cytotoxicity against mock-infected human HeLa cells by MTT assay	2015	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6	Design, synthesis of new β-carboline derivatives and their selective anti-HIV-2 activity.
AID302251	Antiviral activity against HIV1 with reverse transcriptase IRLL98 mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID366518	Cytotoxicity against human MT4 cells by MTT assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID1323000	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells.
AID328885	Toxicity in human HeLa cells transfected with GFP-prelamin A construct assessed as accumulation of uncleaved protein at 20 uM by Western blot	2007	Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33	HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells.
AID1126507	Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	2014	Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8	Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID685333	Cytotoxicity against mock-infected human MT4 cells by MTT assay	2012	Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
AID1736359	Antiviral activity against VSVG/HIV-1 harboring reverse transcriptase Y188L mutant infected in human HEK 293T cells assessed as inhibition of virus replication preincubated with cells for 15 mins prior to viral infection and measured at 48 hrs post-infect
AID1773451	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring L1001 mutant infected in human MT4 cells
AID46375	Antiviral activity against site directed 4X AZT resistant isolate HIV-1 in CEM cells	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID106600	Cytotoxic concentration required to reduce MT-4 cell viability by 50%	1992	Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16	TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro -5''- (4''-amino-1'',2''-oxathiole 2'',2''-dioxide) pyrimidine and pyrimidine-modified nucleosides.
AID718372	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2012	Bioorganic & medicinal chemistry, Dec-01, Volume: 20, Issue:23	Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
AID105905	Effective dose required to achieve protection of MT-4 cells from Y181C HIV-1 induced cytopathogenicity	2004	Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4	Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C varia
AID1352322	Antiviral activity against HIV1 harboring reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 4 days by MTT assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID318120	Inhibition of HIV1 reverse transcriptase	2008	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4	Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
AID523478	Antiviral activity against HIV1 with RT connection domain G190A/T369I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID665551	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
AID571967	Antiviral activity against HIV-1 subtype CRF02_AG V022808 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID391994	Selectivity index, ratio of CC50 for human CEM cells to EC50 for HIV1 3B	2008	European journal of medicinal chemistry, Dec, Volume: 43, Issue:12	Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.
AID571976	Antiviral activity against HIV-1 subtype B V022807 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID197776	Compound was evaluated for inhibition of Y181C HIV type I reverse transcriptase.	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 5. 4-Substituted and 2,4-disubstituted analogs of nevirapine.
AID370726	Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 K103N mutant expressed in Escherichia coli JM109	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
AID1352312	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 4 days by MTT assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID622058	Ratio of Ki for HIV1 RT p66/p66 homodimer K103N/Y181C double mutant to Ki for wild-type HIV1 RT p66/p66 homodimer	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID738331	Cytotoxicity against mock-infected human MT4 cells assessed as cell viability after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
AID105537	Inhibitory activity against HIV-1 Cys 181 mutant in MT-4 cells.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
AID1729158	Antiviral activity against HIV1 harboring Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID1457055	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human ML4 cells assessed as protection against virus-induced cytopathic effect measured on day 5 post infection by MTT assay	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID1357786	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild-type HIV1 3B	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID496633	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase V90I/V35T, E36D, K43R, V60I, K101R, K122E, D123S, I135V, S162A, K173T, Q174K, D177E, V179I, G196E, T200A, Q207E mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID558372	Drug level in HIV-infected pregnant woman maternal blood plasma at 200 mg, po BID by HPLC/UV analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.
AID1743626	Antiviral activity against HIV1 harboring RT L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID1185996	Antiviral activity against HIV1 harboring reverse transcriptase L1001/K103N double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID1761011	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID522368	Antiviral activity against wild type HIV1 infected in MAGIC-5 cells using 5-bromo4-chloro-3-indolyl-beta-D-galactopyranoside staining based light microscopy	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID46380	Antiviral activity against site directed resistant isolate HIV-1 V106A in CEM cells	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID1888705	Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT RES056 mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells
AID734259	Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 A17 double mutant infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID1357796	Resistance factor, ratio of EC50 for HIV1 harboring reverse transcriptase E138K mutant to EC50 for wild-type HIV-1 3B	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID508652	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K101P, K103N, V108I mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1729157	Antiviral activity against HIV1 harboring K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID105891	Cytotoxicity against uninfected MT-4 cells	1995	Journal of medicinal chemistry, May-12, Volume: 38, Issue:10	Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
AID153130	Effective dose for inhibition of viral replication in cell culture of 0.1 uM	2000	Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5	Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: lead identification and SAR of 3- and 4-substituted derivatives.
AID1460930	Therapeutic index, ratio of TC50 for human MAGI-CCR5 cells to IC50 for HIV-1 Bal infected in MAGI-CCR5 cells	2017	Bioorganic & medicinal chemistry, 12-01, Volume: 25, Issue:23	An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors.
AID318123	Antiviral activity against HIV2 ROD in MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2008	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4	Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
AID1391087	Antiviral activity against HIV1 harboring reverse transcriptase RES056 double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
AID1520058	Antiviral activity against HIV1 3B harbouring NNRTI K103N mutant infected in human MT4 cells assessed as virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID1057039	Antiviral activity against HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.
AID263512	Antiviral activity against HIV1 L100I mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID619635	Antiviral activity against HIV-1 3B harboring RT K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID665271	Antiviral activity against HIV1 3B harboring wild type RT infected in MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	European journal of medicinal chemistry, Jul, Volume: 53	Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID508797	Ratio of EC50 for HIV1 in presence of 45 mg/ml HSA to EC50 for HIV1 in absence of serum proteins by GFP assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID698144	Inhibition of HIV1 reverse transcriptase L100I mutant RNA-dependent DNA polymerase activity using poly(rA)/oligo(dT)10:1 and [3H]-dTTP substrate	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID155273	Ability to inhibit the replication of RT-MDR (V106A) strain of HIV-1 p24 antigen production in PBMC	1999	Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24	N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
AID279464	Antiviral activity against HIV1 isolate with RT 101Q, 103N, 225H mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID366528	Resistance index, ratio of ID50 for reverse transcriptase K103N mutant to IC50 for wild-type HIV1 sreverse transcriptase	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID1520057	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID508634	Antiviral activity against Human immunodeficiency virus 2 ROD infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID287000	Inhibition of RNase H activity of HIV1 reverse transcriptase	2007	Journal of medicinal chemistry, May-17, Volume: 50, Issue:10	De novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variants.
AID198080	Inhibitory activity against HIV-1 Mutant Reverse transcriptase V106A	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones.
AID266345	Inhibition of wild type HIV1 reverse transcriptase in 293T cells	2006	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11	New HIV-1 reverse transcriptase inhibitors based on a tricyclic benzothiophene scaffold: synthesis, resolution, and inhibitory activity.
AID197934	HIV-1 reverse transcriptase inhibitory activity against Wild Type Reverse transcriptase using (poly)rC600*(oligo)dGT as template primer.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
AID302268	Resistance index, ratio of Ki for HIV1 reverse transcriptase V106A mutant to Ki for wild type HIV1 3B reverse transcriptase	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID1731748	Inhibition of reverse transcriptase Y183C mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID1171578	Cytotoxic activity against human MT4 cells by MTT assay	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1483275	Inhibition of HIV1 RES056 reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID735080	Ratio of EC50 for HIV harboring reverse transcriptase Y181C mutant to EC50 for wild type HIV	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Synthesis and biological evaluation of phosphonate analogues of nevirapine.
AID573468	Inhibition of Human immunodeficiency virus 1 subtype B reverse transcriptase DNA-dependent DNA polymerase activity by gel-based primer extension assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID1572526	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytotoxicity after 5 days by MTT assay
AID457959	Inhibition of HIV1 reverse transcriptase L100I mutant by RNA-dependent DNA polymerase activity assay	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1072797	Inhibition of HIV1 reverse transcriptase assessed as inhibition of biotinylated dUTP incorporation after 1 hr by ELISA	2014	Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6	Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
AID1775803	Inhibition of recombinant wild type HIV1 reverse transcriptase assessed as inhibition of biotin-dUTP incorporation into template	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies.
AID1335212	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/P225H double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID1610039	Therapeutic index, ratio of CC50 for human TZM-bl cells to IC50 for antiviral activity against HIV1 92/BR/018 infected in human TZM-bl cells	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.
AID1763903	Antiviral activity against HIV-1 IIIB harboring RT F227L/V106A mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
AID405412	Antiviral activity against PERV infected in human 293T cells assessed as inhibition of proximal DNA synthesis after 24 hrs by RT-PCR	2007	Antimicrobial agents and chemotherapy, Jul, Volume: 51, Issue:7	Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates.
AID586906	Inhibition of BCRP activity	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID1822276	Antiviral activity against HIV-1 harboring RT L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID1460941	Antiviral activity against HIV-1 NL4-3 harboring reverse transcriptase K103N mutant infected in human MAGI-CCR5 cells assessed as reduction in viral infection after 48 hrs by fluorescence based beta-galactosidase reporter gene assay	2017	Bioorganic & medicinal chemistry, 12-01, Volume: 25, Issue:23	An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors.
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID197807	In vitro inhibition of HIV-1 reverse transcriptase	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]pi
AID508782	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase E138Q mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1390715	Resistance index, ratio of EC50 for HIV1 RES056 harboring K103N/Y181C double mutant infected in human MT4 cells to EC50 for wild-type HIV1 3B infected in human MT4 cells	2018	Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.
AID1761019	Antiviral activity against HIV-1 harboring reverse transcriptase F227L/V106A mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect measured after 5 days by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID247495	Inhibitory activity against HIV-1 mutant strain 100I	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID298061	Antiviral activity against HIV1 3B in human MT4 cells by XTT assay	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID632799	Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT4 cells assessed as inhibition of viral infection	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
AID1743618	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID105523	Inhibition of HIV-1(IIIB) variants (Ile100/Asn103) in HIV-1 MT-4 cells	1996	Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21	Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.
AID1191668	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenic effect	2015	Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5	Scaffold hopping: exploration of acetanilide-containing uracil analogues as potential NNRTIs.
AID482700	Cytotoxicity against human Jurkat A72 cells by MTT assay	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID247505	Inhibitory activity against HIV-1 mutant strain 227C	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID622049	Inhibition of DNA-dependent DNA polymerase activity of HIV1 reverse transcriptase p66/p66 homodimer Y181C mutant using activated DNA and [alpha-32P]dATP after 30 mins by liquid scintillation counting	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID1811036	Anti-viral activity against HIV1 harboring RT Y181C mutant infected MV4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
AID281486	Cytotoxicity against MT4 cells after 4 days by MTT method	2007	Journal of medicinal chemistry, Apr-19, Volume: 50, Issue:8	Synthesis and anti-HIV-1 activity evaluation of 5-alkyl-2-alkylthio-6-(arylcarbonyl or alpha-cyanoarylmethyl)-3,4-dihydropyrimidin-4(3H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID492278	Antiviral activity against HIV1 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID1435514	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 expressing reverse transcriptase Y181C mutant
AID1141975	Inhibition of HIV1 wild-type reverse transcriptase using [3H]dTTP by scintillation counting	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1163253	Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID105866	Compound was tested for potency to achieve protection of MT-4 cells from LAI strain of HIV-1 virus	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).
AID1636147	Antiviral activity against NNRTI resistant HIV1 harboring reverse transcriptase V106I/Y181C/G190A/H221Y mutant assessed as inhibition of viral infection in human TZM-bl cells after 48 hrs by luciferase reporter gene assay	2016	Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15	Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
AID366531	Inhibition of RNA dependent DNA polymerase activity of HIV1 reverse transcriptase L100I mutant	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID1335217	Inhibition of wild-type HIV-1 reverse transcriptase RNA-dependent DNA polymerase activity assessed as reduction in digoxigenin-11-dUTP incorporation using poly(rA)/oligo(dT) as template/primer incubated for 1 hr	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID556526	Antiviral activity against Human immunodeficiency virus 1 clone Q9016 harboring K122E, Q145M, I202V, F214L mutation in reverse transcriptase by phenosense assay relative to wild type	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
AID523480	Antiviral activity against HIV1 with RT connection domain G190S/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID1763906	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
AID269688	Antiviral activity against HIV1 NNTRI resistant K103N mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269688	Antiviral activity against HIV1 NNTRI resistant K103N mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269688	Antiviral activity against HIV1 NNTRI resistant K103N mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1784209	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Discovery, optimization, and target identification of novel coumarin derivatives as HIV-1 reverse transcriptase-associated ribonuclease H inhibitors.
AID1249716	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 4 days by MTT assay	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID199993	Effective concentration required against L100I mutant HIV-1 reverse transcriptase (as per ref 6 in the article)	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.
AID1316340	Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID622053	Ratio of Ki for HIV1 RT p66/p66 homodimer L100I mutant to Ki for wild-type HIV1 RT p66/p66 homodimer	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID198910	In vitro inhibitory activity against HIV-1 wild type reverse transcriptase (RT)	1999	Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21	Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: further structure-activity relationship studies and identification of more potent broad-spectrum HIV-1 RT inhibitors with antiviral activity.
AID586911	Induction of SLCO1B1 activity	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID105326	Inhibition of HIV-1 (IIIB) induced cytopathicity in MT-4 cells.	2004	Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15	Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID105862	Compound was tested for potency to achieve protection of MT-4 cells from 181C strain of HIV-1 virus	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).
AID298090	Inhibition of HIV1 RT L100I mutant	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID440083	Antiviral activity against HIV1 HXB2 harboring 227C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID508637	Antiviral activity against Human immunodeficiency virus 1 subtype D infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID96296	Compound was evaluated for antiviral activity against L100I mutant virus; ND is Not Determined.	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID1316803	Antiviral activity against HIV-1 3B infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Synthesis of arylated coumarins by Suzuki-Miyaura cross-coupling. Reactions and anti-HIV activity.
AID726439	Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4	Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.
AID482694	Antiviral activity against HIV2 ROD infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID235264	Selectivity index is ratio of CC50 to that of EC50	2000	Bioorganic & medicinal chemistry letters, Feb-07, Volume: 10, Issue:3	1-[2-(Diphenylmethoxy)ethyl]-2-methyl-5-nitroimidazole: a potent lead for the design of novel NNRTIs.
AID1773454	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring Y188L mutant infected in human MT4 cells
AID253494	Dose required to inhibit HIV-1 reverse transcriptase activity (Y188L mutant) by 50%	2005	Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13	Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure-activity relationship investigation.
AID508789	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K103S mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1687686	Cytotoxicity against human MT4 cells assessed as inhibition of cell viability by measuring reduction in absorbance at OD540 by MTT assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
AID1157586	Antiviral activity against MDR-resistant HIV1 harboring 41L, 74V, 106A, 215Y mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID583847	Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase V108I, E138K mutant infected in human SupT1 cells derived from 9 viral passages with lersivirine assessed as inhibition of viral replication after 21 days relative to drug sensitive HIV	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID371903	Antiviral activity against HIV1 NL4-3 with L100I/V108I double mutant in human TZM-b1 cells assessed as beta-galactosidase activity after 48 hrs by single round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID1594864	Oral bioavailability in human	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
AID302250	Selectivity index, ratio of CC50 for MT4 cells to EC50 for HIV1 NL43 infected MT4 cells	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID508798	Ratio of EC50 for HIV1 in presence of 50% human serum to EC50 for HIV1 in absence of serum proteins by GFP assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1157584	Antiviral activity against A17-sensitive HIV1 harboring 103N, 181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID252955	Ratio of CC50 and EC50 against wild type human immunodeficiency virus type 1 LAI strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID717260	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity by MTT assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
AID1880379	Antiviral activity against HIV-1 IIIB harboring reverse transcriptase Y188L mutant infected in human MT4 cells by MTT assay	2022	Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12	Structure-Based Discovery of Novel NH
AID1228735	Antiviral activity against HIV1-3B infected in human MT4 cells assessed as inhibition of virus induced cell death measured after 5 days of infection by MTT assay	2015	Journal of natural products, May-22, Volume: 78, Issue:5	Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata.
AID525108	Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID1141965	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1537495	Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 48 hrs by CellTiter 96 aqueous one solution assay	2019	ACS medicinal chemistry letters, Feb-14, Volume: 10, Issue:2	Aryl Substituted Benzimidazolones as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.
AID1731750	Inhibition of reverse transcriptase E138K mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID198410	Tested for the inhibition of mutant type (Ile100) HIV-1 (IIIB) RT	1996	Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21	Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.
AID279468	Antiviral activity against HIV1 isolate with RT 98G, 108I, 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID246393	Effective concentration against human immunodeficiency virus type 1 mutated at 103N+181C	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID557023	Antiviral activity against HIV1 clade A harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID198396	Inhibitory activity against HIV-1 reverse transcriptase (HIV-RT)	1993	Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17	Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2,3-dihydrothiazolo[2,3-a]isoindol-5(9bH)-ones and related compounds with anti-HIV-1 activity.
AID1456306	Inhibition of HIV-1 3B wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8	Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR.
AID508776	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V179T mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID518739	Selectivity ratio of IC50 for DNA-dependent DNA polymerase activity of HIV1 subtype B reverse transcriptase M230L mutant to IC50 for DNA-dependent DNA polymerase activity of wild type HIV1 subtype B reverse transcriptase	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
AID293555	Antiviral activity against wild type HIV1 LAI infected in MT4 cells by EGFP based replication assay	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID586324	Inhibition of HIV1 3B reverse transcriptase activity	2011	Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6	Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID1141973	Ratio of EC50 for HIV1 harboring reverse transcriptase L1001 mutant to EC50 for wild type HIV1 NL4.3	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID82604	The effect of protein binding on the antiviral activity versus wild type virus strain HXB2 was tested in the presence of both acid glycoprotein and human serum in HeLa MAGI assay	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1357805	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring reverse transcriptase F227L/V106A mutant	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID1446812	Antiviral activity against HIV-2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID1636930	Antiviral activity against HIV1 3B harboring reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as protection against viral infection by MTT method	2016	Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20	Computer-aided discovery of anti-HIV agents.
AID1736362	Selectivity index, ratio of EC50 for antiviral activity against VSVG/HIV-1 harboring reverse transcriptase K103N mutant infected in human HEK 293T cells to EC50 for antiviral activity against VSVG/wild type HIV-1 infected in human HEK293T cells
AID1228737	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1-3B	2015	Journal of natural products, May-22, Volume: 78, Issue:5	Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata.
AID1217710	Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID82469	Antiviral activity against V106A/Y181C strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID279479	Antiviral activity against HIV1 isolate with RT 179D, 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1784212	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Discovery, optimization, and target identification of novel coumarin derivatives as HIV-1 reverse transcriptase-associated ribonuclease H inhibitors.
AID1171593	Inhibition of wild type HIV1 reverse transcriptase assessed as reduction in enzyme activity	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID389379	Cytotoxicity against human MT4 cells	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1435525	Inhibition of recombinant wild type HIV1 reverse transcriptase using poly (A).oligo (dT)15 as template/primer assessed as decrease in biotin-dUTP incorporation after 1 hr by ELISA
AID44798	In vitro concentration required to reduce the amount of p24 by 90% in WTIIIB infected C8166 cells	2004	Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15	Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID269687	Antiviral activity against HIV1 NNTRI resistant Y181C mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269687	Antiviral activity against HIV1 NNTRI resistant Y181C mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269687	Antiviral activity against HIV1 NNTRI resistant Y181C mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID257167	Antiviral activity against HIV1 IRLL98 mutant strain infected MT4 cells by MTT method	2005	Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25	Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.
AID235708	Selectivity index measured as the ratio of CC50 / EC50.	1999	Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4	5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives.
AID82464	Antiviral activity against K103N/Y181C strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID757622	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2013	European journal of medicinal chemistry, Jul, Volume: 65	Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1485965	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID83551	Potency evaluated against NNRTI-Resistant HIV-1 strain Tyr181Cys	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 varian
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1391082	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
AID1705187	Antiviral activity against HIV1 harboring RT Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID1741396	Inhibition of reverse transcriptase Y188L mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID242545	Fold increase in inhibitory concentration against HIV 1 reverse transcriptase mutant type Ile100 over wild type HIV 1 reverse transcriptase	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
AID482701	Selectivity index, ratio of CC50 for human Jurkat A72 cells to EC50 for HIV1 3B	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID767497	Cytotoxicity against human MT2 cells assessed as growth inhibition	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.
AID1186689	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV-1 RES056 harboring RT K103N/Y181C double mutant infected in human MT4 cells	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach.
AID496627	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase E138A/K32R, V35E, T39S, S48T, V60I, D121Y, K122E, I135T, S162A, K173A, Q174K, D177E, V179I, T200E, Q207D, R211K mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID522577	Resistance index, ratio of EC50 for recombinant HIV1 harboring reverse transcriptase V106I mutant clone to EC50 for wild type HIV1	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID482697	Antiviral activity against HIV S056 infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID199994	Effective concentration required against L100I mutant HIV-1 reverse transcriptase (as per ref 7 in the article)	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.
AID1217707	Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1267609	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Design and Synthesis of DiselenoBisBenzamides (DISeBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity.
AID79121	Inhibitory activity against multidrug resistant HIV-1 strain RT-MDR	2000	Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18	Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID105715	Antiviral activity against HIV-1 resistant to 2-(2-Benzoyl-4-chloro-phenyl)-N-[4-(3-dimethylamino-propoxy)-2-methyl-phenyl]-acetamide in MT-4 cells	1995	Journal of medicinal chemistry, May-12, Volume: 38, Issue:10	Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
AID105704	Anti-HIV-1 activity against Y181C strain, in MT-4 cells by the MTT method	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID297139	Antiviral activity against HIV1 with RT K101E mutation by cytopathic cell killing assay	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme.
AID360710	Inhibition of HIV1 RT Y181C mutant mediated DNA-dependent DNA polymerization using RNA PPT primed substrate by scintillation proximity assay	2007	The Journal of biological chemistry, Mar-16, Volume: 282, Issue:11	HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.
AID373387	Antiviral activity against 0.1 MOI HIV1 3B infected in human TZM-b1 cells assessed as inhibition of viral replication at 0.18 uM after 24 hrs by luciferase assay	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID522376	Resistance index, ratio of EC50 for recombinant HIV1 harboring reverse transcriptase V179D mutant clone to EC50 for wild type HIV1	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID1685254	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	ACS medicinal chemistry letters, Feb-11, Volume: 12, Issue:2	Covalent Inhibition of Wild-Type HIV-1 Reverse Transcriptase Using a Fluorosulfate Warhead.
AID1171592	Resistance index, ratio of EC50 for HIV1 NL4-3 expressing reverse transcriptase K103N-Y181C mutant to EC50 for wild type HIV1 NL4-3	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1574389	Resistance index, ratio of ID50 for recombinant HIV-1 His-tagged reverse transcriptase p66/p51 Y181I mutant to ID50 for recombinant wild type HIV-1 reverse transcriptase His-tagged p66/p51	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID246203	Concentration required to achieve 50% protection of infected MT-4 cells from Y181C-HIV-1 strain	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID1741393	Inhibition of reverse transcriptase L100I mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID1141967	Antiviral activity against HIV1 harboring reverse transcriptase L1001 mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID279481	Antiviral activity against HIV1 isolate with RT 101E mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1741399	Inhibition of reverse transcriptase RES056 mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID650695	Ratio of ID50 for HIV 1 reverse transcriptase L100I mutant to ID50 for wild type HIV 1 NL4-3 reverse transcriptase	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID1244340	Anti-trichomonas activity against MTZ-susceptible Trichomonas vaginalis incubated for 3 to 48 hrs by trypan blue exclusion assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	N-Alkyl/aryl-4-(3-substituted-3-phenylpropyl)piperazine-1-carbothioamide as dual-action vaginal microbicides with reverse transcriptase inhibition.
AID557021	Antiviral activity against HIV1 CRF02_AG harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID573482	Fold resistance, ratio of EC50 for Human immunodeficiency virus 1 isolate 9225 harboring A98S, G190A mutation in reverse transcriptase to wild-type	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID366529	Inhibition of RNA dependent DNA polymerase activity of HIV1 reverse transcriptase Y181I mutant	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID1275543	Antiviral activity against HIV1 RES056 expressing reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
AID235859	CC50/EC50 ratio of the compound	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID391686	Antiviral activity against HIV1 infected in human 293T cells	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.
AID678721	Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1231485	Antiviral activity against wild-type HIV1 3B infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action.
AID360709	Inhibition of HIV1 RT Y181C mutant mediated DNA-dependent DNA polymerization using RNA/DNAM duplex primed substrate by scintillation proximity assay	2007	The Journal of biological chemistry, Mar-16, Volume: 282, Issue:11	HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.
AID557050	Antiviral activity against HIV1 clade H harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID663308	Inhibition of HIV1 recombinant reverse transcriptase Y181I mutant assessed as [3H]dTTP incorporation into poly(rA)/oligo(dT)	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID630787	Antiviral activity against X4 tropic Human immunodeficiency virus 1 subtype B-3B infected in human TZM-bl cells assessed as inhibition of virus-induced cytopathic effect after 2 days by luciferase assay	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID297143	Antiviral activity against HIV1 with RT Y188C mutation by cytopathic cell killing assay	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme.
AID522370	Antiviral activity against recombinant HIV1 harboring reverse transcriptase V106I mutant clone infected in MAGIC-5 cells using 5-bromo4-chloro-3-indolyl-beta-D-galactopyranoside staining based light microscopy	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1316804	Antiviral activity against HIV-2 ROD infected in human MT-4 cells assessed as protection against virus induced cytopathic effect after 5 days by MTT assay	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Synthesis of arylated coumarins by Suzuki-Miyaura cross-coupling. Reactions and anti-HIV activity.
AID619637	Antiviral activity against HIV-1 3B harboring RT Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID366522	Antiviral activity against HIV1 isolates with reverse transcriptase Y181C mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID1141960	Antiviral activity against HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID246519	Effective concentration against human immunodeficiency virus type 1 mutated at 227L+106A; ND:Not determined	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID1217708	Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1815382	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID298081	Selectivity index, ratio of TC50 for lymphocytes to ED50 for HIV1 3B	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID1731753	Inhibition of HIV-1 reverse transcriptase assessed as inhibition of biotin-dUTP incorporation into wild type RT measured after 1 hr by ELISA
AID235503	Selectivity index calculated as the ratio between CC50 and EC50	1995	Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17	Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzyloxopyrimidines.
AID1249707	Antiviral activity against wild-type HIV-1 infected in human MT4 cells	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif.
AID1435508	Antiviral activity against HIV1 expressing reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
AID1520061	Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells to EC50 for antiviral activity against HIV1 3B harbouring NNRTI K103N mutant infected in human MT4 cells	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID82468	Antiviral activity against V106A strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1200844	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
AID279461	Antiviral activity against HIV1 isolate with RT 179D, 188L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID635346	Cytotoxicity against human MT4 cells measured by MTT assay	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.
AID1228840	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 3 to 4 days by MTT assay	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Limonoids with Anti-HIV Activity from Cipadessa cinerascens.
AID1743621	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID499279	Selectivity index, ratio of CC50 for human MT4 cells to IC50 for HIV2 ROD	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Anti-HIV and antiplasmodial activity of original flavonoid derivatives.
AID592681	Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	QSAR-based permeability model for drug-like compounds.
AID499275	Cytotoxicity against human MT4 cells after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Anti-HIV and antiplasmodial activity of original flavonoid derivatives.
AID1157594	Antiviral activity against TMC120-resistant HIV1 harboring RT 100I, 138G mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID698298	Selectivity index, ratio of EC50 for HIV1 containing reverse transcriptase K103N mutant to EC50 for wild type HIV1 NL4-3	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1435506	Antiviral activity against HIV1 expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
AID368569	Inhibition of HIV1 recombinant reverse transcriptase K103N mutant-DNA-dNTP ternary complex expressed in Escherichia coli BL21	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1320866	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 3B expressing wild type reverse transcriptase	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
AID1171579	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1485971	Inhibition of HIV-1 reverse transcriptase V106A mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID1152248	Selectivity index, ratio of CC50 for human TZM-bl cells to EC50 for R5 tropic Human immunodeficiency virus 1 VB59 subtype C	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID736443	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	2013	Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID649827	Cytotoxicity against human CEMx174 cells	2012	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5	Discovery of 3,4-dihydropyrimidin-2(1H)-ones with inhibitory activity against HIV-1 replication.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID279460	Antiviral activity against HIV1 isolate with RT 103N, 108I, 181C, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID348905	Antiviral activity against drug-resistant HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as virus-induced cell death by MTT method	2008	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21	Towards novel S-DABOC inhibitors: synthesis, biological investigation, and molecular modeling studies.
AID152788	Tested for the ability to inhibit the replication of HIV-1 strain HTLV IIIB in human peripheral blood mononuclear cells (PBMC)	2001	Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4	Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds.
AID1322998	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells.
AID1377175	Antiviral activity against NNRTI-resistant HIV1 isolate N119 infected in PHA-stimulated human PBMC assessed as reduction in p24 level after 7 days by ELISA	2017	Journal of natural products, 06-23, Volume: 80, Issue:6	Potent Inhibitor of Drug-Resistant HIV-1 Strains Identified from the Medicinal Plant Justicia gendarussa.
AID370727	Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 Y181I mutant expressed in Escherichia coli JM109	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
AID269802	Antiviral activity against HIV1 Y188L mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269802	Antiviral activity against HIV1 Y188L mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269802	Antiviral activity against HIV1 Y188L mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID630955	Antiviral activity against R5 tropic Human immunodeficiency virus 1 subtype C-VB59 infected in human TZM-bl cells assessed as inhibition of virus-induced cytopathic effect after 2 days by luciferase assay	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID248492	In vitro inhibitory concentration against HIV K101E and K103N mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID1572521	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells
AID608390	Inhibition of HIV1 reverse transcriptase assessed as residual enzyme activity at 50 uM after 1 hr by ELISA	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Imidazo[1,2-a]pyridin-3-amines as potential HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID508751	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase Y181C, F227C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1884489	Antiviral activity against drug-resistant HIV-1 L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID197792	Compound was tested for Inhibition of HIV-1 RT activity.	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity.
AID430056	Cytotoxicity against human MT4 cells after 5 days	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Design, synthesis, and structure-activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents.
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID199999	Effective concentration required against wild type HIV-1 reverse transcriptase (as per ref 7 in the article)	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.
AID106777	Compound was evaluated for antiviral activity in MT-4 cells. Cell culture inhibitor concentration (CIC95) is defined as concentration which inhibited >95% the spread of HIV-1 IIIb infection in susceptible cell culture	1992	Journal of medicinal chemistry, Oct-16, Volume: 35, Issue:21	Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 2. Analogues of 3-aminopyridin-2(1H)-one.
AID198400	Tested for inhibitory concentration on HIV-1 Reverse transcriptase in the presence of poly(c)-oligo-(dG)	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Synthesis and antiviral activity of 4-benzyl pyridinone derivatives as potent and selective non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors.
AID1460944	Therapeutic index, ratio of TC50 for human MAGI-CCR5 cells to IC50 for HIV-1 NL4-3 harboring reverse transcriptase K103N mutant infected in MAGI-CCR5 cells	2017	Bioorganic & medicinal chemistry, 12-01, Volume: 25, Issue:23	An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors.
AID299024	Cytotoxicity against MT4 cells assessed as reduction of cell viability	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
AID1705188	Antiviral activity against HIV1 harboring RT Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID619632	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 3B infected in human MT4 cells	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID496615	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase V90I/V35T, K64R, K102Q, D123E, S162A, K173T, Q174K, D177E, G196E,T200A, Q207E, R211K mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID279410	Antiviral activity against HIV1 isolate with RT 179E mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID104785	Cytotoxic concentration based on the reduction of viability of mock-infected cells	1995	Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12	Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors.
AID248256	In vitro inhibitory concentration against HIV F227C mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID561941	Antibacterial activity against Haemophilus influenzae ATCC 4927 after 18 to 24 hrs by agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Lack of antimicrobial activity by the antiretroviral drug nevirapine against common bacterial pathogens.
AID1687681	Antiviral activity against HIV-1 K103N mutant strain infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
AID1460938	Therapeutic index, ratio of TC50 for human MAGI-CCR5 cells to IC50 for HIV-1 NL4-3 infected in MAGI-CCR5 cells	2017	Bioorganic & medicinal chemistry, 12-01, Volume: 25, Issue:23	An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors.
AID523483	Antiviral activity against HIV1 with RT connection domain L100I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID1811046	Selectivity index, ratio of CC50 for mock infected human MT4 cells to IC50 for HIV1 IIIB infected human MT4 cells	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
AID496617	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase V90I/V35T, E36D, T39K, I50V, V60I, S68G, I135V, S162A, K173V, Q174K,D177E, T200A, E203Q, Q207D, R211K mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID1572522	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells
AID246517	Effective concentration against human immunodeficiency virus type 1 mutated at 100I+103N; ND:Not determined	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID279321	Inhibition of reverse transcriptase activity in HIV1 infected HeLa-MAGI cells at 37 deg C after 48 hrs	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Development of a new methodology for screening of human immunodeficiency virus type 1 microbicides based on real-time PCR quantification.
AID455986	Permeability across human Caco-2 cells	2009	Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19	Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID1357790	Antiviral activity against HIV1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID1156487	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
AID1609110	Inhibition of recombinant HIV-1 reverse transcriptase p66/p51 incubated for 40 mins by picogreen dye based spectrofluorometric assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1815381	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID1186684	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as protection from viral cytopathicity after 5 days by MTT assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach.
AID267645	Antiviral activity against wild type HIV1 virus	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID698302	Antiviral activity against HIV1 containing reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1357799	Resistance factor, ratio of EC50 for HIV1 harboring reverse transcriptase F227L/V106A mutant to EC50 for wild-type HIV-1 3B	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1304400	Antiviral activity against HIV-1 RF infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID476468	Cytotoxicity against human MT2 cells by MTT assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.
AID105571	Antiviral activity was determined against wild type HIV-1 in MT-4 cells infected with HIV-1 IIIB using an XTT assay	1998	Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12	Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1572525	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytotoxicity after 5 days by MTT assay
AID1171580	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 NL4-3 infected in human MT4 cells	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1435505	Antiviral activity against HIV1 expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay
AID1736150	Inhibition of recombinant HIV-1 subtype B BH10 p66/p51 reverse transcriptase heterodimer K103N mutant assessed as inhibition of dTTP incorporation on poly(rA)-oligo(dT) template primer duplex at 50 uM preincubated with enzyme for 2 mins followed by incuba	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Design, synthesis and biological evaluation of quinoxaline compounds as anti-HIV agents targeting reverse transcriptase enzyme.
AID1292365	Inhibition of recombinant HIV1 reverse transcriptase using 234-nt long RNA/18-mer DNA oligonucleotide as template/primer assessed as remaining activity at 50 uM preincubated for 15 mins followed by incubation with template/primer for 40 mins by liquid sci	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Design, discovery, modelling, synthesis, and biological evaluation of novel and small, low toxicity s-triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1141970	Ratio of EC50 for HIV1 harboring reverse transcriptase K103N mutant to EC50 for wild type HIV1 NL4.3	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1152371	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1156484	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
AID1249717	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID287006	Inhibition of reverse transcriptase binding to DNA assessed as formation of RT-DNA complex by gel mobility shift assay	2007	Journal of medicinal chemistry, May-17, Volume: 50, Issue:10	De novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variants.
AID1460933	Therapeutic index, ratio of TC50 for human PBMC to IC50 for HIV-1 Bal infected in human PBMC	2017	Bioorganic & medicinal chemistry, 12-01, Volume: 25, Issue:23	An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors.
AID391685	Antiviral activity against HIV1 infected in human CEM cells	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.
AID557037	Antiviral activity against HIV1 isolate R8 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs in presence of 50% human serum	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID242248	Concentration required for 50% inhibition of human immunodeficiency virus type 1 reverse transcriptase mutant type Cys181	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
AID666416	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for NNRTI-resistant HIV1 A17 expressing reverse transcriptase K103N and Y181C mutant	2012	Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5	Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.
AID632795	Antiviral activity against Human immunodeficiency virus 1 NL4.3 infected in human MT2 cells assessed as inhibition of viral infection	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
AID586907	Induction of ABCB1 activity	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID297138	Antiviral activity against HIV1 with RT L100I mutation by cytopathic cell killing assay	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme.
AID508653	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K103N, V179I, Y181C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID246300	Effective concentration of the compound to inhibit HIV-1 mutant Y181C replication in HIV-infected MT-4 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID105863	Compound was tested for potency to achieve protection of MT-4 cells from 188L strain of HIV-1 virus	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).
AID1175435	Inhibition of HIV-1 recombinant reverse transcriptase after 1 hr by streptavidinalkaline phosphatase reporter system	2015	Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1	Synthesis and biological evaluation of pyridinone analogues as novel potent HIV-1 NNRTIs.
AID282736	Inhibition of HIV1 RT L100I mutant	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
AID1152243	Selectivity index, ratio of CC50 for human TZM-bl cells to EC50 for R5 tropic Human immunodeficiency virus 1 ADA5 subtype B	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1705191	Resistance index, ratio of EC50 for antiviral activity against HIV1 harboring RT Y181C mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 NL4-3 infected in human MT4 cells	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID665275	Selectivity index ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2012	European journal of medicinal chemistry, Jul, Volume: 53	Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID518734	Inhibition of RNA-dependent DNA polymerase activity of wild type HIV1 subtype B reverse transcriptase by filter-based filtration assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
AID105543	Inhibition of wild type HIV-1 in MT-4 cell culture (human T cell line)	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
AID586903	Activity at MRP3	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID1069710	Inhibition of GST-tagged recombinant wild type HIV-1 reverse transcriptase p66/p51 RNA-dependent DNA polymerase activity expressed in Escherichia coli JM109 using dTTP as substrate after 40 mins by spectrofluorometric analysis	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design and synthesis of N₁-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID457956	Antiviral activity against HIV1 3B infected in human MT4 cells assessed inhibition of viral-induced cytopathic effect after 5 days	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1231488	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action.
AID440081	Antiviral activity against HIV1 HXB2 harboring 190A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID717256	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
AID155290	Inhibit the replication of the HIV-1 strain HTLV111B in human peripheral blood mononuclear cell	2000	Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18	Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID235701	Selectivity index is the ratio of CC50 and EC50 in MT-4 cells.	1995	Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12	Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors.
AID440082	Antiviral activity against HIV1 HXB2 harboring 190S mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID572181	Antiviral activity against HIV-1 SM007 harboring NNTRI 103N mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID591001	Antiviral activity against HIV1 Env-pseudovirus infected in human Jurkat E6-1 cells after 2 days by luciferase assay	2011	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8	Asymmetric total synthesis of (+)- and (-)-clusianone and (+)- and (-)-clusianone methyl enol ether via ACC alkylation and evaluation of their anti-HIV activity.
AID279409	Antiviral activity against HIV1 isolate with RT 101P, 103N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1773448	Antiviral activity against wild type HIV1 harboring Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenic effect by MTT assay
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1822279	Antiviral activity against HIV-1 harboring Y188L mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID491828	Antiviral activity against HIV1 with reverse transcriptase A17 (K103N, Y181C) mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	2010	Journal of medicinal chemistry, Jul-08, Volume: 53, Issue:13	Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1736360	Antiviral activity against VSVG/HIV-1 harboring reverse transcriptase G190A/K103N double mutant infected in human HEK 293T cells assessed as inhibition of virus replication preincubated with cells for 15 mins prior to viral infection and measured at 48 hr
AID351451	Hydrolytic stability in rat plasma assessed as half life by electrospray ionization mass spectrometry	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Synthesis of alkenyldiarylmethanes (ADAMs) containing benzo[d]isoxazole and oxazolidin-2-one rings, a new series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1729163	Inhibition of HIV1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation into template incubated for 1 hr by ELISA	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID1761016	Antiviral activity against HIV-1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect measured after 5 days by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID561943	Antibacterial activity against Staphylococcus aureus ATCC 29213 after 18 to 24 hrs by agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Lack of antimicrobial activity by the antiretroviral drug nevirapine against common bacterial pathogens.
AID1888697	Antiviral activity against HIV1 with RT Y188L mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay
AID1320869	Inhibition of recombinant wild type HIV1 p66/p51 using poly(rA) template/oligo(dT)16 primer after 40 mins by PicoGreen-based spectrofluorometric method	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
AID1884493	Antiviral activity against drug-resistant HIV-1 E138K mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID1565098	Antiviral activity against drug resistant HIV-1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID373571	Antiviral activity against 0.1 MOI HIV1 3B in 24 hrs pretreated human TZM-b1 cells infected 48 hrs post drug removal assessed as inhibition of viral replication at 0.04 to 0.18 uM measured 24 hrs postinfection by luciferase assay	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID496623	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase E138A/G18V, Q23P, V35T, E40D, V60I, S68G, D123E, I135V, S162A, K173T, Q174N, T200A, Q207E, R211K, F214L mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID496626	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase E138A/K22N, V35T, T39A, K122E, I135V, T139A, S162A, K173T, Q174A, D177E, T200A, Q207E, R211K, F214L mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID1456311	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 3B wild type reverse transcriptase infected in human MT4 cells	2017	Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8	Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR.
AID267650	Antiviral activity against HIV1 K103N/L100I mutant	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID482693	Antiviral activity against HIV1 3B infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID198758	Percent inhibitory activity against wild type (WT) HIV type I reverse transcriptase at a concentration of 1 uM	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 5. 4-Substituted and 2,4-disubstituted analogs of nevirapine.
AID371908	Antiviral activity against HIV1 NL4-3 with V108I mutant in human TZM-b1 cells assessed as beta-galactosidase activity after 48 hrs by single round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID82475	Antiviral activity against Y188C strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID525102	Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID81597	Inhibitory activity against NNI-resistant HIV-1 strain A17 with Y181C,K103N mutation	2000	Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18	Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID88384	Antiviral activity against wild-type HIV-1 in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID279404	Antiviral activity against HIV1 isolate with RT 103N, 181C, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1352321	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103 N/Y181C double mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 4 days by MTT assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID302270	Resistance index, ratio of Ki for HIV1 reverse transcriptase Y181I mutant to Ki for wild type HIV1 3B reverse transcriptase	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID1165078	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
AID1335210	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/G190A double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID368565	Inhibition of wild type HIV1 reverse transcriptase-DNA binary complex	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID622056	Ratio of Ki for HIV1 RT p66/p66 homodimer Y188L mutant to Ki for wild-type HIV1 RT p66/p66 homodimer	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID1741391	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID492045	Cytotoxicity against human MT4 cells after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13	Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors.
AID1558858	Inhibition of recombinant wild type HIV1 reverse transcriptase p66/p51 incubated for 40 mins by picogreen dye-based spectrofluorometric analysis	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
AID267858	Antiviral activity against HIV1 Y188L mutant in MT4 cells by MTT assay	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
AID1175437	Cytotoxicity against human TZM-bl cells after 3 days by XTT assay	2015	Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1	Synthesis and biological evaluation of pyridinone analogues as novel potent HIV-1 NNRTIs.
AID197799	Compound was tested for inhibitory activity against HIV-1 mutant type reverse transcriptase (Y181C)	1998	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16	A dipyrido [2,3-b:3',2'-f]azepine analog of the HIV-1 reverse transcriptase inhibitor nevirapine.
AID279446	Antiviral activity against HIV1 isolate with RT 101Q, 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1637387	Inhibition of HIV-1 reverse transcriptase assessed as reduction in biotin-duTP incorporation using biotin-labeled dUTP and hybrid poly(A)-oligo (dT)15 template primer after 2 hrs by ELISA	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID525104	Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID491834	Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	2010	Journal of medicinal chemistry, Jul-08, Volume: 53, Issue:13	Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID573476	Antiviral activity of wild-type Human immunodeficiency virus 1 isolate 5512 by cell based assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1077219	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach.
AID572176	Antiviral activity against HIV-1 subtype H V022827 harboring NNRTI V179I mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1380572	Resistance index, ratio of IC50 for antiviral activity against HIV1 virions containing reverse transcriptase Y181C mutant derived from HIV/VSG-G or HIV/HA virions infected 293T cells using human A549 cells as target cells to IC50 for antiviral activity ag	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and biological evaluation of substituted (+)-SG-1 derivatives as novel anti-HIV agents.
AID1391076	Inhibition of wild type HIV1 reverse transcriptase using poly (A)/oligo (dT)15 as template/primer assessed as decrease in biotin-dUTP incorporation after 1 hr by ELISA	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
AID492285	Antiviral activity against HIV1 with reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID1335209	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/V108I double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID259754	Antiviral activity against wild-type HIV1 in MT2 cells by MTT assay	2006	Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3	Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1761006	Antiviral activity against wild type HIV1 NL4-3 infected in human TZM-bl cells assessed as reduction in viral infection measured after 1 day by luciferase reporter gene assay based luminiscence assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID279406	Antiviral activity against HIV1 isolate with RT 103N, 238T mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1171591	Resistance index, ratio of EC50 for HIV1 NL4-3 expressing reverse transcriptase L100I mutant to EC50 for wild type HIV1 NL4-3	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1884538	Fold resistance, ratio of EC50 for antiviral activity against drug-resistant HIV-1 L100I mutant infected in human MT4 cells to EC50 for antiviral activity against NNRTI resistant wild type HIV-1 infected in human MT4 cells	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID1736348	Antiviral activity against VSVG/HIV-1 harboring reverse transcriptase K103N mutant infected in human HEK 293T cells assessed as inhibition of virus replication preincubated with cells for 15 mins prior to viral infection and measured at 48 hrs post-infect
AID248491	In vitro inhibitory concentration against HIV F227L and V106A mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID734266	Antiviral activity against Human immunodeficiency virus 1 SF33 infected in human TZM-bl cells assessed decrease in p24 level after 7 days by ELISA	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID82608	The effect of protein binding on the antiviral activity versus wild type virus strain K103N was tested in the presence of human serum in HeLa MAGI assay	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1773456	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring F227L/V106A double mutant infected in human MT4 cells
AID1687680	Antiviral activity against wild type HIV-1 strain 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
AID1126510	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to IC50 for HIV1 3B infected in human MT4 cells	2014	Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8	Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1627029	Inhibition of HIV1 RT using 17-mer DNA/Alexa Fluor 488 5'-end labeled DNA/Alexa Fluor 555-aha-dUTP as primer/template/substrate preincubated for 10 mins followed substarte addition measured after 30 mins by FRET assay	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID267854	Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
AID282739	Inhibition of HIV1 RT Y181I mutant	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity.
AID1379961	Antiviral activity against HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by measuring virus-induced syncytium formation by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.
AID391684	Antiviral activity against HIV1 infected in human MT4 cells	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.
AID198075	Inhibitory activity against HIV-1 Mutant Reverse transcriptase K103N	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 7. 8-Arylethyldipyridodiazepinones as potent broad-spectrum inhibitors of wild-type and mutant enzymes.
AID200150	Activity of selected HIV-1 N-acylthiocarbamates in enzyme assay against Virion-Associated reverse transcriptase	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Design, synthesis, SAR, and molecular modeling studies of acylthiocarbamates: a novel series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors structurally related to phenethylthiazolylthiourea derivatives.
AID1163231	Antitrypanocidal activity against suramin-sensitive Trypanosoma brucei rhodesiense STIB-900 assessed as reduction in parasite growth after 72 hrs	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID94313	Antiviral activity toward K103N mutant HIV-1 virus as protein binding adjusted (PB adj).	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID230127	Tested for the ratio between CC50 (MT-4) to EC50 (MT-4)	1994	Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24	1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole 2",2"-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID621981	Resistance index, ratio of EC50 for HIV1 3B expressing reverse transcriptase K103N/Y181C double mutant to EC50 for wild-type HIV1 3B	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID1373162	Inhibition of reverse transcriptase F227L/V106A double mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID1155810	Fold resistance, ratio of EC50 for HIV-1 harboring NNTRI-resistant reverse transcriptase K103N mutant infected in human MT4 cells to EC50 for wild type HIV-1 NL4-3 infected in human MT4 cells	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID1380574	Resistance index, ratio of IC50 for antiviral activity against HIV1 virions containing reverse transcriptase E138K/M184V mutant derived from HIV/VSG-G or HIV/HA virions infected 293T cells using human A549 cells as target cells to IC50 for antiviral activ	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and biological evaluation of substituted (+)-SG-1 derivatives as novel anti-HIV agents.
AID573479	Antiviral activity of Human immunodeficiency virus 1 isolate 9225 harboring A98S, G190A mutation in reverse transcriptase by cell based assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID1741392	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV IIIB	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID197946	In vitro inhibitory activity against human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT)	1991	Journal of medicinal chemistry, Jul, Volume: 34, Issue:7	Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones.
AID1773453	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring Y18IC mutant infected in human MT4 cells
AID779528	Antiviral activity against HIV-1 RESO56 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
AID508770	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase G190S mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID491833	Antiviral activity against HIV1 with reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	2010	Journal of medicinal chemistry, Jul-08, Volume: 53, Issue:13	Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID508651	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase L100I, V179I, Y181C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID525113	Antiviral activity against HIV 1 NL4.3 integrase E92Q mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID279395	Antiviral activity against HIV1 isolate with RT 101Q mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID368562	Cytotoxicity against human MT4 cells by MTT assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID1171596	Inhibition of wild type HIV1 reverse transcriptase L100I mutant assessed as reduction in enzyme activity	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID246348	Effective concentration against human immunodeficiency virus type 1 mutated at 100I	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID279441	Antiviral activity against HIV1 isolate with RT 101Q, 190S mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1249718	Antiviral activity against HIV1 expressing reverse transcriptase L100I mutant	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID663300	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 NL4-3	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID496624	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase E138A/A33E, V35T, T39A, D123E, S162A, Q174G, T200E, I202V, Q207E mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID279425	Antiviral activity against HIV1 isolate with RT 179G mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID81442	Inhibition of HIV-1 D34 replication in human peripheral blood mononuclear cells.	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]pi
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID625276	FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI	2011	Drug discovery today, Aug, Volume: 16, Issue:15-16	FDA-approved drug labeling for the study of drug-induced liver injury.
AID1743619	Antiviral activity against HIV1 RES056 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID197797	Compound was tested for inhibitory activity against HIV-1 mutant type reverse transcriptase (L1001)	1998	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16	A dipyrido [2,3-b:3',2'-f]azepine analog of the HIV-1 reverse transcriptase inhibitor nevirapine.
AID587751	Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as level of 2 mins magnetic nanopartials-medated infection in human HeLaT4 cells treated at 10	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID619642	Ratio of EC50 for HIV-1 3B harboring RT E138K mutant infected in human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID384955	Intrinsic aqueous solubility at pH 10 by shake-flask method	2008	Journal of medicinal chemistry, May-22, Volume: 51, Issue:10	Molecular characteristics for solid-state limited solubility.
AID1171583	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID525114	Antiviral activity against HIV 1 NL4.3 integrase S230N mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID279420	Antiviral activity against HIV1 isolate with RT 190S mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID508769	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase H221Y mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID368555	Inhibition of wild type HIV1 reverse transcriptase-mediated RNA-dependent DNA polymerase activity assessed as [3H]dTTP incorporation by cell free-based scintillation counting	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID106950	Anti-HIV-1 activity against Y181C HIV-1 strain in MT-4 cells	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID443750	Antiviral activity against 100 TCID50 HIV1 infected in human TZM-b1 cells assessed as inhibition of viral replication by pseudovirus based assay	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile.
AID1072804	Antiviral activity against HIV1 3B harboring wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2014	Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6	Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
AID1731745	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV IIIB
AID46385	Antiviral activity against site directed wild-type enzyme isolate HIV-1 NL4-3WT in CEM cells	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID685330	Antiviral activity against HIV-1 RES056 harboring RT K103N/Y181C mutant gene infected human MT4 cells assessed as inhibition in viral syncytium formation by MTT assay	2012	Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
AID1736365	Selectivity index, ratio of EC50 for antiviral activity against VSVG/HIV-1 harboring reverse transcriptase L100I/K103N double mutant infected in human HEK 293T cells to EC50 for antiviral activity against VSVG/wild type HIV-1 infected in human HEK293T cel
AID523481	Antiviral activity against HIV1 with RT connection domain G190S/T369I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID246189	Effective concentration against human immunodeficiency virus type 1 wild type	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
AID1773461	Resistance factor, ratio of EC50 for HIV1 harboring E138K mutant infected in human MT4 cells to EC50 for HIV1 3B infected in MT4 cells
AID1736344	Antiviral activity against VSVG/wild-type HIV-1 infected in human HEK 293T cells assessed as inhibition of virus replication preincubated with cells for 15 mins prior to viral infection and measured at 48 hrs post-infection by luciferase reporter gene ass
AID257169	Antiviral activity against HIV1 Y188L mutant strain infected MT4 cells by MTT method	2005	Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25	Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.
AID1191402	Cytotoxicity against human MT4 cells after 5 days MTT assay	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1275554	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV2 ROD infected in human MT4 cells	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
AID1654241	Toxicity in C57BL/6J mouse primary hepatocytes assessed as reduction in cell viability by measuring EtBr-positive cell nuclei level at 400 uM incubated for 8 hrs by EtBr/AcrO staining based assay (Rvb = 19%)	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death.
AID82607	The effect of protein binding on the antiviral activity versus wild type virus strain K103N was tested in the presence of both acid glycoprotein and human serum in HeLa MAGI assay	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID734271	Cytotoxicity against human TZM-bl cells	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID1335204	Ratio of IC50 for HIV-1 NL4-3 harboring RT-Y188L mutant infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein to IC50 for wild-type HIV-1 NL4-3 infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID508758	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K103N, Y181I mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1163233	Antiviral activity against HIV1 infected in human TZM-bl cells assessed as viral inhibition pre-incubated for 30 mins prior to infection measured after 48 hrs by	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID1520060	Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID508771	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase G190A mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID302260	Inhibition of HIV1 reverse transcriptase K103N mutant	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID1884224	Antiviral activity against HIV-1 harboring L100I mutant infected in human MT4 cells assessed as reduction in virus induced cytotoxicity incubated for 5 to 7 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID1249719	Antiviral activity against HIV1 expressing reverse transcriptase K103N mutant	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID1380571	Antiviral activity against HIV1 virions containing reverse transcriptase Y181C mutant derived from HIV/VSG-G or HIV/HA virions infected 293T cells using human A549 cells as target cells assessed as inhibition of viral replication using compound pre-mixed	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and biological evaluation of substituted (+)-SG-1 derivatives as novel anti-HIV agents.
AID82459	Antiviral activity against K103N strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1636927	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against viral infection by MTT method	2016	Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20	Computer-aided discovery of anti-HIV agents.
AID587742	Drug uptake in human HeLaT4 cells assessed as compound persist measured after 3 times washout at 100 time EC95 for HIV1 for 24 hrs	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID571987	Antiviral activity against HIV-1 subtype C V022831 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1880369	Inhibition of HIV-1 reverse transcriptase using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorometric analysis	2022	Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12	Structure-Based Discovery of Novel NH
AID1654220	Drug metabolism in human primary hepatocytes assessed as O-GlucNVP metabolite formation at 10 uM incubated for 24 hrs by uHPLC-MS analysis	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death.
AID302262	Inhibition of HIV1 reverse transcriptase V106A mutant	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1162233	Antiviral activity against HIV1	2014	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18	Novel indole based NNRTIs with improved potency against wild type and resistant HIV.
AID1654208	Drug metabolism in C57BL/6J mouse primary hepatocytes assessed as Cytochrome P450-mediated formation of 8-OHNVP at 10 uM incubated for 24 hrs by uHPLC-MS analysis	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death.
AID29811	Oral bioavailability in human	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	QSAR model for drug human oral bioavailability.
AID1141961	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 NL4.3 infected in human MT4 cells	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1373159	Inhibition of reverse transcriptase K103N mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID496632	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase V90I/V35T, T39L, K122E, D123N, S162A, E169T, K173E, Q174E, D177E,T200A, I202V, Q207E mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID1815391	Inhibition of HIV1 reverse transcriptase K103N/Y181C double mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID328846	Inhibition of human MRP1 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence at 10 uM by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID279408	Antiviral activity against HIV1 isolate with RT 101Q, 103N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1316343	Selectivity index, ratio of CC50 for human mock-infected MT4 cells to EC50 for HIV1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID246298	Effective concentration of the compound to inhibit HIV-1 mutant K103N replication in HIV-infected MT-4 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1435516	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 expressing reverse transcriptase E138K mutant
AID246780	Compound concentration required to reduce the amount of p24 by 90% in wtIIIBinfected C8166 cells	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID508762	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K101E, K103N mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID572189	Antiviral activity against HIV-1 SM058 harboring NNTRI 227L and 106A mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1380569	Antiviral activity against HIV1 virions containing reverse transcriptase K103N mutant derived from HIV/VSG-G or HIV/HA virions infected 293T cells using human A549 cells as target cells assessed as inhibition of viral replication using compound pre-mixed	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and biological evaluation of substituted (+)-SG-1 derivatives as novel anti-HIV agents.
AID266347	Inhibition of HIV1 reverse transcriptase Y181C mutant in 293T cells	2006	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11	New HIV-1 reverse transcriptase inhibitors based on a tricyclic benzothiophene scaffold: synthesis, resolution, and inhibitory activity.
AID630786	Inhibition of biotin-dNTP labeled HIV-1 reverse transcriptase using ABST as substrate at 100 ug/ml after 1 hr by ELISA	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID366519	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 NL4-3	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID1773458	Resistance factor, ratio of EC50 for HIV1 harboring K103N mutant infected in human MT4 cells to EC50 for HIV1 3B infected in MT4 cells
AID571974	Antiviral activity against HIV-1 subtype CRF01_AE V029521 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID344815	Antiviral activity against HIV1 NL4-3 infected in HEK293T cells assessed as inhibition of virion-associated p24 antigen production after 24 hrs by ELISA	2008	Bioorganic & medicinal chemistry, Nov-01, Volume: 16, Issue:21	Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action.
AID346971	Antiviral activity against HIV ROD in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Studies on anti-HIV quinolones: new insights on the C-6 position.
AID104772	Concentration required to reduce the viability of mock-infected MT-4 cells by 50%	1996	Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2	2-Sulfonyl-4-chloroanilino moiety: a potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones.
AID457957	Cytotoxicity in human MT4 cells assessed as reduction in cell viability	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1485969	Inhibition of HIV-1 reverse transcriptase L100I mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID197803	Inhibitory effect on wild type HIV- 1 reverse transcriptase using rCdG as template and dGTP as substrate.	1998	Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12	Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1637389	Antiviral activity against human HIV-1 3B harboring RES056 mutant infected in human MT4 cells assessed as protection from virus-induced cytopathic effect measured 5 days post infection by MTT assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID389378	Antiviral activity against HIV1 3B in human MT4 cells assessed as protection of cell against virus-induced cytopathogenicity	2008	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20	1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID766743	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1	2013	Bioorganic & medicinal chemistry, Sep-15, Volume: 21, Issue:18	Synthesis and evaluation of novel 3-(3,5-dimethylbenzyl)uracil analogs as potential anti-HIV-1 agents.
AID572170	Antiviral activity against HIV-1 subtype D V022818 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID322393	Cytotoxicity against human MT4 cells after 4 days by MTT assay	2008	Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1	Synthesis and anti-HIV evaluation of novel 1,3-disubstituted thieno[3,2-c][1,2,6]thiadiazin-4(3H)-one 2,2-dioxides(TTDDs).
AID492043	Inhibition of HIV1 reverse transcriptase	2010	Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13	Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors.
AID1248226	Antiviral activity against wild type HIV 2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20	A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities.
AID199980	Inhibitory activity against human immunodeficiency virus type 1 reverse transcriptase (HIV-1 RT)	2002	Journal of medicinal chemistry, Jul-04, Volume: 45, Issue:14	Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations.
AID518736	Selectivity ratio of IC50 for RNA-dependent DNA polymerase activity of HIV1 subtype B reverse transcriptase M230L mutant to IC50 for RNA-dependent DNA polymerase activity of wild type HIV1 subtype B reverse transcriptase	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
AID663313	Resistance ratio of ID50 for HIV1 reverse transcriptase Y181I mutant to ID50 HIV1 wild type reverse transcriptase	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID260238	Cytotoxicity against human MT2 cells by MTT assay	2006	Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3	Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1705185	Selectivity ratio of CC50 for human MT4 cells to EC50 for antiviral activity against HIV-1 NL4-3 infected in human MT4 cells	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID1743620	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID317731	Antiviral activity against HIV2ROD infected in human MT4 cells	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID1056586	Antiviral activity against wild-type HIV-1 infected in human 293T cells co-transfected with VSVG protein assessed as inhibition of viral-replication incubated 15 mins prior to viral-infection measured after 48 hrs by luciferase reporter gene assay	2013	Journal of natural products, Dec-27, Volume: 76, Issue:12	Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73.
AID1460932	Cytotoxicity against human PBMC assessed as reduction in cell viability by MTS assay	2017	Bioorganic & medicinal chemistry, 12-01, Volume: 25, Issue:23	An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors.
AID1228734	Cytotoxicity against human MT4 cells assessed as inhibition of cell metabolism after 72 hrs by MTS assay	2015	Journal of natural products, May-22, Volume: 78, Issue:5	Antiviral Activity of Flexibilane and Tigliane Diterpenoids from Stillingia lineata.
AID1815401	Inhibition of HIV1 reverse transcriptase E138K mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID1485970	Inhibition of HIV-1 reverse transcriptase K103N mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID1435515	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 expressing reverse transcriptase Y188L mutant
AID1156488	Selectivity index, ratio of CC50 for human MT4 cells to IC50 for wild type HIV1 3B	2014	European journal of medicinal chemistry, Jul-23, Volume: 82	Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors.
AID650688	Inhibition of HIV 1 reverse transcriptase L100I mutant assessed as inhibition of time-dependent incorporation of [3H]dTTP into poly(rA)n.oligo(dT)	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID492279	Cytotoxicity against human MT4 cells after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID279389	Antiviral activity against HIV1 isolate with RT 103N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID253332	Cytotoxic concentration against wild type human immunodeficiency virus type 1 LA1 strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID1304399	Inhibition of HIV-1 BH10 recombinant reverse transcriptase expressed in Escherichia coli assessed as incorporation of [32P]GTP into poly(rC)/oligo(dG) as template primer	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID1410483	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.
AID440087	Antiviral activity against HIV1 HXB2 harboring 227L and 106A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID1636148	Ratio of IC50 for NNRTI resistant HIV1 harboring reverse transcriptase A98G/K101E/Y181C/G190A mutant infected in human TZM-bl cells to IC50 for wild type HIV1 NL4-3 infected in human TZM-bl cells	2016	Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15	Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
AID396620	Cytotoxicity against human MT4 cells by MTT assay	2008	European journal of medicinal chemistry, Dec, Volume: 43, Issue:12	Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.
AID1298250	Inhibition of HIV1 reverse transcriptase p66/p51 V106A mutant using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID508760	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K103N, V108I mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID573467	Inhibition of Human immunodeficiency virus 1 subtype B reverse transcriptase G190A-81C mutant by filter-based filtration assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID104314	50% inhibitory concentration against HIV-1 rRT in MT-4 cells	2000	Journal of medicinal chemistry, May-04, Volume: 43, Issue:9	Structure-based design, synthesis, and biological evaluation of novel pyrrolyl aryl sulfones: HIV-1 non-nucleoside reverse transcriptase inhibitors active at nanomolar concentrations.
AID587740	Selectivity index, ratio of CC50 for human HeLa-T4 cells to EC50 for single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID1056573	Ratio of EC50 for HIV-1 expressing reverse transcriptase K103N/P225H double mutant to EC50 for wild-type HIV-1	2013	Journal of natural products, Dec-27, Volume: 76, Issue:12	Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73.
AID1705189	Antiviral activity against HIV1 harboring RT K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID361907	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase Y181C mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1741398	Inhibition of reverse transcriptase F227L and V106A mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID508648	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase L100I, K103N, T386A mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1784206	Antiviral activity against HIV1 RES056 infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Discovery, optimization, and target identification of novel coumarin derivatives as HIV-1 reverse transcriptase-associated ribonuclease H inhibitors.
AID1784211	Antiviral activity against HIV1 L1001 infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Discovery, optimization, and target identification of novel coumarin derivatives as HIV-1 reverse transcriptase-associated ribonuclease H inhibitors.
AID1731747	Inhibition of reverse transcriptase K103N mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID371910	Antiviral activity against HIV1 NL4-3 with K103N mutant in human TZM-b1 cells assessed as beta-galactosidase activity after 48 hrs by single round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID1654240	Drug metabolism in human liver microsomes assessed as Cytochrome P450-mediated formation of 2-OHNVP formation at 5 to 400 uM in presence of NADPH regenerating reagents by uHPLC-MS/MS analysis	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1200843	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
AID1188001	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands.
AID1267623	Antiviral activity against NNRTI-resistant HIV1 RES056 harboring reverse transcriptase K103N/181C double mutant infected in human MT4 cells	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Design and Synthesis of DiselenoBisBenzamides (DISeBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity.
AID1126506	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of viral cytopathogenicity after 5 days by MTT assay	2014	Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8	Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID199243	Inhibitory effect on recombinant HIV- 1 reverse transcriptase which has a mutation Tyr 181 to Cys 181 (clone 90)	1998	Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12	Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID492044	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13	Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors.
AID1152244	Inhibition of HIV reverse transcriptase at 100 ug/ml after 1 hr by ELISA relative to control	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1888702	Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT Y188L mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells
AID197782	Inhibition of HIV-1 reverse transcriptase.	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID757626	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2013	European journal of medicinal chemistry, Jul, Volume: 65	Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID523485	Antiviral activity against HIV1 with RT connection domain L100I/T369I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID693587	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 3B infected in human MT4 cells	2012	European journal of medicinal chemistry, Dec, Volume: 58	Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors.
AID561948	Antibacterial activity against Escherichia coli after 18 to 24 hrs by agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Lack of antimicrobial activity by the antiretroviral drug nevirapine against common bacterial pathogens.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1357801	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring reverse transcriptase K103N mutant	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID630954	Antiviral activity against X4 tropic Human immunodeficiency virus 1 subtype D-UG070 infected in human TZM-bl cells assessed as inhibition of virus-induced cytopathic effect after 2 days by luciferase assay	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1705192	Resistance index, ratio of EC50 for antiviral activity against HIV1 harboring RT Y188L mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 NL4-3 infected in human MT4 cells	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID198593	In vitro inhibition of HIV-1 reverse transcriptase at 100 uM	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]pi
AID199998	Effective concentration required against wild type HIV-1 reverse transcriptase (as per ref 6 in the article)	2001	Bioorganic & medicinal chemistry letters, Nov-05, Volume: 11, Issue:21	Antiviral drug design: computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs.
AID298060	Antiviral activity against HIV1 RF in human CEM-SS cells by XTT assay	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID508777	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V179F mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID279436	Antiviral activity against HIV1 isolate with RT 103R, 179D mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1754642	Antiviral activity against HIV1 harboring K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID1888693	Resistance index, ratio of EC50 for antiviral activity against HIV1 with RT L100I mutant infected in human MT4 cells to EC50 for antiviral activity against wild type HIV1 infected in human MT4 cells
AID1884223	Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells to EC50 for antiviral activity against wildtype HIV-1 3B infected in human MT4 cells	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID328841	Inhibition of human MRP1 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID198757	Percent inhibitory activity against Y181C HIV type I reverse transcriptase at a concentration of 10 uM	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 5. 4-Substituted and 2,4-disubstituted analogs of nevirapine.
AID302255	Antiviral activity against HIV1 with reverse transcriptase Y188L mutation in MT4 cells assessed as inhibition of viral induced cytopathic effect by MTT method	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID1705196	Inhibition of RNA-dependent DNA polymerase activity of recombinant HIV-1 p66/p51 reverse transcriptase Y188L mutant assessed as inhibition of [3H]dTTP incorporation using poly(rA)/oligo(dT) as templates incubated for 15 mins by MicroBeta scintillation cou	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID1456307	Inhibition of HIV-1 reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8	Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR.
AID1316334	Selectivity index, ratio of CC50 for human mock-infected MT4 cells to EC50 for wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID1152240	Antiviral activity against R5 tropic Human immunodeficiency virus 1 ADA5 subtype B infected in human TZM-bl cells assessed as reduction in virus-induced cytopathic effect after 48 hrs by luminescence assay	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1191671	Inhibition of HIV1 recombinant wild type reverse transcriptase p66/p51 pre-incubated with compound before enzyme addition using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry	2015	Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5	Scaffold hopping: exploration of acetanilide-containing uracil analogues as potential NNRTIs.
AID328882	Toxicity in mouse fibroblast cells assessed as accumulation of prelamin A at 400 uM after 10 days by Western blot	2007	Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33	HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells.
AID1754644	Antiviral activity against HIV1 harboring RT Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID440073	Antiviral activity against HIV1 HXB2 harboring K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID622051	Inhibition of DNA-dependent DNA polymerase activity of HIV1 reverse transcriptase p66/p66 homodimer G190A mutant using activated DNA and [alpha-32P]dATP after 30 mins by liquid scintillation counting	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID1558856	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
AID738332	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for wild type HIV1 3B	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID665274	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2012	European journal of medicinal chemistry, Jul, Volume: 53	Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID81595	Inhibitory activity against NNI-resistant HIV-1 strain A17 with Y181C mutation	2000	Bioorganic & medicinal chemistry letters, Sep-18, Volume: 10, Issue:18	Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID279475	Antiviral activity against HIV1 isolate with RT 101E, 103N, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID105153	Dose required to achieve 50% protection of MT-4 cells from HIV-1(IIIB) induced cytopathogenicity, determined by MIT method.	1998	Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21	Novel 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit human immunodeficiency virus type 1 replication.
AID1275544	Antiviral activity against HIV1 3B expressing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
AID257168	Antiviral activity against HIV1 K103N mutant strain infected MT4 cells by MTT method	2005	Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25	Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.
AID1298252	Inhibition of HIV1 reverse transcriptase p66/p51 G190A mutant using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID587750	Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as level of 2 mins magnetic nanopartials-medated residual infection in human HeLaT4 cells trea	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID105568	Antiviral activity was determined against HIV-1 (clone 90) in MT-4 cells infected with HIV-1 IIIB using an XTT assay	1998	Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12	Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1741397	Inhibition of reverse transcriptase E138K mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID44664	Ability to inhibit HIV-2 multiplication in acutely infected C8166 cells	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.
AID1171411	Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay	2014	ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11	Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.
AID738333	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathicity after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
AID1244341	Anti-trichomonas activity against MTZ-resistant Trichomonas vaginalis incubated for 3 to 48 hrs by trypan blue exclusion assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	N-Alkyl/aryl-4-(3-substituted-3-phenylpropyl)piperazine-1-carbothioamide as dual-action vaginal microbicides with reverse transcriptase inhibition.
AID279459	Antiviral activity against HIV1 isolate with RT 101H mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1223492	Oral bioavailability in human	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID584080	Antiviral activity against HIV1 NL4-3 harboring reverse transcriptase V108I, E138K, F227F/L mutant infected in human SupT1 cells derived from 11 viral passages with lersivirine assessed as inhibition of viral replication after 21 days relative to drug sen	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.
AID1761012	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV-1 3B infected in human MT4 cells	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID1736153	Inhibition of wild type recombinant HIV-1 subtype B BH10 p66/p51 reverse transcriptase heterodimer expressed in Escherichia coli BL21 (DE3) assessed as inhibition of dTTP incorporation on poly(rA)-oligo(dT) template primer duplex at 10 uM preincubated wit	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Design, synthesis and biological evaluation of quinoxaline compounds as anti-HIV agents targeting reverse transcriptase enzyme.
AID663309	Inhibition of HIV1 recombinant reverse transcriptase V106A mutant assessed as [3H]dTTP incorporation into poly(rA)/oligo(dT)	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID492280	Selectivity index, CC50 for human MT4 cells to EC50 for wild type HIV1 3B	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID88381	Antiviral activity against Y181C mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID622054	Ratio of Ki for HIV1 RT p66/p66 homodimer K103N mutant to Ki for wild-type HIV1 RT p66/p66 homodimer	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID152775	Inhibitory activity of compound on p24 production in peripheral blood mononuclear cells infected with HIV strain RT-MDR.	1999	Bioorganic & medicinal chemistry letters, Jun-07, Volume: 9, Issue:11	Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
AID1880378	Antiviral activity against HIV-1 IIIB harboring reverse transcriptase Y181C mutant infected in human MT4 cells by MTT assay	2022	Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12	Structure-Based Discovery of Novel NH
AID1157585	Antiviral activity against zidovudine-resistant HIV1 harboring RT 67N, 70R, 215F, 219Q mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID1241792	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 infected in human MT4 cells	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
AID1197835	Inhibition of HIV1 reverse transcriptase assessed as reduction in biotin-labeled dUTP incorporation into DNA after 1 hr using poly(A) x oligo(dT)15 template/primer hybrid, digoxigenin and biotin-labeled nucleotides	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
AID293561	Antiviral activity against HIV1 LAI with RT Y181C mutation in MT4 cells by EGFP based replication assay	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID247503	Inhibitory activity against HIV-1 mutant strain 190A	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID279455	Antiviral activity against HIV1 isolate with RT 103N, 188H mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1655526	Inhibition of recombinant HIV-1 BH10 reverse transcriptase p51/p66 expressed in Escherichia coli preincubated for 10 mins followed by D38/25PGA template-primer addition and measured after 10 to 30 secs by denaturing PAGE based single nucleotide incorporat	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Peptides Mimicking the β7/β8 Loop of HIV-1 Reverse Transcriptase p51 as "Hotspot-Targeted" Dimerization Inhibitors.
AID361912	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190A mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1191399	Antiviral activity against wild type HIV-1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID276231	Antiviral activity against HIV1 3B in MT2 cells	2006	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21	Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1784208	Antiviral activity against HIV1 ROD infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Discovery, optimization, and target identification of novel coumarin derivatives as HIV-1 reverse transcriptase-associated ribonuclease H inhibitors.
AID1443669	Antiviral activity against HIV1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
AID1186008	Antiviral activity against HIV1 infected in 293T cells assessed as time of 50% failure	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID1357802	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring reverse transcriptase E138K mutant	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID645832	Cytotoxicity against human MT2 cells by MTT assay	2012	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4	Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase.
AID623217	Cytotoxicity against human MT4 cells after 4 days by MTT assay	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID298087	Inhibition of wild type HIV1 RT	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID1186003	Antiviral activity against HIV1 harboring reverse transcriptase K103N/G190A double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay r	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID650547	Resistance ratio of EC50 for HIV 1 harboring reverse transcriptase K103N mutant infected in human MT4 cells to EC50 for wild type HIV 1 NL4-3 infected in human MT4 cells	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID360705	Inhibition of HIV1 RT mediated DNA-dependent DNA synthesis initiation using RNA PPT primed substrate by scintillation proximity assay	2007	The Journal of biological chemistry, Mar-16, Volume: 282, Issue:11	HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.
AID1754640	Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect measured after 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID105566	Antiviral activity was determined against HIV-1 (clone 118) in MT-4 cells infected with HIV-1 IIIB using an XTT assay	1998	Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12	Synthesis and anti-HIV activities of urea-PETT analogs belonging to a new class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID246463	Compound concentration required to achieve 50% protection of infected MT-4 cells from Y181C strain was determined by the MTT method	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID508757	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase E138K, M230L mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1483271	Inhibition of HIV1 3B reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID1217705	Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1884540	Fold resistance, ratio of EC50 for antiviral activity against drug-resistant HIV-1 Y181C mutant infected in human MT4 cells to EC50 for antiviral activity against NNRTI resistant wild type HIV-1 infected in human MT4 cells	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID767498	Antiviral activity against HIV1 3B harboring reverse transcriptase K103N/Y181C double mutant infected in human MT2 cells assessed as protection against virus-induced effect by MTT assay	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.
AID197775	Compound was evaluated for inhibition of WT HIV type I reverse transcriptase.	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 5. 4-Substituted and 2,4-disubstituted analogs of nevirapine.
AID246269	Effective concentration against human immunodeficiency virus type 1 Y188L mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
AID1691438	Selectivity index, ratio of CC50 for cytotoxicity against human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells	2020	European journal of medicinal chemistry, May-01, Volume: 193	In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP.
AID1056583	Inhibition of HIV-1 reverse transcriptase after 1 hr by spectrophotometry	2013	Journal of natural products, Dec-27, Volume: 76, Issue:12	Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73.
AID736441	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2013	Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID1637391	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for human HIV-1 3B infected in human MT4 cells	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID650692	Inhibition of HIV 1 reverse transcriptase Y188L mutant assessed as inhibition of time-dependent incorporation of [3H]dTTP into poly(rA)n.oligo(dT)	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID663295	Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID587735	Antiviral activity against HIV1 NL4-3.Luc assessed as infectivity using human PBMC pretreated for 24 hrs followed by exposed to virus after compound washout measured after 2 to 3 days by luciferase assay	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID1537494	Inhibition of wild-type HIV1 reverse transcriptase in HIV1 infected HEK293T cells harboring luciferase gene assessed as reduction in viral infection after 48 hrs by Bright-Glo luciferase assay	2019	ACS medicinal chemistry letters, Feb-14, Volume: 10, Issue:2	Aryl Substituted Benzimidazolones as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors.
AID302257	Resistance index, Ratio of EC50 for drug-resistant HIV1 with RT Y181C mutation in MT3 cells to EC50 for HIV1 NL43 in MT3 cells	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID361925	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/Y181C mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1418468	Inhibition of recombinant wild-type HIV1 GST-fused reverse transcriptase p66/p51 RNA-dependent DNA polymerase activity expressed in Escherichia coli assessed as reduction in biotin-dUTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40	2018	Bioorganic & medicinal chemistry letters, 12-01, Volume: 28, Issue:22	Design and synthesis of a novel series of non-nucleoside HIV-1 inhibitors bearing pyrimidine and N-substituted aromatic piperazine.
AID246445	Effective concentration of the compound to inhibit HIV-1 mutant L100I+K103N replication in HIV-infected MT-4 cells; Not determined	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID557020	Antiviral activity against HIV1 clade B harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID1456308	Inhibition of HIV1 RES056 reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8	Structural modifications of diarylpyrimidines (DAPYs) as HIV-1 NNRTIs: Synthesis, anti-HIV activities and SAR.
AID1320865	Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
AID46585	Inhibitory activity against the HIV-1 in CEM cells	1996	Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5	Betulinic acid derivatives: a new class of specific inhibitors of human immunodeficiency virus type 1 entry.
AID1191401	Antiviral activity against wild type HIV-2 ROD infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry, Feb-01, Volume: 23, Issue:3	Synthesis and biological evaluation of DAPY-DPEs hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID198908	In vitro inhibitory activity against HIV-1 mutant Reverse transcriptase containing the single amino acid substitution Y181I	1999	Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21	Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: further structure-activity relationship studies and identification of more potent broad-spectrum HIV-1 RT inhibitors with antiviral activity.
AID1282050	Antiretroviral activity against HIV-1 based virus like particles infected in U2OS cells assessed as Gluc activity at highest non-toxic concentration	2016	Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8	Antiretroviral (HIV-1) activity of azulene derivatives.
AID82603	The effect of protein binding on the antiviral activity versus wild type virus strain HXB2 was tested in the presence of acid glycoprotein in HeLa MAGI assay	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID613686	Induction of human A375 cell differentiation assessed as microtubule reorganization at 20 uM after 96 hrs by immunofluorescence analysis	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitors.
AID1352320	Antiviral activity against HIV1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 4 days by MTT assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID1410484	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild-type HIV1 3B reverse transcriptase infected in human MT4 cells	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.
AID368560	Antiviral activity against HIV1 reverse transcriptase Y181C mutant infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID1373155	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID1316807	Selectivity index, ratio of CC50 for human MT-4 cells to IC50 for HIV-2 ROD infected in human MT-4 cells	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Synthesis of arylated coumarins by Suzuki-Miyaura cross-coupling. Reactions and anti-HIV activity.
AID105701	Anti-HIV-1 activity against LAI strain in MT-4 cells by the MTT method	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID373389	Antiviral activity against 0.1 MOI HIV1 3B infected in human TZM-b1 cells assessed as inhibition of viral replication at 0.11 uM after 24 hrs by luciferase assay	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID1231486	Antiviral activity against HIV1 harboring K103N/Y181C double mutant infected in human MT4 cells assessed as protection of cells from virus-induced cytopathic after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Anti-HIV diarylpyrimidine-quinolone hybrids and their mode of action.
AID527375	Antiviral activity against wild type HIV1 NL4-3 infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Discovery and SAR of a series of 4,6-diamino-1,3,5-triazin-2-ol as novel non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID302258	Resistance index, Ratio of EC50 for drug-resistant HIV1 with RT Y188L mutation in MT3 cells to EC50 for HIV1 NL43 in MT3 cells	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID1171413	Antiviral activity against wild type HIV1 harboring reverse transcriptase K103N/Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay	2014	ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11	Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.
AID1357794	Resistance factor, ratio of EC50 for HIV1 harboring reverse transcriptase L100I mutant to EC50 for wild-type HIV-1 3B	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID508759	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K103N, Y181C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1292361	Cytotoxicity against human TZM-bl cells assessed as reduction of cell viability after 48 hrs	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Design, discovery, modelling, synthesis, and biological evaluation of novel and small, low toxicity s-triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID317732	Cytotoxicity against human HIV1RF infected CEM-SS cells by MTT assay	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID1743628	Antiviral activity against HIV1 harboring RT Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID608392	Cytotoxicity against human MAGI-CCR5 cells after 48 hrs by MTS cell viability assay	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Imidazo[1,2-a]pyridin-3-amines as potential HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1574374	Antiviral activity against HIV-1 IRLL98 harboring reverse transcriptase M41L, D67N, Y181C, M184V, R211K, and T215Y mutants infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID1574385	Inhibition of recombinant HIV-1 His-tagged reverse transcriptase p66/p51 K103N mutant expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer after 20 mins by scintillation counting analysi	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID88366	Antiviral activity against K103N mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1248222	Antiviral activity against wild type HIV 1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20	A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities.
AID1637396	Antiviral activity against human HIV-1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection from virus-induced cytopathic effect measured 5 days post infection by MTT assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID366521	Resistance index, ratio of EC50 for drug-resistant HIV1 isolate with reverse transcriptase K103N mutation to EC50 for wild type HIV1 NL4-3	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID1610042	Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 5 days by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.
AID279394	Antiviral activity against HIV1 isolate with RT 98G mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1275550	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
AID1303217	Cytotoxicity against African green monkey Vero cells assessed as cell growth inhibition after 24 hrs by MTT assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	Design, synthesis and anti-HIV activity of novel quinoxaline derivatives.
AID366520	Antiviral activity against HIV1 isolates with reverse transcriptase K103N mutation in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID557041	Antiviral activity against HIV1 isolate R8 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 72 hrs in presence of 10% FBS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID104760	Dose required to reduce the viability of mock-infected cells by 50%	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.
AID1059144	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2013	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24	Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1822333	Antiviral activity against HIV-1 harboring F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity at 2 uM incubated for 5 days by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID46378	Antiviral activity against site directed resistant isolate HIV-1 L100I in CEM cells	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID235444	Selective index as the ratio of CD50 to that of ED50 against HIV-1 HxB2 strain.	2002	Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.
AID106048	Inhibitory activity against 100I strain and 103N strain of HIV-I in MT-4 cell was determined; Not determined	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
AID557019	Inhibition of HIV1 isolate R8 reverse transcriptase after 90 mins	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID1217729	Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID297144	Antiviral activity against HIV1 with RT V106A mutation by cytopathic cell killing assay	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme.
AID586910	Induction of BCRP activity	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID525112	Antiviral activity against HIV 1 NL4.3 harboring integrase L74M mutant infected in human MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID104963	Compound was evaluated for the anti-viral activity against cultured MT-4 cells	1994	Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15	Synthesis of a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1460939	Antiviral activity against HIV-1 A17 harboring reverse transcriptase K103N/Y181C double mutant infected in human MAGI-CCR5 cells after 48 hrs by fluorescence based beta-galactosidase reporter gene assay	2017	Bioorganic & medicinal chemistry, 12-01, Volume: 25, Issue:23	An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors.
AID44808	Inhibitory concentration against cell culture of Human T-cell line c8166 infected with HIV-1 IIIB strain was determined	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse transcriptase enzymes.
AID1304406	Inhibition of wild type HIV-1 BH10 recombinant reverse transcriptase expressed in Escherichia coli assessed as incorporation of [32P]GTP into poly(rA)/oligo(dT) as template primer	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID678714	Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1637395	Antiviral activity against human HIV-1 3B harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection from virus-induced cytopathic effect measured 5 days post infection by MTT assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID1410411	Antiviral activity against HIV1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the "NNRTI Adjacent" Binding Site.
AID735083	Inhibition of HIV reverse transcriptase	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Synthesis and biological evaluation of phosphonate analogues of nevirapine.
AID473115	Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV.
AID622052	Inhibition of DNA-dependent DNA polymerase activity of HIV1 reverse transcriptase p66/p66 homodimer K103N/Y181C mutant using activated DNA and [alpha-32P]dATP after 30 mins by liquid scintillation counting	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID1610044	Therapeutic index, ratio of CC50 for human PBMC cells to IC50 for antiviral activity against HIV1 VB51 infected in human TZM-bl cells	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.
AID269797	Antiviral activity against HIV1 I135V mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269797	Antiviral activity against HIV1 I135V mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269797	Antiviral activity against HIV1 I135V mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID648425	Inhibition of HIV1 reverse transcriptase assessed as incorporation of biotin-dUTP into poly(rA)-oligo(dT)	2012	European journal of medicinal chemistry, May, Volume: 51	Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1705184	Cytotoxicity against human MT-4 cells assessed as reduction in cell viability by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID648424	Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	2012	European journal of medicinal chemistry, May, Volume: 51	Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID738336	Inhibition of HIV 1 reverse transcriptase assessed as incorporation of biotin-dUTP into poly rA.dT by ELISA	2013	Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7	Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
AID44797	In vitro reduction of p24 by 90% in Efavirenz resistant HIV-1 (K103R, V179D, P225H) infected C8166 cells.	2004	Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15	Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID1736346	Selectivity index, ratio of CC50 for human HEK 293T cells to EC50 for VSVG/wild type HIV1 infected in human HEK 293T cells
AID499277	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Anti-HIV and antiplasmodial activity of original flavonoid derivatives.
AID649826	Antiviral activity against HIV1 LAI infected in human CEMx174 cells coexpressing GFP preincubated for 1 hr measured after 5 days by fluorimetry	2012	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5	Discovery of 3,4-dihydropyrimidin-2(1H)-ones with inhibitory activity against HIV-1 replication.
AID279428	Antiviral activity against HIV1 isolate with RT 101E, 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID105860	Compound was tested for potency to achieve protection of MT-4 cells from 103N strain of HIV-1 virus	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).
AID726438	Antiviral activity against multidrug resistant HIV1 IIIB containing reverse transcriptase Y181C mutation infected in human MT2 cells assessed as cytoprotection from infection by MTT colorimetric method	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4	Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.
AID46384	Antiviral activity against site directed resistant isolates in HIV-1 A98G CEM cells	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID1316339	Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID1609108	Antiviral activity against HIV-1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 4 days by MTT assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID572186	Antiviral activity against HIV-1 SM034 harboring NNTRI 188L mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1165074	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
AID523482	Antiviral activity against HIV1 with RT connection domain G190S/T369I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID1292364	Inhibition of recombinant HIV1 reverse transcriptase using 234-nt long RNA/18-mer DNA oligonucleotide as template/primer assessed as remaining activity at 200 uM preincubated for 15 mins followed by incubation with template/primer for 40 mins by liquid sc	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Design, discovery, modelling, synthesis, and biological evaluation of novel and small, low toxicity s-triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID523351	Antiviral activity against HIV1 with RT connection domain K103N/T369I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID586909	Induction of MRP3 activity	2011	Antimicrobial agents and chemotherapy, Mar, Volume: 55, Issue:3	Interaction potential of etravirine with drug transporters assessed in vitro.
AID416755	Antiviral activity against HIV1 with reverse transcriptase L100I mutation in human CEM cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID698306	Antiviral activity against HIV1 containing reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID561945	Antibacterial activity against Salmonella group B ATCC 31194 after 18 to 24 hrs by agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Lack of antimicrobial activity by the antiretroviral drug nevirapine against common bacterial pathogens.
AID1784216	Antiviral activity against HIV1 harboring reverse transcriptase V106A/F227 mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Discovery, optimization, and target identification of novel coumarin derivatives as HIV-1 reverse transcriptase-associated ribonuclease H inhibitors.
AID105695	Anti-HIV-1 activity against K103N strain in MT-4 cells by the MTT method	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID246350	Effective concentration against human immunodeficiency virus type 1 mutated at 181C	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID1141971	Ratio of EC50 for HIV1 harboring reverse transcriptase Y181C mutant to EC50 for wild type HIV1 NL4.3	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1304402	Cytotoxicity against mock-infected human CEM-SS cells	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID197931	HIV-1 reverse transcriptase inhibitory activity against Asn103 mutant using (poly)rC600*(oligo)dGT as template primer.	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
AID373562	Antiviral activity against 0.1 MOI HIV1 3B in 24 hrs pretreated human TZM-b1 cells infected 0 hr post drug removal assessed as inhibition of viral replication at 0.18 uM measured 24 hrs postinfection by luciferase assay	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID1637397	Antiviral activity against human HIV-1 3B harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection from virus-induced cytopathic effect measured 5 days post infection by MTT assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID561951	Antibacterial activity against Shigella flexneri group B after 18 to 24 hrs by agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Lack of antimicrobial activity by the antiretroviral drug nevirapine against common bacterial pathogens.
AID635347	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2011	Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23	Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs.
AID1819220	Inhibition of wild type HIV-1 reverse transcriptase using biotin-labelled dNTPs as substrate incubated for 2 hrs by ELISA
AID351450	Therapeutic index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Synthesis of alkenyldiarylmethanes (ADAMs) containing benzo[d]isoxazole and oxazolidin-2-one rings, a new series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID246343	Effective concentration of the compound to inhibit HIV-1 mutant K103N+Y181C replication in HIV-infected MT-4 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID457955	Inhibition of RNA-dependent DNA polymerase activity of HIV1 reverse transcriptase using poly(rA)/pligo(dT) template	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1736347	Inhibition of HIV-1 reverse transcriptase RNA-dependent DNA polymerase activity assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT) as template/primer incubated for 1 hr followed by transferring into streptavidin plate for 1 hr by absorba
AID247497	Inhibitory activity against HIV-1 mutant strain 103N	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1561722	Resistance index, ratio of EC50 for antiviral activity against HIV1 3B infected in human MT4 cells grown under 30 passages in presence of 4-[[4-[[4-[4-[2-cyanovinyl]-2,6-dimethylphenoxy]thieno[3,2-d]pyrimidin-2-yl]amino]-1-piperidyl]methyl]benzenesulfonam
AID1729161	Antiviral activity against HIV1 harboring F227L/V106A mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect by MTT assay	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp
AID613676	Antiproliferative activity against human A375 cells assessed as cell growth at 350 uM after 96 hrs by trypan blue assay	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitors.
AID525110	Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.
AID1217727	Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID650545	Antiviral activity against HIV 1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID413266	Antiviral activity against multidrug-resistant HIV1 with reverse transcriptase 41L, 74V, 184V, 210W, 215Y, ins SS, 98G mutation infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	2008	Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24	Development and preclinical studies of broad-spectrum anti-HIV agent (3'R,4'R)-3-cyanomethyl-4-methyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (3-cyanomethyl-4-methyl-DCK).
AID1292014	Inhibition of wild type HIV1 Reverse transcriptase assessed as reduction of biotin deoxyuridine triphosphate incorporation into the wild type HIV1 reverse transcriptase after 1 hr by ELISA	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
AID1884220	Antiviral activity against HIV-1 harboring F227L/V106A double mutant infected in human MT4 cells assessed as reduction in virus induced cytotoxicity incubated for 5 to 7 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID1685253	Covalent inhibition of recombinant wild type HIV-1 reverse transcriptase using poly(rA)350/oligo(dT)16 as template/primer preincubated followed by substrate addition measured after 1 hr by pico-green reagent based fluorescence analysis	2021	ACS medicinal chemistry letters, Feb-11, Volume: 12, Issue:2	Covalent Inhibition of Wild-Type HIV-1 Reverse Transcriptase Using a Fluorosulfate Warhead.
AID1443663	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1773462	Resistance factor, ratio of EC50 for HIV1 harboring F227L/V106A double mutant infected in human MT4 cells to EC50 for HIV1 3B infected in MT4 cells
AID1056580	Antiviral activity against HIV-1 expressing reverse transcriptase K103N/V108I double mutant infected in human 293T cells co-transfected with VSVG protein assessed as inhibition of viral-replication incubated 15 mins prior to viral-infection measured after	2013	Journal of natural products, Dec-27, Volume: 76, Issue:12	Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73.
AID440086	Antiviral activity against HIV1 HXB2 harboring K103N and Y181C mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID1391085	Antiviral activity against HIV1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
AID622047	Inhibition of DNA-dependent DNA polymerase activity of HIV1 reverse transcriptase p66/p66 homodimer K103N mutant using activated DNA and [alpha-32P]dATP after 30 mins by liquid scintillation counting	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID1457065	Inhibition of HIV1 reverse transcriptase p66 Y181I mutant associated RNA dependent DNA polymerase activity expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer by scintillation counting	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID1197829	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
AID1435518	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES056 expressing reverse transcriptase mutant
AID663305	Inhibition of HIV1 wild type recombinant reverse transcriptase assessed as [3H]dTTP incorporation into poly(rA)/oligo(dT)	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID1292360	Cytotoxicity against human U2OS cells assessed as reduction of cell viability after 48 hrs	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Design, discovery, modelling, synthesis, and biological evaluation of novel and small, low toxicity s-triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID351445	Antiviral activity against HIV1 3B in human MT4 cells assessed as inhibition of virus-induced cytopathicity after 5 days by MTT assay	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Synthesis of alkenyldiarylmethanes (ADAMs) containing benzo[d]isoxazole and oxazolidin-2-one rings, a new series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID370728	Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 V106A mutant expressed in Escherichia coli JM109	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
AID508796	Ratio of EC50 for HIV1 in presence of 1 mg/ml alpha-1 acid-glycoprotein to EC50 for HIV1 in absence of serum proteins by GFP assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID82277	Inhibition of HIV-1 IIIB replication in MT-4-infected wild type cells.	2002	Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.
AID1750721	Inhibition of HIV-1 p66/p51 reverse transcriptase E138K mutant incubated for 40 mins by picogreen dye-based spectrofluorometric analysis	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID523346	Antiviral activity against HIV1 with RT connection domain T369V mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID1572518	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytotoxicity after 5 days by MTT assay
AID571975	Antiviral activity against HIV-1 subtype CRF01_AE V029525 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1750715	Cytotoxicity against in human MT-4 cells after 5 days by MTT assay	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID457958	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1275546	Antiviral activity against HIV1 3B expressing reverse transcriptase E138K mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
AID1736156	Cytotoxicity against human MT2 cells assessed as reduction in cell viability measured after 4 days by Trypan blue assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Design, synthesis and biological evaluation of quinoxaline compounds as anti-HIV agents targeting reverse transcriptase enzyme.
AID1410405	Inhibition of recombinant wild type HIV1 reverse transcriptase assessed as decrease in biotin-dUTP incorporation using DIG-labeled dUTP/biotin-labeled dUTP and dTTP as template and viral nucleotides after 1 hr by ELISA	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the "NNRTI Adjacent" Binding Site.
AID1691435	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cell death incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, May-01, Volume: 193	In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP.
AID1161108	Inhibition of HIV1 reverse transcriptase assessed as inhibition of biotin-dUTP incorporation using hybrid poly (A).oligo (dT)15 template primer incubated for 1 hr at 37 degC by ELISA method	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.
AID1657474	Antiviral activity against HIV1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	2020	Bioorganic & medicinal chemistry, 04-15, Volume: 28, Issue:8	Inhibition of HIV-1 RT activity by a new series of 3-(1,3,4-thiadiazol-2-yl)thiazolidin-4-one derivatives.
AID1199053	Selectivity index, ratio of CC50 for human MT4 cells to IC50 for Human immunodeficiency virus 1 3b infected in human MT4 cells	2014	Journal of natural products, Jun-27, Volume: 77, Issue:6	Jatrophane diterpenes as inhibitors of chikungunya virus replication: structure-activity relationship and discovery of a potent lead.
AID105707	Anti-HIV-1 activity against Y188L strain was determined in MT-4 cells by the MTT method	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1390710	Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.
AID1583030	Inhibition of recombinant HIV-1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation in to cDNA chain incubated for 1 hr by ELISA	2020	Journal of medicinal chemistry, 02-13, Volume: 63, Issue:3	Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.
AID279423	Antiviral activity against HIV1 isolate with RT 106I, 188L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID200161	Compound concentration required to inhibit the HIV-1 recombinant Reverse transcriptase (rRT) activity by 50%.	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.
AID269799	Antiviral activity against HIV1 L100I mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269799	Antiviral activity against HIV1 L100I mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269799	Antiviral activity against HIV1 L100I mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1391079	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2.
AID155274	Anti-HIV activity by its ability to inhibit the replication of HIV-1 strain A17 (Y181C) in peripheral blood mononuclear cells (PBMC)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
AID508793	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K101E mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID361919	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase E138K mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1124998	Inhibition of recombinant HIV1 reverse transcriptase assessed as inhibition of biotin-dUTP incorporation in to poly [A] x oligo[dT]15 by ELISA	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives.
AID678716	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID105861	Compound was tested for potency to achieve protection of MT-4 cells from 106A strain of HIV-1 virus	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).
AID717253	Inhibition of HIV1 reverse transcriptase assessed as biotin-dUTP incorporation into enzyme using poly(rC)-oligo(dG) as template primer by colorimetric analysis	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs.
AID619634	Antiviral activity against HIV-1 3B harboring RT E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID198073	Inhibitory activity against HIV-1 Mutant Reverse transcriptase G190A	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones.
AID1292359	Antiviral activity against HIV1 virus-like particles harboring wild type reverse transcriptase infected in human U2OS cells after 24 hrs by Renilla luciferase assay	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Design, discovery, modelling, synthesis, and biological evaluation of novel and small, low toxicity s-triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID665550	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 3B	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
AID197798	Compound was tested for inhibitory activity against HIV-1 mutant type reverse transcriptase (P236L)	1998	Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16	A dipyrido [2,3-b:3',2'-f]azepine analog of the HIV-1 reverse transcriptase inhibitor nevirapine.
AID198907	In vitro inhibitory activity against HIV-1 mutant Reverse transcriptase containing the single amino acid substitution V106A	1999	Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21	Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: further structure-activity relationship studies and identification of more potent broad-spectrum HIV-1 RT inhibitors with antiviral activity.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1457062	Ratio of EC50 for HIV-1 harboring reverse transcriptase K103N/Y1881C double mutant infected in human MT4 cells to EC50 for HIV1 NL4-3 infected in human MT4 cells	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID235796	Selectivity index was measured as the ratio of CC50(HIV-1) to that of EC50(HIV-1); SI Selectivity Index	1998	Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21	Novel 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit human immunodeficiency virus type 1 replication.
AID1241795	Selectivity index, ratio of IC50 for human CEM-SS cells to EC50 for HIV1 infected in human CEM-SS cells	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
AID104761	Cytotoxicity against mock-infected MT-4 cells.	1999	Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4	5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives.
AID391679	Inhibition of RNA dependent DNA polymerase activity of Escherichia coli DNA polymerase 1 Klenow fragment assessed as residual enzyme activity at 50 ug/ml relative to control	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.
AID440076	Antiviral activity against HIV1 HXB2 harboring 100I mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID440671	Antiviral activity against NNRTI-resistant HIV1 A17 with reverse transcriptase K103N, Y181C mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Activity and molecular modeling of a new small molecule active against NNRTI-resistant HIV-1 mutants.
AID105545	Inhibition of mutant type (Cys181) HIV-1 (IIIB) replication in MT-4 cells	1996	Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21	Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.
AID1187998	Inhibition of HIV1 recombinant wild type reverse transcriptase p66/p51 using dsDNA by microplate reader based assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands.
AID1298246	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 3B infected in human MT4 cells	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID757627	Inhibition of HIV RT K103N/Y181C mutant by cell based assay	2013	European journal of medicinal chemistry, Jul, Volume: 65	Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1773450	Antiviral activity against HIV1 harboring F227L/V106A mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenic effect by MTT assay
AID1217728	Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1636150	Ratio of IC50 for NNRTI resistant HIV1 harboring reverse transcriptase L100I/K103N/H221Y mutant infected in human TZM-bl cells to IC50 for wild type HIV1 NL4-3 infected in human TZM-bl cells	2016	Journal of medicinal chemistry, Aug-11, Volume: 59, Issue:15	Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
AID1186687	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach.
AID1298247	Inhibition of HIV1 wild type reverse transcriptase p66/p51 using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID1687692	Antiviral activity against wild type HIV1 infected in human SupT1 cells assessed as inhibitory effect at 100 nM by cell based inhibition assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Rational design and Structure-Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase.
AID1457059	Ratio of EC50 for HIV-1 harboring reverse transcriptase K103N mutant infected in human MT4 cells to EC50 for HIV1 NL4-3 infected in human MT4 cells	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID666972	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2012	European journal of medicinal chemistry, Aug, Volume: 54	Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors.
AID473114	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV.
AID1200848	Inhibition of HIV1 reverse transcriptase assessed as reduction in biotin-labeled dUTP incorporation into DNA using poly(A) x oligo(dT)15 as template/primer after 1 hr by ELISA	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
AID1267610	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Design and Synthesis of DiselenoBisBenzamides (DISeBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity.
AID153129	Cytotoxic concentration was determined	2000	Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5	Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: lead identification and SAR of 3- and 4-substituted derivatives.
AID263519	Antiviral activity against HIV1 Y181C mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID1822280	Antiviral activity against HIV-1 harboring E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID1057035	Inhibition of HIV-1 reverse transcriptase assessed as inhibition of biotin dUTP incorporation by primer extension assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.
AID1161107	Cytotoxicity against human MT4 cells by MTT assay	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.
AID623214	Antiviral activity against HIV1 3B expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID370730	Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 Y188L mutant expressed in Escherichia coli JM109	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
AID1731752	Inhibition of reverse transcriptase RES056 mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID1377174	Antiviral activity against NRTI-resistant HIV1 isolate 1617-1 infected in PHA-stimulated human PBMC assessed as reduction in p24 level after 7 days by ELISA	2017	Journal of natural products, 06-23, Volume: 80, Issue:6	Potent Inhibitor of Drug-Resistant HIV-1 Strains Identified from the Medicinal Plant Justicia gendarussa.
AID152777	Inhibitory activity of compound won p24 production in peripheral blood mononuclear cells infected with HIV strain HTLV IIIB wild type.	1999	Bioorganic & medicinal chemistry letters, Jun-07, Volume: 9, Issue:11	Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
AID1171587	Antiviral activity against HIV1 NL4-3 expressing reverse transcriptase K103N-Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cell death by MTT assay	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID558386	Drug level in HIV-infected pregnant woman amniotic fluid at 200 mg, po BID by HPLC/UV analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID665549	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
AID587737	Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef infected in human HeLa-T4 cells assessed as time required to cause 50% loss in compound potency at 10 t	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID242064	Concentration required for 50% inhibition of wild type human immunodeficiency virus type 1 reverse transcriptase	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
AID757621	Inhibition of recombinant wild type HIV1 RT using poly(rA)/oligo(dT)16 as template after 40 mins by spectrofluorometric analysis	2013	European journal of medicinal chemistry, Jul, Volume: 65	Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID298076	Antiviral activity against HIV1 RT K103N-Y181C mutant in MT4 cells by MTT assay	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity.
AID1357788	Antiviral activity against HIV1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID492283	Antiviral activity against HIV1 with reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID200171	Inhibition single mutant of HIV-1 RT (Y181C)	1993	Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9	5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
AID368557	Inhibition of HIV1 recombinant reverse transcriptase Y181I mutant-mediated RNA-dependent DNA polymerase activity assessed as [3H]dTTP incorporation by cell free-based scintillation counting	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID632801	Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase K103N and Y181C double mutant infected in human MT4 cells assessed as inhibition of viral infection	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
AID508775	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase Y181C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID572171	Antiviral activity against HIV-1 subtype D V022819 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID587734	Antiviral activity against HIV1 NL4-3.Luc assessed as infectivity using human MDM pretreated for 24 hrs followed by exposed to virus after compound washout measured after 2 to 3 days by luciferase assay	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID619628	Inhibition of HIV-1 reverse transcriptase assessed as inhibition of biotin-dUTP incorporation into enzyme by colorimetry	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID106057	Inhibitory activity against 103N strain and 181C strain of HIV-I in MT-4 cells	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
AID1654198	Drug metabolism in human assessed as formation of 12-OH-NVP	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death.
AID1248224	Selectivity index, ratio of CC50 for uninfected human MT4 cells to EC50 for wild type HIV 1 3B infected in human MT4 cells	2015	Bioorganic & medicinal chemistry, Oct-15, Volume: 23, Issue:20	A novel family of diarylpyrimidines (DAPYs) featuring a diatomic linker: Design, synthesis and anti-HIV activities.
AID1609105	Selectivity index, ratio of CC50 for human MT4 cells to EC50 of antiviral activity against HIV-1 IIIB infected in human MT4 cells	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID279398	Antiviral activity against HIV1 isolate with RT 103N, 108I mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID104244	Cytotoxic concentration against MT-2 cells	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]pi
AID558580	Ratio of drug level in HIV-infected pregnant woman amniotic fluid to maternal blood plasma at 200 mg, po BID by HPLC/UV analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.
AID1335219	Ratio of IC50 for HIV-1 NL4-3 harboring RT-K103N/Y181C double mutant infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein to IC50 for wild-type HIV-1 NL4-3 infected in HEK293T cells co-expressing vesicular stomatitis virus glyco	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID82466	Antiviral activity against P225H strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID440085	Antiviral activity against HIV1 HXB2 harboring 101E and K103N mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID279405	Antiviral activity against HIV1 isolate with RT 101E, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1124989	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay	2014	Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7	Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives.
AID293558	Antiviral activity against HIV1 LAI with RT L100I mutation in MT4 cells by EGFP based replication assay	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID571969	Antiviral activity against HIV-1 subtype CRF02_AG V022826 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID279401	Antiviral activity against HIV1 isolate with RT 181C, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID621982	Inhibition of DNA-dependent DNA polymerase activity of HIV1 reverse transcriptase p66/p66 homodimer L100I mutant using activated DNA and [alpha-32P]dATP after 30 mins by liquid scintillation counting	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID269685	Antiviral activity against HIV1	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269685	Antiviral activity against HIV1	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269685	Antiviral activity against HIV1	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1610054	Therapeutic index, ratio of CC50 for human TZM-bl cells to IC50 for antiviral activity against HIV1 NARI-DR infected in human TZM-bl cells	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.
AID685335	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 3B	2012	Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors.
AID1155816	Inhibition of HIV-1 recombinant NNTRI-resistant reverse transcriptase L100I mutant assessed as incorporation of [3H]dTTP into poly(rA)/oligo(dT)10:1	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID1572520	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
AID1773439	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenic effect by MTT assay
AID1750714	Antiviral activity against HIV-1 infected in human MT-4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1435511	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B expressing wild type reverse transcriptase
AID1558847	Antiviral activity against HIV1 3B infected in human MT4 cells incubated assessed as reduction in virus-induced cytopathic effect for 5 days by MTT assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
AID1152370	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post viral infection by MTT assay	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID766432	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as protection against virus-induced cytopathogenicity by MTT assay	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.
AID1561718	Antiviral activity against HIV1 3B infected in human MT4 cells grown under 30 passages in presence of 4-[[4-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]-1-piperidyl]methyl]benzenesulfonamide assessed as protection against virus-indu
AID630951	Cytotoxicity in human TZM-bl cells assessed as cell viability after 48 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID391688	Inhibition of DNA dependent DNA polymerase activity of HIV1 BH10 recombinant reverse transcriptase p66/p51 assessed as residual enzyme activity	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.
AID1574382	Resistance index, ratio of EC50 for HIV-1 harboring reverse transcriptase K103N mutant to EC50 for wild type HIV-1 NL4-3	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID508639	Antiviral activity against Human immunodeficiency virus 1 subtype C infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1877037	Antiviral activity against HIV-1 pseudovirus infected in human TZM-bl cells preincubated with virus for 30 mins followed by cell infection and measured after 3 days by luciferase assay	2021	Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22	HIV-1 gp120 Antagonists Also Inhibit HIV-1 Reverse Transcriptase by Bridging the NNRTI and NRTI Sites.
AID88379	Antiviral activity against V108I mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1754638	Cytotoxicity against mock-infected human MT4 cells incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID1443661	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
AID1316332	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID440078	Antiviral activity against HIV1 HXB2 harboring 106A mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID1188000	Antiviral activity against HIV2 ROD acutely infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenic effect after 5 days by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands.
AID1736367	Selectivity index, ratio of EC50 for antiviral activity against VSVG/HIV-1 harboring reverse transcriptase G190A/K103N double mutant infected in human HEK 293T cells to EC50 for antiviral activity against VSVG/wild type HIV-1 infected in human HEK293T cel
AID572182	Antiviral activity against HIV-1 SM012 harboring NNTRI 108I mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID105864	Compound was tested for potency to achieve protection of MT-4 cells from 190A strain of HIV-1 virus	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 1: From alpha-anilinophenylacetamide (alpha-APA) to imidoyl thiourea (ITU).
AID1594856	Half life in human serum at 200 mg, bid	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
AID1200847	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
AID586317	Antiviral activity against HIV1 infected in human PBMC assessed as inhibition of gag gene expression at 0.27 ug/ml after 5 days post infection by quantitative real time RT-PCR	2011	Bioorganic & medicinal chemistry, Mar-15, Volume: 19, Issue:6	Antiviral activity of seed extract from Citrus bergamia towards human retroviruses.
AID1352314	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 days by MTT assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID302259	Inhibition of wild type HIV1 3B reverse transcriptase	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID457961	Inhibition of HIV1 reverse transcriptase K103N mutant by RNA-dependent DNA polymerase activity assay	2010	Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4	Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID508792	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K101P mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1610038	Antiviral activity against HIV1 92/BR/018 infected in human TZM-bl cells incubated for 48 hrs by bright Glo-luciferase reporter gene assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.
AID1162234	Antiviral activity against HIV1 infected in HEK293T cells by p24 ELISA based phenotypic assay	2014	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18	Novel indole based NNRTIs with improved potency against wild type and resistant HIV.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1460942	Antiviral activity against HIV-1 NL4-3 harboring reverse transcriptase E138A mutant infected in human MAGI-CCR5 cells assessed as reduction in viral infection after 48 hrs by fluorescence based beta-galactosidase reporter gene assay	2017	Bioorganic & medicinal chemistry, 12-01, Volume: 25, Issue:23	An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors.
AID88380	Antiviral activity against V108I/Y181C mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1357803	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring reverse transcriptase Y181C mutant	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID1373161	Inhibition of reverse transcriptase E138K mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID361915	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106M mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID229259	Antiviral activity was evaluated for the inhibition of wild-type RF strain of HIV-1 in an in vitro enzyme assay.	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID1750727	Selectivity index, ratio of CC50 for cytotoxicity against human MT-4 cells to EC50 for inhibition of HIV-1 p66/51 reverse transcriptase E138K mutant	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID663310	Inhibition of HIV1 recombinant reverse transcriptase Y188L mutant assessed as [3H]dTTP incorporation into poly(rA)/oligo(dT)	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID1750724	Selectivity index, ratio of CC50 for cytotoxicity against human MT-4 cells to EC50 for inhibition of HIV-1 p66/51 reverse transcriptase K103N mutant	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID200169	Inhibition of HIV-1 RT using rC-dG as template	1993	Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9	5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
AID557053	Antiviral activity against NRTI-, PI-resistant HIV1 harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID413268	Antiviral activity against wild type HIV1 3B in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA	2008	Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24	Development and preclinical studies of broad-spectrum anti-HIV agent (3'R,4'R)-3-cyanomethyl-4-methyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (3-cyanomethyl-4-methyl-DCK).
AID630956	Selectivity index, ratio of CC50 for human TZM-bl cells to EC50 for X4 tropic Human immunodeficiency virus 1 subtype D-UG070	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1558848	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
AID197794	In vitro for inhibition of HIV-1 reverse transcriptase.	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 3. Dipyrido[2,3-b:2',3'-e]diazepinones.
AID499276	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16	Anti-HIV and antiplasmodial activity of original flavonoid derivatives.
AID105342	Inhibitory activity against resistant HIV-1 strain NevR was determined.	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.
AID675274	Inhibition of HIV reverse transcriptase activity at 10 ug/ml incubated at 37 degC for 1 hr by ELISA RT assay	2012	European journal of medicinal chemistry, Sep, Volume: 55	One pot efficient diversity oriented synthesis of polyfunctional styryl thiazolopyrimidines and their bio-evaluation as antimalarial and anti-HIV agents.
AID1446820	Antiviral activity against HIV1 harboring F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	2017	European journal of medicinal chemistry, Apr-21, Volume: 130	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization.
AID650546	Antiviral activity against HIV 1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID302264	Inhibition of HIV1 reverse transcriptase Y1811 mutant	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID587743	Antiviral activity against single-round HIV1 NLX.Lux-R harboring inactivating mutations in env, vpr and carries firefly luciferase gene in place of nef assessed as level of infection using human HeLaT4 cells pretreated at 100 time EC95 for 24 hrs followed	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID587756	Ratio of EC50 for HIV1 NL4-3.Luc assessed as infectivity using human PBMC pretreated for 24 hrs followed by exposed to virus after compound washout to standard EC50 for HIV1 NL4-3.Luc	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID663301	Resistance ratio of EC50 for HIV1 harboring reverse transcriptase K103N mutant to EC50 for wild type HIV1 NL4-3	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID440080	Antiviral activity against HIV1 HXB2 harboring 179E mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID496628	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase E138A/K20R, V35T, E36A, T39D, V60I, I135V, T139I, K173A, Q174K, T200E, Q207A, R211K, F214L mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID105348	Tested for the inhibitory activity of HIV-1 infected MT-4 cells	1994	Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24	1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole 2",2"-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity.
AID1249724	Inhibition of HIV1 reverse transcriptase p66/p51 assessed as inhibition of biotin-dUTP incorporation using poly (rA)/oligo(dT)16 as template/primer incubated for 40 mins	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID1773460	Resistance factor, ratio of EC50 for HIV1 harboring Y188L mutant mutant infected in human MT4 cells to EC50 for HIV1 3B infected in MT4 cells
AID1636356	Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID361916	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V108I mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1654212	Drug metabolism in human primary hepatocytes assessed as Cytochrome P450-mediated formation of 3-OHNVP at 10 uM incubated for 24 to 48 hrs by uHPLC-MS analysis	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death.
AID508768	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase M230I mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1815377	Anti-HIV activity against HIV-1 IIIB infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID106061	Inhibitory activity against 103N strain of HIV-I in MT-4 cells	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
AID1884226	Antiviral activity against HIV-1 harboring Y181C mutant infected in human MT4 cells assessed as reduction in virus induced cytotoxicity incubated for 5 to 7 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID106775	Inhibition of cell culture in MT-4 cells	1993	Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9	5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
AID368564	Inhibition of wild type HIV1 free reverse transcriptase	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID46374	Antiviral activity against site directed 4X AZT resistant isolate HIV-1 L100I in CEM cells	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID1335215	Antiviral activity against HIV-1 NL4-3 harboring RT-Y181C mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID557049	Antiviral activity against HIV1 clade G harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID1175921	Cytotoxicity against HEK293 cells infected with VSV-G protein pseudotyped HIV1	2014	Journal of natural products, Dec-26, Volume: 77, Issue:12	Diterpenes from a Chinese collection of the brown alga Dictyota plectens.
AID297142	Antiviral activity against HIV1 with RT Y181C mutation by cytopathic cell killing assay	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis, biological activity, and crystal structure of potent nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain activity against mutant forms of the enzyme.
AID279453	Antiviral activity against HIV1 isolate with RT 98G, 100I, 103N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID781024	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV-1 3B infected in human MT4 cells	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs.
AID1335211	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y188L double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID106069	Inhibitory activity against 188L strain of HIV-I in MT-4 cells	2001	Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17	Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
AID1862265	Inhibition of wild-type recombinant HIV-1 group M subtype B BH10 reverse transcriptase RNase-associated RNase H activity expressed in Escherichia coli XL1 blue using 32P-labeled 5'-UUUUUUUUUAGGAUACAUAUGGUUAAAGUAU-3'/5'-ATACTTTAACCATATGTATCC-3' RNA/DNA tem	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Design, synthesis, and biological evaluation of novel double-winged galloyl derivatives as HIV-1 RNase H inhibitors.
AID396619	Antiviral activity against HIV1 3B replication in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by tetrazolium-based colorimetric assay	2008	European journal of medicinal chemistry, Dec, Volume: 43, Issue:12	Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.
AID1763902	Antiviral activity against HIV-1 IIIB harboring RT E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
AID1165075	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
AID1185992	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID1736349	Inhibition of RNase H activity of HIV-1 reverse transcriptase using DNA/RNA hybrid as substrate incubated for 30 mins by fluorescence based analysis
AID269795	Antiviral activity against HIV1 E138K mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269795	Antiviral activity against HIV1 E138K mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269795	Antiviral activity against HIV1 E138K mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID726436	Cytotoxicity in human MT2 cells assessed as inhibition of cell growth	2013	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 23, Issue:4	Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.
AID373554	Antiviral activity against 0.1 MOI HIV1 3B infected in human TZM-b1 cells assessed as inhibition of viral replication after 24 hrs by luciferase assay	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine, a novel thymidine analog.
AID496742	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase E138A/V35T, K122E, I135V, T139A, S162A, K173T, Q174K, N175Y, D177E, T200A, Q207E, R211K mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID1483274	Inhibition of HIV1 3B reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID1822334	Antiviral activity against HIV-1 harboring RES056 mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity at 2 uM incubated for 5 days by MTT assay	2022	Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3	Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
AID508646	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase Y181C, Y188L mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1637394	Antiviral activity against human HIV-1 3B harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection from virus-induced cytopathic effect measured 5 days post infection by MTT assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID1773445	Antiviral activity against HIV1 harboring L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenic effect by MTT assay
AID1185999	Antiviral activity against HIV1 harboring reverse transcriptase Y188L mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay relative HIV1	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID1637399	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for human HIV-1 3B harboring L100I mutant infected in human MT4 cells	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID368556	Inhibition of HIV1 recombinant reverse transcriptase K103N mutant-mediated RNA-dependent DNA polymerase activity expressed in Escherichia coli BL21 assessed as [3H]dTTP incorporation by cell free-based scintillation counting	2009	Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3	Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants.
AID1773447	Antiviral activity against wild type HIV1 harboring Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenic effect by MTT assay
AID1357804	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring reverse transcriptase Y188L mutant	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID1773446	Antiviral activity against HIV1 harboring K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenic effect by MTT assay
AID1884228	Antiviral activity against HIV-1 harboring E138K mutant infected in human MT4 cells assessed as reduction in virus induced cytotoxicity incubated for 5 to 7 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Chemical space exploration around indolylarylsulfone scaffold led to a novel class of highly active HIV-1 NNRTIs with spiro structural features.
AID1161103	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.
AID523352	Antiviral activity against HIV1 with RT connection domain K103N/T369I/N348I mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID523479	Antiviral activity against HIV1 with RT connection domain G190S mutant transfected in HEK293 cells assessed as inhibition of viral replication relative to HIV1 NL4-3	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
AID79450	Ability to inhibit HIV-1 multiplication in chronically infected H9/IIIB cells	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID371906	Antiviral activity against HIV1 NL4-3 with K103N/V108I double mutant in human TZM-b1 cells assessed as beta-galactosidase activity after 48 hrs by single round replication assay	2009	Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12	New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID473116	Cytotoxicity against human MT4 cells after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV.
AID1298248	Inhibition of HIV1 reverse transcriptase p66/p51 L100I mutant using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID248879	Inhibitory concentration against human immunodeficiency virus type 1 (with K103N/V108I resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID351448	Cytotoxicity against human MT4 cells by MTT assay	2009	European journal of medicinal chemistry, Mar, Volume: 44, Issue:3	Synthesis of alkenyldiarylmethanes (ADAMs) containing benzo[d]isoxazole and oxazolidin-2-one rings, a new series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1157580	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Synthesis of novel fluoro analogues of MKC442 as microbicides.
AID143387	Inhibitory activity against non-nucleoside reverse transcriptase inhibitors (NNRTI) -resistant HIV-1 strain A17 with a Y181C mutation in RT (reverse transcriptase)	2001	Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4	Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds.
AID1457063	Inhibition of HIV1 NL4-3 reverse transcriptase His-tagged p66/p51 associated RNA dependent DNA polymerase activity expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer by scintillation c	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID1609107	Antiviral activity against HIV-1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 4 days by MTT assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID663311	Resistance ratio of ID50 for HIV1 reverse transcriptase K103N mutant to ID50 HIV1 wild type reverse transcriptase	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID608391	Antiviral activity against HIV1 3B infected in human MAGI-CCR5 cells assessed as inhibition of viral replication after 48 hrs by beta-galactosidase reporter assay	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Imidazo[1,2-a]pyridin-3-amines as potential HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID227244	The compound was evaluated for antiviral activity using whole cell assay	2000	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2	Novel 2,2-dioxide-4,4-disubstituted-1,3-H-2,1,3-benzothiadiazines as non-nucleoside reverse transcriptase inhibitors.
AID1750718	Inhibition of HIV-1 p66/p51 reverse transcriptase K103N mutant incubated for 40 mins by picogreen dye-based spectrofluorometric analysis	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID736039	Inhibition of HIV1 reverse transcriptase p66/p51 G190A mutant after 30 mins by liquid scintillation counting	2013	Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID492276	Antiviral activity against wild type HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID287002	Inhibition of HIV1 wild type p66/p51 reverse transcriptase	2007	Journal of medicinal chemistry, May-17, Volume: 50, Issue:10	De novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variants.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID197787	In vitro ability to inhibit mutant P236L reverse transcriptase	2000	Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5	Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: lead identification and SAR of 3- and 4-substituted derivatives.
AID1191669	Cytotoxicity against human MT4 cells assessed as reduction in cell viability	2015	Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5	Scaffold hopping: exploration of acetanilide-containing uracil analogues as potential NNRTIs.
AID153102	Cytotoxic concentration against PBMC cells	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]pi
AID665552	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES056 harboring reverse transcriptase K103N/Y181C RT mutant	2012	Bioorganic & medicinal chemistry, Jun-15, Volume: 20, Issue:12	Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors.
AID508635	Antiviral activity against Human immunodeficiency virus 1 subtype (H) infected in human MT4 cells assessed as reduction in virus induced cytopathicity	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID508794	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase L100I mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1815402	Inhibition of HIV1 reverse transcriptase F227L/V106A double mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID1267608	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Design and Synthesis of DiselenoBisBenzamides (DISeBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity.
AID1561721	Resistance index, ratio of EC50 for antiviral activity against HIV1 3B infected in human MT4 cells grown under 30 passages in presence of 4-[[4-[[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino]-1-piperidyl]methyl]benzenesulfonamide to EC
AID361921	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase P236L mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1460928	Cytotoxicity against human MAGI-CCR5 cells assessed as reduction in cell viability after 48 hrs by MTS assay	2017	Bioorganic & medicinal chemistry, 12-01, Volume: 25, Issue:23	An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors.
AID1811045	Cytotoxicity against mock infected human MT4 cells by MTT assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
AID263520	Antiviral activity against HIV1 Y188L mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID198779	In vitro inhibitory activity against HIV-1 mutant Reverse transcriptase containing the single amino acid substitution K103N	1999	Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21	Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: further structure-activity relationship studies and identification of more potent broad-spectrum HIV-1 RT inhibitors with antiviral activity.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1163232	Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell growth after 72 hrs	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID248845	Inhibitory concentration against human immunodeficiency virus type 1 (with Y181C resistant mutation) was determined in HeLa-CD4 MAGI assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID1249714	Antiviral activity against HIV1 3B expressing reverse transcriptase K103N + Y181C mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity incubated for 4 days by MTT method	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Pyrimidine sulfonylacetanilides with improved potency against key mutant viruses of HIV-1 by specific targeting of a highly conserved residue.
AID1335220	Ratio of IC50 for HIV-1 NL4-3 harboring RT-K103N/Y188L double mutant infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein to IC50 for wild-type HIV-1 NL4-3 infected in HEK293T cells co-expressing vesicular stomatitis virus glyco	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID1637400	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for human HIV-1 3B harboring K103N mutant infected in human MT4 cells	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID1862269	Cytotoxicity against human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	Design, synthesis, and biological evaluation of novel double-winged galloyl derivatives as HIV-1 RNase H inhibitors.
AID143385	Inhibitory activity against non-nucleoside reverse transcriptase inhibitors (NNRTI) -resistant HIV-1 strain A17 variant with Y181C plus K103N mutations in RT (reverse transcriptase)	2001	Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4	Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds.
AID1572523	Antiviral activity against HIV1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as inhibition of virus-induced cytotoxicity after 5 days by MTT assay
AID571973	Antiviral activity against HIV-1 subtype CRF01_AE V022822 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID198912	Inhibition of HIV-1 Mutant HIV-1 RT enzymes containing the single amino acid substitution L1001	2001	Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3	Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.
AID267652	Selectivity for wild type HIV1 virus over HIV1 Y181C mutant	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID1485972	Inhibition of HIV-1 reverse transcriptase E138K mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID1743634	Resistance index, ratio of EC50 for antiviral activity against HIV1 expressing RT L100I mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID279400	Antiviral activity against HIV1 isolate with RT 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID632797	Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase K103N and Y181C double mutant infected in human MT2 cells assessed as inhibition of viral infection	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
AID279448	Antiviral activity against HIV1 isolate with RT 101H, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID267654	Selectivity for wild type HIV1 virus over HIV1 K103N/L100I mutant	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID630950	Antiviral activity against R5 tropic Human immunodeficiency virus 1 subtype B-ADA5 infected in human TZM-bl cells assessed as inhibition of virus-induced cytopathic effect after 2 days by luciferase assay	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID302249	Antiviral activity against HIV1 NL43 in MT4 cells assessed as inhibition of viral induced cytopathic effect after 4 days by MTT method	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID298062	Antiviral activity against HIV2 ROD in human MT4 cells by XTT assay	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID736438	Inhibition of HIV1 reverse transcriptase p66/p51 K103N mutant after 30 mins by liquid scintillation counting	2013	Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID1888698	Antiviral activity against HIV1 with RT E138K mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay
AID482699	Antiviral activity against HIV S07 infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID1736361	Antiviral activity against VSVG/HIV-1 harboring reverse transcriptase V108I/K103N double mutant infected in human HEK 293T cells assessed as inhibition of virus replication preincubated with cells for 15 mins prior to viral infection and measured at 48 hr
AID757624	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2013	European journal of medicinal chemistry, Jul, Volume: 65	Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1373153	Inhibition of recombinant wild-type HIV-1 3B reverse transcriptase p66/p51 RNA-dependent DNA polymerase activity expressed in Escherichia coli JM109 assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID1173645	Cytotoxicity against human CEmx174 cells expressing GFP after 5 days by resazurin assay	2014	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 24, Issue:23	Serendipitous discovery of 2-((phenylsulfonyl)methyl)-thieno[3,2-d]pyrimidine derivatives as novel HIV-1 replication inhibitors.
AID267646	Cytotoxicity against HEK293T cells	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID619640	Antiviral activity against HIV-1 3B harboring RT K103N and Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID1199052	Antiviral activity against Human immunodeficiency virus 1 3b infected in human MT4 cells assessed as inhibition of virus replication after 5 days by MTT assay	2014	Journal of natural products, Jun-27, Volume: 77, Issue:6	Jatrophane diterpenes as inhibitors of chikungunya virus replication: structure-activity relationship and discovery of a potent lead.
AID317730	Antiviral activity against HIV13B infected in human MT4 cells	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID508754	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V179F, Y181C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1763897	Antiviral activity against HIV-1 IIIB infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 06-15, Volume: 40	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs.
AID104450	Concentration required to protect the cell against HIV-2 strain ROD viral cytopathogenicity by 50% in MT-4 cells; NA denotes not active	2004	Bioorganic & medicinal chemistry letters, Jun-21, Volume: 14, Issue:12	5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.
AID1335214	Antiviral activity against HIV-1 NL4-3 harboring RT-L100I/K103N double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID781025	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs.
AID279450	Antiviral activity against HIV1 isolate with RT 98G, 103N, 181C mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID440077	Antiviral activity against HIV1 HXB2 harboring 101E mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID269805	Antiviral activity against HIV1 Y181S mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269805	Antiviral activity against HIV1 Y181S mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269805	Antiviral activity against HIV1 Y181S mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID551466	Selectivity index, ratio of CC50 for human C1866 cells to EC50 for HIV1 3B infected in human C8166 cells	2011	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 21, Issue:2	Synthesis and biological evaluation of novel dihydro-aryl/alkylsulfanyl-cyclohexylmethyl-oxopyrimidines (S-DACOs) as high active anti-HIV agents.
AID619639	Antiviral activity against HIV-1 3B harboring RT F227L and V106A mutant infected in human MT4 cells assessed as inhibition of virus-induced syncytium formation after 5 days by MTT assay	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID1165079	Inhibition of HIV1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation using poly(rA)-oligo(dT) as template/primer and digoxigenin-/biotin-labeled dUTP nucleotides incubated for 1 hr	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
AID1335213	Antiviral activity against HIV-1 NL4-3 harboring RT-Y188L mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID1199051	Cytotoxicity against human MT4 cells assessed as inhibition of overall cell metabolism after 5 days by MTT assay	2014	Journal of natural products, Jun-27, Volume: 77, Issue:6	Jatrophane diterpenes as inhibitors of chikungunya virus replication: structure-activity relationship and discovery of a potent lead.
AID197943	In vitro inhibition of mutant Y181C recombinant reverse transcriptase of HIV-1 IIIB	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors.
AID1379959	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity by measuring virus-induced syncytium formation by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.
AID1741390	Inhibition of reverse transcriptase in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID734263	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for Human immunodeficiency virus 1 SF33 infected in human MT4 cells	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID1352318	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 4 days by MTT assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID1884492	Antiviral activity against drug-resistant HIV-1 Y188L mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID492281	Antiviral activity against wild type HIV1 LAI infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1335202	Ratio of IC50 for HIV-1 NL4-3 harboring RT-K103N/G190A double mutant infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein to IC50 for wild-type HIV-1 NL4-3 infected in HEK293T cells co-expressing vesicular stomatitis virus glyco	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID248262	In vitro inhibitory concentration against HIV V106A mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID247526	Inhibitory activity against wild type HIV-1 LAI cell line	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID265470	Cytotoxicity against human lymphocytes	2006	Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11	Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide.
AID496630	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase Y181C/V35T, V60I, I135V, S162A, K173T, Q174K, N175Y, D177E, T200A, Q207E, R211K, H221Y mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID200170	Inhibition single mutant of HIV-1 RT (K103 N)	1993	Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9	5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
AID279473	Antiviral activity against HIV1 isolate with RT 230L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID257916	Antiviral activity against HIV1 K103N mutant using HeLa MAGI assay	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.
AID248257	In vitro inhibitory concentration against HIV G190A mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID508772	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase Y188L mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID246556	Concentration required for 50% protection of infected MT-4 cells from wtIIIB-HIV-1-induced cytopathogenicity was determined by the MTT method	2005	Journal of medicinal chemistry, Jan-13, Volume: 48, Issue:1	Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives.
AID155280	Anti-HIV activity by its ability to inhibit the replication of HIV-1 strain RT-MDR(V106A) in peripheral blood mononuclear cells (PBMC)	1999	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 9, Issue:18	N-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea and N'-[2-(1-cyclohexenyl)ethyl]-N'-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1.
AID1705190	Resistance index, ratio of EC50 for antiviral activity against HIV1 harboring RT K103N mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 NL4-3 infected in human MT4 cells	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	New indolylarylsulfone non-nucleoside reverse transcriptase inhibitors show low nanomolar inhibition of single and double HIV-1 mutant strains.
AID197941	In vitro inhibition of mutant P236L recombinant reverse transcriptase of HIV-1 IIIB	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors.
AID492047	Antiviral activity against HIV1 bearing reverse transcriptase K103N and Y181C double mutation infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13	Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors.
AID1165077	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
AID561940	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 after 18 to 24 hrs by agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Lack of antimicrobial activity by the antiretroviral drug nevirapine against common bacterial pathogens.
AID663297	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID1815396	Inhibition of wild type HIV1 reverse transcriptase using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID1217711	Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay	2011	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7	Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID413565	Ratio of EC50 for multidrug-resistant HIV1 with reverse transcriptase 41L, 74V, 184V, 210W, 215Y, ins SS, 98G mutation to EC50 for wild type HIV1 3B	2008	Journal of medicinal chemistry, Dec-25, Volume: 51, Issue:24	Development and preclinical studies of broad-spectrum anti-HIV agent (3'R,4'R)-3-cyanomethyl-4-methyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (3-cyanomethyl-4-methyl-DCK).
AID508766	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase M230V mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID734270	Inhibition of HIV1 reverse transcriptase after 1 hr by colorimetric assay	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID279442	Antiviral activity against HIV1 isolate with RT 98G, 190A mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID698299	Selectivity index, ratio of EC50 for HIV1 containing reverse transcriptase Y188L mutant to EC50 for wild type HIV1 NL4-3	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID286999	Inhibition of DNA polymerase activity of HIV1 reverse transcriptase	2007	Journal of medicinal chemistry, May-17, Volume: 50, Issue:10	De novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variants.
AID1316330	Antiviral activity against wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID1609106	Antiviral activity against HIV-1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 4 days by MTT assay	2019	European journal of medicinal chemistry, Nov-15, Volume: 182	Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1435510	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay
AID573477	Antiviral activity of Human immunodeficiency virus 1 isolate 8116 harboring A98S, G190A mutation in reverse transcriptase by cell based assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID1815388	Resistance fold, ratio of EC50 for HIV1 harboring reverse transcriptase K103N mutant infected MV4 cells to EC50 for wild type HIV1 infected MV4 cells	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID1304405	Selectivity index, ratio of CC50 for cytotoxicity against mock-infected human MT4 cells to EC50 for antiviral activity against HIV-1 3B	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID1460947	Inhibition of HIV1 NL4-3 reverse transcriptase assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer after 1 hr by microbeta scintillation counting analysis	2017	Bioorganic & medicinal chemistry, 12-01, Volume: 25, Issue:23	An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors.
AID279447	Antiviral activity against HIV1 isolate with RT 236L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID105324	Inhibition of Efavirenz resistant HIV-1 (K103N-Y181C) induced cytopathicity in MT-4 cells.	2004	Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15	Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations.
AID1161106	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.
AID1815380	Antiviral activity against HIV1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID573471	Inhibition of DNA-dependent DNA polymerase activity of wild-type Human immunodeficiency virus 1 subtype B reverse transcriptase G190A-81C mutant by filter-based filtration assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID1811044	Antiviral activity against HIV1 IIIB infected human MT4 cells assessed as protection against virus-induced cytopathic effect by MTT assay	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
AID279427	Antiviral activity against HIV1 isolate with RT 103R, 179D, 188L mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID293559	Antiviral activity against HIV1 LAI with RT Y188L mutation in MT4 cells by EGFP based replication assay	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID650690	Inhibition of HIV 1 reverse transcriptase Y181I mutant assessed as inhibition of time-dependent incorporation of [3H]dTTP into poly(rA)n.oligo(dT)	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level.
AID370724	Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 expressed in Escherichia coli JM109	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
AID246265	Effective concentration against human immunodeficiency virus type 1 G190S mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
AID1056582	Antiviral activity against HIV-1 expressing reverse transcriptase K103N mutant infected in human 293T cells co-transfected with VSVG protein assessed as inhibition of viral-replication incubated 15 mins prior to viral-infection measured after 48 hrs by lu	2013	Journal of natural products, Dec-27, Volume: 76, Issue:12	Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73.
AID198086	Inhibitory activity against HIV-1 Y181C Reverse transcriptase (RT)	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse transcriptase enzymes.
AID360711	Inhibition of HIV1 RT Y181C mutant mediated DNA-dependent DNA polymerization using DNA PPT primed substrate by scintillation proximity assay	2007	The Journal of biological chemistry, Mar-16, Volume: 282, Issue:11	HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro.
AID1687683	Antiviral activity against HIV-1 E138K mutant strain infected in human MT4 cells assessed as reduction in virus-induced cytopathogenicity by MTT assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Indazolyl-substituted piperidin-4-yl-aminopyrimidines as HIV-1 NNRTIs: Design, synthesis and biological activities.
AID510360	Inhibition of HIV1 reverse transcriptase after 1 hr by ELISA	2010	European journal of medicinal chemistry, Sep, Volume: 45, Issue:9	Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents.
AID1171589	Resistance index, ratio of EC50 for HIV1 NL4-3 expressing reverse transcriptase Y181C mutant to EC50 for wild type HIV1 NL4-3	2014	Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23	Indolylarylsulfones carrying a heterocyclic tail as very potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1457061	Ratio of EC50 for HIV-1 harboring reverse transcriptase Y188L mutant infected in human MT4 cells to EC50 for HIV1 NL4-3 infected in human MT4 cells	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID269793	Antiviral activity against HIV1	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269793	Antiviral activity against HIV1	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269793	Antiviral activity against HIV1	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID573466	Inhibition of Human immunodeficiency virus 1 subtype B reverse transcriptase Y181C mutant by filter-based filtration assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID1152373	Cytotoxicity against human MT4 cells by MTT assay	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID279452	Antiviral activity against HIV1 isolate with RT 103N, 108I, 238T mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID572178	Antiviral activity against HIV-1 subtype H V029523 harboring NNRTI K101Q and V179I mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID734257	Antiviral activity against NNRTI-resistant Human immunodeficiency virus 1 harboring reverse transcriptase K103N mutation infected in human MT4 cells assessed decrease in p24 level after 7 days by ELISA	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID566900	Cytotoxicity against human MT4 cells after 5 days by spectrophotometry	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection.
AID1163234	Cytotoxicity against human TZM-bl cells assessed as cell viability after 48 hrs by WST1 assay	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID1186000	Antiviral activity against HIV1 harboring reverse transcriptase K103N/P225H double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID571981	Antiviral activity against HIV-1 subtype B V022813 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1773449	Antiviral activity against wild type HIV1 harboring E138K mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathogenic effect by MTT assay
AID1636928	Cytotoxicity against human MT2 cells assessed as growth inhibition by MTT method	2016	Bioorganic & medicinal chemistry, 10-15, Volume: 24, Issue:20	Computer-aided discovery of anti-HIV agents.
AID736439	Inhibition of HIV1 reverse transcriptase p66/p51 L100I mutant after 30 mins by liquid scintillation counting	2013	Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID440079	Antiviral activity against HIV1 HXB2 harboring 138K mutant reverse transcriptase infected in human MT4 cells after 5 days by MTT assay	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents.
AID522369	Antiviral activity against recombinant HIV1 harboring reverse transcriptase V106A mutant clone infected in MAGIC-5 cells using 5-bromo4-chloro-3-indolyl-beta-D-galactopyranoside staining based light microscopy	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
AID298065	Metabolic stability in rat plasma	2007	Journal of medicinal chemistry, Oct-04, Volume: 50, Issue:20	Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
AID1292011	Cytotoxicity against mock infected human MT4 cells after 4 days by MTT assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
AID1352316	Antiviral activity against HIV1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 4 days by MTT assay	2018	European journal of medicinal chemistry, Feb-10, Volume: 145	Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1.
AID1637402	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for human HIV-1 3B harboring Y188L mutant infected in human MT4 cells	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID392513	Antiviral activity against HIV1	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID1185994	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID1410486	Inhibition of wild-type HIV1 reverse transcriptase infected in human MT4 cells assessed as reduction in biotin-dUTP incorporation	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery.
AID247618	Inhibitory activity against HIV-1 double mutants strain 101E and 103N	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID621974	Inhibition of DNA-dependent DNA polymerase activity of HIV1 reverse transcriptase p66/p66 homodimer using activated DNA and [alpha-32P]dATP after 30 mins by liquid scintillation counting	2011	Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19	1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents.
AID257163	Inhibition of wild type HIV1 reverse transcriptase by [3H]dTTP poly(rA)/oligo(dT) incorporation	2005	Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25	Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.
AID1750719	Inhibition of HIV-1 p66/p51 reverse transcriptase Y181C mutant incubated for 40 mins by picogreen dye-based spectrofluorometric analysis	2021	Journal of medicinal chemistry, 04-22, Volume: 64, Issue:8	Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
AID572174	Antiviral activity against HIV-1 subtype CRF05_DF V022833 harboring NNRTI V179I mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID479214	Inhibition of biotin-dUTP labeled HIV-1 reverse transcriptase after 30 mins colorimetric streptavidin alkaline phosphatase reporter system	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of novel 2-arylalkylthio-4-amino-6-benzyl pyrimidines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID496634	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase V90I,A98G/V35T, E36D, T39K, S48A, I50V, V60I, S68G, I135V, S162A, K173T, Q174K, D177E, G196E, T200A, E203G, Q207D, R211K, Q222P mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID508755	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V179E, Y181C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID416757	Antiviral activity against HIV1 with reverse transcriptase Y181C mutation in human CEM cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1275545	Antiviral activity against HIV1 3B expressing reverse transcriptase Y181C mutant infected in human MT4 cells assessed as reduction of virus-induced cytopathic effect after 5 days by MTT assay	2016	European journal of medicinal chemistry, Feb-15, Volume: 109	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
AID614140	Cytotoxicity against human MT4 cells after 4 days by MTT assay	2011	Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17	Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.
AID1741395	Inhibition of reverse transcriptase Y181C mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID279440	Antiviral activity against HIV1 isolate with RT 101R, 103N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID82605	The effect of protein binding on the antiviral activity versus wild type virus strain HXB2 was tested in the presence of human serum in HeLa MAGI assay	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID257173	Cytotoxicity against MT4 cells by MTT method	2005	Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25	Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.
AID1197834	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 RES056 expressing reverse transcriptase K103N + Y181C double mutant	2015	European journal of medicinal chemistry, Mar-06, Volume: 92	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches.
AID363037	Cytotoxicity against human MT4 cells after 4 days by MTT assay	2008	European journal of medicinal chemistry, Jun, Volume: 43, Issue:6	Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 11: structural modulations of diaryltriazines with potent anti-HIV activity.
AID105202	Antiviral activity against MT-4 cells infected with Nev-R strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1059143	Cytotoxicity against human MT4 cells after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24	Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID198074	Inhibitory activity against HIV-1 Mutant Reverse transcriptase K103N	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones.
AID736041	Inhibition of HIV1 reverse transcriptase p66/p51 V106A mutant after 30 mins by liquid scintillation counting	2013	Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID1483279	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 3B harboring reverse transcriptase infected in human MT4 cells	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID1520066	Inhibition of recombinant wild type HIV-1 His-tagged reverse transcriptase p66/p51 expressed in Escherichia coli JM109 using poly(rA)/oligo(dT)16 as template/primer incubated for 40 mins by pico-green based spectrofluorometric analysis	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID83550	Potency evaluated against NNRTI-Resistant HIV-1 strain Lys103Asn	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 varian
AID508780	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase E138S mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1636357	Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1060625	Inhibition of wild-type HIV1 reverse transcriptase assessed as incorporation of biotin-labeled dUTP	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.
AID1141964	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cell death measured after 5 days of infection by MTT method	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1880373	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay	2022	Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12	Structure-Based Discovery of Novel NH
AID613673	Induction of apoptosis in human A375 cells seeded as high density at 20 uM after 96 hrs by DAPI staining-based FACS analysis	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitors.
AID443751	Toxicity in African green monkey Vero cells	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile.
AID693586	Cytotoxicity against human MT4 cells assessed as decrease in cell viability after 5 days by MTT assay	2012	European journal of medicinal chemistry, Dec, Volume: 58	Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1815397	Inhibition of HIV1 reverse transcriptase L100I mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.
AID1373160	Inhibition of reverse transcriptase Y188L mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	2018	Bioorganic & medicinal chemistry, 02-01, Volume: 26, Issue:3	Structural optimization of N
AID279429	Antiviral activity against HIV1 isolate with RT 103N, 106M mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID561939	Antiviral activity against HIV infected in human PBMC assessed as decrease in viral p24 antigen production at 0.25 to 4 ug/ml after 14 days by ELISA	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Lack of antimicrobial activity by the antiretroviral drug nevirapine against common bacterial pathogens.
AID198257	Inhibitory concentration against mutant reverse transcriptase of E138K was determined which is in turn resistant to TSAO	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse transcriptase enzymes.
AID279435	Antiviral activity against HIV1 isolate with RT 101Q, 103R mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID155272	Ability to inhibit the replication of HTLV IIIb strain of HIV-1 p24 antigen production in PBMC	1999	Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24	N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
AID1185990	Antiviral activity against wild type HIV1 infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID1171414	Cytotoxicity against human MT2 cells assessed as reduction in cell viability by MTT assay	2014	ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11	Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.
AID1457064	Inhibition of HIV1 reverse transcriptase p66 K103N mutant associated RNA dependent DNA polymerase activity expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer by scintillation counting	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Chiral Indolylarylsulfone Non-Nucleoside Reverse Transcriptase Inhibitors as New Potent and Broad Spectrum Anti-HIV-1 Agents.
AID557046	Antiviral activity against HIV1 clade C harboring mutant reverse transcriptase relative to HIV1 CNDO with wild type reverse transcriptase	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.
AID476473	Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase K103N/Y181C mutation by MTT assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.
AID198916	Inhibition of HIV-1 Mutant HIV-1 RT enzymes containing the single amino acid substitution Y188L	2001	Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3	Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.
AID199102	Inhibitory concentration against wild-type reverse transcriptase of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1292010	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/YI81C double mutant infected in human MT4 cells assessed as cell viability after 4 days by MTT assay	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
AID318125	Cytotoxicity against human MT4 cells	2008	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4	Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
AID152659	Inhibitory activity of compound on p24 production in peripheral blood mononuclear cells infected with HIV strain A17.	1999	Bioorganic & medicinal chemistry letters, Jun-07, Volume: 9, Issue:11	Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus.
AID246349	Effective concentration against human immunodeficiency virus type 1 mutated at 103N	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
AID508773	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase Y181V mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID235889	Ratio of effective concentration to that of cytotoxic concentration against HIV-1 induced cytopathogenicity in MT-4 cells	1992	Journal of medicinal chemistry, Jul-24, Volume: 35, Issue:15	3'-Spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2'-5'-bis-O-(tert-butyldimethylsilyl)-beta-D-xylo- and -ribofuranose]-3'-spiro-5"-[4"-amino-1",2"-oxathiole 2",2"-dioxide] (
AID269686	Antiviral activity against HIV1 NNTRI resistant Y188L mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I.
AID269686	Antiviral activity against HIV1 NNTRI resistant Y188L mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID269686	Antiviral activity against HIV1 NNTRI resistant Y188L mutant	2006	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16	Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID698303	Cytotoxicity against mock-infected human MT4 cells measured after 5 days by MTT assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID279393	Antiviral activity against HIV1 isolate with RT 106I mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1335203	Ratio of IC50 for HIV-1 NL4-3 harboring RT-K103N/P225H double mutant infected in HEK293T cells co-expressing vesicular stomatitis virus glycoprotein to IC50 for wild-type HIV-1 NL4-3 infected in HEK293T cells co-expressing vesicular stomatitis virus glyco	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID561950	Antibacterial activity against Salmonella group D after 18 to 24 hrs by agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Lack of antimicrobial activity by the antiretroviral drug nevirapine against common bacterial pathogens.
AID318124	Cytotoxicity against human CEM-SS cells	2008	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4	Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
AID1572524	Antiviral activity against HIV1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as inhibition of virus-induced cytotoxicity after 5 days by MTT assay
AID1072803	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2014	Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6	Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
AID781021	Inhibition of HIV1 reverse transcriptase assessed as inhibition of biotinylated dUTP incorporation after 1 hr by ELISA	2013	Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22	Design, synthesis and biological evaluation of N2,N4-disubstituted-1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs.
AID248648	Inhibitory concentration against wild type human immunodeficiency virus type 1 was determined by recombinant virus assay	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
AID46379	Antiviral activity against site directed resistant isolate HIV-1 L74V in CEM cells	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID1460945	Therapeutic index, ratio of TC50 for human MAGI-CCR5 cells to IC50 for HIV-1 NL4-3 harboring reverse transcriptase E138A mutant infected in MAGI-CCR5 cells	2017	Bioorganic & medicinal chemistry, 12-01, Volume: 25, Issue:23	An integrated chemical biology approach reveals the mechanism of action of HIV replication inhibitors.
AID1186688	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV-1 3B infected in human MT4 cells	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach.
AID1483284	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for reverse transcriptase E138K mutant in human MT4 cells infected HIV1 3B	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
AID571970	Antiviral activity against HIV-1 subtype CRF02_AG V022830 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID496631	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase V90I,Y181C/V35T, T39M, P119S, D123E, S162A, E169D, K173T, Q174K, D177E, T200A, Q207E, K219N, V245Q, E248D mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID1754647	Antiviral activity against HIV1 harboring RT RES056 mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	Bioorganic & medicinal chemistry, 07-15, Volume: 42	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses.
AID482698	Antiviral activity against HIV S067 infected in human A72 Jurkat cells assessed as inhibition of GFP expression after 48 hrs by flow cytometry	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID613681	Antiproliferative activity against human A375 cells at 350 uM after 96 hrs by trypan blue assay	2011	Journal of medicinal chemistry, Aug-25, Volume: 54, Issue:16	Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitors.
AID246362	Effective concentration against rhuman immunodeficiency virus type 1 K103N and Y181C mutant strains	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
AID1377176	Antiviral activity against HIV1 isolate LAV infected in PHA-stimulated human PBMC assessed as reduction in p24 level after 7 days by ELISA	2017	Journal of natural products, 06-23, Volume: 80, Issue:6	Potent Inhibitor of Drug-Resistant HIV-1 Strains Identified from the Medicinal Plant Justicia gendarussa.
AID317728	Inhibition of HIV1 reverse transcriptase	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
AID571982	Antiviral activity against HIV-1 subtype B V022814 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID630952	Selectivity index, ratio of CC50 for human TZM-bl cells to EC50 for X4 tropic Human immunodeficiency virus 1 subtype B-3B	2011	Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22	Lead optimization at C-2 and N-3 positions of thiazolidin-4-ones as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1811038	Inhibition of recombinant wild-type HIV1 p66/p51 reverse transcriptase assessed as inhibition of [3H]dGTP incorporation using poly (rA) as templates incubated for 40 mins by spectrofluorometer	2021	Journal of medicinal chemistry, 07-22, Volume: 64, Issue:14	Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
AID431619	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as virus-induced cytopathic effect by MTT assay	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID440672	Antiviral activity against HIV1 EFV with reverse transcriptase K103R, V179D, P225H mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Activity and molecular modeling of a new small molecule active against NNRTI-resistant HIV-1 mutants.
AID83553	Potency evaluated against NNRTI-Resistant HIV-1 strain Val106Ala	2004	Journal of medicinal chemistry, May-06, Volume: 47, Issue:10	Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 varian
AID279422	Antiviral activity against HIV1 isolate with RT 190E mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID476471	Cytotoxicity against human MT2 cells infected with HIV1 harboring reverse transcriptase Y181C mutation by MTT assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives.
AID246299	Effective concentration of the compound to inhibit HIV-1 mutant L100I replication in HIV-infected MT-4 cells	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID348904	Antiviral activity against wild type HIV1 NL4-3 infected in human MT4 cells assessed as virus-induced cell death by MTT method	2008	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21	Towards novel S-DABOC inhibitors: synthesis, biological investigation, and molecular modeling studies.
AID257164	Inhibition of K103N mutant HIV1 reverse transcriptase by [3H]-dTTP poly(rA)/oligo(dT) incorporation	2005	Journal of medicinal chemistry, Dec-15, Volume: 48, Issue:25	Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.
AID391990	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B	2008	European journal of medicinal chemistry, Dec, Volume: 43, Issue:12	Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.
AID1322997	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days MTT assay	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Synthesis and antiproliferative evaluation of novel 2-(4H-1,2,4-triazole-3-ylthio)acetamide derivatives as inducers of apoptosis in cancer cells.
AID1485975	Inhibition of HIV-1 reverse transcriptase G190A mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis	2017	Bioorganic & medicinal chemistry, 07-15, Volume: 25, Issue:14	Searching for novel N
AID302261	Inhibition of HIV1 reverse transcriptase L100I mutant	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID1191972	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as protection against virus-induced cytotoxicity after 5 days by MTT assay	2015	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 25, Issue:6	Design, synthesis of new β-carboline derivatives and their selective anti-HIV-2 activity.
AID1126509	Cytotoxicity against mock-infected human MT4 cells after 5 days by MTT assay	2014	Bioorganic & medicinal chemistry, Apr-15, Volume: 22, Issue:8	Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1610040	Antiviral activity against HIV1 N119 infected in human TZM-bl cells incubated for 48 hrs by bright Glo-luciferase reporter gene assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Synthesis and in-vitro anti-HIV-1 evaluation of novel pyrazolo[4,3-c]pyridin-4-one derivatives.
AID698305	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathicity measured 5 days post infection by MTT assay	2012	Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14	New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1191670	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2015	Bioorganic & medicinal chemistry, Mar-01, Volume: 23, Issue:5	Scaffold hopping: exploration of acetanilide-containing uracil analogues as potential NNRTIs.
AID734262	Selectivity index, ratio of CC50 for human TZM-bl cells to EC50 for Human immunodeficiency virus 1 A17 infected in human TZM-bl cells	2013	Journal of medicinal chemistry, May-09, Volume: 56, Issue:9	Novel pyridinone derivatives as non-nucleoside reverse transcriptase inhibitors (NNRTIs) with high potency against NNRTI-resistant HIV-1 strains.
AID1558854	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
AID492046	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type HIV1 3B	2010	Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13	Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors.
AID1141969	Ratio of EC50 for HIV1 harboring reverse transcriptase K103N/Y181C double mutant to EC50 for wild type HIV1 NL4.3	2014	European journal of medicinal chemistry, Jun-10, Volume: 80	New indolylarylsulfones as highly potent and broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID1743635	Resistance index, ratio of EC50 for antiviral activity against HIV1 expressing RT K103N mutant infected in human MT4 cells to EC50 for antiviral activity against HIV1 3B infected in human MT4 cells	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility.
AID766431	Cytotoxicity against human MT2 cells by MTT assay	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.
AID508790	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase K103N mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1190617	Inhibition of HIV-1 reverse transcriptase using digoxigenin/biotin-labeled dUTP as substrate at 100 ug/ml incubated for 1 hr followed by compound washout measured after 1 hr by non-radioactive ELISA relative to control	2015	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 25, Issue:4	Dithiocarbamate-thiourea hybrids useful as vaginal microbicides also show reverse transcriptase inhibition: design, synthesis, docking and pharmacokinetic studies.
AID587739	Cytotoxicity against human HeLaT4 cells by WST-1 assay	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.
AID391993	Cytotoxicity against human CEM cells by MTT assay	2008	European journal of medicinal chemistry, Dec, Volume: 43, Issue:12	Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.
AID430057	Selectivity index, CC50 for human MT4 cells to EC50 for HIV1 3B	2009	Bioorganic & medicinal chemistry, Aug-15, Volume: 17, Issue:16	Design, synthesis, and structure-activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents.
AID106774	Cell culture inhibitory concentration against spread of HIV-I infection in MT-4 cells was determined	1993	Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2	Synthesis and evaluation of 2-pyridinone derivatives as specific HIV-1 reverse transcriptase inhibitors. 3. Pyridyl and phenyl analogs of 3-aminopyridin-2(1H)-one.
AID361904	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K103N/L100I mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID416758	Antiviral activity against HIV1 with reverse transcriptase Y181I mutation in human CEM cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1357800	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 harboring reverse transcriptase L100I mutant	2018	European journal of medicinal chemistry, May-10, Volume: 151	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
AID663296	Antiviral activity against HIV1 harboring reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	2-(Alkyl/aryl)amino-6-benzylpyrimidin-4(3H)-ones as inhibitors of wild-type and mutant HIV-1: enantioselectivity studies.
AID1520059	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Jan-01, Volume: 185	Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.
AID46382	Antiviral activity against site directed resistant isolate HIV-1 Y181C in CEM cells	2001	Journal of medicinal chemistry, Nov-22, Volume: 44, Issue:24	The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
AID1761014	Antiviral activity against HIV-1 harboring reverse transcriptase L100I mutant infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect measured after 5 days by MTT assay	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase.
AID1888690	Antiviral activity against HIV1 3B infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay
AID1741394	Inhibition of reverse transcriptase K103N mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2020	European journal of medicinal chemistry, Sep-15, Volume: 202	Bioisosterism-based design and enantiomeric profiling of chiral hydroxyl-substituted biphenyl-diarylpyrimidine nonnucleoside HIV-1 reverse transcriptase inhibitors.
AID263513	Antiviral activity against HIV1 K103N mutant	2006	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 16, Issue:8	Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2.
AID440639	Antiviral activity against NNRTI-resistant HIV1 NL4-3 with reverse transcriptase Y181C mutation infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20	Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase.
AID440669	Cytotoxicity against human MT4 cells assessed as reduction of cell viability after 4 days by MTT assay	2009	European journal of medicinal chemistry, Dec, Volume: 44, Issue:12	Activity and molecular modeling of a new small molecule active against NNRTI-resistant HIV-1 mutants.
AID1171412	Antiviral activity against wild type HIV1 harboring reverse transcriptase Y181C mutant infected in human MT2 cells assessed as protection from virus-induced cytopathicity by MTT assay	2014	ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11	Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.
AID619631	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	2011	European journal of medicinal chemistry, Oct, Volume: 46, Issue:10	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
AID1292012	Selectivity index, ratio of CC50 for mock infected human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket.
AID571979	Antiviral activity against HIV-1 subtype B V022811 infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID590348	Inhibition of Human immunodeficiency virus 1 NL4.3 reverse transcriptase activity at 0.1 ug/ml	2011	European journal of medicinal chemistry, Apr, Volume: 46, Issue:4	Synthesis of 9-substituted derivatives of berberine as anti-HIV agents.
AID736038	Inhibition of HIV1 reverse transcriptase p66/p51 K103N/Y181C mutant after 30 mins by liquid scintillation counting	2013	Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID1880380	Antiviral activity against HIV-1 IIIB harboring reverse transcriptase E138K mutant infected in human MT4 cells by MTT assay	2022	Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12	Structure-Based Discovery of Novel NH
AID1654197	Plasma concentration in human	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death.
AID299031	Antiviral activity against HIV1 with reverse transcriptase Y188H mutation in CEM cells assessed as inhibition of virus-induced giant cell formation	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
AID1155807	Antiviral activity against HIV-1 harboring NNTRI-resistant reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT method	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID318127	Inhibition of PDE4B2 expressed in COS7 cells assessed as cAMP hydrolysis	2008	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4	Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
AID279421	Antiviral activity against HIV1 isolate with RT 101E, 190S mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1390714	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 RES056 expressing reverse transcriptase K103N/Y181C double mutant	2018	Bioorganic & medicinal chemistry letters, 05-01, Volume: 28, Issue:8	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.
AID105000	Inhibitory concentration which prevents the spread of HIV-1 IIIB infection in MT2 T-lymphoid cells	1993	Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17	Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2,3-dihydrothiazolo[2,3-a]isoindol-5(9bH)-ones and related compounds with anti-HIV-1 activity.
AID607876	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for wild type Human immunodeficieny virus 1 3B infected in human MT4 cells	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID361918	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase K101E mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID779526	Cytotoxicity against human MT4 cells assessed as cell viability after 5 days by MTT assay	2013	Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21	Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.
AID197948	In vitro inhibitory concentration against HIV-1 reverse transcriptase using rC-dG template primer	1993	Journal of medicinal chemistry, Jan-22, Volume: 36, Issue:2	Synthesis and evaluation of 2-pyridinone derivatives as specific HIV-1 reverse transcriptase inhibitors. 3. Pyridyl and phenyl analogs of 3-aminopyridin-2(1H)-one.
AID248012	In vitro inhibitory concentration against HIV LAI cell line	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID1308895	Inhibition of HIV reverse transcriptase transfected in HEK293T cells assessed as reduction in viral replication measured at 48 hrs postinfection by luciferase reporter based single-cycle non replicative phenotypic assay	2016	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 26, Issue:15	Application of the Huisgen cycloaddition and 'click' reaction toward various 1,2,3-triazoles as HIV non-nucleoside reverse transcriptase inhibitors.
AID1654200	Drug metabolism in C57BL/6J mouse primary hepatocytes assessed as Cytochrome P450-mediated formation of 3-OHNVP at 10 uM incubated for 24 hrs by uHPLC-MS analysis	2020	Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12	Twelfth-Position Deuteration of Nevirapine Reduces 12-Hydroxy-Nevirapine Formation and Nevirapine-Induced Hepatocyte Death.
AID508633	Cytotoxicity against human MT4 cells by cell based assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID241996	Concentration required for 50% inhibition of human immunodeficiency virus type 1 reverse transcriptase Ile100	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
AID267651	Selectivity for wild type HIV1 virus over HIV1 K103N mutant	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID391680	Selectivity index, ratio of inhibition of DNA dependent DNA polymerase activity of Escherichia coli DNA polymerase 1 Klenow fragment to inhibition of DNA dependent DNA polymerase activity of HIV1 BH10 recombinant reverse transcriptase p66/p51	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Virtual screening, identification, and biochemical characterization of novel inhibitors of the reverse transcriptase of human immunodeficiency virus type-1.
AID157558	Cytotoxic concentration was evaluated using microculture tetrazolium assay (MTA)	1999	Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24	N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
AID1637403	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for human HIV-1 3B harboring E138K mutant infected in human MT4 cells	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach.
AID1888699	Antiviral activity against HIV1 with RT RES056 mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay
AID279471	Antiviral activity against HIV1 isolate with RT 103N, 238N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1155815	Inhibition of HIV-1 recombinant NNTRI-resistant reverse transcriptase Y181I mutant assessed as incorporation of [3H]dTTP into poly(rA)/oligo(dT)10:1	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Exploring the role of 2-chloro-6-fluoro substitution in 2-alkylthio-6-benzyl-5-alkylpyrimidin-4(3H)-ones: effects in HIV-1-infected cells and in HIV-1 reverse transcriptase enzymes.
AID1888695	Antiviral activity against HIV1 with RT K103N mutant infected in human MT4 cells cells assessed as protection against viral-induced cytopathogenecity by MTT assay
AID496629	Antiviral activity against HIV-1 subtype CRF02_AG containing reverse transcriptase E138A/K20R, V35T, E36D, T39N, V60I, D123N, I135V, S162A, K173T, Q174K, D177E, T200A, Q207E, R211K mutant relative to control	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
AID561942	Antibacterial activity against Escherichia coli ATCC 25922 after 18 to 24 hrs by agar dilution method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Lack of antimicrobial activity by the antiretroviral drug nevirapine against common bacterial pathogens.
AID361926	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase V106A/Y181C mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID573469	Inhibition of DNA-dependent DNA polymerase activity of wild-type Human immunodeficiency virus 1 subtype B reverse transcriptase G190A mutant by filter-based filtration assay	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine.
AID279399	Antiviral activity against HIV1 isolate with RT 179D mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID1335216	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase reporter gene	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID1784215	Antiviral activity against HIV1 harboring reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect incubated for 5 days by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Discovery, optimization, and target identification of novel coumarin derivatives as HIV-1 reverse transcriptase-associated ribonuclease H inhibitors.
AID247500	Inhibitory activity against HIV-1 mutant strain 179E	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains.
AID1379962	Cytotoxicity in mock-infected human MT4 cells assessed as reduction in cell viability by MTT assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs.
AID302265	Inhibition of HIV1 reverse transcriptase Y188L mutant	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID1187999	Antiviral activity against HIV1 3B acutely infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenic effect after 5 days by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands.
AID1572519	Antiviral activity against HIV1 RES056 harboring reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as inhibition of virus-induced cytotoxicity after 5 days by MTT assay
AID105697	Anti-HIV-1 activity against K103N+K1001 strain was determined	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1884487	Cytotoxicity against human MT4 cells assessed as cell growth inhibition incubated for 5 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID1069709	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Design and synthesis of N₁-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID508756	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase V179D, Y181C mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1320863	Antiviral activity against HIV1 3B expressing wild type reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect after 5 days by MTT assay	2016	European journal of medicinal chemistry, Oct-04, Volume: 121	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket.
AID1487264	Inhibition of recombinant wild type HIV1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation at 50 uM using poly(A)/oligo(dT)15 as template/primer by ELISA relative to control	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.
AID1882470	Antiviral activity against HIV-1 harboring K103N/Y181C mutant infected in human MT2 cells assessed as protection against virus-induced cytopathicity by MTT assay	2022	Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5	Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
AID198917	Inhibition of HIV-1 wild-type RT	2001	Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3	Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.
AID294633	Inhibition of HIV1 reverse transcriptase using Poly rC.dG template	2007	European journal of medicinal chemistry, Jul, Volume: 42, Issue:7	Synthesis and anti-HIV studies of 2-adamantyl-substituted thiazolidin-4-ones.
AID328842	Inhibition of human MRP2 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence by CMFDA assay	2007	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3	Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors.
AID1335208	Antiviral activity against HIV-1 NL4-3 harboring RT-K103N/Y181C double mutant infected in HEK293T cells coexpressing vesicular stomatitis virus glycoprotein pretreated with cells for 15 mins followed by viral infection measured after 48 hrs by luciferase	2016	European journal of medicinal chemistry, Nov-10, Volume: 123	2,4,5-Trisubstituted thiazole derivatives as HIV-1 NNRTIs effective on both wild-type and mutant HIV-1 reverse transcriptase: Optimization of the substitution of positions 4 and 5.
AID293556	Cytotoxicity against human MT4 cells after 3 days by EGFP based replication assay	2007	European journal of medicinal chemistry, May, Volume: 42, Issue:5	Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
AID492284	Antiviral activity against HIV1 with reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
AID632796	Antiviral activity against Human immunodeficiency virus 1 NL4.3 reverse transcriptase Y181C mutant infected in human MT2 cells assessed as inhibition of viral infection	2011	Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24	Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
AID248258	In vitro inhibitory concentration against HIV G190S mutant strain	2005	Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6	4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains.
AID1152374	Selectivity index, ratio CC50 for human MT4 cells to EC50 for HIV 1 3B	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors.
AID105127	Compound was evaluated for the inhibition of HIV-1 induced CPE (HTLV-III B strain ) replication in MT-4 cells	1995	Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12	Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors.
AID725389	Antiviral activity against HIV1 LAI infected in CEMx174-LTR-GFP cells assessed as inhibition of viral replication after 5 days by fluorescence assay	2013	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1	Synthesis and biological evaluation of triazolothienopyrimidine derivatives as novel HIV-1 replication inhibitors.
AID1316329	Inhibition of recombinant wild type HIV1 reverse transcriptase using DIG-dUTP/biotin-dUTP/dTTP assessed as suppression of biotin-dUTP incorporation after 1 hr by ELISA	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.
AID1884490	Antiviral activity against drug-resistant HIV-1 K103 N mutant infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay	2022	European journal of medicinal chemistry, Aug-05, Volume: 238	Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
AID267653	Selectivity for wild type HIV1 virus over HIV1 L100I mutant	2006	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13	Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
AID82141	Effective concentration required to achieve 50% inhibition of HIV-1 multiplication in MT-4-infected K103N strain	2002	Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26	Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants.
AID302256	Resistance index, Ratio of EC50 for drug-resistant HIV1 with RT K103N mutation in MT3 cells to EC50 for HIV1 NL43 in MT3 cells	2007	Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22	Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains.
AID1627028	Cytotoxicity against HIV1 infected African green monkey Vero cells assessed as reduction in cell viability after 7 days by MTT assay	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID572173	Antiviral activity against HIV-1 subtype CRF05_DF V022824 harboring NNRTI V106I mutant infected in human MT4 cells assessed as inhibition of viral replication relative to HIV-1 3B	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
AID1241796	Selectivity index, ratio of IC50 for human C8166 cells to EC50 for HIV1 3B infected in human C8166 cells	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
AID1443667	Antiviral activity against HIV1 harboring reverse transcriptase Y181C mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by MTT assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
AID1185991	Cytotoxicity against HEK293T cells at 10 uM after 48 hrs	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID88369	Antiviral activity against K103N/V108I mutant virus in the HeLa MAGI assay.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID736440	Non-competitive inhibition of wild type HIV1 reverse transcriptase p66/p51 after 30 mins by liquid scintillation counting	2013	Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5	N1,N3-disubstituted uracils as nonnucleoside inhibitors of HIV-1 reverse transcriptase.
AID1152239	Antiviral activity against X4 tropic Human immunodeficiency virus 1 3B subtype B infected in human TZM-bl cells assessed as reduction in virus-induced cytopathic effect after 48 hrs by luminescence assay	2014	Bioorganic & medicinal chemistry, Jun-15, Volume: 22, Issue:12	Rational design and synthesis of novel thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID718366	Inhibition of HIV1 recombinant reverse transcriptase assessed as incorporation of biotin-dUTP into poly(rC)-oligo(dG) by colorimetric analysis	2012	Bioorganic & medicinal chemistry, Dec-01, Volume: 20, Issue:23	Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
AID105203	Antiviral activity against MT-4 cells infected with wild-type HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID1186001	Antiviral activity against HIV1 harboring reverse transcriptase K103N/P225H double mutant infected in HEK293T cells transfected with plasmid VSV-G/pNL4-3.luc.R-E- assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay r	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	2,4,5-Trisubstituted thiazole derivatives: a novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase.
AID1736358	Antiviral activity against VSVG/HIV-1 harboring reverse transcriptase L100I/K103N double mutant infected in human HEK 293T cells assessed as inhibition of virus replication preincubated with cells for 15 mins prior to viral infection and measured at 48 hr
AID518737	Inhibition of DNA-dependent DNA polymerase activity of wild type HIV1 subtype B reverse transcriptase by gel-based primer extension assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
AID366527	Inhibition of RNA dependent DNA polymerase activity of HIV1 reverse transcriptase K103N mutant	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile.
AID1731746	Inhibition of reverse transcriptase L100I mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay
AID416756	Antiviral activity against HIV1 with reverse transcriptase K103N mutation in human CEM cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID259755	Cytotoxicity against MT2 cells	2006	Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3	Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID592539	Selectivity index, CC50 for human CEM cells to IC50 for HIV1 3B	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide.
AID666415	Selectivity index, ratio of CC50 for human MT4 cells to EC50 for HIV1 SF33	2012	Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5	Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.
AID1200846	Selectivity index, ratio of CC50 for mock-infected human MT4 cells to EC50 for HIV1 3B infected in human MT4 cells	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines.
AID279407	Antiviral activity against HIV1 isolate with RT 98G, 103N mutation relative to wild type	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
AID155133	Ability to inhibit the replication of A17 (Y181C) strain of HIV-1 p24 antigen production in PBMC	1999	Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24	N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1.
AID82457	Antiviral activity against G190A strain of HIV-1	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
AID232779	Selectivity index was defined as the ratio of CC50 to EC50	1992	Journal of medicinal chemistry, Aug-07, Volume: 35, Issue:16	TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro -5''- (4''-amino-1'',2''-oxathiole 2'',2''-dioxide) pyrimidine and pyrimidine-modified nucleosides.
AID1627030	Antiviral activity against HIV-1 LAI infected in human PBM cells after 7 days	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Discovery, characterization, and lead optimization of 7-azaindole non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1574372	Antiviral activity against wild type HIV 1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay	2019	Journal of medicinal chemistry, 01-24, Volume: 62, Issue:2	Effect of α-Methoxy Substitution on the Anti-HIV Activity of Dihydropyrimidin-4(3 H)-ones.
AID606672	Inhibition of HIV1 reverse transcriptase K103N mutant	2011	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 21, Issue:13	Enantioselective binding of second generation pyrrolobenzoxazepinones to the catalytic ternary complex of HIV-1 RT wild-type and L100I and K103N drug resistant mutants.
AID1175920	Antiviral activity against VSV-G protein pseudotyped HIV1 system in HEK293T cells assessed as reduction in p24 level after 48 hrs by ELISA	2014	Journal of natural products, Dec-26, Volume: 77, Issue:12	Diterpenes from a Chinese collection of the brown alga Dictyota plectens.
AID508645	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase Y181C, G190S mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID1304404	Selectivity index, ratio of CC50 for cytotoxicity against mock-infected human CEM-SS cells to EC50 for antiviral activity against HIV-1 RF	2016	Bioorganic & medicinal chemistry, 07-01, Volume: 24, Issue:13	Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
AID508784	Antiviral activity against Human immunodeficiency virus 1 HXB2 containing reverse transcriptase E138G mutant relative to Human immunodeficiency virus 1 3B	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
AID518741	Antiviral activity against HIV 1 subtype B harboring reverse transcriptase M230L mutant infected in human TZM-bl cells assessed as inhibition of viral growth by luciferase reporter gene assay	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity.
AID361913	Antiviral activity against NNRTI-resistant HIV1 with reverse transcriptase G190S mutant in HeLa cells by MAGI assay	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1795346	HIV-1 RT Assay from Article 10.1021/jm00025a010: \\Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs.\\	1995	Journal of medicinal chemistry, Dec-08, Volume: 38, Issue:25	Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs.
AID1803151	HIV-1 RT Activity Assay from Article 10.3109/14756366.2011.636362: \\Synthesis and HIV-1 RT inhibitory action of novel (4/6-substituted benzo[d]thiazol -2-yl)thiazolidin-4-ones. Divergence from the non-competitive inhibition mechanism.\\	2013	Journal of enzyme inhibition and medicinal chemistry, Feb, Volume: 28, Issue:1	Synthesis and HIV-1 RT inhibitory action of novel (4/6-substituted benzo[d]thiazol -2-yl)thiazolidin-4-ones. Divergence from the non-competitive inhibition mechanism.
AID1802330	HIV-1 RT Inhibitory Assay from Article 10.1021/acs.biochem.6b00943: \\Physiological Mg(2+) Conditions Significantly Alter the Inhibition of HIV-1 and HIV-2 Reverse Transcriptases by Nucleoside and Non-Nucleoside Inhibitors in Vitro.\\
AID1795390	HIV-1 RT Assay from Article 10.1021/jm960802y: \\Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.\\	1997	Journal of medicinal chemistry, May-09, Volume: 40, Issue:10	Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series.
AID1796846	HIV-1 RT Assay. from Article 10.1021/jm040071z: \\Design of Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 1.\\	2004	Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24	Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
AID1795386	HIV-1 RT Assay from Article 10.1021/jm980260f: \\5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives.\\	1999	Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4	5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives.
AID1797479	HIV-1 RT Assay from Article 10.1021/jm0613121: \\De Novo Parallel Design, Synthesis and Evaluation of Inhibitors against the Reverse Transcriptase of Human Immunodeficiency Virus Type-1 and Drug-Resi\\	2007	Journal of medicinal chemistry, May-17, Volume: 50, Issue:10	De novo parallel design, synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variants.
AID1795327	HIV-1 RT Assay from Article 10.1021/jm00024a011: \\Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 5. 4-Substituted and 2,4-disubstituted analogs of nevirapine.\\	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 5. 4-Substituted and 2,4-disubstituted analogs of nevirapine.
AID1798816	Reverse Transcriptase Assay from Article 10.1021/jm801395v: \\Specific Targeting of Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. 2. Stereoselective Interaction to Overcome the Effects of Drug Resistant Mutations.\\	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations.
AID1795322	HIV-1 RT Assay from Article 10.1021/jm00024a010: \\Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 rev	1995	Journal of medicinal chemistry, Nov-24, Volume: 38, Issue:24	Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse transcriptase enzymes.
AID1795349	HIV-1 RT Assay from Article 10.1021/jm960158n: \\Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors.\\	1996	Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19	Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors.
AID1795423	HIV-1 RT Assay from Article 10.1021/jm990095j: \\Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.\\	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues.
AID1796564	HIV-1 RT Assay from Article 10.1021/jm0009437: \\Synthesis and antiviral activity of 4-benzyl pyridinone derivatives as potent and selective non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors.\\	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Synthesis and antiviral activity of 4-benzyl pyridinone derivatives as potent and selective non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors.
AID1795743	HIV-1 RT Assay from Article 10.1016/j.bmc.2004.08.050: \\Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides.\\	2004	Bioorganic & medicinal chemistry, Dec-01, Volume: 12, Issue:23	Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides.
AID1799587	In Vitro Enzyme Assay from Article 10.1111/j.1747-0285.2009.00852.x: \\In silico screening for non-nucleoside HIV-1 reverse transcriptase inhibitors using physicochemical filters and high-throughput docking followed by in vitro evaluation.\\	2009	Chemical biology & drug design, Sep, Volume: 74, Issue:3	In silico screening for non-nucleoside HIV-1 reverse transcriptase inhibitors using physicochemical filters and high-throughput docking followed by in vitro evaluation.
AID1795381	HIV-1 RT Assay from Article 10.1021/jm00061a022: \\5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.\\	1993	Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9	5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase.
AID1795395	HIV-1 RT Assay from Article 10.1021/jm0211063: \\Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies.\\	2003	Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12	Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies.
AID1795330	HIV-1 RT Assay from Article 10.1021/jm00111a045: \\Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones.\\	1991	Journal of medicinal chemistry, Jul, Volume: 34, Issue:7	Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones.
AID1795385	HIV RT Assay from Article 10.1021/jm950568w: \\2-Sulfonyl-4-chloroanilino moiety: a potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones.\\	1996	Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2	2-Sulfonyl-4-chloroanilino moiety: a potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones.
AID1795367	HIV-1 RT Assay from Article 10.1021/jm950639r: \\Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.\\	1996	Journal of medicinal chemistry, Oct-11, Volume: 39, Issue:21	Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs.
AID1795311	HIV-1 RT Assay from Article 10.1021/jm00069a011: \\Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2,3-dihydrothiazolo[2,3-a]isoindol-5(9bH)-ones and related compounds with anti-HIV-1 activity.\\	1993	Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17	Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2,3-dihydrothiazolo[2,3-a]isoindol-5(9bH)-ones and related compounds with anti-HIV-1 activity.
AID1795355	HIV-1 RT Assay from Article 10.1021/jm9707030: \\Novel Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. 8. 8-Aryloxymethyl- and 8-Arylthiomethyldipyridodiazepinones\\	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 8. 8-Aryloxymethyl- and 8-arylthiomethyldipyridodiazepinones.
AID1795358	HIV-1 RT Assay from Article 10.1021/jm9707028: \\Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 7. 8-Arylethyldipyridodiazepinones as potent broad-spectrum inhibitors of wild-type and mutant enzymes.\\	1998	Journal of medicinal chemistry, Jul-30, Volume: 41, Issue:16	Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 7. 8-Arylethyldipyridodiazepinones as potent broad-spectrum inhibitors of wild-type and mutant enzymes.
AID1802585	RT Assay from Article 10.1016/j.bioorg.2017.01.006: \\Dihydropyrimidinone-isatin hybrids as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.\\	2017	Bioorganic chemistry, 02, Volume: 70	Dihydropyrimidinone-isatin hybrids as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
AID1801807	HIV-1 RT Inhibition Assay from Article 10.1111/cbdd.12751: \\Arylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5-b]pyridin-2-ylthioacetanilides as Potent HIV NNRTIs Via a Structure-based Bioisosterism Approach.\\	2016	Chemical biology & drug design, 08, Volume: 88, Issue:2	Arylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5-b]pyridin-2-ylthioacetanilides as Potent HIV NNRTIs Via a Structure-based Bioisosterism Approach.
AID1795433	HIV-1 RT Assay from Article 10.1021/jm990580e: \\Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.\\	2000	Journal of medicinal chemistry, May-18, Volume: 43, Issue:10	Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
AID1795382	HIV-1 RT Assay from Article 10.1021/jm00062a027: \\Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-c	1993	Journal of medicinal chemistry, May-14, Volume: 36, Issue:10	Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)-carbonyl]-4-[3- [(1-methylethyl)amino]-pyridinyl]pi
AID1795384	HIV-1 RT Assay from Article 10.1021/jm010853h: \\Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibit	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
AID1795394	HIV-1 RT Assay from Article 10.1016/0968-0896(96)00075-2: \\5H-pyrrolo[1,2-b] [1,2,5]benzothiadiazepines (PBTDs): a novel class of non-nucleoside reverse transcriptase inhibitors.\\	1996	Bioorganic & medicinal chemistry, Jun, Volume: 4, Issue:6	5H-pyrrolo[1,2-b] [1,2,5]benzothiadiazepines (PBTDs): a novel class of non-nucleoside reverse transcriptase inhibitors.
AID1795388	HIV-1 RT Assay from Article 10.1021/jm9901125: \\Structure-based design, synthesis, and biological evaluation of novel pyrrolyl aryl sulfones: HIV-1 non-nucleoside reverse transcriptase inhibitors active at nanomolar concentrations.\\	2000	Journal of medicinal chemistry, May-04, Volume: 43, Issue:9	Structure-based design, synthesis, and biological evaluation of novel pyrrolyl aryl sulfones: HIV-1 non-nucleoside reverse transcriptase inhibitors active at nanomolar concentrations.
AID1801345	In vitro Anti-HIV RT Assay from Article 10.1111/cbdd.12497: \\Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Anti-HIV-1 Agents.\\	2015	Chemical biology & drug design, Sep, Volume: 86, Issue:3	Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Anti-HIV-1 Agents.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2006	The FEBS journal, Aug, Volume: 273, Issue:16	Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	1995	Nature structural biology, Apr, Volume: 2, Issue:4	High resolution structures of HIV-1 RT from four RT-inhibitor complexes.
AID1224864	HCS microscopy assay (F508del-CFTR)	2016	PloS one, , Volume: 11, Issue:10	Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	357 (11.76)	18.2507
2000's	1377 (45.37)	29.6817
2010's	1158 (38.15)	24.3611
2020's	143 (4.71)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	509 (15.85%)	5.53%
Reviews	202 (6.29%)	6.00%
Case Studies	162 (5.04%)	4.05%
Observational	32 (1.00%)	0.25%
Other	2,307 (71.82%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (169)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase II, Parallel, Randomized, Clinical Trials Comparing the Responses to Initiation of NNRTI-Based Versus PI-Based Antiretroviral Therapy in HIV Infected Infants Who Have and Have Not Previously Received Single Dose Nevirapine for Prevention of Mother-t [NCT00307151]	Phase 2	452 participants (Actual)	Interventional	2005-12-31	Completed
Clinical Trial of CNS Penetrating ART to Prevent NeuroAIDS in China [NCT01340950]	Phase 4	250 participants (Actual)	Interventional	2010-07-31	Completed
Phase 2 Comparison of Low-Dose Naltrexone vs ARV Effectiveness in HIV+ Progression [NCT01174914]	Phase 2	171 participants (Actual)	Interventional	2008-03-31	Completed
Optimal Combination Therapy After Nevirapine Exposure [NCT00089505]	Phase 3	745 participants (Actual)	Interventional	2006-11-30	Completed
NEVIRAPINE Plus LAMIVUDINE (3TC) for HIV Maintenance Therapy - A Single Center Pilot Study [NCT03223402]		20 participants (Actual)	Interventional	2016-12-23	Completed
Efficacy of Rilpivirine-based Regimens as Switch Therapy From Nevirapine-based Regimens in HIV-infected Patients With Complete Virological Suppression: A Randomized Controlled Trial [NCT03664440]		106 participants (Actual)	Interventional	2016-12-01	Completed
"Safeguard the Household - A Study of HIV Antiretroviral Therapy Treatment Strategies Appropriate for a Resource Poor Country" [NCT00255840]		812 participants (Actual)	Interventional	2006-07-31	Completed
Randomized, Open Label Study Evaluating the Lipid Profile Difference and Efficacy of a Combined Therapy Including Tenofovir, Emtricitabine + Atazanavir / r or NVP in Naive HIV - 1 Infected Patients. [NCT00389207]	Phase 3	576 participants (Actual)	Interventional	2006-10-31	Completed
Maintaining Options for Mothers Study (MOMS): A Phase II Randomized Comparison of Three Antiretroviral Strategies Administered for 7 or 21 Days to Reduce the Emergence of Nevirapine Resistant HIV-1 Following a Single Intrapartum Dose of Nevirapine [NCT00099632]	Phase 2	484 participants (Actual)	Interventional	2006-03-31	Completed
An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE® ) and Ethinyl Estradiol/Norethindrone [ORTHO-NOVUM® 1/35 (21 Pack)] in HIV-1 Infected Women [NCT02182791]	Phase 1	14 participants (Actual)	Interventional	1998-04-30	Completed
A Prospective Randomised Open Label Clinical Trial to Determine the Efficacy of Nevirapine, Compared With a Combination of ZDV + 3TC, in Decreasing the Peripartum Mother to Child Transmission of HIV. Women, Who Present After 38 Weeks Gestation or in Labou [NCT02181933]	Phase 3	2,648 participants (Actual)	Interventional	1999-04-30	Completed
Steady State Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Steady State 400 mg of Viramune® (200 mg BID), in HIV-1 Infected Subjects, an Open Label, Non Randomised, Multidose and Multistage Parallel Group Study. (ERVI [NCT02194179]	Phase 1	92 participants (Actual)	Interventional	2006-12-31	Completed
Clinical and Therapeutic Evaluation of the Infection by HIV/AIDS [NCT02191215]		442 participants (Actual)	Observational	2003-06-30	Completed
Long-term Observational Study in Patients Under Anti-retroviral Combination Therapy Who Were Switched From Protease Inhibitors or Other NNRTI to Viramune® Plus Two Nucleoside Reverse Transcriptase Inhibitors (NRTI) for Reasons of Therapy. (Long-Term Switc [NCT02191293]		228 participants (Actual)	Observational	2002-05-31	Completed
Relative Bioavailability of Different Oral Viramune Extended Release Formulations Containing 300 mg or 400 mg Compared to 200 mg or 400 mg as One or Two 200 mg IR Tablets Following Administration in Healthy Male Volunteers - an Openlabel, Non-randomized, [NCT02192463]	Phase 1	204 participants (Actual)	Interventional	2006-04-30	Completed
PI or NNRTI as First-line Treatment of HIV in a West African Population With Low Adherence - the PIONA Trial [NCT01192035]	Phase 4	400 participants (Actual)	Interventional	2011-05-31	Completed
Intensive Pharmacokinetic Studies of Antiretroviral Drug Combinations in Children [NCT00260078]	Phase 1/Phase 2	75 participants (Actual)	Interventional	2006-02-28	Completed
Phase II Study of the Pharmacokinetics of Nevirapine and the Incidence of Nevirapine Resistance Mutations in HIV-Infected Women Receiving a Single Intrapartum Dose of Nevirapine With the Concomitant Administration of Zidovudine/Didanosine or Zidovudine/Di [NCT00109590]	Phase 2	175 participants (Actual)	Interventional	2006-06-30	Completed
A Phase III, Randomized, Open-Label Trial to Evaluate Strategies for Providing Antiretroviral Therapy to Infants Shortly After Primary Infection in a Resource Poor Setting [NCT00102960]	Phase 3	377 participants (Actual)	Interventional	2005-07-31	Completed
An Open-label Study in HIV+ Patients to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) [NCT02184078]	Phase 4	19 participants (Actual)	Interventional	1998-10-31	Completed
An Open-label, Non-randomised, Single-dose, Parallel-group Study of Pharmacokinetic Properties of 200 mg (2 x 100 mg Tablets Once Daily) and 300 mg (3 x 100 mg Tablets Once Daily) Nevirapine Extended Release Formulations Compared to 200 mg VIRAMUNE® Table [NCT02184312]	Phase 1	96 participants (Actual)	Interventional	2008-04-30	Completed
Collecting Data in Patients With HIV Infection Type 1 After Switching From a Protease Inhibitor-containing Therapy Regimen and a Viral Load Below Detection Level to a Viramune®-Containing Therapy Regimen [NCT02191332]		147 participants (Actual)	Observational	1999-12-31	Completed
An Open-label, Randomised, Single Dose, Parallel-group Phase I Study to Investigate the Pharmacokinetic Properties of 200 mg Nevirapine Extended Release Tablets When Administered Orally as 2x100 mg Tablets or as 4x50 mg Tablets in Healthy Male Volunteers [NCT02194218]	Phase 1	48 participants (Actual)	Interventional	2009-09-30	Completed
An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE®) and Saquinavir-sgc (Fortovase®) in HIV-1 Infected Patients [NCT02184286]	Phase 1	5 participants (Actual)	Interventional	1999-05-31	Terminated
An Open-label Study in HIV+ Patients to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Fluconazole (DIFLUCAN®) [NCT02181946]	Phase 4	24 participants (Actual)	Interventional	2001-05-31	Completed
Phase III Randomized Trial of the Safety and Efficacy of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV-1 Transmission [NCT00099359]	Phase 3	1,735 participants (Actual)	Interventional	2004-02-29	Completed
Role of Pharmacogenetics in Efavirenz and Nevirapine Pharmacokinetics, Efficacy and Safety in Mother-infant Pairs During Pregnancy and Lactation [NCT02269462]		460 participants (Actual)	Observational	2012-12-31	Completed
A Phase I/II Comparative Pharmacokinetic Study of the Fixed-Dose Combination (FDC) of Zidovudine (ZDV), Lamivudine (3TC), and Nevirapine (NVP) as GPO-Vir Z30 Pediatric Tablets Versus the Individual Liquid Formulations in HIV-Infected Children Greater Than [NCT00672412]	Phase 1/Phase 2	42 participants (Actual)	Interventional	2008-10-31	Completed
Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum [NCT00042289]		1,578 participants (Actual)	Observational	2003-06-09	Completed
A Randomized Open Label Trial of HIV Protease Inhibitors for the Prevention of Malaria in HIV-Infected Children [NCT00978068]	Phase 3	176 participants (Actual)	Interventional	2009-09-30	Completed
Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in the Treatment of Tuberculosis Patient With HIV Infection in South Africa: A Phase II Trial [NCT00640887]	Phase 2	48 participants (Anticipated)	Interventional	2009-02-28	Completed
A Multicenter, Randomized, Open-label, Controlled Study of Nevirapine (VIRAMUNE®) and a Short Course of Prednisone to Determine the Safety and Effectiveness of This Strategy in Preventing Nevirapine (VIRAMUNE®) Associated Rash. [NCT02184299]	Phase 4	138 participants (Actual)	Interventional	1999-04-30	Completed
Observational Study With Antiretroviral Treated Patients Switching Therapy Because of Therapeutic Reasons From Protease Inhibitor- or NNRTI-containing Regimens to Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor (NRTI) Regimens [NCT02191319]		55 participants (Actual)	Observational	2002-01-31	Completed
A Phase I/II Comparative Pharmacokinetic Study of the Fixed-Dose Combination (FDC) of Stavudine (d4T), Lamivudine (3TC), and Nevirapine (NVP) as GPO-VIR Pediatric Chewable Tablets Versus the Individual Liquid Formulations in HIV Infected Children 6 Months [NCT00312091]	Phase 1/Phase 2	44 participants (Actual)	Interventional	2006-12-31	Completed
Pharmacokinetic Evaluation of Changes in Nevirapine AUC Due to Differences in Weight [NCT01335360]		21 participants (Actual)	Observational	2003-05-31	Completed
An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE®), Abacavir and Amprenavir in HIV-1 Infected NNRTI Naive Adults [NCT02182765]	Phase 1	8 participants (Actual)	Interventional	1999-04-30	Terminated
An Open-Label, Single Dose Study to Evaluate the Effects of Underlying Renal or Hepatic Dysfunction on the Pharmacokinetics of Nevirapine (VIRAMUNE®) [NCT02184091]	Phase 1	41 participants (Actual)	Interventional	1999-01-31	Completed
A Single-dose, 2-part, Open-label, Randomised, Pharmacoscintigraphic Investigation Into the Absorption of Nevirapine When Released Into Different Parts of the Gastro-intestinal Tract [NCT02191189]	Phase 1	27 participants (Actual)	Interventional	2005-05-31	Completed
Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors [NCT00730223]	Phase 1	33 participants (Actual)	Interventional	2004-03-31	Completed
A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care Versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples [NCT00074581]	Phase 3	3,526 participants (Actual)	Interventional	2005-02-28	Completed
A Randomised, Double Blind, Double Dummy, Parallel Group, Active Controlled Trial to Evaluate the Antiviral Efficacy of 400 mg QD neVirapine Extended Release Formulation in Comparison to 200 mg BID neVirapinE Immediate Release in Combination With Truvada® [NCT00561925]	Phase 3	1,068 participants (Actual)	Interventional	2007-11-30	Completed
An Open-label, Multiple Dose, Cross-over Study to Evaluate the Steady-state Pharmacokinetic Parameters of Nevirapine Extended Release Tablets in HIV-1 Infected Children, With an Optional Extension Phase [NCT00905489]	Phase 1	85 participants (Actual)	Interventional	2009-06-30	Completed
[NCT00618176]	Phase 4	198 participants (Actual)	Interventional	2005-01-31	Completed
Pharmacokinetic Interaction Between Coartem® and Either Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients [NCT00620438]	Phase 4	90 participants (Anticipated)	Interventional	2008-02-29	Active, not recruiting
A Phase I, Open-label, Single-sequence Drug-drug Interaction Trial to Investigate the Pharmacokinetic Interaction Between Steady-state Nevirapine and Single-dose TMC207 in HIV-1 Infected Subjects. [NCT00910806]	Phase 1	16 participants (Actual)	Interventional	2009-06-30	Completed
A Phase III Randomized Clinical Trial of the Standard Two Dose Nevirapine (NVP) Regimen With the Addition of HIV Immune Globulin(HIVIGLOB) or Extended Infant NVP Dosing Compared With the Standard NVP Regimen Alone for the Prevention of Maternal-Infant HIV [NCT00639938]	Phase 3	722 participants (Actual)	Interventional	2004-07-31	Completed
P1060 Substudy Comparing Differences in Malaria Parasitemia by Real Time Quantitative PCR in HIV-Infected Infants and Children on PI-Based HAART Versus NNRTI-Based HAART [NCT00719602]	Early Phase 1	105 participants (Actual)	Interventional	2009-08-31	Completed
Randomized Multicenter Study to Compare Starting Nevirapine at the Full Dose With Dose Escalation in Patients Who Require Efavirenz to be Withdrawn Due to Adverse Reactions [NCT00704249]	Phase 4	80 participants (Anticipated)	Interventional	2006-07-31	Completed
Prospective, Open Label and Randomized Clinical Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in Co-infected HIV/HCV Patients [NCT00661349]	Phase 4	9 participants (Actual)	Interventional	2008-02-29	Terminated(stopped due to It has been impossible to achieve the number of patients defined by protocol)
Multicenter, Randomized, Open-Label Trial, Assessing the Efficacy of Zidovudine, Lamivudine and Nevirapine Combination Administered Twice Daily, Versus the Association of Tenofovir, Lamivudine and Nevirapine, Once Daily, in Antiretroviral Naive HIV-1 Infe [NCT00199979]	Phase 3	250 participants	Interventional	2005-04-30	Recruiting
A 48 Week, Randomized, Open-label, 2 Arm Study to Compare the Efficacy, Safety and Tolerability of HAART Containing Nevirapine 400mg/Day Versus Nevirapine 600 mg/Day in HIV-1 Infected Patients Started at 2-6 Weeks After Initiating Rifampin Containing Anti [NCT00476853]	Phase 2	42 participants (Actual)	Interventional	2005-10-31	Completed
[NCT00523458]	Phase 4	5 participants (Actual)	Interventional	2007-07-31	Terminated(stopped due to A delay in protocol approval and approval of laboratory sites in Salvador, Brazil left too little time for completion of enrollment into the study.)
Phase I Three-way Crossover Bioequivalence Study of Pediatric Formulations of Lamivudine/Zidovudine/Nevirapine Using Healthy Adult Volunteers [NCT01469520]	Phase 1	24 participants (Actual)	Interventional	2010-10-31	Active, not recruiting
An Open Label, Phase IIIb, Randomised Parallel Group Study to Assess the Efficacy and Safety of Switching HIV-1 Infected Patients Successfully Treated With a Nevirapine IR Based Regiment to Nevirapine XR 400 mg QD or Remaining on Nevirapine IR 200 mg BID [NCT00819052]	Phase 3	445 participants (Actual)	Interventional	2008-12-31	Completed
Cell Cycle Independent Antiretroviral Therapy: Combination of Nevirapine, FTC, and Tenofovir [NCT00344461]	Phase 4	54 participants (Actual)	Interventional	2004-03-31	Completed
Comparison of Nevirapine Levels With and Without Dose Escalation in HIV-infected Patients Commencing Antiretroviral Therapy Who Are Also Receiving Rifampicin Based Anti-tuberculous Therapy [NCT00617643]	Phase 4	18 participants (Anticipated)	Interventional	2008-05-31	Completed
Randomized Control Trial of Early vs Delayed ART in the Treatment of Cryptococcal Meningitis. [NCT00830856]		54 participants (Actual)	Interventional	2006-10-31	Completed
Pathogenesis of MAC Disease in Advanced HIV-1-Infected Subjects and the Impact of Highly-Active Antiretroviral Treatment (HAART) on Immune Functions Relevant for MAC and Other Opportunistic Infections [NCT00000895]		85 participants	Interventional		Completed
A Randomized, Open-Label Study of the Long-Term Effectiveness of Three Initial Highly Active Antiretroviral Therapy (HAART) Strategies in HAART-Niave, HIV-Infected Persons [NCT00000922]		1,710 participants	Interventional		Completed
An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3 [NCT00000747]	Phase 2	10 participants	Interventional		Completed
Randomized Trial of Protease Inhibitor-Including vs. Protease Inhibitor-Sparing Regimens for Women Who Initiate Therapy of HIV Infection During Pregnancy [NCT00017719]	Phase 3	440 participants	Interventional	2002-05-31	Completed
Use of Combination Antiviral Therapy to Delineate the Identity and Longevity of Persistent Reservoirs of HIV-1 Infection and Replication [NCT00001644]	Phase 1	42 participants (Actual)	Interventional	1997-03-03	Completed
HIV Infection and Breastfeeding: Interventions for Maternal and Infant Health [NCT00164736]	Phase 3	2,369 participants (Actual)	Interventional	2004-03-31	Completed
A Multiple Dose, Open Label, Pivotal, 4 Period, 2 Treatment, Sequence Full Replicative Crossover Study to Assess the Bioequivalence (BE) of TEVA's Generic Once Daily Nevirapine 400 mg Prolonged Release (PR) Formulation Compared With the Approved Reference [NCT02202005]	Phase 1	46 participants (Actual)	Interventional	2014-08-31	Completed
Substitution by Nevirapine in HIV-1 Infected Patients on Triple Treatment of Reverse Transcriptase Nucleoside/Nucleotide Inhibitors [NCT00415090]	Phase 4	28 participants (Actual)	Interventional	2004-08-31	Completed
Nevirapine (NVP) Use to Prevent Maternal-Infant HIV Transmission: A Randomized Clinical Trial of Two Doses of NVP Compared to Six Weeks of NVP for the Prevention of Maternal-Infant HIV Transmission in the Breastfeeding Infant [NCT00074399]	Phase 3	775 participants (Actual)	Interventional	2001-02-28	Completed
Phase 3 Randomized Trial Evaluating the Virological Efficacy and the Tolerance of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Dakar and Yaounde [NCT00573001]	Phase 3	120 participants (Actual)	Interventional	2008-07-31	Completed
Phase I/II Study to Assess the Safety and Plasma Concentrations of Nevirapine Given Daily, Twice a Week or Weekly as Prophylaxis in Breastfeeding Infants From Birth to 6 Months [NCT00006279]	Phase 1	75 participants	Interventional		Completed
A Phase III Placebo-Controlled Trial to Determine the Efficacy of Oral AZT and the Efficacy of Oral Nevirapine for the Prevention of Vertical Transmission of HIV-1 Infection in Pregnant Ugandan Women and Their Neonates [NCT00006396]	Phase 3	1,500 participants	Interventional		Completed
A Double-Blinded, Randomized Trial Comparing Zidovudine (AZT) Versus AZT Plus Didanosine (ddI) Versus AZT Plus ddI Plus Nevirapine in Asymptomatic Patients on AZT Monotherapy Who Develop a Mutation at Codon 215 of HIV Reverse Transcriptase in Serum/Plasma [NCT00001045]	Phase 2	300 participants	Interventional		Completed
Pharmacokinetics, Safety, Tolerance, and Activity of Nevirapine (BI-RG-587) Alone and in Combination With AZT in Mildly to Moderately Symptomatic HIV-1 Infected Children [NCT00001111]		35 participants	Interventional		Completed
Treatment Outcome of Children With HIV Infection [NCT00476606]		1,000 participants (Anticipated)	Observational	2003-03-31	Active, not recruiting
Durability of Stavudine, Lamivudine and Nevirapine Among Advanced HIV-1 Infected Patients With/Without Prior Co-Administration of Rifampicin: A 144-Week Prospective Study [NCT00703898]	Phase 4	140 participants (Actual)	Interventional	2004-11-30	Completed
Breastfeeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere) [NCT01061151]	Phase 3	3,747 participants (Actual)	Interventional	2011-03-01	Completed
A Randomised Prospective Study Assessing Changes in Neurocognitive Function, Using a Computerised Test Battery, in Treatment Naïve HIV-1 Positive Subjects Commencing Two Different Antiretroviral Regimens [NCT00540137]	Phase 4	21 participants (Actual)	Interventional	2007-07-31	Completed
Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Nevirapine on the Pharmacokinetics of Atazanavir in HIV-Infected Individuals [NCT00162149]	Phase 1	46 participants	Interventional	2005-10-31	Completed
Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective, Non-randomised, 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes, Protein Levels and Cellular Stru [NCT00192660]	Phase 4	80 participants (Actual)	Interventional	2003-02-28	Completed
Clinical Relevance of Nevirapine Resistance [NCT00117728]	Phase 3	250 participants (Anticipated)	Interventional	2005-04-30	Recruiting
ART Pharmacokinetics, Mitochondrial Integrity, and Antioxidant Capacity in Severely Malnourished HIV-infected Malawian Children [NCT01529125]		42 participants (Actual)	Observational	2011-07-31	Completed
The Adult Antiretroviral Treatment and Resistance Study (Tshepo) [NCT00197613]	Phase 3	650 participants	Interventional	2002-12-31	Completed
A Phase II Randomized, Multicenter Protocol Evaluating Two Antiretroviral Regimens Containing Combinations of Protease Inhibitors, NRTIs, and an NNRTI [NCT00000924]	Phase 2	120 participants	Interventional		Completed
A Phase II, 24-Week, Open-Label Study Designed to Evaluate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Novel Combination Therapy With Videx (Didanosine), Zerit (Stavudine), Viramune (Nevirapine), and MKC-442 (With or Without Hydroxyurea) f [NCT00002418]	Phase 2	25 participants	Interventional		Terminated
Comparison of the Steady State Pharmacokinetics of Nevirapine, Stavudine Plus Lamivudine in HIV Positive Ugandan Patients Taking Triomune 40 With the Pharmacokinetics of the Originator Products. [NCT00455585]	Phase 4	18 participants	Interventional	2007-01-31	Completed
Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin [NCT00483054]	Phase 3	142 participants (Actual)	Interventional	2007-01-31	Completed
Randomized Non-inferiority Trial Comparing the Nevirapine-based Antiretroviral Therapy Versus the Standard Efavirenz-based ART for the Treatment of HIV-TB Co-infected Patients on Rifampicin-based Therapy (ANRS 12146 CARINEMO) [NCT00495326]	Phase 2/Phase 3	570 participants (Actual)	Interventional	2007-12-31	Completed
The Tshilo Dikotla Study: Metabolic Outcomes of Children HIV/ARV-Exposed Uninfected in Botswana (MOCHA) [NCT03088410]	Phase 4	495 participants (Actual)	Interventional	2016-08-22	Completed
A Pharmacokinetic Evaluation of Levonorgestrel Implant and Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in HIV-infected Ugandan Women [NCT01789879]	Phase 2	60 participants (Actual)	Interventional	2014-03-04	Completed
A Phase III Randomized, Double-Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women [NCT00000942]	Phase 3	1,244 participants	Interventional		Completed
An Open-Label, Non-Randomized Trial to Evaluate the Tolerability and Safety of Viramune (Nevirapine) in Adult and Pediatric Patients With Progressive HIV Disease [NCT00002166]	Phase 3	0 participants	Interventional		Completed
Comparison Atazanavir/Ritonavir (ATV/r) vs Nevirapine (NVP) Twice a Day (Bid) on Truvada Backbone [NCT00552240]	Phase 4	154 participants (Actual)	Interventional	2007-09-30	Completed
An Open Label, Randomized Study to Compare Antiretroviral Therapy (ART) Initiation When CD4 is Between 15% to 24% to ART Initiation When CD4 Falls Below 15% in Children With HIV Infection and Moderate Immune Suppression [NCT00234091]	Phase 3	300 participants (Actual)	Interventional	2006-04-30	Completed
[NCT00398684]	Phase 3	1,792 participants	Interventional	2001-01-31	Completed
A Pharmacokinetic Study to Evaluate the Interaction Between Nevirapine (Viramune®) and Methadone in HIV-1 Infected, Opioid-dependent Adults on Stable Methadone Maintenance Therapy [NCT00273988]	Phase 4	10 participants	Interventional	2002-04-30	Completed
A Case-Control Toxicogenomics Study to Identify Unique Genetic Polymorphisms in Patients Who Have Experienced Symptomatic Hepatotoxicity or Severe Cutaneous Toxicity Within the First 8 Weeks of Nevirapine Therapy [NCT00310843]		889 participants (Actual)	Observational	2006-02-28	Completed
The Effect of Single Dose Carbamazepine on the Pharmacokinetics of Single Dose Nevirapine (Viramune, NVP) and Development of NVP Resistance, PMTCT Program of Moshi, Tanzania (VITA1) [NCT00294892]	Phase 2	144 participants (Actual)	Interventional	2006-02-28	Completed
MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS) [NCT00122226]	Phase 4	50 participants	Interventional	2003-01-31	Active, not recruiting
Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study [NCT02140255]	Phase 1/Phase 2	905 participants (Anticipated)	Interventional	2015-01-23	Recruiting
Tenofovir, Emtricitabine, and Nevirapine for Recently HIV-Infected Subjects: Can Short-Course, Once Daily Therapy Reduce the Viral Load at 12 Months From Estimated Date of Infection? [NCT00087464]		0 participants (Actual)	Interventional		Withdrawn(stopped due to study was withdrawn before any participants were recruited and enrolled)
Randomised, Prospective Multicentre Clinical Study on the Effect of the Combination of Lopinavir/Rtv + Nevirapine as Maintenance Bitherapy (Without Nucleoside Analogues) in Comparison With a Triple Therapy Including Lopinavir/Rtv + Nucleoside Analogues in [NCT00335686]	Phase 4	67 participants (Actual)	Interventional	2003-10-31	Completed
An Open-label Study Evaluating the Resistance Profile of Single Dose Nevirapine(NVP) When Combined With a 4 or 7 Day Course of Combivir® (ZDV/3TC) Compared to Single Dose Nevirapine for the Prevention of Mother to Child Transmission (pMTCT) of HIV - Treat [NCT00144183]	Phase 3	407 participants	Interventional	2003-01-31	Completed
[NCT00466180]	Phase 4	62 participants (Actual)	Interventional	2004-06-30	Completed
An Open-label, Non-randomized, Single-arm Study, to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma High Density Lipoproteins Concentration in HIV+ Subjects Treated With VIRAMUNE® Tablets [NCT00144261]	Phase 4	15 participants (Actual)	Interventional	2003-11-30	Completed
Efavirenz to Nevirapine Switch in HIV-1 Infected Patients With Severe Dyslipidemia: A Randomized Controlled Study [NCT00405171]	Phase 4	40 participants	Interventional	2003-06-30	Completed
Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin in Antiretroviral Naive Patients Co-infected With HIV and Tuberculosis in India. [NCT01805258]	Phase 3	135 participants (Actual)	Interventional	2007-06-30	Completed
A Phase II Rolling Arm Master Protocol (PRAM) of Novel Antiretroviral Therapy in Stable Experienced HIV- Infected Children; PRAM-1: ZDV+3TC vs. d4T+Ritonavir vs. ZDV+3TC+Ritonavir; PRAM-1, Step 2: d4T+Nevirapine+Ritonavir; PRAM-1, Step 3: d4T+Indinavir vs [NCT00001083]	Phase 2	240 participants	Interventional		Completed
Evaluation of Safety and Efficacy of Two Different Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment in Patients With HIV-1 and Tuberculosis [NCT00332306]	Phase 3	180 participants (Anticipated)	Interventional	2006-06-30	Active, not recruiting
A Randomized Controlled Trial to Compare the Efficacy of a Four Drug Antiretroviral Regimen Alone or in Combination With GM-CSF or IL-12 Administered to HIV-1 Infected Subjects as Measured by the Characteristics of Viral Decay [NCT00000896]		24 participants	Interventional		Completed
A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3) [NCT00000781]	Phase 2	1,292 participants	Interventional		Completed
A Master Protocol to Evaluate the Safety and Efficacy of Multi-Drug Combination Antiretroviral Therapy for the Treatment of HIV Infection: Retrovir/HIVID/Nevirapine and Retrovir/HIVID/Invirase [NCT00002347]	Phase 2	225 participants	Interventional		Completed
Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission [NCT00115648]	Phase 3	3,300 participants (Anticipated)	Interventional	2004-04-30	Completed
Phase II, Randomized, Open-Label Study of Switching to Protease Inhibitor-Sparing Regimens for Improvement of Metabolic Abnormalities [NCT00021463]	Phase 2	342 participants	Interventional		Completed
A Phase III Randomized, Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women [NCT00000869]	Phase 3	2,009 participants	Interventional		Completed
An Open Label, Staggered Rising Dose Cohort Study Assessing Safety, Tolerance, and Activity of BI-RG-587 in Patients With HIV Infection (CD4+ Cell Count < 400 Cells/mm3) [NCT00000962]	Phase 1	30 participants	Interventional		Completed
A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and Stavudine [NCT00001688]	Phase 2	25 participants	Interventional	1998-01-31	Completed
Prevention of Maternal to Infant HIV Transmission in India [NCT00061321]	Phase 3	770 participants (Actual)	Interventional	2002-08-31	Completed
A Pilot Study of a Nucleoside Analogue Reverse Transcriptase Inhibitor Sparing Regimen in Antiretroviral-Naïve, HIV-infected Patients [NCT00143689]	Phase 4	13 participants (Actual)	Interventional	2002-04-30	Completed
An Open-Label Study of Nevirapine Plus Combivir® (ZDV+3TC) Treatment in Women Who Have Previously Received a Nevirapine Regimen for the Prevention of Mother to Child Transmission (pMTCT) of HIV-1. [NCT00144157]	Phase 4	53 participants (Actual)	Interventional	2003-06-30	Completed
Phase III, Randomized, Double-Blind Comparison of Three Protease Inhibitor-Sparing Regimens for the Initial Treatment of HIV Infection [NCT00013520]	Phase 3	1,125 participants	Interventional		Completed
An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Between Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) and Selected Protease Inhibitor (PI) and Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Therapies Among HIV-Infected W [NCT00016601]		76 participants	Interventional	2001-06-30	Completed
A Restrictively Randomized, Open-Label, Controlled, Pilot Study of the Effect of a Thymidine Analogue Substitution or Change to a Nucleoside-Sparing Regimen on Peripheral Fat Wasting [NCT00028314]		150 participants	Interventional	2002-03-31	Completed
Phase III Trial of Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission [NCT00021671]	Phase 3	3,720 participants	Interventional		Completed
A Retrospective Study to Compare the 3-Year Antiviral Efficacy of Nevirapine and Efavirenz in Combination With D4t and 3tc in 2NN Patients and of Trizivir Versus Trizivir Plus Nevirapine in CHARM Patients [NCT00127972]	Phase 4	763 participants (Actual)	Interventional	2004-02-29	Completed
A Phase II Open Label Clinical Trial of Maternal Zidovudine/Lamivudine and Either Nevirapine or Nelfinavir for Maximal Reduction of Mother-to-child HIV Transmission in Resource-limited Settings Among Breastfeeding Populations [NCT00146380]	Phase 2	520 participants (Anticipated)	Interventional	2003-07-31	Active, not recruiting
ARVs to Prevent Breastmilk HIV:Viral and Immune Responses [NCT00167674]	Phase 2	58 participants (Actual)	Interventional	2003-05-31	Completed
Maternal and Infant Peripartum Nevirapine, Versus Infant Only Peripartum Nevirapine, or Maternal Lopinavir/Ritonavir in Addition to Standard Zidovudine Prophylaxis for the Prevention of Perinatal HIV in Thailand. [NCT00409591]	Phase 3	435 participants (Actual)	Interventional	2008-07-31	Terminated(stopped due to Change in National PMTCT guidelines in Thailand)
"Prevention of Milk-Borne Transmission of HIV-1C in Botswana (Mashi)" [NCT00197587]		1,200 participants (Actual)	Interventional	2002-08-31	Completed
Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya (6-12 Month RCT) [NCT00427297]	Phase 3	34 participants (Actual)	Interventional	2007-09-30	Terminated(stopped due to There is no longer equipoise. DSMB recommended termination.)
Influence of Nevirapine on HCV Viral Load Among HIV/HCV-coinfected Patients [NCT01277627]		60 participants (Anticipated)	Interventional	2011-01-31	Not yet recruiting
Clinical Pilot Trial to Evaluate the Influence of Nevirapine in Exposure to Atazanavir in Steady State Equilibrium in HIV-infected Adult Patients. [NCT00355719]	Phase 4	14 participants (Actual)	Interventional	2007-01-31	Completed
A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission During Breastfeeding [NCT00074412]	Phase 3	2,026 participants (Actual)	Interventional	2007-01-31	Completed
A Randomised Open Label Multi-centre Trial to Evaluate the Pharmacokinetic, Efficacy and Safety Parameters of Nevirapine 150mg/m2 and Nevirapine 4 or 7 mg/kg When Administered in Combination With AZT and 3TC for 48 Weeks in Antiretroviral naïve Paediatric [NCT00273975]	Phase 2	123 participants	Interventional	2002-01-31	Completed
An Open, Randomised, Multicentre, Comparative Trial, to Evaluate the Benefit of Switching From a PI-based Regimen to a Nevirapine-based Regimen on the Quality of Life, Patient Adherence, Patient's Perception of Fat Redistribution and Metabolic Changes, in [NCT00274001]	Phase 4	158 participants (Actual)	Interventional	2001-09-30	Completed
Cross-sectional Study for the Characterisation of the Pharmacokinetic Parameters of Protease Inhibitors and Non-nucleoside Analog Reverse Transcriptase Inhibitors in the Spanish Population of HIV-infected Subjects [NCT00307502]	Phase 1	675 participants (Actual)	Interventional	2005-01-31	Completed
PHPT-5 Second Phase: Perinatal Antiretroviral Intensification for the Prevention of Mother-to-child Transmission of HIV in Thai Women Having Received Less Than 8 Weeks of HAART During Pregnancy [NCT01511237]	Phase 3	379 participants (Actual)	Interventional	2011-12-31	Completed
Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study) [NCT01637558]	Phase 4	200 participants (Actual)	Interventional	2012-11-30	Completed
Nevirapine vs Ritonavir-boosted Lopinavir in ART HIV-infected Adults in a Resource-limited Setting; a Randomized, Multicenter, Parallel Group Study [NCT01772940]	Phase 4	425 participants (Actual)	Interventional	2008-12-31	Completed
A Phase II Study of 1) Amprenavir (141W94/VX478) Plus 3TC Plus ZDV (or d4T) or 2) IDV Plus NVP Plus 3TC Plus d4T in Subjects Previously Treated With Amprenavir and 3) Other Treatment Regimens (Observational ARM) in Subjects Previously Treated With Amprena [NCT00001095]	Phase 2	94 participants	Interventional		Completed
Lopinavir/Ritonavir/Combivir vs. Abacavir/Zidovudine/Lamivudine for Virologic Efficacy and the Prevention of Mother-to-Child HIV Transmission Among Breastfeeding Women With CD4 Counts Greater Than or Equal to 200 Cells/mm3 in Botswana [NCT00270296]	Phase 2	730 participants (Actual)	Interventional	2006-06-30	Completed
A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers [NCT00000808]	Phase 1	49 participants	Interventional		Completed
A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease [NCT00000814]	Phase 1	390 participants	Interventional		Completed
Multi-Drug Antiretroviral Therapy for Heavily Pretreated Pediatric AIDS Patients: A Phase I Proof of Concept Trial [NCT00001108]	Phase 1	6 participants	Interventional		Completed
A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children [NCT00000634]		6 participants	Interventional		Completed
An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4. [NCT00002194]	Phase 1	36 participants	Interventional		Completed
An International, Double Blind, Randomized, Phase III Study to Evaluate the Tolerance, Safety, and Effectiveness of Viramune (Nevirapine) in Preventing Clinical AIDS Progression Events or Death When Used in Combination With Lamivudine (3TC) and Stable (>= [NCT00002368]	Phase 3	2,000 participants	Interventional		Completed
Effect of Moringa Oleifera (Moringa, Drumstick/Horseradish Tree) on The Pharmacokinetics of Efavirenz and Nevirapine In-vivo. [NCT01410058]		19 participants (Actual)	Observational	2013-01-31	Completed
A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine [NCT00000770]	Phase 2	400 participants	Interventional		Completed
Early Intensive Antiretroviral Combination Therapy in HIV-1 Infected Infants and Children [NCT00000872]	Phase 2	55 participants (Anticipated)	Interventional		Completed
RAD-1: A Phase I/II Antiretroviral Management Algorithm for Pediatric Subjects of Four-Drug Combination Therapies Based on Prior Antiretroviral Experience [NCT00000902]	Phase 1	217 participants	Interventional		Completed
A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Activity, Safety, and Tolerance of 1) 400 Mg Nevirapine in Combination With 500-600 Mg Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 3-24 Mo [NCT00002324]	Phase 2	250 participants	Interventional		Completed
An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3) [NCT00000649]	Phase 1	30 participants	Interventional		Completed
A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of P [NCT00002323]		60 participants	Interventional		Completed
A Phase III Randomized, Double-Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women [NCT00001135]	Phase 3	2,009 participants	Interventional		Completed
A Randomized Open-Label Strategic Study to Evaluate the Safety and Efficacy of 3 Different Convergent and Divergent Drug Combination Therapies in Anti-Retroviral Naive HIV-1 Infected Patients With CD4+ Counts Above 200/mm3 [NCT00002407]		0 participants	Interventional		Completed
An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium Falciparum Subclinical Parasitemia in HIV-infected Adults With CD4+ Counts >200 and <500 Cells/mm^3 [NCT01632891]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2014-01-10	Completed
Phase I/II Study of ABT-378/Ritonavir in Protease Inhibitor Experienced HIV-Infected Patients [NCT00004580]	Phase 1	0 participants	Interventional		Completed
A Randomized, Open-Label, Pilot Treatment Trial Evaluating Cellular Dynamics and Immune Restoration in Treatment-Naive HIV-Infected Subjects Receiving Either the Protease Inhibitor LPV/r or the Nucleoside Analogue Reverse Transcriptase Inhibitors d4T/3TC/ [NCT00004855]		55 participants	Interventional		Completed
A Phase II Rolling Arm Master Protocol (PRAM) of Novel Antiretroviral Therapy in Stable Experienced HIV-Infected Children. PRAM-2: A Phase I/II Randomized, Multicenter Protocol Comparing Four Antiretroviral Regimens Containing Combinations of Protease Inh [NCT00001091]	Phase 1	200 participants	Interventional		Completed
An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (Viramune) and Nelfinavir (Viracept) and the Efficacy of This Combination Therapy in HIV-1 Infected Adults Treated With Stavudine [d4T] (Zerit) [NCT00002381]	Phase 1	24 participants	Interventional		Completed
A Randomized, Open-Label, Phase III Study of ABT-378/Ritonavir in Combination With Nevirapine and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) vs. Investigator Selected Protease Inhibitor(s) in Combination With Nevirapine and Two NRTIs in Antir [NCT00004581]	Phase 3	300 participants	Interventional		Completed
A Pharmacokinetic Study to Assess Nevirapine Levels in HIV-infected Patients With Impaired Hepatic Function [NCT00144248]	Phase 4	51 participants (Actual)	Interventional	2004-06-25	Completed
Neuropsychiatric Adverse Effects of Efavirenz in Children Living With HIV in Kilimanjaro, Tanzania [NCT03227653]		144 participants (Actual)	Observational	2017-06-19	Completed
Switching From Regimens Consisting of a RTV-Boosted Protease Inhibitor Plus TDF/FTC to a Combination of Raltegravir Plus Nevirapine and Lamivudine in HIV Patients With Suppressed Viremia and Impaired Renal Function (RANIA Study) (Pilot Study) Protocol MK- [NCT02116660]	Phase 2	11 participants (Actual)	Interventional	2014-09-03	Terminated(stopped due to This study was terminated early due to poor recruitment.)
Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial [NCT02431975]	Phase 4	73 participants (Actual)	Interventional	2015-08-31	Completed
Population Pharmacokinetics of Antiretroviral in Children [NCT03194165]		65 participants (Actual)	Observational	2017-06-16	Completed
Steady State Bioequivalence of Generic and Innovator Formulations of Stavudine, Lamivudine, and Nevirapine in HIV-infected Ugandan Adults [NCT01025830]	Phase 4	20 participants (Actual)	Interventional	2006-02-28	Completed
BHP Early Infant Treatment Study: A Clinical Treatment Trial of HIV+ Infants in Botswana [NCT02369406]	Phase 2/Phase 3	67 participants (Actual)	Interventional	2015-05-04	Active, not recruiting
Antiretroviral Regime for Viral Eradication in Newborns After Intervention Failure of Mother-to-child Transmission of HIV [NCT02712801]	Phase 4	600 participants (Actual)	Interventional	2016-04-30	Completed
Randomized Clinical Trial to Evaluate the Interest of a Down-scaled Treatment Strategy Using Dual Therapy (Nucleoside Analogs) in HIV Infected Patients Already Being Treated Using Triple Therapy, Who Present With a Successful Virological Control and for W [NCT02302547]	Phase 3	224 participants (Actual)	Interventional	2014-12-31	Completed
A Randomised Trial of Monitoring Practice and Induction Maintenance Drug Regimens in the Management of Antiretroviral Therapy in Children With HIV Infection in Africa [NCT02028676]	Phase 4	1,206 participants (Actual)	Interventional	2007-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Plasma Concentration for Contraceptives
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]	Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs
NCT00042289 (26) [back to overview]	Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]	Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms
NCT00042289 (26) [back to overview]	PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs
NCT00042289 (26) [back to overview]	PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs
NCT00074412 (5) [back to overview]	Frequency and Severity of Adverse Reactions Among Participating Infants
NCT00074412 (5) [back to overview]	HIV Infection in Infants Determined to be HIV Uninfected at 6 Weeks Enrolled in Each Arm of the Study
NCT00074412 (5) [back to overview]	Infant Survival Rates (Mortality Regardless of HIV Infection) in the Two Arms
NCT00074412 (5) [back to overview]	Proportion of Infants Who Are Alive and HIV-uninfected in the Two Arms
NCT00074412 (5) [back to overview]	Relative Rates of HIV Infection in the Two Arms
NCT00074581 (2) [back to overview]	All Partner HIV Infection Rates in Early-ART and Delayed-ART Arms
NCT00074581 (2) [back to overview]	Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms
NCT00089505 (9) [back to overview]	Number of Participants Who Experienced HIV-related Disease Progression or Death
NCT00089505 (9) [back to overview]	Number of Participants Who Experienced Treatment-related Toxicity That Led to Discontinuation of Randomized Regimen.
NCT00089505 (9) [back to overview]	Number of Participants Who Experienced Virologic Failure or Died.
NCT00089505 (9) [back to overview]	Number of Participants Who Received NVP-containing Regimens at Randomization and Experienced NVP-associated Rash or Grade 2+ Liver Lab Abnormality
NCT00089505 (9) [back to overview]	CD4 Count Change From Randomization
NCT00089505 (9) [back to overview]	Percent of Participants Who Experienced Virologic Failure or Died
NCT00089505 (9) [back to overview]	Percent of Participants Who Reported to Never Missed Any of the Study Drug Regimen in the Past Month
NCT00089505 (9) [back to overview]	Time From Randomization to Virologic Failure or Death for Participants Who Had SD NVP Exposure Prior to Study Entry
NCT00089505 (9) [back to overview]	Time From Randomization to Virologic Failure or Death for Participants Without SD NVP Exposure Prior to Study Entry
NCT00099359 (7) [back to overview]	NVP Pharmacokinetics
NCT00099359 (7) [back to overview]	Infant HIV Infection Status
NCT00099359 (7) [back to overview]	Participant Deaths
NCT00099359 (7) [back to overview]	Infant HIV-1 Infection Status
NCT00099359 (7) [back to overview]	Risk Factors for Perinatal HIV-1 Transmission
NCT00099359 (7) [back to overview]	Participants With Serious Adverse Events
NCT00099359 (7) [back to overview]	3TC and NFV Pharmacokinetics
NCT00099632 (5) [back to overview]	Severe (Grade 3) and Higher Adverse Events and Any Grade Adverse Event That Leads to a Treatment Change From First Day of Study Treatment to Week 12
NCT00099632 (5) [back to overview]	Number of Participants With New PI-resistant Variants as Detected by Standard Composite (Bulk) Genotyping.
NCT00099632 (5) [back to overview]	Number of Participants With New Circulating NRTI-resistant Variants Detected by Standard Composite (Bulk) Genotyping.
NCT00099632 (5) [back to overview]	Number of Participants With New Circulating Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant Variants as Detected by Standard Composite (Bulk) Genotyping
NCT00099632 (5) [back to overview]	Number of Participants Who Discontinued Study Treatment Prematurely
NCT00102960 (13) [back to overview]	Number of Participants Who Experienced Virological Failure Defined as Confirmed HIV-1 RNA Value of at Least 10,000 Copies Per/ml Recorded on Two Consecutive Separate Occasions After 24 Weeks of Treatment (Initial Therapy or Restart)
NCT00102960 (13) [back to overview]	Time From Randomization to Starting or Needing to Start Continuous Therapy
NCT00102960 (13) [back to overview]	Time to Death Alone or Death Plus Life Threatening Stage C Events or HIV Events Associated With Permanent End-organ Damage.
NCT00102960 (13) [back to overview]	Time to Failure of First Line Therapy or Death
NCT00102960 (13) [back to overview]	Time to First Hospitalization
NCT00102960 (13) [back to overview]	Total Occurrence of Grade 3 or 4 Laboratory Events
NCT00102960 (13) [back to overview]	Number of Participants Who Experienced Immunological Failure Defined as Failure of CD4% to Reach 20% or CD4% Falls Below 20% on Two Occasions, Within 4 Weeks, at Any Time After the First 24 Weeks of Therapy (Initial Therapy or Restart)
NCT00102960 (13) [back to overview]	Total Occurrence of Grade 3 or 4 Clinical Events
NCT00102960 (13) [back to overview]	Duration of Hospitalisation
NCT00102960 (13) [back to overview]	Hospitalization Rates
NCT00102960 (13) [back to overview]	Number of Children Experiencing Severe CDC Stage B or Stage C Disease or Death (Cumulative After 3.5 Years)
NCT00102960 (13) [back to overview]	Number of Participants Who Experienced Clinical Failure (Defined as Development of Severe CDC Stage B or Stage C Disease.) on Therapy.
NCT00102960 (13) [back to overview]	Number of Participants Who Experienced Regimen-limiting ART Drug Toxicity
NCT00109590 (12) [back to overview]	The Proportion of Women With Any New ZDV, ddI, or LPV/r Resistance Mutations.
NCT00109590 (12) [back to overview]	Proportion of Women With New NVP Resistance Mutation Within 8 Weeks Postpartum Who Had a NVP Resistance Mutation Detected at 72 Weeks Postpartum.
NCT00109590 (12) [back to overview]	The Proportion of Women Who Develop One or More New NVP Resistance Mutations as Identified by Consensus Sequencing or Oligonucleotide Ligation Assay in Plasma (Sampling Was Done at Days 10,21,30, and Weeks 5,6, and 8 Postpartum).
NCT00109590 (12) [back to overview]	The Proportion of Women in Each Randomized Arm Who Have One or More New NVP Resistance Mutations for the Subgroup of Women With Plasma HIV RNA >= 500 Copies/ml At Entry
NCT00109590 (12) [back to overview]	The Proportion of Women in Each Randomized Arm Who Have One or More New NVP Resistance Mutations as Identified by Consensus Sequencing or Oligonucleotide Ligation Assay (OLA) in Plasma
NCT00109590 (12) [back to overview]	Area Under the Curve Pharmacokinetic Outcome for LPV/r. (AUC ug*hr/mL)
NCT00109590 (12) [back to overview]	Four (4) Hour Concentration Pharmacokinetic Outcome for LPV/r (C4hour ug/mL).
NCT00109590 (12) [back to overview]	Maximum Concentration Pharmacokinetic Outcome for LPV/r (Cmax ug/mL) .
NCT00109590 (12) [back to overview]	Median HIV-1 Viral Load at 24 Weeks Postpartum in Women
NCT00109590 (12) [back to overview]	Number of Women With Grade >=3 Events After Start of Study Treatment
NCT00109590 (12) [back to overview]	Pre-dose Concentration Pharmacokinetic Outcome for LPV/r (Cpredose ug/mL).
NCT00109590 (12) [back to overview]	Resistance Mutations in HIV Infected Infants
NCT00255840 (1) [back to overview]	Cumulative Treatment Failure Rate of Participants on First Line Antiretroviral Therapy Monitored by Primary Health Care Nurses (Investigative Arm)is Not Inferior to the Cumulative Treatment Failure Rate of Participants Monitored by Doctors (Control Arm).
NCT00270296 (2) [back to overview]	Number of Participants With Virologic Suppression
NCT00270296 (2) [back to overview]	Number of HIV+ Infants
NCT00307151 (9) [back to overview]	Time From Randomization to Death
NCT00307151 (9) [back to overview]	Percent of Participants With Treatment Failure, Defined as a Confirmed Virologic Failure or Permanent Discontinuation of the Randomized NNRTI or PI Component of Study Treatment
NCT00307151 (9) [back to overview]	Percent of Participants Experiencing Virologic Failure
NCT00307151 (9) [back to overview]	Number of Participants Developing New NRTI, NNRTI or PI-resistant Virus
NCT00307151 (9) [back to overview]	Change in CD4 Percent From Entry to Week 48
NCT00307151 (9) [back to overview]	Time From Start of Study Treatment to First New Grade >=3 Lab Abnormality, Sign or Symptom Occurring on Study Treatment
NCT00307151 (9) [back to overview]	Time From Randomization to Virologic Failure
NCT00307151 (9) [back to overview]	Time From Randomization to Treatment Failure, Defined as Virologic Failure or Permanent Discontinuation of the Randomized NNRTI or PI Component of Study Treatment
NCT00307151 (9) [back to overview]	Time From Randomization to HIV-related Disease Progression or Death
NCT00344461 (6) [back to overview]	Patients With Plasma HIV RNA < 50 Copies/mL
NCT00344461 (6) [back to overview]	Patients With Plasma HIV RNA < 400 Copies/mL
NCT00344461 (6) [back to overview]	Patients With Grade 2, 3 and 4 Adverse Events and Laboratory Toxicities
NCT00344461 (6) [back to overview]	Number of Participants With Sustained Virologic Response
NCT00344461 (6) [back to overview]	Changes in CD4 Cell Count From Baseline and Week 96
NCT00344461 (6) [back to overview]	Change in Plasma HIV RNA From Baseline to Week 96
NCT00389207 (34) [back to overview]	Proportion of Patients With VL < 400 Copies/ml
NCT00389207 (34) [back to overview]	Time to Treatment Response (First Confirmed VL<50 Copies/mL)
NCT00389207 (34) [back to overview]	Proportion of Patients Reporting CNS (Central Nervous System) Side Effects of Any Severity
NCT00389207 (34) [back to overview]	Proportion of Patients Reporting Hepatic Events of Any Severity
NCT00389207 (34) [back to overview]	Proportion of Patients Reporting Rash of Any Severity
NCT00389207 (34) [back to overview]	Time to Loss of Virologic Response (Rebound)
NCT00389207 (34) [back to overview]	Time to Treatment Failure
NCT00389207 (34) [back to overview]	Change in CD4+ Count From Baseline
NCT00389207 (34) [back to overview]	Change in Framingham Score From Baseline
NCT00389207 (34) [back to overview]	Change in Mental Health Summary (MHS) Score From Baseline
NCT00389207 (34) [back to overview]	Change in Physical Health Summary (PHS) Score From Baseline
NCT00389207 (34) [back to overview]	Change in the Calculated Glomerular Filtration Rate (GFR) at Week 48, 96 and 144
NCT00389207 (34) [back to overview]	Change of Cholesterol Values From Baseline to Week 48, 96, 144
NCT00389207 (34) [back to overview]	Change of hsCRP From Baseline to Week 48, 96, 144
NCT00389207 (34) [back to overview]	Change of Total Cholesterol to HDL-cholesterol Ratio From Baseline to Week 48, 96, 144
NCT00389207 (34) [back to overview]	Change of Total Triglycerides From Baseline to Week 48, 96, 144
NCT00389207 (34) [back to overview]	Changes of Apolipoprotein Values From Baseline to Week 48, 96, 144
NCT00389207 (34) [back to overview]	Genotypic Resistance Associated With Virologic Failure
NCT00389207 (34) [back to overview]	Glycaemic Abnormalities
NCT00389207 (34) [back to overview]	Lipodystrophy
NCT00389207 (34) [back to overview]	Non-scheduled Physician Visits
NCT00389207 (34) [back to overview]	Number of Patients Hospitalized
NCT00389207 (34) [back to overview]	Proportion of Patients With >= DAIDS Grade 2 Laboratory Abnormalities
NCT00389207 (34) [back to overview]	Proportion of Patients With Virologic Failure at Week 48, 96, 144
NCT00389207 (34) [back to overview]	Proportion of Patients With Virological Rebound With VL >=400 Copies/mL After CVR at Week 24, 48, 96, 144
NCT00389207 (34) [back to overview]	Proportion of Patients With Virological Rebound With VL >=50 Copies/mL After CVR (Confirmed Virological Response) at Week 24, 48, 96, 144
NCT00389207 (34) [back to overview]	Proportion of Patients With VL < 50 Copies/ml
NCT00389207 (34) [back to overview]	Serum Lipid Abnormalities
NCT00389207 (34) [back to overview]	Treatment Response at Week 144
NCT00389207 (34) [back to overview]	Treatment Response at Week 48
NCT00389207 (34) [back to overview]	Treatment Response at Week 48 (TLOVR Algorithm)
NCT00389207 (34) [back to overview]	Treatment Response at Week 96
NCT00389207 (34) [back to overview]	Treatment-emergent AIDS-defining Illness
NCT00389207 (34) [back to overview]	Treatment-emergent AIDS-defining Illness Leading to Death
NCT00427297 (4) [back to overview]	Immunologic Failure
NCT00427297 (4) [back to overview]	Incidence of Severe Adverse Events (Excluding Mortality)
NCT00427297 (4) [back to overview]	Viral Failure
NCT00427297 (4) [back to overview]	Incidence of Mortality
NCT00552240 (46) [back to overview]	Change in Fasting High Density Lipoprotein (HDL) Cholesterol Level
NCT00552240 (46) [back to overview]	Number of Participants With Virologic Success (FDA Definition)
NCT00552240 (46) [back to overview]	Number of Patients With Virologic Rebound to >400 Copies/ml
NCT00552240 (46) [back to overview]	Proportion of Patients With DAIDS Grade >= 2 Laboratory Abnormalities
NCT00552240 (46) [back to overview]	Number of Participants With Loss of Virologic Response Following Confirmed Virologic Response
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 2 of Treatment
NCT00552240 (46) [back to overview]	Change in Fasting Total Cholesterol to High Density Lipoprotein (HDL) Ratio
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 8.
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 6.
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 48.
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 4.
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 36.
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 24.
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 2.
NCT00552240 (46) [back to overview]	AIDS Progression and Death: Number of Patients With a Treatment-emergent AIDS Defining Illness or an AIDS-defining Illness Leading to Death
NCT00552240 (46) [back to overview]	Change in Fasting Plasma Triglycerides Level
NCT00552240 (46) [back to overview]	Change in Fasting Plasma Total Cholesterol Level
NCT00552240 (46) [back to overview]	Change in Fasting Low Density Lipoprotein (LDL)Cholesterol Level
NCT00552240 (46) [back to overview]	Change in Glomerular Filtration Rate (GFR) From Baseline to Week 48
NCT00552240 (46) [back to overview]	Change in Framingham Score
NCT00552240 (46) [back to overview]	Percentage Adherence by Pill Count
NCT00552240 (46) [back to overview]	Proportion of Patients Reporting CNS Side Effects of Any Severity
NCT00552240 (46) [back to overview]	Proportion of Patients Reporting Hepatic Events of Any Severity
NCT00552240 (46) [back to overview]	Proportion of Patients Reporting Rash of Any Severity
NCT00552240 (46) [back to overview]	Time to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), All Participants
NCT00552240 (46) [back to overview]	Time to Virologic Response (First Confirmed Viral Load < 50 Copies/ml), Only Participants With Confirmed Viral Load < 50 Copies/ml
NCT00552240 (46) [back to overview]	Incidence of Patients With AIDS Progression at Each Visit
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 12 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 2 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 24 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 36 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 4 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 48 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 6 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 400 Copies/ml at Week 8 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 12 of Treatment
NCT00552240 (46) [back to overview]	Change in CD4+ Cell Count From Baseline to Week 12.
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 24 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 36 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 4 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 48
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 48 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 6 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With HIV Viral Load < 50 Copies/ml at Week 8 of Treatment
NCT00552240 (46) [back to overview]	Number of Participants With Virologic Response (VR)
NCT00552240 (46) [back to overview]	Number of Participants With Virologic Response According to the Time to Loss of Virologic Response (TLOVR) Algorithm
NCT00561925 (15) [back to overview]	Kaplan -Meier Estimate of Cumulative Probability of Group III or IV Drug-related Rash
NCT00561925 (15) [back to overview]	Kaplan -Meier Estimate of Cumulative Probability of Permanent Discontinuation of Study Medication
NCT00561925 (15) [back to overview]	Kaplan-Meier Estimates for Time to New AIDS or AIDS-related Progression Event or Death, Full Analysis Set Population
NCT00561925 (15) [back to overview]	Kaplan-Meier Estimates of the Proportions of Patients Without Loss of Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population
NCT00561925 (15) [back to overview]	Occurrence of Elevations in Laboratory Measurement by DAIDS Grade
NCT00561925 (15) [back to overview]	Proportion of Sustained Virologic Response at Week 144 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population
NCT00561925 (15) [back to overview]	Comparison of CD4+ Cell Count (Cells/Cubic Millimeter) Change From Baseline at Week 144, Full Analysis Set Population
NCT00561925 (15) [back to overview]	Occurrence of Rashes
NCT00561925 (15) [back to overview]	Comparison of HIV-1 Viral Load (log10 Copies/mL) Change From Baseline at Week 144, Full Analysis Set Population
NCT00561925 (15) [back to overview]	Occurrence of Hepatic Events
NCT00561925 (15) [back to overview]	Relative Bioavailability Trough C_pre,ss,1
NCT00561925 (15) [back to overview]	Comparison of Proportion of Virologic Response at Week 48 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population
NCT00561925 (15) [back to overview]	Kaplan -Meier Estimate of Cumulative Probability of Clinical Hepatic Events
NCT00561925 (15) [back to overview]	Kaplan -Meier Estimate of Cumulative Probability of Grade 3 or 4 ALT/AST Abnormalities
NCT00561925 (15) [back to overview]	Kaplan -Meier Estimate of Cumulative Probability of Grade 3 or 4 Asymptotic Transaminases Abnormalities
NCT00819052 (42) [back to overview]	Trough Plasma Concentration
NCT00819052 (42) [back to overview]	Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Last Available Visit, Observed Cases, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 108, Observed Cases, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 12, Observed Cases, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 120, Observed Cases, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 132, Observed Cases, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 144, Observed Cases, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 2, Observed Cases, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 24, Observed Cases, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 4, Observed Cases, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 48, Observed Cases, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 60, Observed Cases, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 72, Observed Cases, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 8, Observed Cases, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 84, Observed Cases, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Change From Baseline in CD4 Count (Cells/Cubic Millimeter) at Week 96, Observed Cases, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Comparison of CD4 Count (Cells/Cubic Millimeter) Change From Baseline at Week 24, Observed Cases, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Occurence of Hepatic Events
NCT00819052 (42) [back to overview]	Summary of CD4 Count (Cells/Cubic Millimeter) at Baseline, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Time to Loss of Virologic Response
NCT00819052 (42) [back to overview]	Change From Baseline in VL (HIV-1 Viral Load) at Each Visit
NCT00819052 (42) [back to overview]	Changes in Safety Parameters Related to Treatment
NCT00819052 (42) [back to overview]	Comparison of Virologic Response at Week 24 Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Kaplan-Meier Estimates of the Proportions of Patients Without Loss of Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population
NCT00819052 (42) [back to overview]	New AIDS or AIDS-related Progression Event or Death
NCT00819052 (42) [back to overview]	Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 400 Copies/mL, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 400 Copies/mL, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 400 Copies/mL, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 400 Copies/mL, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 400 Copies/mL, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Number of Participants With Virologic Response Using Lower Limit of Quantification (LLOQ) = 50 Copies/mL, Full Analysis Set Population
NCT00819052 (42) [back to overview]	Occurence of Rashes
NCT00819052 (42) [back to overview]	Proportion of Virologic Response (Viral Load <400 Copies/mL) Trough Week 144
NCT00905489 (16) [back to overview]	Efficacy: Patients Maintaining a VL < 50 Copies/mL
NCT00905489 (16) [back to overview]	Efficacy: Patients Maintaining a VL < 400 Copies/mL in Optional Extension Phase
NCT00905489 (16) [back to overview]	Efficacy: Patients Maintaining a VL < 400 Copies/mL
NCT00905489 (16) [back to overview]	CL/F,ss
NCT00905489 (16) [back to overview]	Tmax,ss
NCT00905489 (16) [back to overview]	Ratio Cmax,ss/Cmin,ss
NCT00905489 (16) [back to overview]	Percentage Change From Baseline in Mean CD4+ Count
NCT00905489 (16) [back to overview]	Cmin,ss (for IR and XR Formulations by Nevirapine XR Dose Group)
NCT00905489 (16) [back to overview]	Cmax,ss (for IR and XR Formulations by Nevirapine XR Dose Group)
NCT00905489 (16) [back to overview]	Cavg
NCT00905489 (16) [back to overview]	Change From Baseline in Mean CD4+ Count (Absolute)
NCT00905489 (16) [back to overview]	Efficacy: Patients Maintaining a VL < 50 Copies/mL at Last Available Visit
NCT00905489 (16) [back to overview]	Efficacy: Patients Maintaining a VL < 50 Copies/mL at Week 24 of Optional Extension Phase
NCT00905489 (16) [back to overview]	Trough Cpre,N.
NCT00905489 (16) [back to overview]	%PTF
NCT00905489 (16) [back to overview]	AUCt,ss
NCT00978068 (6) [back to overview]	Percentage of Uncomplicated Malaria Episodes With Accompanying Adverse Events That Occurred in the 28 Days Following Antimalarial Therapy
NCT00978068 (6) [back to overview]	Incidence-density of Malaria Defined as the Number of Incident Episodes of Malaria Per Time at Risk.
NCT00978068 (6) [back to overview]	Incidence-density of Malaria Defined as the Number of Incident Episodes of Complicated Malaria Per Time at Risk.
NCT00978068 (6) [back to overview]	Estimates of the 6-month Risk of a First Episode of Malaria
NCT00978068 (6) [back to overview]	28-day Risk of Recurrent Parasitemia
NCT00978068 (6) [back to overview]	63-day Risk of Recurrent Malaria
NCT01025830 (2) [back to overview]	Area Under the Concentration-Time Curve(AUC)
NCT01025830 (2) [back to overview]	Maximum Plasma Concentration of Drug
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Confirmed Infant HIV Infections
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Infant HIV Infections
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of AIDS-defining Illness
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of Death
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of HIV/AIDS-related Event or Death
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of HIV/AIDS-related Event or World Health Organization (WHO) Clinical Stage 2 or 3 Events
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of HIV/AIDS-related Events
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of Progression to AIDS-defining Illness or Death
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence of Tuberculosis
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Mothers With Adverse Pregnancy Outcomes (e.g.,Stillbirth, Preterm Delivery (< 37 Weeks), Low Birth Weight (< 2,500 Grams), and Congenital Anomalies)
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Mothers With Grade 3 or Higher Toxicities and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse Events
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Mothers With Grade 3 or Higher Toxicities and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse Events
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Mothers With Obstetrical Complications
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Mothers With Obstetrical Complications
NCT01061151 (28) [back to overview]	Antepartum Component: Probability of Overall and HIV-free Infant Survival Until 104 Weeks of Age, by Antepartum Arm (in Conjunction With Infants in the Postpartum Component)
NCT01061151 (28) [back to overview]	Antepartum Component: Probability of Overall and HIV-free Infant Survival Until 104 Weeks of Age, by Antepartum Arm (in Conjunction With Infants in the Postpartum Component)
NCT01061151 (28) [back to overview]	Postpartum Component: Proportion of Infants Alive Through 12 and 24 Months Post-delivery
NCT01061151 (28) [back to overview]	Antepartum Component: Maternal HIV RNA Less Than 400 Copies/mL at Delivery
NCT01061151 (28) [back to overview]	Postpartum Component: Adherence to the Maternal and/or Infant ARV Regimens, as Measured by Maternal Report and Hair Measures
NCT01061151 (28) [back to overview]	Postpartum Component: Incidence of Grade 3 or Higher Adverse Events and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse Events
NCT01061151 (28) [back to overview]	Postpartum Component: Incidence of Confirmed Infant HIV Infection
NCT01061151 (28) [back to overview]	Maternal Health Component: Toxicity: Incidence of Grade 3 or Greater Laboratory Results or Signs and Symptoms and Selected Grade 2 Hematologic, Renal, and Hepatic Laboratory Results
NCT01061151 (28) [back to overview]	Maternal Health Component: Other Targeted Medical Conditions
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence Rate of Progression to AIDS-defining Illness, Death, or a Serious Non-AIDS Cardiovascular, Hepatic, or Renal Event
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence Rate of Death or Any Condition of Particular Concern
NCT01061151 (28) [back to overview]	Maternal Health Component: Incidence Rate of Cardiovascular or Other Metabolic Events
NCT01061151 (28) [back to overview]	Postpartum Component: Proportion of Mother-Infant Pairs With no Death or HIV Diagnosis Through 24 Months Post-delivery
NCT01061151 (28) [back to overview]	Antepartum Component: Number of Mothers With Adverse Pregnancy Outcomes (e.g.,Stillbirth, Preterm Delivery (< 37 Weeks), Low Birth Weight (< 2,500 Grams), and Congenital Anomalies)
NCT01410058 (3) [back to overview]	Cmax
NCT01410058 (3) [back to overview]	AUC
NCT01410058 (3) [back to overview]	C12h
NCT01632891 (7) [back to overview]	Change in log10(Pf Gametocyte Density) From Entry to Day 30
NCT01632891 (7) [back to overview]	Number of Participants With Uncomplicated Clinical Malaria
NCT01632891 (7) [back to overview]	Time to First Pf SCP Clearance
NCT01632891 (7) [back to overview]	Log10(Pf Parasite Density)
NCT01632891 (7) [back to overview]	Number of Participants With Detectable Pf Gametocyte Density
NCT01632891 (7) [back to overview]	Proportion of Participants With Plasmodium Falciparum (Pf) Subclinical Parasitemia (SCP) Clearance
NCT01632891 (7) [back to overview]	Change in log10(Pf Parasite Density) From Entry to Day 30
NCT02028676 (58) [back to overview]	Cotrimoxazole: New Severe Pneumonia
NCT02028676 (58) [back to overview]	CDM vs LCM, Induction ART: Suppression of HIV RNA Viral Load 144 Weeks After Baseline
NCT02028676 (58) [back to overview]	CDM vs LCM, Induction ART: Suppression of HIV RNA Viral Load 72 Weeks After Baseline
NCT02028676 (58) [back to overview]	Cotrimoxazole: Adherence to ART as Measured by Self-reported Questionnaire (Missing Any Pills in the Last 4 Weeks)
NCT02028676 (58) [back to overview]	Cotrimoxazole: All-cause Mortality
NCT02028676 (58) [back to overview]	Cotrimoxazole: Body Mass Index-for-age Z-score
NCT02028676 (58) [back to overview]	Cotrimoxazole: Change From Baseline in Absolute CD4 to Week 72
NCT02028676 (58) [back to overview]	Cotrimoxazole: Change From Baseline in CD4% to Week 72
NCT02028676 (58) [back to overview]	Cotrimoxazole: Height-for-age Z-score
NCT02028676 (58) [back to overview]	Cotrimoxazole: New Clinical and Diagnostic Positive Malaria
NCT02028676 (58) [back to overview]	Cotrimoxazole: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV
NCT02028676 (58) [back to overview]	Cotrimoxazole: New Hospitalisation or Death
NCT02028676 (58) [back to overview]	Cotrimoxazole: New Serious Adverse Events Not Solely Related to HIV
NCT02028676 (58) [back to overview]	Cotrimoxazole: New WHO Stage 3 or 4 Event or Death
NCT02028676 (58) [back to overview]	Cotrimoxazole: New WHO Stage 3 Severe Recurrent Pneumonia or Diarrhoea
NCT02028676 (58) [back to overview]	Cotrimoxazole: New WHO Stage 4 Event or Death
NCT02028676 (58) [back to overview]	Cotrimoxazole: Weight-for-age Z-score
NCT02028676 (58) [back to overview]	Induction ART: Change From Baseline in CD4% 72 Weeks After ART Initiation
NCT02028676 (58) [back to overview]	Induction ART: Change From Baseline in CD4% to 144 Weeks From ART Initiation
NCT02028676 (58) [back to overview]	Induction ART: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV
NCT02028676 (58) [back to overview]	Induction ART: New WHO Stage 4 Event or Death
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Adherence to ART as Measured by Self-reported Questionnaire (Missing Any Pills in the Last 4 Weeks)
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: All-cause Mortality
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Body Mass Index-for-age Z-score
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Cessation of First-line Regimen for Clinical/Immunological Failure
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Change From Baseline in Absolute CD4 to Week 144
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Change From Baseline in Absolute CD4 to Week 72
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Height-for-age Z-score
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: New ART-modifying Adverse Event
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: New Grade 3 or 4 Adverse Event Definitely/Probably or Uncertainly Related to ART
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: New or Recurrent WHO Stage 3 or 4 Event or Death
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: New Serious Adverse Events Not Solely Related to HIV
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: New WHO Stage 3 or 4 Event or Death
NCT02028676 (58) [back to overview]	LCM vs CDM, Induction ART: Weight-for-age Z-score
NCT02028676 (58) [back to overview]	LCM vs CDM: Change From Baseline in CD4% to Week 144
NCT02028676 (58) [back to overview]	LCM vs CDM: Change From Baseline in CD4% to Week 72
NCT02028676 (58) [back to overview]	LCM vs CDM: Disease Progression to a New WHO Stage 4 Event or Death
NCT02028676 (58) [back to overview]	LCM vs CDM: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Adherence to ART as Measured by Self-reported Questionnaire (Missing Any Pills in the Last 4 Weeks)
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Adherence to ART as Measured by Self-reported Questionnaire (Missing Any Pills in the Last 4 Weeks) at 48 Weeks
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Adherence to ART as Measured by Self-reported Questionnaire (Missing Any Pills in the Last 4 Weeks) at 96 Weeks
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: All-cause Mortality
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Body Mass Index-for-age Z-score
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Change From Baseline in Absolute CD4 to Week 48
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Change From Baseline in Absolute CD4 to Week 72
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Change From Baseline in Absolute CD4 to Week 96
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Change From Baseline in CD4% to Week 48
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Change From Baseline in CD4% to Week 72
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Change From Baseline in CD4% to Week 96
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Height-for-age Z-score
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV, Judged Definitely/Probably or Uncertain Whether Related to Lamivudine or Abacavir
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: New Serious Adverse Events Not Solely Related to HIV
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: New WHO Stage 3 or 4 Event or Death
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: New WHO Stage 4 Event or Death
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Suppressed HIV RNA Viral Load 48 Weeks After Randomisation
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Suppression of HIV RNA Viral Load 96 Weeks After Randomisation
NCT02028676 (58) [back to overview]	Once Versus Twice Daily Abacavir+Lamivudine: Weight-for-age Z-score
NCT02116660 (1) [back to overview]	Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs

Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.

Intervention	ng*hour/mL (Geometric Mean)
	2nd Trimester	3rd Trimester	Postpartum
MVC 150 or 300mg b.i.d.	NA	2717	3645

Intervention	pg/mL (Median)
ATV/RTV/TFV 300/100/300mg q.d. With ENG	604
LPV/RTV 400/100 b.i.d. With ENG	428
EFV 600mg q.d. With ENG	125

Intervention	mcg/mL (Median)
	2-10 hours after birth	18-28 hours after birth	36-72 hours after birth	5-9 days after birth
DRV/COBI 800/150 mg q.d.	0.35	1.43	1.87	1.72
DTG 50mg q.d.	1.73	1.53	1.00	0.06
EFV 600 mg q.d. (Outside THA)	1.1	1.0	0.9	0.4
EVG/COBI 150/150mg q.d.	0.132	0.032	0.005	0.005

Intervention	hour (Median)
DTG 50mg q.d.	32.8
EVG/COBI 150/150mg q.d.	7.6
DRV/COBI 800/150 mg q.d.	NA
EFV 600 mg q.d. (Outside THA)	65.6

Intervention	unitless (Median)
TAF 10mg q.d. w/COBI	0.97
EFV 600 mg q.d. (Outside THA)	0.67
EFV 600mg q.d.	0.49
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d.	0.2
RAL 400mg b.i.d.	1.5
ETR 200mg b.i.d.	0.52
MVC 150 or 300mg b.i.d.	0.33
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d.	0.14
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d.	0.16
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d.	0.19
IDV/RTV Arm 2: 400/100mg q.d. (Only THA)	0.12
RPV 25mg q.d.	0.55
ATV/RTV 300/100mg q.d. or TFV/ATV/RTV 300/300/100mg q.d.	0.18
DRV/RTV 800/100mg q.d. or DRV/RTV 600/100mg b.i.d.	0.18

Intervention	mcg*hr/mL (Median)
	Before contraceptive initiation	After contraceptive initiation
ATV/RTV/TFV 300/100/300mg q.d. With ENG	53.96	55.25
EFV 600mg q.d. With ENG	53.64	56.65

Intervention	unitless (Median)
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d.	0.15
DTG 50mg q.d.	1.25
EVG/COBI 150/150mg q.d.	0.91
DRV/COBI 800/150 mg q.d.	0.07
ATV/COBI 300/150 mg q.d.	0.07
TFV 300mg q.d.	0.88

Intervention	Number of Adverse Events (Number)
	Death	Life-Threatening	Severe	Moderate	Mild
Nevirapine	26	87	375	694	832
Placebo	30	87	332	677	838

Intervention	participants (Number)
	# of HIV infections at 6 months	# of Infants at risk for HIV infection at 6 months
Nevirapine	8	700
Placebo	18	699

Intervention	participants (Number)
	# Infant Deaths at 18 months	# Infants at risk of death at 18 months
Nevirapine	26	678
Placebo	30	684

Intervention	participants (Number)
	Number of Infants Alive and HIV-free at 6 months	Number of Infants Alive and HIV-free at 18 months
Nevirapine	689	629
Placebo	683	616

Intervention	participants (Number)
	# of infants with HIV infection at 18 months	# of infants @ risk for HIV infection at 18 months
Nevirapine	16	664
Placebo	23	663

Intervention	cells/mm^3 (Median)
	Week 48 CD4 count change from randomization	Week 96 CD4 count change from randomization
NoNVP/LPV_r	172	256
NoNVP/NVP	172	223
NVP/LPV_r	201	278
NVP/NVP	191	291

Intervention	Percent of participants (Number)
	week 48 percent of virologic failure or death	week 96 percent of virologic failure or death
NoNVP/LPV_r	14	20
NoNVP/NVP	14	17
NVP/LPV_r	4	12
NVP/NVP	23	31

Intervention	percent of participants (Number)
	week 48 percent of full adherence in past month	week 96 percent of full adherence in past month
NoNVP/LPV_r	86	87
NoNVP/NVP	90	93
NVP/LPV_r	88	95
NVP/NVP	89	94

Intervention	weeks (Number)
	5th percentile	10th percentile	25th percentile
NVP/LPV_r	60	84	NA
NVP/NVP	12	12	60

Intervention	ng/mL (Median)
	NVP conc prior to 3rd dose	NVP peak conc (Cmax) post 3rd dose	NVP conc 3-5 day post 3rd dose	NVP conc 7 day post 3rd dose
ARM B (ZDV + NVP)	362	2286	459	76

Intervention	participants (Number)
ARM A (ZDV - Standard of Care)	24
ARM B (ZDV + NVP)	11
ARM C (ZDV +3TC+NFV)	12

Intervention	participants (Number)
Arm A (ZDV Only)	11
ARM B (ZDV + NVP)	15
ARM C (ZDV + 3TC + NFV)	17

Intervention	participants (Number)
	Treatment Arm C (ZDV+3TC/NFV)	Treatment Arm B (ZDV+NFV)	Treatment Arm A (ZDV only)	Illegal Substance Abuse during pregnancy
Infected	12	11	24	7
Uninfected	516	523	505	130

Intervention	participants (Number)
ARM A (ZDV Only)	86
ARM B (ZDV + NVP)	59
ARM C (ZDV + 3TC/NFV)	110

nevirapine

Description

Cross-References

Synonyms (148)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (2)

Pathways (1)

Protein Targets (50)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (156)

Molecular Functions (91)

Ceullar Components (48)

Bioassays (2791)

Research

Studies (3,035)

Market Indicators

Research Demand Index: 63.20

Study Types

Clinical Trials (169)

Trial Overview

Trial Outcomes

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Geometric Mean (95% CI) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 24 Hours (AUC24) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (Range) for ARVs and TB Drugs

PK Parameter: Area Under the Curve From 0 to 12 Hours (AUC12) With Median (IQR) for ARVs and TB Drugs

Plasma Concentration for Contraceptives

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C24) With Median (Range) for ARVs and TB Drugs

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Concentration of ARVs and TB Drugs

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Pharmacokinetic (PK) Parameter: Infant Plasma Washout Half-life (T1/2) of ARVs and TB Drugs

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (Range) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (IQR) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in mg/L With Median (Range) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (95% CI) for ARVs and TB Drugs

PK Parameter: Maximum Concentration (Cmax) in ng/mL With Median (IQR) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Geometric Mean (95% CI) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Trough Concentration (C12) With Median (Range) for ARVs and TB Drugs

Number of Women Who Met PK Target of Area Under the Curve (AUC) for ARVs

Area Under the Curve From 0 to 24 Hours (AUC24) of ARVs for Contraceptive Arms

Area Under the Curve From 0 to 12 Hours (AUC12) of ARVs for Contraceptive Arms

PK Parameter: Trough Concentration (C24) With Median (IQR) for ARVs and TB Drugs

PK Parameter: Cord/Maternal Blood Concentration Ratio With Median (IQR) for ARVs and TB Drugs

Frequency and Severity of Adverse Reactions Among Participating Infants

HIV Infection in Infants Determined to be HIV Uninfected at 6 Weeks Enrolled in Each Arm of the Study

Infant Survival Rates (Mortality Regardless of HIV Infection) in the Two Arms

Proportion of Infants Who Are Alive and HIV-uninfected in the Two Arms

Relative Rates of HIV Infection in the Two Arms

All Partner HIV Infection Rates in Early-ART and Delayed-ART Arms

Linked Partner HIV Infection Rates in Early-ART and Delayed-ART Arms

Number of Participants Who Experienced HIV-related Disease Progression or Death

Number of Participants Who Experienced Treatment-related Toxicity That Led to Discontinuation of Randomized Regimen.

Number of Participants Who Experienced Virologic Failure or Died.

Number of Participants Who Received NVP-containing Regimens at Randomization and Experienced NVP-associated Rash or Grade 2+ Liver Lab Abnormality

CD4 Count Change From Randomization

Percent of Participants Who Experienced Virologic Failure or Died

Percent of Participants Who Reported to Never Missed Any of the Study Drug Regimen in the Past Month

Time From Randomization to Virologic Failure or Death for Participants Who Had SD NVP Exposure Prior to Study Entry

Time From Randomization to Virologic Failure or Death for Participants Without SD NVP Exposure Prior to Study Entry

NVP Pharmacokinetics

Infant HIV Infection Status

Participant Deaths

Infant HIV-1 Infection Status

Intervention	ug*h/mL (Median)
	(NFV-AUC-12h) 4-7 day	(NFV-AUC-12h) 10-14 day	(3TC-AUC-12 h) 4-7 day	(3TC-AUC-12h) 10-14 day
ARM C (ZDV + 3TC/NFV)	20.7	25.5	4.0	7.9

Intervention	participants (Number)
7-day Lamivudine/Zidovudine (3TC/ZDV)	5
21-day Lamivudine/Zidovudine (3TC/ZDV)	1
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)	1
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)	0
7-day Lopinavir/Ritonavir (LPV/r)	2
21-day Lopinavir/Ritonavir (LPV/r)	2

Intervention	Participants (Count of Participants)
Deferred Therapy	10
Early Therapy 40 Weeks	1
Early Therapy 96 Weeks	1

Intervention	Participants (Count of Participants)
Deferred Therapy	48
Early Therapy up to 40 Weeks	32
Early Therapy up to 96 Weeks	26

Intervention	Weeks (Median)
Deferred Therapy	73.1
Early Therapy 40 Weeks	NA
Early Therapy 96 Weeks	NA

Intervention	Participants (Count of Participants)
Deferred Therapy	9
Early ART for 40 Weeks	14
Early Therapy for 96 Weeks	11

Intervention	Days (Number)
Deferred Therapy	1018
Early Therapy 40 Weeks	533
Early Therapy 96 Weeks	414

Intervention	Events per 100 person years (Number)
Deferred Therapy	27.6
Early Therapy 40 Weeks	16.4
Early Therapy 96 Weeks	14.2

Intervention	percent of participants (Number)
	The proportion of women with new ZDV resistance	The proportion of women with new ddI resistance	The proportion of women with new LPV/r resistance
Arm A : LPV/r x 7d	0	0	0
Arm B : no LPV/r	1.78	0	0
Arm C: LPV/r x 30d	0	0	0

Intervention	participants (Number)
	OLA in plasma samples	OLA in PBMC
Arm A : LPV/r x 7d	0	0
Arm B : no LPV/r	0	0
Arm C: LPV/r x 30d	0	1